<SEC-DOCUMENT>0001520138-21-000706.txt : 20211110
<SEC-HEADER>0001520138-21-000706.hdr.sgml : 20211110
<ACCEPTANCE-DATETIME>20211110161309
ACCESSION NUMBER:		0001520138-21-000706
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211110
DATE AS OF CHANGE:		20211110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOVIE INC.
		CENTRAL INDEX KEY:			0001580149
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				462510769
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39015
		FILM NUMBER:		211396730

	BUSINESS ADDRESS:	
		STREET 1:		2120 COLORADO AVE.
		STREET 2:		SUITE 230
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90404
		BUSINESS PHONE:		310-444-4300

	MAIL ADDRESS:	
		STREET 1:		2120 COLORADO AVE.
		STREET 2:		SUITE 230
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOANTIBIOTICS, INC.
		DATE OF NAME CHANGE:	20130625
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bivi-20210930_10q.htm
<DESCRIPTION>FORM 10-Q FOR PERIOD ENDING SEPTEMBER 30, 2021
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:bivi="http://nanoantibiotics.com/20210930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_bivi_nanoantibiotics.com_20210930 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20210701_20210930 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001580149 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wNi0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:EntityCentralIndexKey">0001580149</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-01to2021-09-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:CurrentFiscalYearEndDate">--06-30</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2021-06-30" id="xdx2ixbrl0078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2021-06-30" id="xdx2ixbrl0084" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-09-30" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-06-30" id="xdx2ixbrl0096" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="From2021-07-01to2021-09-30" id="xdx2ixbrl0152" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="bivi:DeemedDividend" contextRef="From2021-07-01to2021-09-30" id="xdx2ixbrl0167" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0201" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="bivi:InterestExpenseFromConvertibleDebenture" contextRef="From2021-07-01to2021-09-30" id="xdx2ixbrl0203" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="From2021-07-01to2021-09-30" id="xdx2ixbrl0206" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="bivi:PaymentOfConvertibleDebentureRelatedParty" contextRef="From2021-07-01to2021-09-30" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="bivi:ProceedsFromConvertibleDebentureRelatedParty" contextRef="From2021-07-01to2021-09-30" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-07-01to2021-09-30" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="bivi:DeemedDividend" contextRef="From2021-07-01to2021-09-30" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedParty" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="bivi:DeemedDividendForCommitmentShares" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0321" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">P4Y8M24D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" name="bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" name="bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4">P4Y7M6D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">P4Y8M24D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2020-07-012021-06-30_us-gaap_StockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2020-07-012021-06-30_us-gaap_StockOptionMember_srt_DirectorMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P4Y8M12D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-012021-09-30_us-gaap_WarrantMember217574359" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">P3Y1M6D</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2021-07-012021-09-30_us-gaap_WarrantMember217574359" id="xdx2ixbrl0524" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" contextRef="From2021-07-012021-09-30_us-gaap_WarrantMember217574359" id="xdx2ixbrl0525" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2021-07-012021-09-30_us-gaap_WarrantMember217574359" name="bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2">P2Y9M18D</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="bivi-20210930.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-07-01to2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-22_custom_AcuitasGroupHoldingsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bivi:AcuitasGroupHoldingsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_StockOptionMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_StockOptionMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption9Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption9Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption10Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption10Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption10Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption10Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption11Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption11Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption11Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption11Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption12Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption12Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption12Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption12Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption13Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption13Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption13Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption13Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption14Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption14Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption14Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption14Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption15Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption15Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption15Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption15Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOption16Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption16Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOption16Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption16Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_WarrantMember217574359">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
D.C.&#160;&#160;20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>Form
<span id="xdx_904_edei--DocumentType_c20210701__20210930_zCVMKnfRpM1b"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Mark
One)&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--DocumentQuarterlyReport_c20210701__20210930_zAVqky2WmD82"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>QUARTERLY
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the quarterly period ended: <span id="xdx_906_edei--DocumentPeriodEndDate_c20210701__20210930_zV8a0R4o5Cnk"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 30, 2021</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--DocumentTransitionReport_c20210701__20210930_z1rP77jfMTB4"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the transition period from ____________to _____________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Commission
File Number:&#160;<b><span style="text-decoration: underline"><span id="xdx_900_edei--EntityFileNumber_c20210701__20210930_zt6TWf6LQBdh"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:EntityFileNumber">001-39015</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 24pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_900_edei--EntityRegistrantName_c20210701__20210930_zOEEgicDd9Kk"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:EntityRegistrantName">BIOVIE INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(Exact
name of registrant as specified in its charter<b>)</b></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20210701__20210930_zmPybevaTSb7"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20210701__20210930_zPbetk3d0k2c"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:EntityTaxIdentificationNumber">46-2510769</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(State
    or other jurisdiction of&#160;<br />
    incorporation or organization)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(I.R.S.
    Empl. Ident. No.)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20210701__20210930_zZP242WOz9W4"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:EntityAddressAddressLine1">9120 Double Diamond Parkway Suite 1400</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityAddressCityOrTown_c20210701__20210930_ztNfdxauznh8"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:EntityAddressCityOrTown">Reno</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20210701__20210930_z6dbecwtzGB8"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:EntityAddressStateOrProvince">NV</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressPostalZipCode_c20210701__20210930_zKWJakzsnD72"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:EntityAddressPostalZipCode">89521</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(Address
    of principal executive offices, Zip Code)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--CityAreaCode_c20210701__20210930_zwRAB2PkIJog"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:CityAreaCode">(775)</ix:nonNumeric></span> <span id="xdx_90A_edei--LocalPhoneNumber_c20210701__20210930_zMGWJWjun1Oa"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:LocalPhoneNumber">888-3162</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(Registrant&#146;s
    telephone number, including area code)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Title
    of each class</span></td>
    <td style="border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Trading
    Symbol(s)</span></td>
    <td style="border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--Security12bTitle_c20210701__20210930_zWMiPKJ8wjs8"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:Security12bTitle">Class A Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--TradingSymbol_c20210701__20210930_zPbKG8Qsqdqk"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:TradingSymbol">BIVI</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The <span id="xdx_908_edei--SecurityExchangeName_c20210701__20210930_zDQI2UAczwF4"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market, LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during
the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntityCurrentReportingStatus_c20210701__20210930_zfEbPt3pj5ae"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--EntityInteractiveDataCurrent_c20210701__20210930_zsQWeoON1Yv9"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company
or emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148;, &#147;smaller
reporting company&#148; and &#147;emerging growth company&#148; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font: 10pt Times New Roman, Times, Serif">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--EntityFilerCategory_c20210701__20210930_zOHoOMPVYoH8"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Smaller reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_907_edei--EntitySmallBusiness_c20210701__20210930_zEHeDwlQ3cv6"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Emerging growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20210701__20210930_zWuGOdqu7P3l"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Yes&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span id="xdx_90C_edei--EntityShellCompany_c20210701__20210930_zDWpCbG39K8c"><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">There
were <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_c20211104_z4DTqUe1nsC2"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2021-11-04" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,962,373</ix:nonFraction></span> shares of the Registrant&#146;s $0.0001 par value Class A common stock outstanding as of November 4, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></p>



<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->




<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 0pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="TableOfContents"></span>TABLE
OF CONTENTS</b></span></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><a href="#a001_v1"><span style="font: 10pt Times New Roman, Times, Serif"><b>PART I &#8211; FINANCIAL INFORMATION</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><a href="#a002_v1"><span style="font: 10pt Times New Roman, Times, Serif">Item 1.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 85%"><a href="#a001_v1"><span style="font: 10pt Times New Roman, Times, Serif">Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%; text-align: right"><a href="#a001_v1"><span style="font: 10pt Times New Roman, Times, Serif">1</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a003_v1"><span style="font: 10pt Times New Roman, Times, Serif">Condensed Balance Sheets at September 30, 2021 (unaudited) and June 30, 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a003_v1"><span style="font: 10pt Times New Roman, Times, Serif">1</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a004_v1"><span style="font: 10pt Times New Roman, Times, Serif">Condensed Statements of Operations (unaudited) - for the three months ended September 30, 2021 and 2020</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a004_v1"><span style="font: 10pt Times New Roman, Times, Serif">2</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a005_v1"><span style="font: 10pt Times New Roman, Times, Serif">Condensed Statements of Cash Flows (unaudited) - for the three months ended September 30, 2021 and 2020</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a005_v1"><span style="font: 10pt Times New Roman, Times, Serif">3</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a006_v1"><span style="font: 10pt Times New Roman, Times, Serif">Condensed Statements of Changes in Stockholders&#146; Equity (unaudited) - for the three months ended September 30, 2021 and September 30, 2020</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a006_v1"><span style="font: 10pt Times New Roman, Times, Serif">4</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a007_v1"><span style="font: 10pt Times New Roman, Times, Serif">Notes to Unaudited Condensed Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a007_v1"><span style="font: 10pt Times New Roman, Times, Serif">5</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a008_v1"><span style="font: 10pt Times New Roman, Times, Serif">Item 2.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a008_v1"><span style="font: 10pt Times New Roman, Times, Serif">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a008_v1"><span style="font: 10pt Times New Roman, Times, Serif">13</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a009_v1"><span style="font: 10pt Times New Roman, Times, Serif">Item 3.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a009_v1"><span style="font: 10pt Times New Roman, Times, Serif">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a009_v1"><span style="font: 10pt Times New Roman, Times, Serif">17</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a010_v1"><span style="font: 10pt Times New Roman, Times, Serif">Item 4.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a010_v1"><span style="font: 10pt Times New Roman, Times, Serif">Controls and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a010_v1"><span style="font: 10pt Times New Roman, Times, Serif">17</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><a href="#a011_v1"><span style="font: 10pt Times New Roman, Times, Serif"><b>PART II &#8211; OTHER INFORMATION</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a012_v1"><span style="font: 10pt Times New Roman, Times, Serif">Item 1.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a012_v1"><span style="font: 10pt Times New Roman, Times, Serif">Legal Proceedings</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a012_v1"><span style="font: 10pt Times New Roman, Times, Serif">18</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a013_v1"><span style="font: 10pt Times New Roman, Times, Serif">Item 1A.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a013_v1"><span style="font: 10pt Times New Roman, Times, Serif">Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a013_v1"><span style="font: 10pt Times New Roman, Times, Serif">18</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a014_v1"><span style="font: 10pt Times New Roman, Times, Serif">Item 2.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a014_v1"><span style="font: 10pt Times New Roman, Times, Serif">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a014_v1"><span style="font: 10pt Times New Roman, Times, Serif">18</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a015_v1"><span style="font: 10pt Times New Roman, Times, Serif">Item 3.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a015_v1"><span style="font: 10pt Times New Roman, Times, Serif">Defaults Upon Senior Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a015_v1"><span style="font: 10pt Times New Roman, Times, Serif">18</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a016_v1"><span style="font: 10pt Times New Roman, Times, Serif">Item 4.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a016_v1"><span style="font: 10pt Times New Roman, Times, Serif">Mine Safety Disclosures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a016_v1"><span style="font: 10pt Times New Roman, Times, Serif">18</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a017_v1"><span style="font: 10pt Times New Roman, Times, Serif">Item 5.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a017_v1"><span style="font: 10pt Times New Roman, Times, Serif">Other Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a017_v1"><span style="font: 10pt Times New Roman, Times, Serif">18</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a018_v1"><span style="font: 10pt Times New Roman, Times, Serif">Item 6.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a018_v1"><span style="font: 10pt Times New Roman, Times, Serif">Exhibits</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a018_v1"><span style="font: 10pt Times New Roman, Times, Serif">19</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><a href="#a019_v1"><span style="font: 10pt Times New Roman, Times, Serif">SIGNATURES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><a href="#a019_v1"><span style="font: 10pt Times New Roman, Times, Serif">20</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>FORWARD-LOOKING
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">This
report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A
of the Securities Act of 1933. Any statements contained in this report that are not statements of historical fact may be
forward-looking statements. When we use the words &#147;intends,&#148; &#147;estimates,&#148; &#147;predicts,&#148;
&#147;potential,&#148; &#147;continues,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;believes,&#148;
&#147;should,&#148; &#147;could,&#148; &#147;may,&#148; &#147;will&#148; or the negative of these terms or other comparable
terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may
cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking
statements. These factors include, among others; our research and development activities and, distributor channel; compliance with
regulatory impositions requirements; and our capital needs. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or
achievements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Except
as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume
no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments.
Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking
statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with
the Securities and Exchange Commission that attempt to advise interested parties of the risks, uncertainties and other factors that may
affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">When
used in this report, the terms &#147;BioVie&#148;, &#147;Company&#148;, &#147;we&#148;, &#147;our&#148;, and &#147;us&#148;
refer to BioVie Inc.</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a001_v1"></span>PART
I &#8211; FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a002_v1"></span>Item
1. Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>BioVie
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a003_v1"></span>Condensed
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_zwbGaIPbC74d" summary="xdx: Statement - Condensed Balance Sheet (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 17.3pt; white-space: nowrap; text-align: center; text-indent: -8.65pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20210930_zOHvuv68ANJ7" style="white-space: nowrap; font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20210630_zTlFPm46r8P6" style="white-space: nowrap; font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 17.3pt; white-space: nowrap; text-align: center; text-indent: -8.65pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 17.3pt; white-space: nowrap; text-align: center; text-indent: -8.65pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsAbstract_iB_zQVTpKPKaeFf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 8.65pt; font-weight: bold; text-indent: -8.65pt">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 17.3pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrentAbstract_i01B_zXpS2rp0JTLd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; font-weight: bold; text-align: left; padding-left: 8.65pt">CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Cash_i02I_maCzbav_znQ8oJeD7Hu5" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; width: 74%; padding-left: 17.3pt">Cash</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,488,025</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,511,642</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_i02I_maCzbav_zlqzJrTBr9U8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1.5pt; padding-left: 17.3pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,923</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,487</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrent_i01TI_mtCzbav_maCzZ9q_z3WM52paF7Jl" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1.5pt; padding-left: 25.95pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,593,948</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,605,129</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsNoncurrentAbstract_i01B_zB6NmT6FGJr4" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; font-weight: bold; text-align: left; padding-left: 8.65pt">OTHER&#160;&#160;ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maCzZlL_zicTdZWVoX73" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,038,505</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,095,849</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Goodwill_i02I_maCzZlL_zmt28QE6fSvd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-bottom: 1.5pt; padding-left: 17.3pt">Goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,711</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,711</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsNoncurrent_i01TI_mtCzZlL_maCzZ9q_ztCluOCUNW06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1.5pt; padding-left: 25.95pt">Total other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,384,216</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,441,560</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Assets_iTI_mtCzZ9q_zVGAGeM8h7n2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 8.65pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,978,164</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,046,689</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zYlEOEl83iUd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; font-weight: bold; text-align: left; padding-left: 8.65pt">LIABILITIES AND STOCKHOLDERS&#146; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrentAbstract_i01B_zHWVVsyKX8el" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; font-weight: bold; text-align: left; padding-left: 8.65pt">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableCurrent_i02I_maCzfkF_zlfB8zTcUE85" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">679,393</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">996,374</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzfkF_zWqKvbejmQ37" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1.5pt; padding-left: 17.3pt">Current portion of other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">580,625</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0078">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrent_i01TI_mtCzfkF_maCzaiX_zqq7FRCb8PF6" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1.5pt; padding-left: 25.95pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,260,018</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">996,374</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherLiabilitiesNoncurrent_i01I_maCzaiX_zw51mPkzfymk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">483,854</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0084">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-bottom: 1.5pt; padding-left: 17.3pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Liabilities_i01TI_mtCzaiX_maCz6hF_zY3KMTzNcRXc" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 8.65pt">TOTAL LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,743,872</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">996,374</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommitmentsAndContingencies_i01I_zVwhlC9JqdA7" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; text-align: left; padding-left: 8.65pt">Commitments and contingencies (Note 8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquityAbstract_i01B_ztKb45HirU7j" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; font-weight: bold; text-align: left; padding-left: 8.65pt">STOCKHOLDERS&#146; EQUITY :</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PreferredStockValue_i02I_maCzmhH_zz6QZlVVlCq2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.95pt">Preferred stock; $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210930_z82bIIZHeUV7" title="Preferred Stock, Par Value"><span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210630_zLRdALCfNHSh" title="Preferred Stock, Par Value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20210930_z7nzcUcjxKU"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20210630_zo3XKXijBDV5"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_c20210930_znpTWHCOYoRd"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20210630_zuHS05LYhi9i"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20210930_zmBu5w0MuTIf"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20210630_ztK7HLSdqd3a"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0096">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CommonStockValue_i02I_maCzmhH_zWoR54zkp4Yb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.95pt">Common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210930_zBsyMyD379A6"><span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210630_zuvq0kbHFCF4"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20210930_zbFp8Pp30BSa"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20210630_zKM5NVqlWjc7"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized at September 30, 2021 and June 30, 2021, respectively; <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20210930_zKNYIdrq4Qjj"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20210930_zI6L8EnD8Zhe"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,962,373</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20210630_zAUzkQkWpPt6"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20210630_zh54O7Se2S7g"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,333,324</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at September 30, 2021 and June 30, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,494</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,232</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 17.3pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maCzmhH_zFns64pBNVu8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.95pt">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,657,973</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,933,505</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzmhH_zllv8mFEw7i4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.65pt; padding-left: 25.95pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">230,426,175</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">224,885,422</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquity_i01TI_mtCzmhH_maCz6hF_zB4S7svtOeId" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1.5pt; padding-left: 25.95pt">Total stockholders&#146; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,234,292</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,050,315</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCz6hF_zYyXsc7VXG3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 8.65pt">TOTAL LIABILITIES AND STOCKHOLDERS&#146; EQUITY</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,978,164</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,046,689</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">See
accompanying notes to unaudited condensed financial statements</span></p>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>BioVie
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a004_v1"></span>Condensed
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_113_zR0MUy3umac5" summary="xdx: Statement - Condensed Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt; white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20210701__20210930_z2aj0lnulLp7" style="white-space: nowrap; font-weight: bold; text-align: center">Three Months<br />
Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20200701__20200930_zX1xP1xo7Zlg" style="white-space: nowrap; font-weight: bold; text-align: center">Three Months<br />
Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt; white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30<br />
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30<br />
2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt; white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingExpensesAbstract_iB_zVl9pCUo5lw" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt; font-weight: bold; text-align: left">OPERATING EXPENSES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AmortizationOfIntangibleAssets_i01_maCzQ0N_zO3kjzDSIhkl" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt; width: 74%">Amortization</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,344</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,344</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzQ0N_zJpBqg5l6OAb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,845,594</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,914</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maCzQ0N_z202Lf0CInX8" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt; text-align: left; padding-bottom: 1.5pt">Selling, general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,644,346</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">228,497</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpenses_iT_mtCzQ0N_msCzaUS_zSCcCWbfh5rd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 25.95pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL OPERATING EXPENSES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,547,284</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386,755</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingIncomeLoss_iT_mtCzaUS_maNILz4Ye_zJ8aAvYwr9Gd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">LOSS FROM OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,547,284</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">386,755</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherExpensesAbstract_iB_zDDYMwkIL9h5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt; font-weight: bold; text-align: left">OTHER EXPENSE (INCOME) EXPENSE:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GainLossOnSaleOfDerivatives_i01N_di_msCzO1i_z2Z3pxZ67EUd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt; text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0152">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,279,919</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--InterestExpense_i01_maCzO1i_z4zq3dNipor8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,114</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">559,312</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestIncomeOther_i01N_di_msCzO1i_zocV6O5MxlS6" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt; text-align: left; padding-bottom: 1.5pt">Interest income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,645</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--TotalOtherExpenseIncome_iT_msCzv3P_mtCzO1i_msNILz4Ye_z3VjfMqcL9l4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 25.95pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL OTHER INCOME, NET</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="bivi:TotalOtherExpenseIncome" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,531</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="bivi:TotalOtherExpenseIncome" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,720,671</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_mtNILz4Ye_maCz7q1_zR7Y9qAnxwck" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt; font-weight: bold; text-align: left; padding-bottom: 4pt">NET (LOSS)/INCOME</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,540,753</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,333,916</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeemedDividend_msCz7q1_zM32IfRjGbAl" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt; text-align: left; padding-bottom: 1.5pt">Deemed dividends - related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0167">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="bivi:DeemedDividend" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,598,320</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossAttributableToParent_iT_mtCz7q1_zZAH3ifTBTJ4" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt; font-weight: bold; text-align: left; padding-bottom: 4pt">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossAttributableToParent" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,540,753</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossAttributableToParent" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,264,404</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt; font-weight: bold">NET LOSS PER COMMON SHARE</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EarningsPerShareBasic_zuKCSmNyk3Xj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt; padding-bottom: 4pt">- Basic</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.23</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">7.75</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareDiluted_zLb1OsXs74wf" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt; padding-bottom: 4pt">- Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.23</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">7.75</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt; font-weight: bold">WEIGHTED AVERAGE NUMBER OF COMMON&#160;&#160;SHARES OUTSTANDING</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zMQjjrrI7715" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">- Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,719,927</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,971,622</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zgJZQkjpzHP6" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">- Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,719,927</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,971,622</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">See
accompanying notes to unaudited condensed financial statements</span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>BioVie
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a005_v1"></span>Condensed
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_112_z7VzzuNG9Qwa" summary="xdx: Statement - Condensed Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20210701__20210930_zhyzTFfI5Y7d" style="white-space: nowrap; font-weight: bold; text-align: center">Three Months<br /> Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20200701__20200930_zZhBcfO1VwJf" style="white-space: nowrap; font-weight: bold; text-align: center">Three Months<br /> Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30,<br /> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zhSWWflgnakg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_i01_zm5OyXo0E8ba" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Net (loss)/income</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,540,753</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,333,916</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zCEs7Wwvy2ek" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Adjustments to reconcile net (loss) income to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AmortizationOfIntangibleAssets_i02_zqRTFdiP22Wc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,344</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,344</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RestrictedStockExpense_i02_z5ZnpKDWHaW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Stock based compensation - restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">286,759</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0198">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ShareBasedCompensation_i02_zxHaYYwgDwPd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Stock option based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,926,962</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0201">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--InterestExpenseFromConvertibleDebenture_i02_zhn7NZNzRoz6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Interest expense from convertible debenture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0203">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:InterestExpenseFromConvertibleDebenture" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">537,275</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GainLossOnSaleOfDerivatives_i02N_di_zv8GrK2nfO2h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0206">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,279,919</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zzBpdPwGYgag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOtherCurrentAssets_i02_zvlQft3bJVD" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.95pt">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,436</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">323,591</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_z7INRM1qvStd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.95pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">316,981</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,056,032</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOtherOperatingLiabilities_i02_zoseueAf8ash" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.65pt; padding-left: 25.95pt">Other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,064,479</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0219">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivities_maCACEPzdmw_z8eqlesXJQp7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.65pt; padding-left: 17.3pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,534,626</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,083,825</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zNVHUHxniyF6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzXKe_zzFRMkd59CSk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Net proceeds from issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,511,009</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,628,010</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PaymentOfConvertibleDebentureRelatedParty_i01N_di_msCzXKe_zwAPqcLHkvN1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Payment of convertible debenture - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0230">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="bivi:PaymentOfConvertibleDebentureRelatedParty" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,821,818</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--ProceedsFromConvertibleDebentureRelatedParty_i01_maCzXKe_zhw1dkSVc9Ge" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.65pt; padding-left: 17.3pt">Proceeds from convertible debenture - related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="bivi:ProceedsFromConvertibleDebentureRelatedParty" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,000</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzXKe_maCACEPzdmw_z70op4FWnu0h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.65pt; padding-left: 17.3pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,511,009</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,242,192</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsPeriodIncreaseDecrease_iT_mtCACEPzdmw_ziPUie3EzJak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net increase in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,976,383</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,158,367</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Cash_iS_zPBB0Q1CwpCj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -8.65pt; padding-left: 8.65pt">Cash, beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,511,642</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,195</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Cash_iE_zF3XTA684DHk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -8.65pt; padding-left: 8.65pt">Cash, end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,488,025</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,195,562</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zd9cv4C1JtEl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">SUPPLEMENTAL CASH FLOW INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestPaidNet_i01_zlADIqeciGrl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.65pt; padding-left: 25.95pt">Cash paid for interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,114</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,444</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxesPaidNet_i01_zGXdGuB9WDsc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.65pt; padding-left: 25.95pt">Cash paid for taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0254">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_z7DfB60cBOYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DeemedDividend_i01_zzOP9ZeqmJG3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.65pt; padding-left: 25.95pt">Deemed dividends - related party</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="bivi:DeemedDividend" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,598,320</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">See
accompanying notes to unaudited condensed financial statements</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>BioVie
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a006_v1"></span>Condensed
Statements of Changes in Stockholders&#146; (Deficit) Equity </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the Three Months Ended September 30, 2021 and September 30, 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_114_zXAyP8uAdQ7g" summary="xdx: Statement - Statements of Changes in Stockholders&apos; Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Common<br /> Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zq4Rb1yEawEe" style="white-space: nowrap; font-weight: bold; text-align: center">Common<br /> Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z7m3bVDLflMg" style="white-space: nowrap; font-weight: bold; text-align: center">Additional<br /> Paid in</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zkBmmhaSS6W8" style="white-space: nowrap; font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B1_z5HgIeK0AH3d" style="white-space: nowrap; font-weight: bold; text-align: center">Total<br /> Stockholders&#146;<br /> Equity</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">(Deficit)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_433_c20200701__20200930_eus-gaap--StockholdersEquity_iS_zA3sHem8WzU" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-indent: -8.65pt; padding-left: 8.65pt">Balance, June 30, 2020</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhiLwOjxKYJd" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,204,392.00</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">520</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,538,742</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,037,898</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,498,636</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20200701__20200930_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zLncNNHoeHH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Proceeds from issuance of common stock,net of cost of $<span id="xdx_908_ecustom--ProceedsFromIssuanceOfCommonStockNetOfCost_c20200701__20200930_zLzXZQnLPyD5" title="Proceeds from Issuance of Common Stock, Net of Cost"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetOfCost" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,371,790</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3baLeGpyELg" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,799,980</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,627,830</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,628,010</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20200701__20200930_ecustom--RedemptionOfWarrantsAndPurchaseOptionRelatedParty_zDPNjQEu8Xz1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Redemption of warrants&#160;&#160;- related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares_pid_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpP68fPQqZdl" style="text-align: right"><ix:nonFraction name="bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,549,750</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedParty" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedParty" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,132,230</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedParty" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,132,385</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20200701__20200930_ecustom--DeemedDividendForCommitmentShares_zG28pwPXaur9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Deemed dividend for purchase option - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--DeemedDividendForPurchaseOptionRelatedPartyInShares_pid_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuqnqvx9TKO7" style="text-align: right"><ix:nonFraction name="bivi:DeemedDividendForPurchaseOptionRelatedPartyInShares" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,359,832</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:DeemedDividendForCommitmentShares" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">536</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:DeemedDividendForCommitmentShares" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,597,784</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="bivi:DeemedDividendForCommitmentShares" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">53,598,320</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20200701__20200930_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zRqVppiKwZT9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Cashless exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlf7cCaiznzc" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,210</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20200701__20200930_eus-gaap--ProfitLoss_zAYTvSeMnCX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.65pt; padding-left: 8.65pt">Net income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,333,916</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,333,916</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20200701__20200930_eus-gaap--StockholdersEquity_iE_ziFn2mfVpcl5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -8.65pt; padding-left: 8.65pt">Balance, September 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPNvOEmbyNWc" style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,916,164</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,391</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,896,586</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">87,302,302</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,595,675</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20210701__20210930_eus-gaap--StockholdersEquity_iS_zvetFDqAiLmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Balance June, 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbxZnYYr2yu" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,333,324</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,232</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,933,505</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">224,885,422</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,050,315</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20210701__20210930_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z1yWIFUSbMG1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Proceeds from issuance of common stock, net cost of&#160;&#160;$<span id="xdx_90D_ecustom--ProceedsFromIssuanceOfCommonStockNetOfCost_c20210701__20210930_za6tfTlwjdx4"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetOfCost" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,224,992</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9wFZJMRfet7" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,592,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">259</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,510,750</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,511,009</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20210701__20210930_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_zriN0MdRSQq1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Stock based compensation - restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,049</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">286,756</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">286,759</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20210701__20210930_eus-gaap--ShareBasedCompensation_zb4dIsHwkNha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Stock option based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,926,962</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,926,962</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20210701__20210930_eus-gaap--ProfitLoss_zmyUkG1GWPMi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,540,753</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,540,753</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20210701__20210930_eus-gaap--StockholdersEquity_iE_zzlkptcNE5Mb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -8.65pt; padding-left: 8.65pt">Balance, September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEz9qFTzk8v1" style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,962,373</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,494</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,657,973</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">230,426,175</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,234,292</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">See
accompanying notes to unaudited condensed financial statements</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p id="xdx_237_zmYlWQteJQBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>BIOVIE
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a007_v1"></span>Notes
to Condensed Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the Three Months Ended September 30, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p>

<ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zNrpROp71wV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>1.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_824_zfeb1p92e3gf">Background
Information</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">BioVie
Inc. (the &#147;Company&#148; or &#147;we&#148; or &#147;our&#148;) is a clinical-stage company developing innovative drug therapies
to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">In
liver disease, our Orphan Drug candidate BIV201 (continuous infusion terlipressin) is being developed as a future treatment option for
patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by NASH, hepatitis, and alcoholism.
The initial target for BIV201 therapy is refractory ascites. These patients suffer from frequent life-threatening complications, generate
more than $5 billion in annual treatment costs, and have an estimated 50% mortality rate within 6 to 12 months. The US Food and Drug
Administration (FDA) has not approved any drug to treat refractory ascites. A Phase 2a clinical trial of BIV201 was completed in 2019,
and a multi-center, randomized 30-patient Phase 2b trial is currently underway. As of October 31, 2021, the nine planned US study centers
have been activated and are actively screening patients, and multiple patients have been enrolled in the study. The FDA has communicated
to us that pending positive Phase 2 study results, a sufficiently large and well-controlled Phase 3 trial, with supportive trend data
from the Phase 2b (statistical significance not required), could potentially yield the clinical data needed to apply for BIV201 marketing
approval. The Phase 2b clinical trial protocol is summarized on www.clinicaltrials.gov, trial identifier NCT04112199.at nine US study
centers. (NCT04112199). Top-line results from this trial are expected in mid-2022, to be followed by a proposed single pivotal Phase
3 clinical trial beginning in late 2022. In June 2021, BioVie received written feedback from the FDA in response to a Type B meeting
request to conduct a pivotal US Phase 3 clinical trial in HRS-AKI, which is a life-threatening complication of advanced ascites. Based
on the guidance received in subsequent communications with the FDA, we are revising certain elements of our proposed study and are planning
to initiate this study in early 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The BIV201 development program was initiated by LAT Pharma LLC. On April
11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development
and marketing rights to its drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor
entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous
infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In neurodegenerative disease, BioVie acquired the biopharmaceutical assets
of NeurMedix, Inc. (&#8220;NeurMedix&#8221;), a privately held clinical-stage pharmaceutical company, in June 2021 (See Note 5 Related
Party Transactions<i>).</i> The acquired assets included NE3107, a potentially selective inhibitor of inflammatory ERK signaling that,
based on animal studies, is believed to reduce neuroinflammation. NE3107 is a novel orally administered small molecule that is thought
to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There
is emerging scientific consensus that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer&#8217;s
and Parkinson&#8217;s Disease, and NE3107 could, if approved represent an entirely new medical approach to treating these devastating
conditions affecting an estimated 6 million Americans suffering from Alzheimer&#8217;s and 1 million from Parkinson&#8217;s. The FDA has
authorized a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate NE3107
in subjects who have mild to moderate Alzheimer&#8217;s disease (NCT04669028). In August 2021, the study was initiated and the Company
is anticipating top line results in late calendar year 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In September 2021, the FDA authorized the Company to initiate a Phase 2
study assessing NE3107&#8217;s potential pro-motoric impact in Parkinson&#8217;s disease patients, and to assess its safety and tolerability.
The NM201 study (NCT05083260) is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinson&#8217;s
Disease (PD) participants treated with carbidopa/levodopa and NE3107. Forty patients with a defined L-dopa &#8220;off state&#8221; will
be randomized 1:1 placebo: active 20 mg twice daily for 28 days. Safety assessments will look at standard measures of patient health and
potential for drug-drug interactions affecting L-dopa PK and activity. Efficacy assessments will use the Motor Disease Society Unified
Parkinson&#8217;s Disease Rating (MDS-UPDRS) parts 1-4, Hauser ON/OFF Diary, and Non-Motor Symptom Scale. This study is planned to start
in early 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inflammation-driven insulin resistance is believed to be implicated in
a broad range of serious diseases, including multiple myeloma and prostate cancer, and we plan to begin exploring these opportunities
in the coming months using NE3107 or related compounds acquired in the NeurMedix asset purchase. NE3107 is patented in the United States,
Australia, Canada, Europe and South Korea.</p>

<ix:exclude><!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p id="xdx_230_zn8gvBOsJZkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="bivi:LiquidityTextBlock"><p id="xdx_801_ecustom--LiquidityTextBlock_z991OxaD6U2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>2.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_82B_zbJRFTLwN668">Liquidity</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#146;s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors
include, but are not limited to: the results of clinical testing and trial activities of the Company&#146;s products, the Company&#146;s
ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other
companies; the price of, and demand for, Company products; the Company&#146;s ability to negotiate favorable licensing or other manufacturing
and marketing agreements for its products; and the Company&#146;s ability to raise capital. The Company&#146;s financial statements
have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction
of liabilities in the normal course of business. As of September 30, 2021, the Company had working capital of approximately $<span id="xdx_904_ecustom--WorkingCapital_iI_pp0p0_dm_c20210930_za0hGIVuyKTl"><ix:nonFraction name="bivi:WorkingCapital" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">19.3</ix:nonFraction> million</span>,
cash of approximately $20.5 million, stockholders&#146; equity of approximately $20.2 million, and an accumulated deficit of approximately
$230.4 million. In addition, the Company has not generated any revenues to date and no revenues are expected in the foreseeable future.
The Company&#146;s future operations are dependent on the success of the Company&#146;s ongoing development and commercialization efforts,
as well as its ability to secure additional financing as needed. Although our cash balance could possibly sustain operations over the
next 12 months if measures are taken to delay planned expenditures in our research protocols and slow the progress in the Company&#146;s
clinical programs, the Company&#146;s current planned operations to meet certain goals and objectives, project cash flows to be depleted
within that period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management
expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
emergence of widespread health emergencies or pandemics such as the coronavirus (&#147;COVID-19&#148;) pandemic (and its related variants),
may lead to continued regional quarantines, business shutdowns, labor shortages, disruptions to supply chains, and overall economic instability.
<span style="background-color: white">Although some jurisdictions have relaxed these measures, others have not or have reinstated them
as COVID-19 cases surge and variants emerge. </span>The duration and spread of the COVID-19 pandemic and the long-term impact of COVID-19
and its variants on the financial markets and the overall economy are highly uncertain and cannot be predicted at this time. If the financial
markets and/or the overall economy are impacted for an extended period, the Company&#146;s ability to raise funds may be materially
adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Although
management continues to pursue the Company&#146;s strategic plans, there is no assurance that the Company will be successful in obtaining
sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial
doubt on the Company&#146;s ability to continue as a going concern. The financial statements do not include any adjustments that might
result from the outcome of this uncertainty.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKVLHe8KPZtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>3.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_82F_zn1En0B21Igg">Significant
Accounting Policies</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zVt5wK2ghfz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86B_zXIe4pq7YEI2">Basis
of Presentation &#8211; Interim Financial Information</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">These
unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally
accepted in the United State of America (&#147;U.S. GAAP&#148;) for interim financial information and with the instructions to Form
10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the &#147;SEC&#148;) for Interim Reporting. Accordingly,
they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim
condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of
management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily
indicative of the results for the full year. The condensed balance sheet at June 30, 2021 was derived from audited annual financial statements
but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements
and information included under the heading &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
should be read in conjunction with the Company&#146;s audited financial statements for the fiscal years ended June 30, 2021 and 2020
in our Annual Report on Form 10-K filed with the SEC on August 30, 2021. For a summary of significant accounting policies, see the Company&#146;s
Annual Report on Form 10-K for the fiscal year ended June 30, 2021, filed with the SEC on August 30, 2021.</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p id="xdx_237_zTnDMEbQ34S7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zofzqztTEL9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_zX1qceKp9L2f">Net
loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Basic
net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of
shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable
to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common
stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants,
and convertible debentures. For the three months ended September 30, 2021 and 2020, such amounts were excluded from the diluted loss
since their effect was considered anti-dilutive due to the net loss for the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMbKKVIrooBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
table below shows the number of outstanding stock options and warrants as of September 30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B2_z0tX7T0yqcz4" style="display: none">Schedule of Dilutive securities were excluded from the computation of diluted loss per share</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="bivi:DisclosureSignificantAccountingPoliciesDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureSignificantAccountingPoliciesDetailsAbstract_zgt12QaPmEk9" summary="xdx: Disclosure - Significant Accounting Policies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20210701__20210930_zANOx7Ka9fB8" style="white-space: nowrap; font-weight: bold; text-align: center">September 30,<br /> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20200701__20200930_zuPppPHBr576" style="white-space: nowrap; font-weight: bold; text-align: center">September 30,<br /> 2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br /> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br /> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgntrTihfehd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Stock Options</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,047,910</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-07-012020-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,200</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zQJkEJ2hQtqf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-07-012021-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">158,761</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-07-012020-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">214,665</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zSQKHWPtcXL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,206,671</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,865</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A3_zGydOHp7dvJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znuIQdnZzy2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_868_zetsEdpzxnWl">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers the applicability and impact of all Accounting Standards Updates (&#147;ASU&#146;s&#148;). There were no recent
ASUs that are expected to have a material impact on the Company&#146;s balance sheets or statements of operations.</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_zGtlPgtmNg23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>4.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_820_zAyUUkDNcuBc">Intangible
Assets</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#146;s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated
useful lives.</span></p>

<ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zhDBduEhQHwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The following is a <span id="xdx_8B2_zXdi33piIYW3">summary of the intangible assets as of September 30, 2021 and June 30, 2021</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="bivi:DisclosureIntangibleAssetsDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureIntangibleAssetsDetailsAbstract_zdhkg5UeB2ja" summary="xdx: Disclosure - Intangible Assets (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210930_zEV02dG0L4e4" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30,<br /> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20210630_z0RuQ3iaOTMc" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maCzIr2_zHjf2GhR7Qu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Intellectual Property</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,293,770</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,293,770</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzIr2_zqwGU197JWEc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Accumulated Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,255,265</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,197,921</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzIr2_zQyuieteyjx4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Intellectual Property, Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,038,505</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,095,849</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A6_zDpD6RehzK82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
expense was $57,344 in each of the three-month periods ended September 30, 2021 and 2020. The Company amortizes intellectual property
over the expected original useful lives of 10 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zBeeBe3sD9c9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Estimated
future amortization expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B6_zyPIF4pR1JY7" style="display: none">Schedule of Future expected Amortization of intangible assets</span></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="bivi:DisclosureIntangibleAssetsDetails2Abstract"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIntangibleAssetsDetails2Abstract_zCW8JWPDF8o2" summary="xdx: Disclosure - Intangible Assets (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"></td><td></td>
    <td style="text-align: left"></td><td id="xdx_49D_20210930_zTbrrOgzxROd" style="text-align: right"></td><td style="white-space: nowrap; text-align: left"></td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_maFLIANzEri_zgO6p3tEYCzd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: center">Year ending June 30, 2022 (Remaining nine months)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 40%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,033</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_maFLIANzEri_zFjNRrlOHuvk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,377</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_maFLIANzEri_zmKyI8W5u2J9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,377</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_maFLIANzEri_zcqdEgWzFoqe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,377</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_maFLIANzEri_z12jBGdCK2L3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,341</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzEri_zocxriG53r7i" style="vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: center; padding-bottom: 4pt">Intellectual Property, Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,038,505</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A3_zPrO3xzOO9jh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p id="xdx_23C_zHLLhWCZWy63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zLAQgIxIgor" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>5.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_82D_z6w4wutwLP8l">Related
Party Transactions</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Asset
Acquisition with NeurMedix</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
April 27, 2021, the Company entered into an Asset Purchase Agreement (&#147;APA&#148;) with NeurMedix and Acuitas Group Holdings, LLC
(&#147;Acuitas&#148;), which are related party affiliates, pursuant to which the Company acquired certain assets from NeurMedix and
assumed certain liabilities of NeurMedix, in exchange for consideration of cash and shares of common stock. The acquired assets include,
among others, those related to certain drug candidates being developed by NeurMedix, including NE3107, a small molecule orally administered
inhibitor of insulin resistance and the pathological inflammatory cascade, with a novel mechanism of action that has potential applications
for treatment against Alzheimer&#146;s Disease and Parkinson&#146;s Disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Subject
to the terms and conditions of the APA, following the closing, the Company was potentially obligated to deliver contingent stock consideration
to NeurMedix (or its successor). Previously, the Company was obligated to deliver contingent stock consideration to NeurMedix (or its
successor) consisting of shares of the Company&#146;s common stock having an aggregate value of up to $3.0 billion, subject to the Company&#146;s
achievement of certain clinical, regulatory and commercial milestones related to the drug candidates to be acquired from NeurMedix, and
subject to a cap limiting each issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates
exceeding 89.9999% of the Company&#146;s issued and outstanding common stock. Pursuant to Amendment No. 1 to the APA, dated May 9, 2021,
the Company is now obligated to deliver to NeurMedix (or its successor) 4.5 million shares upon the achievement of each of the four milestones
set forth in the APA, for an aggregate of up to 18 million shares, subject to a cap limiting the issuance of shares if such issuance
would result in the beneficial ownership of NeurMedix and its affiliates exceeding 87.5% of the Company&#146;s issued and outstanding
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
June 10, 2021, and pursuant to the APA, the Company issued to Acuitas (as NeurMedix&#146;s assignee) 8,361,308 shares of the Company&#146;s
common stock and made a cash payment of approximately $2.3 million, representing NeurMedix&#146;s direct and documented cash expenditures
to advance certain programs from March 1, 2021 through the closing date and cash payments to other third parties for expenses totaling
approximately $4.0 million for due diligence, legal fees, transaction fees and the fairness opinion. Since the transaction was between
entities under common control, there were no fair value adjustments of the purchased assets, and the historical cost basis of the purchased
assets was zero. The total consideration paid was expensed as research and development expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Equity
Transactions with Acuitas&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
September 22, 2020, concurrent with the closing of the Company&#146;s Offering, approximately $1.8 million was paid to Acuitas satisfying
all amounts owed on the Debenture due September 24, 2020 held by the Company&#146;s controlling stockholder, Acuitas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Additionally,
in connection with the close of the public offering on September 22, 2020, the Company issued an aggregate of <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20200922__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AcuitasGroupHoldingsLLCMember_zvgPmNM7sVxi"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-09-22_custom_AcuitasGroupHoldingsLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,909,582</ix:nonFraction></span> shares of Common
Stock to Acuitas, representing (i) 5.4 million shares issuable pursuant to Acuitas&#146; rights under the Purchase Agreement dated July
3, 2018, as amended on June 24, 2019 and October 9, 2019; and the various extension letters; which resulted in a deemed dividend at the
close of the public offering at price of $10 per share, consistent with the Company&#146;s accounting policy; and (ii) the automatic
exercise of 1.5 million warrants issued to Acuitas in connection with the Debenture financing at the par value of the Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended June 30, 2021, the Company received additional draws under the Debenture totaling $436,000. The total draws as of September
22, 2020 were $1.7 million and the related total number of warrants issuable at $4.00 per share of common stock was 424,750 of which
328,250 warrants had been issued. In accordance with the Debenture agreements, at September 22, 2020 upon the Company&#146;s close of
its public offering, all the warrants issued related to the debenture totaling 1,453,250 were mandatorily redeemed along with the additional
96,500 shares common stock issued to Acuitas.</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p id="xdx_23D_zaxqoMXvV0kl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:OtherLiabilitiesDisclosureTextBlock"><p id="xdx_800_eus-gaap--OtherLiabilitiesDisclosureTextBlock_z27grdkoDrFg" style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>6.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_829_zGDg4XdRTQD2">Other
Liabilities</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Other
liabilities represent retention bonus arrangements with certain employees. Retention bonuses of $<span id="xdx_904_eus-gaap--AccruedBonusesCurrent_iI_c20210930_zNOMLZiWpNrf" title="Retention Bonus"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,161,000</ix:nonFraction></span> were expensed in the accompanying
statements of operations for three months ended September 30, 2021, and will be paid in equal monthly installments, which began in August
2021, over a 24-month period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLic4YiI8IQg" style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>7.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_829_zQxFcBSeMoLb">Equity
Transactions</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zkjsdSwEZukf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the <span id="xdx_8B2_zMhGPBJKM8rg">activity relating to the Company&#146;s stock options</span> for the three months ended September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="bivi:DisclosureEquityTransactionsDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureEquityTransactionsDetailsAbstract_zUDksJz3P2nd" summary="xdx: Disclosure - Equity Transactions (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted-<br /> Average<br /> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br /> Remaining<br /> Average<br /> Contractual<br /> Term</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br /> Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%">Outstanding at June 30, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zc3sQt12uA11" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">755,200</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMxtvcFHYt3d" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.34</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgWpdyzBbep1" title="::XDX::P4Y8M24D" style="width: 8%; text-align: right">4.4</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zItGo8gYfZ73" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,569,232</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3ULBQYYxxkl" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,365,835</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zurnkyE7C562" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.74</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zREAmJUKkSM3" title="::XDX::P5Y" style="text-align: right">5.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6feaz93nisc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBL8tIOO6VKf" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,125</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9GTkYzO0rOa" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.91</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuRonGsbCsVb" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding at September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zcGmFG5ACdGh" style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,047,910</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMJZkkwl6G4" style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.79</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLPY99ECMA2" title="::XDX::P4Y7M6D" style="border-bottom: Black 4pt double; text-align: right">4.6</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zl0mN8nW0oKk" style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,824</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable at&#160;&#160;September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zG06cFgtjtl7" style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">509,667</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYEKm8VMNp02" style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.36</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoaXe3SIlpMk" title="::XDX::P4Y8M24D" style="border-bottom: Black 4pt double; text-align: right">4.4</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zD5o5odkHXR8" style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,824</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A0_zYKHA4IpbzN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="bivi:FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock"><p id="xdx_894_ecustom--FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock_z0Sf7wfJ4g61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflects the following
<span id="xdx_8BE_zZReCL1jqSnk">weighted-average assumptions</span> for the three months ended September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="bivi:DisclosureEquityTransactionsDetails2Abstract"><table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureEquityTransactionsDetails2Abstract_ztDB9NrRcIC" summary="xdx: Disclosure - Equity Transactions (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210701__20210930_zJZX4vp7yhA1" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30,<br />
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20200701__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0UE2NTouSrh" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Expected life of options (In years)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvnvxxV9xDm1" title="::XDX::P5Y" style="width: 8%; text-align: right">5</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20200701__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUcs8CRqY0Ka" title="::XDX::P5Y" style="width: 8%; text-align: right">5</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zxvi4Duh82Qg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">74.96</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-07-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">77.29</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_zjGkd7w4ZJDj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.80</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-07-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.39</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_znPMQ03DqbCk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-07-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A5_zOqXzsw6BJd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Expected
volatility is based on the historical volatilities of the daily closing price of the common stock of three comparable companies and the
expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures
as they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded stock option-based compensation expense of $1,926,962 and $0 for three-month periods ended September 30, 2021 and 2020,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2021, there was approximately $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_dm_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zwW4jAOxrI34"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">6.8</ix:nonFraction> million</span> of unrecognized compensation cost related to non-vested stock options granted
to Directors and Officers, which is expected to be recognized over a weighted-average period of approximately <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxH_c20200701__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zdn0w0PZUJad" title="::XDX::P4Y8M12D">4.7 years</span>.</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p id="xdx_23A_zTZ9IxF1abzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"><p id="xdx_895_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zZkgcsyrksQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following is a <span id="xdx_8B5_z30SSZRKMv1f">summary of stock options outstanding and exercisable by exercise price</span> as of September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="bivi:DisclosureEquityTransactionsDetails3Abstract"><table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureEquityTransactionsDetails3Abstract_zuGgkXD8B0lj" summary="xdx: Disclosure - Equity Transactions (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" id="xdx_482_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_zzse3RhQHwkd" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_z6AVEBugc5fg" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted Average<br /> Contract Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_znLpV2PdUlF2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_41F_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_zlzWDlwQARrg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 0%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.80</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,200</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_z2BhotaHlggb" style="width: 21%; text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">3.3</ix:nonNumeric></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,200</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zK6SEnRVxODh" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.75</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,800</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zkIWEQcIHs36" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption2Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">2.3</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,800</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zNjkQSVc90mf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.25</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,600</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zcAKX7Nj6Qtg" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption3Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">2.1</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,600</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41C_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zXswctEcCdO7" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.50</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,600</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zHv847TXCduf" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption4Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">4.4</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,600</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_zbtwRNK63AS9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.74</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,365,835</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_zMvqH2XqrVIi" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption5Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">4.9</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">273,167</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_ztSnC8kSrty5" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption6Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.75</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption6Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,600</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_zE0hM2NgIRhk" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption6Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">2.5</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption6Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,600</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41E_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_zYe19PNHete6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption7Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.54</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption7Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_zdCFSzIXDAJd" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption7Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">4.0</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption7Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_zTmyxofmFDxf" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption8Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.90</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption8Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_zkUeEtm3VuT3" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption8Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">4.0</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption8Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_412_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_z4SlBLPnFzG9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption9Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption9Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_zOxlQhdvwmtb" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption9Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">1.3</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption9Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zFM8eGshjUQb" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption10Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.91</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption10Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">618,475</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zTlZXajx5WQa" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption10Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">4.2</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption10Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">172,900</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_zlDTv2rgQolb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption11Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.00</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption11Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,600</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_z9Qn1iDR2Xj3" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption11Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">1.0</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption11Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,600</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zEhx08uKnpE4" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption12Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">26.25</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption12Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,400</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zBGQOEMkbi6" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption12Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">0.6</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption12Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,400</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zqCnXaFC2qwc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption13Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.50</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption13Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zBGR9jsY5Y6f" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption13Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">0.5</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption13Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_zCySkBFogFaj" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption14Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.75</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption14Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,600</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_ziYGtqREeKo2" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption14Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">0.8</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption14Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,600</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_z2jLPQp4wguh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption15Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">31.25</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption15Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_zjm1Q8zchuIf" style="text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption15Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">0.1</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption15Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption16Member_zVuBtCZMvXAd" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOption16Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">42.09</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOption16Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,800</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption16Member_zj4aoKSv3kR6" style="padding-bottom: 1.5pt; text-align: right"><ix:nonNumeric contextRef="From2021-07-012021-09-30_custom_StockOption16Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">4.3</ix:nonNumeric></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30_custom_StockOption16Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,800</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20210930_z4xEfT2Ho4y8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,047,910</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">509,667</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A4_zp9zzJdhA1w7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zrw56hMAvk93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following table <span id="xdx_8B7_z0QQjTnsMeX4">summarizes warrant activity</span> during the three months ended September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="bivi:DisclosureEquityTransactionsDetails4Abstract"><table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureEquityTransactionsDetails4Abstract_zkBDdZCjc6Zi" summary="xdx: Disclosure - Equity Transactions (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br /> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Remaining<br /> Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br /> Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: left">Outstanding and exercisable at June 30, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zs7KfeRTh9Xh" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">158,761</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zE5cSaAK3pKd" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" contextRef="AsOf2021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.37</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dxH_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmmEkRQSS2O6" title="::XDX::P3Y1M6D" style="width: 8%; text-align: right">3.1</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlt4gJQyWyR8" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,765,437</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNMcf371zRSg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0524">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuhbLfWasxQ6" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and exercisable at September 30, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zajLGq3UdVYj" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">158,761</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoPZj7imp9Te" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" contextRef="AsOf2021-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.37</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2_dxH_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdh4kevjau9a" title="Weighted Average Remaining Life, at the end of period::XDX::P2Y9M18D" style="border-bottom: Black 1.5pt solid; text-align: right">2.8</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z720uyEvkK52" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2021-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">486,666</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A8_z1xMCc7fxPMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Of
the above warrants, 9,391 expire in the fiscal year ending June 30, 2022, 4,815 expire in the fiscal year ending June 30, 2023, 2,714
expire in the fiscal year ending June 30, 2025, and 141,841 expire in the fiscal year ending June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuance
of common stock for cash</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
August 11, 2021, the Company closed a registered public offering issuing 2,500,000 of its Class A common stock at $8.00&#160;per share,
resulting in net proceeds to the Company of approximately $17.8 million, net of issuance costs of approximately $2.2 million</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
September 24, 2021, the Company issued 92,000 of its Class A common stock at $8.00&#160;per share in connection with the underwriters&#146;
exercise of its over-allotment option in for the August 2021 registered public offering, resulting in net proceeds to the Company of
approximately $707,000, net of issuance cost of approximately $29,000.</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p id="xdx_230_z2FrzBLL1wnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuance
of Shares for Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
August 20, 2021, the Company awarded 58,759 restricted stock units (&#147;RSUs&#148;) to the President and CEO under the Company&#146;s
2019 Omnibus Incentive Equity Plan (the &#147;2019 Omnibus Plan&#148;) as his salary for the period from April 27, 2021, the date of
his appointment, through December 31, 2021. The number of RSUs awarded was based on a prorated annual base salary of $600,000 at a 10%
discount to the grant date fair value of $7.74 per share of the Company&#146;s common stock. Each RSU awarded the to the CEO entitles
him to receive one share of common stock upon vesting. A total of 15,339 RSUs (representing the pro rata portion of the RSU award for
the period from April 27, 2021 to June 30, 2021) vested at the grant date, 21,710 RSUs vested at September 30, 2021, and 21,710 will
vest at December 31, 2021. Accordingly, during the three months ended September 30, 2021, 37,049 RSUs vested and 37,049 shares of common
were issued to the CEO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded stock-based compensation expense related to these RSUs of $286,759 and $0 for three- month periods ended September 30,
2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuance
of Stock Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
August 20, 2021, the Company granted, under the 2019 Omnibus Plan, stock options to purchase 1,365,835 shares of common stock to the
executive management team. Twenty percent (20%) of the shares underlying the options awarded vested on the grant date, and the remaining
80% vest equally over a 5-year period, on the first, second, third, fourth and fifth anniversary of the grant date. The option price
per share is $7.74 per share, the grant date fair value, and the options terminate on the tenth anniversary of the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Forfeiture
of Stock Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
August 27, 2021, the Chief Executive Officer forfeited unvested stock options to purchase up to 73,125 shares of common stock that were
previously granted to him as compensation as an independent director of the board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zAQoMn1NrdT3" style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>8.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_82D_z1IN49lgSPDd">Commitments
and Contingencies</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Office
Lease&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">From
July 1, 2019 to October 31, 2021, the Company paid monthly rent of $1,000 to Acuitas for its headquarter office at 2120 Colorado Avenue
Suite 230, Santa Monica, CA 90404. Effective November 1, 2021, the Company relocated its headquarters to Nevada at 9120 Double Diamond
Parkway, Suite 1400, Reno Nevada 89521.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
June 1, 2021, the Company assumed a NeurMedix office lease that was extended to February 2022 at 6165 Greenwich Dr Suite 150, San Diego,
CA 92122. The lease agreement requires monthly payments of $8,782.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Challenge
to US Patent </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent and Trademark Office (&#147;USPTO&#148;) to institute
an Inter Partes Review (&#147;IPR&#148;) of our U.S. Patent No. 9,655,945 titled &#147;Treatment of Ascites&#148; (the &#147;&#146;945
patent&#148;). On November 13, 2019, the Patent Trial and Appeal Board of USPTO issued a written decision in the IPR from which no appeal
was taken. The decision revoked all of the claims of the patent as lacking novelty or as obvious.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">This
ruling is unrelated to the Company&#146;s Company&#8217;s Orphan drug designations for ascites and hepatorenal syndrome
(&#8220;HRS&#8221;), which remain unchanged. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in
the United States for the designated use(s). In addition, the ruling does not affect the Company&#8217;s rights in its pending patent
application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2 and Phase 3 trials, subject to
FDA review and authorization, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks
patent protection, such as the United States, if a patent issues from a patent application according to the patent laws of each issuing
count.</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p id="xdx_235_zgMO7SHCCrz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Royalty
Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor entities, LAT Pharma LLC and NanoAntibiotics,
Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among
LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company and PharmaIN Corporation, LAT Pharma&#146;s former partner focused on the development of new modified drug candidates in the same
therapeutic field but not including BIV201 and on December 24, 2018, the Company returned its partial ownership rights to the PharmaIN
modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights
to our program remain unchanged and the Company remains obligated to pay royalties equal to less than 1% of future net sales of each
company&#146;s ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company&#146;s net license
revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated
to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign
issuances capped at a maximum of $200,000 per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="bivi:EmployeeBenefitPlanTextBlock"><p id="xdx_809_ecustom--EmployeeBenefitPlanTextBlock_zHPD37oeQPDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>9.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_82D_zFo2qBuLu881">Employee
Benefit Plan</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
August 1, 2021, the Company began sponsoring an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code
(the &#147;401K Plan&#148;) pursuant to which, all employees meeting eligibility requirements are able to participate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Subject
to certain limitations in the Internal Revenue Code, eligible employees are permitted to make contributions to the 401K Plan on a pre-tax
salary reduction basis and the Company will match 5% of the first 5% of an employee&#146;s contributions to the 401K Plan. For the three
months ended September 30, 2021, the Company made contributions of approximately $<span id="xdx_905_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20210701__20210930_zd7Vg0Zg6ZU3" title="Comtribuiton made by Company"><ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="From2021-07-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,600</ix:nonFraction></span>.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-09-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zuHULBLJJ0sg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>10.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_825_zVYGpY83f0xg">Subsequent
Events</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Effective
November 1, 2021, the Company relocated its headquarters to Nevada at 9120 Double Diamond Parkway, Suite 1400, Reno Nevada 89521.</span></p>

</ix:nonNumeric><p id="xdx_815_z8vOJEy6Zbq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a008_v1"></span>Item
2. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">This
report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A
of the Securities Act of 1933. Any statements contained in this report that are not statements of historical fact may be forward-looking
statements. When we use the words &#147;intends,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continues,&#148;
&#147;anticipates,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;believes,&#148; &#147;should,&#148; &#147;could,&#148;
&#147;may,&#148; &#147;will&#148; or the negative of these terms or other comparable terminology, we are identifying forward-looking
statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements
to be materially different from those expressed or implied by forward-looking statements. These factors among others, include our; research
and development activities and, distributor channel; compliance with regulatory impositions requirements; and our capital needs Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity, performance or achievements.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Except
as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume
no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments.
Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking
statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with
the Securities and Exchange Commission (the &#147;SEC&#148;) that attempt to advise interested parties of the risks, uncertainties
and other factors that may affect our business.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following discussion of the Company&#146;s financial condition and the results of operations should be read in conjunction with the
Financial Statements and Notes thereto appearing elsewhere in this report.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Management&#146;s
Discussion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">BioVie
Inc. is a clinical-stage company developing innovative drug therapies to overcome unmet medical needs in chronic debilitating conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>In
liver disease</i>,</b> our Orphan Drug candidate BIV201 (continuous infusion terlipressin) is being developed as a future
treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by NASH,
hepatitis, and alcoholism. The initial target for BIV201 therapy is refractory ascites. These patients suffer from frequent life-threatening
complications, generate more than $5 billion in annual treatment costs, and have an estimated 50% mortality rate within 6 to 12 months.
The US Food and Drug Administration (FDA) has not approved any drug to treat refractory ascites. A Phase 2a clinical trial of BIV201 was
completed in 2019, and a multi-center, randomized and controlled Phase 2b trial is currently underway at nine US medical centers including
Vanderbilt University, the Mayo Clinic, and University of Pennsylvania (NCT04112199). Top-line results from this trial are expected in
mid-2022, to be followed by a proposed single pivotal Phase 3 clinical trial beginning in late 2022. In June 2021, we received written
feedback from the FDA in response to a Type B meeting request to conduct a pivotal US Phase 3 clinical trial in HRS-AKI, which is a life-threatening
complication of advanced ascites. Based on the guidance received in subsequent communications with the FDA, we are revising certain elements
of our proposed study and planning to initiate this study in early 2022.</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>In
neurodegenerative disease,</i></b> BioVie acquired the biopharmaceutical assets of NeurMedix, Inc., a privately held clinical-stage
pharmaceutical company, in June 2021. The acquired assets include NE3107, a potentially selective inhibitor of inflammatory ERK signaling
that, based on animal studies, is believed to reduce neuroinflammation. NE3107is a novel orally administered small molecule that is thought
to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There
is emerging scientific consensus that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer&#8217;s
and Parkinson&#8217;s Disease, and NE3107 could, if approved, represent an entirely new medical approach to treating these devastating
conditions affecting an estimated 6 million Americans suffering from Alzheimer&#8217;s and 1 million from Parkinson&#8217;s. The FDA has
authorized a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate NE3107
in subjects who have mild to moderate Alzheimer&#8217;s disease (NCT04669028). We initiated this trial on August 5, 2021, and are targeting
primary completion in late 2022. In addition to Alzheimer&#8217;s disease, in September 2021, the FDA authorized the company to initiate
a Phase 2 study assessing NE3107&#8217;s potential pro-motoric impact in Parkinson&#8217;s disease patients, and to assess its safety
and tolerability. The NM201 study (NCT05083260) is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study
in Parkinson&#8217;s Disease (PD) participants treated with carbidopa/levodopa and NE3107. Forty (40) patients with a defined L-dopa &#8220;off
state&#8221; will be randomized 1:1 placebo: active 20 mg twice daily for 28 days. Safety assessments will look at standard measures of
patient health and potential for drug-drug interactions affecting L-dopa PK and activity. Efficacy assessments will use the Motor Disease
Society Unified Parkinson&#8217;s Disease Rating (MDS-UPDRS) parts 1-4, Hauser ON/OFF Diary, and Non-Motor Symptom Scale. This study is
planned to start in early 2022. Inflammation-driven insulin resistance is believed to be implicated in a broad range of serious diseases,
including multiple myeloma and prostate cancer, and we plan to begin exploring these opportunities in the coming months using NE3107 or
related compounds acquired in the NeurMedix asset purchase.</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Comparison
of the three months ended September 30, 2021 to the three months ended September 30, 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Net
income (loss)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
net loss for the three months ended September 30, 2021 was approximately $5.5 million as compared to net income of $7.3 million for the
three months ended September 30, 2020. The decrease in net income of approximately $12.8 million was primarily due to a change in fair
value of derivative liabilities of approximately $8.3 million and an increase in operating expenses of approximately $5.1 million, offset
by a decrease in interest expense of approximately $558,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Total
operating expenses for the three months ended September 30, 2021 were approximately $5.5 million as compared to $387,000 for the three
months ended September 30, 2020.&#160;&#160;The net increase of approximately $5.2 million during the three months ended September 30,
2021 was primarily due to an increase in research and development expenses of approximately $2.7 million, primarily attributed to the
development of the recently purchased Neuroscience biopharmaceutical assets and continuation of our Orphan Drug candidate BIV201&#146;s
Phase 2b clinical trial, which was initiated earlier in the 2021 calendar year, as well as an increase in selling, general and administration
expenses of $2.4 million, primarily due to stock-based compensation awarded to the management team.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development expenses were approximately $2.8 million and $101,000 for the three months ended September 30, 2021 and 2020, respectively.
The net increase of approximately $2.7 million, was primarily due to additional operating expenses related to our Neuroscience operations
totaling approximately $2 million and the increased activities of our Liver Cirrhosis operations totaling approximately $700,000, as
our Orphan Drug candidate BIV201&#146;s Phase 2b clinical trial initiated in June 2021 continues to ramp up. The level of research and
development activity for the three months ended September 30, 2021 strongly contrasts to the three months ended September 30, 2020, when
the Company was focused on closing its capital raise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Approximately
$1.7 million of the $2.7 million increase in research and development expenses was attributed to increased compensation expense in connection
with the hiring of two executives that oversee our Neuroscience research and development and product development. The $1.7 million increase
consisted of an increase in payroll expense by approximately $151,000, bonus expense of approximately $1.1 million, including a retention
bonus to certain employees totaling $1.0 million to be paid in 24 equal monthly installments, and stock compensation granted to the management
team totaling approximately $420,000. The remaining increase in research and development expense of approximately $1 million consisted
of expenses for the clinical operations related to BIV201&#146;s Phase 2b clinical trials totaling approximately $506,000 and the preparation
and initiation of the Alzheimer potentially pivotal Phase 3 study, which was initiated in August 2021 totaling approximately $533,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Selling,
General and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Selling,
general and administrative expenses were approximately $2.6 million and $228,000 for the three months ended September 30, 2021 and 2020,
respectively. The net increase of approximately $2.4 million was primarily attributed to increased compensation expense of approximately
$1.9 million, which consisted of stock-based compensation expense of approximately $1.7 million representing restricted stock units and
stock options awarded to the executive management team of approximately $1.3 million and the amortization cost of $385,000 for the stock
option granted the directors in the prior fiscal year; and approximately $227,000 related to bonus and salary increases. The remaining
net increase of approximately $500,000 is attributed to increased expenses related to being listed on a national exchange including listing
fees and investor relations, legal and professional fees, office expenses and website development expenses, as the Company expanded its
operations in the development of the recent neuroscience pharmaceutical assets.</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Capital
Resources and Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2021, the Company had working capital of approximately $19.3 million, cash of approximately $20.5 million, stockholders&#146;
equity of approximately $20.2 million, and an accumulated deficit of approximately $230.4 million. In addition, the Company has not generated
any revenues and no revenues are expected in the foreseeable future. The Company&#146;s future operations are dependent on the success
of the Company&#146;s ongoing development and commercialization efforts, as well as its ability to to secure additional financing as
needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">In
August and September of 2021, the Company closed two capital raises issuing an aggregate of 2.6 million shares of its common stock at
a price of $8.00 per share for aggregate net proceeds of approximately $18.5 million. Although the increase in the Company&#146;s cash
balance could possibly sustain operations over the next 12 months if measures are taken to delay planned expenditures in our research
protocols and slow the progress in the Company&#146;s clinical programs, the Company&#146;s current planned operations to meet certain
goals and objectives, project cash flows to be depleted within that period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. We cannot
assure you that our drug candidate will be developed, work, or receive regulatory approval; that we will ever earn revenues sufficient
to support our operations or that we will ever be profitable. Furthermore, since we have no committed source of sufficient financing,
we cannot assure that we will be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and
when we need them, we may be required to severely curtail, or even to cease, our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Although
management continues to pursue its strategic plans, there is no assurance that the Company will be successful in obtaining sufficient
financing on terms acceptable to the Company, if at all, to fund continuing operations. Management intends to attempt to secure additional
required funding primarily through additional equity or debt financings.&#160;&#160;We may also seek to secure required funding through
sales or out-licensing of intellectual property assets, seeking partnerships with other pharmaceutical companies or third parties to
co-develop and fund research and development efforts, or similar transactions.&#160;&#160;However, there can be no assurance that we
will be able to obtain required funding.&#160;&#160;If we are unsuccessful in securing funding from any of these sources, we will defer,
reduce or eliminate certain planned expenditures in our research protocols.&#160;&#160;If we do not have sufficient funds to continue
operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders losing some
or all of their investment in us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
emergence of widespread health emergencies or pandemics such as the coronavirus (&#147;COVID-19&#148;) pandemic (and its related variants),
may lead to continued regional quarantines, business shutdowns, labor shortages, disruptions to supply chains, and overall economic instability.
<span style="background-color: white">Although some jurisdictions have relaxed these measures, particularly as more and more people are
vaccinated, others have not or have reinstated them as COVID-19 cases surge and variants emerge</span> The duration and spread of the
COVID-19 pandemic and the long-term impact of COVID-19 and its variants on the financial markets and the overall economy, are highly
uncertain and cannot be predicted at this time. If the financial markets and/or the overall economy are impacted for an extended period,
the Company&#146;s ability to raise funds may be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">These
circumstances raise substantial doubt on our ability to continue as a going concern. The financial statements included in this report
do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification
of liabilities that might result from this uncertainty.</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the
Company&#146;s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources
that are material to investors. The term &#147;off-balance sheet arrangement&#148; generally means any transaction, agreement or other
contractual arrangement to which an entity unconsolidated with the Company is a party, under which the Company has (i) any obligation
arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred
to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">For
the three-month period ended September 30, 2021, there were no significant changes to the Company&#146;s critical accounting policies
as identified in the Annual Report Form 10-K for the fiscal year ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>New
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considered the applicability and impact of recent accounting pronouncements and determined those to be either not applicable
or expected to have minimal impact on our balance sheets or statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a009_v1"></span>Item
3.&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable to smaller reporting companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a010_v1"></span>Item
4.&#160;&#160;Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">We
maintain &#147;disclosure controls and procedures.&#148; Such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act
that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act
is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms,
and that such information is accumulated and communicated to our management, including our Chief Executive Office and Chief Financial
officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls
and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide
only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls
and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures,
our management necessarily was required to apply its judgement in evaluating the cost-benefit relationship of possible disclosure and
procedures. The design of and disclosure controls and procedures also are based in part upon certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future
conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Based
on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer and&#160;Chief
Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance
level, as appropriate, to allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Changes
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">There
were no changes in our internal control over financial reporting (as defined in Rule 13a-15f and 15d-15(f) under the Exchange Act) that
occurred during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting.</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a011_v1"></span>PART
II. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a012_v1"></span>Item
1. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">To
our knowledge, neither the Company nor any of its officers or directors is a party to any material legal proceeding or litigation and
such persons know of no material legal proceeding or contemplated or threatened litigation. There are no judgments against us or our
officers or directors. None of our officers or directors has been convicted of a felony or misdemeanor relating to securities or performance
in corporate office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a013_v1"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>You
may experience future dilution as a result of future equity offerings or if we issue shares subject to options, warrants, stock awards
or other arrangements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">In
order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into
or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or
other securities in any other offering at a price per share that is less than the price per share paid by investors in this offering,
and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per
share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future
transactions may be higher or lower than the price per share paid by investors in this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, as of September 30, 2021, there were warrants outstanding to purchase an aggregate of 158,761 shares of common stock at exercise
prices ranging from $1.88 to $75.00 per share, 2,121,035 shares issuable upon exercise of outstanding options at exercise prices ranging
from $2.80 to $42.09 per share, and 43,420 restricted stock units convertible to an equal amount shares. We may grant additional options,
warrants or stock awards. To the extent such shares are issued, the interest of holders of our common stock will be diluted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Moreover,
we are obligated to issue shares of common stock upon achievement of certain clinical, regulatory and commercial milestones with respect
to certain of our drug candidates (i.e., NE3107, NE3291, NE3413, NE3789) pursuant to the asset purchase agreement, dated April 27, 2021,
by and among the Company, NeurMedix, Inc. and Acuitas Group Holdings, LLC, as amended on May 9, 2021. The achievement of these milestones
could result in the issuance of up to 18 million shares of our common stock, further diluting the interest of holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a014_v1"></span>Item
2. Unregistered sales of equity securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">None&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a015_v1"></span>Item
3. Defaults Upon Senior Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a016_v1"></span>Item
4.&#160;&#160;Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a017_v1"></span>Item
5.&#160;&#160;Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
June 16, 2020, the Company amended its bylaws to increase the size of its board of directors to nine directors.</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a018_v1"></span>Item
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">(a)<b>&#160;</b>Exhibit
index</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex3z5.htm">3.5*</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 92%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex3z5.htm">Amended
    and Restated Bylaws of the Company, dated June 16, 2020</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex10z14.htm">10.14*</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex10z14.htm">Employment
    Offer &amp; Agreement Chris Reading and Company, dated June 18, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex10z15.htm">10.15*</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex10z15.htm">Employment
    Offer &amp; Agreement Clarence Ahlem and Company, dated June 18, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex10z16.htm">10.16*</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex10z16.htm">Employment
    Agreement Joanne Wendy Kim and Company, dated June 26, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex10z17.htm">10.17*</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex10z17.htm">Employment
    Agreement Jonathan Adams and Company dated, August 26, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex10z18.htm">10.18*</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex10z18.htm">Employment
    Agreement Penelope Markham and Company, dated September 7, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex10z19.htm">10.19*</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex10z19.htm">Employment
    Agreement Joseph Palumbo and Company, dated September 3, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex31z1.htm">31.1*</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex31z1.htm">Certification
    of Chief Executive Officer (Principal Executive Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange
    Act of 1934, as amended.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex31z2.htm">31.2*</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex31z2.htm">Certification
    of Chief Financial Officer (Principal Financial Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange
    Act of 1934, as amended.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex32z1.htm">32.1**</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex32z1.htm">Certifications
    of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex32z2.htm">32.2**</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210930_10qex32z2.htm">Certification
    of Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
    the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 94%"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Definition Linkbase Document</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 96%"><span style="font: 10pt Times New Roman, Times, Serif">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Furnished
    herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being
    filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings
    of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr>
  </table>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a019_v1"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>BioVie
Inc.,</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Signature</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Titles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">/s/
    Cuong V Do</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;<span style="font: 10pt Times New Roman, Times, Serif">Cuong
    V Do</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chairman
    and Chief Executive Officer (Principal Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">November
    10, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">/s/
    Joanne Wendy Kim</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;<span style="font: 10pt Times New Roman, Times, Serif">Joanne
    Wendy Kim</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer (Principal Financial and Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">November
    10, 2021</span></td></tr>
  </table>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</p></div>
    <!-- Field: /Page -->
</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>2
<FILENAME>bivi-20210930_10qex3z5.htm
<DESCRIPTION>EXHIBIT 3.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 3.5 Amended and Restated Bylaws of the Company, dated June 16, 2020</P>
<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="margin-top: auto; text-align: center; margin-bottom: auto"><IMG SRC="image_001.jpg" ALT="" STYLE="border: Black 1.5pt solid">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="margin-top: auto; text-align: center; margin-bottom: auto"><IMG SRC="image_002.jpg" ALT="" STYLE="border: Black 1.5pt solid">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
    <P STYLE="margin: 0">&nbsp;</P>
<P STYLE="margin-top: auto; text-align: center; margin-bottom: auto"><IMG SRC="image_003.jpg" ALT="" STYLE="border: Black 1.5pt solid">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
    <P STYLE="margin: 0">&nbsp;</P>
<P STYLE="margin-top: auto; text-align: center; margin-bottom: auto"><IMG SRC="image_004.jpg" ALT="" STYLE="border: Black 1.5pt solid">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
    <P STYLE="margin: 0">&nbsp;</P>
<P STYLE="margin-top: auto; text-align: center; margin-bottom: auto"><IMG SRC="image_005.jpg" ALT="" STYLE="border: Black 1.5pt solid">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
    <P STYLE="margin: 0">&nbsp;</P>
<P STYLE="margin-top: auto; text-align: center; margin-bottom: auto"><IMG SRC="image_006.jpg" ALT="" STYLE="border: Black 1.5pt solid">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
    <P STYLE="margin: 0">&nbsp;</P>
<P STYLE="margin-top: auto; text-align: center; margin-bottom: auto"><IMG SRC="image_007.jpg" ALT="" STYLE="border: Black 1.5pt solid">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
    <P STYLE="margin: 0">&nbsp;</P>
<P STYLE="margin-top: auto; text-align: center; margin-bottom: auto"><IMG SRC="image_008.jpg" ALT="" STYLE="border: Black 1.5pt solid">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>3
<FILENAME>bivi-20210930_10qex10z14.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="bf001_v1.jpg" ALT="(BIOVIE LOGO)"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
18, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dr. Chris Reading<BR>
5833 Cozzens Street<BR>
San Diego, CA 92122</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:
&#9;Offer of Employment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Chris,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIOVIE,
INC.</B>, a Nevada corporation (the &#147;<B><I>Company</I></B>&#148;) is pleased to offer you the position of <B>Executive Vice President,
Neuroscience Research &amp; Development</B> on the following terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will be responsible for efforts to advance the development of the NE3107 and the portfolio with particular emphasis on conducting the
various clinical trials and preparing NE3107 for commercial launch and overseeing the preclinical work for other assets in the portfolio.
You will report to Cuong Do and will work at our San Diego facility. Of course, the Company may change your position, duties, and work
location from time to time in its discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
the Company completes its fundraising round, your base salary will be <B>$120,000 </B>on an annualized basis, less payroll deductions
and withholdings, paid bi-weekly on the Company&#146;s normal payroll schedule. Upon completion of the fundraising, your annualized
salary will increase to <B>$240,000</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will receive a $500,000 retention bonus that increases by $10,000 per month for the period of time between your start date and the time
your monthly salary increases to the $240,000 annualized rate. This retention bonus will become payable when the Company completes its
fundraise and will be payable over the subsequent 24 months. Should you separate from the company before the bonus is fully paid, the
monthly payout will be reduced by one-half and continue until the full amount has been paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will also be eligible to earn an annual discretionary performance bonus that will be determined by the Company&#146;s CEO and the Board&#146;s
Compensation Committee. The amount of this bonus will be determined in the sole discretion of the Company and based, in part, on your
performance and the performance of the Company during the calendar year. The Company will pay you this bonus, if any, by no later than
March 15th of the following calendar year. The bonus is not earned until paid and no pro-rated amount will be paid if your employment
terminates for any reason prior to the payment date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &#9679; Santa Monica, CA 90404</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
your employment, you will be eligible to participate in the standard benefits plans offered to similarly situated employees by the Company
from time to time, subject to plan terms and generally applicable Company policies. Currently, the Company is pleased to offer an enhanced
benefits program. You will have a range of options to choose from for medical, dental and vision coverage. The Company will cover 80%
of the lowest cost plan, and you can pay for the difference between the company-supported amount and the actual cost of the plan you
select. The company will also provide Basic Life &amp; AD&amp;D coverage of 2X your basic salary. A full description of these benefits
is available upon request. You will also qualify to participate in the 401(k) plan, which matches your contributions dollar-for-dollar
up to five percent (5%) of your salary. Exempt employees may take a reasonable amount of time off with pay, as permitted by their duties
and responsibilities, and as approved in advance by their supervisor. As such, you will qualify for three (3) weeks of paid vacation
leave annually (prorated in the first calendar year of employment) plus any approved company holidays. The Company may change compensation
and benefits from time to time in its discretion. Additionally, you will be entitled to paid sick leave as provided by applicable state
law and/or local ordinance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to approval by the Company&#146;s Board of Directors (the &#147;<B><I>Board</I></B>&#148;), the Company anticipates granting you options
to purchase the Company&#146;s common stock at the fair market value as determined by the Board as of the date of grant (the &#147;<B><I>Option</I></B>&#148;)
when the Company has completed its fundraise and a compensation study has been conducted to determine market practices for such grants.
The anticipated Option will be governed by the terms and conditions of the Company&#146;s Inc. 2019 Omnibus Equity Incentive Plan (the
&#147;<B><I>Plan</I></B>&#148;) and your grant agreement, and will vest over five (<B>5</B>) year schedule, subject to your Continuous
Service (as defined in the Plan) as of each such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Company employee, you will be expected to abide by all Company rules and policies. As a condition of employment, you must sign and
comply with the attached Employee Confidential Information and Inventions Assignment Agreement which prohibits unauthorized use or disclosure
of the Company&#146;s proprietary information, among other obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any
former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information
which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry
or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring
onto Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation
of confidentiality. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities
on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Normal
business hours are from 9:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to work additional
hours as required by the nature of your work assignments.</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
employment with the Company will be &#147;at-will.&#148; You may terminate your employment with the Company at any time and for any
reason whatsoever simply by notifying the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Likewise,
the Company may terminate your employment at any time, with or without cause or advance notice. Your employment at-will status can only
be modified in a written agreement signed by you and by an officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer is contingent upon a reference check and satisfactory proof of your right to work in the United States. You agree to assist as
needed and to complete any documentation at the Company&#146;s request to meet these conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, and in exchange
for the mutual promises contained in this Agreement and the sign-on bonus you and the Company agree to arbitrate all disputes relating
to your employment with the Company, the parties agree to arbitration administered by JAMS pursuant to its Employment Arbitration Rules
&amp; Procedures and subject to JAMS Policy on Employment Arbitration Minimum Standards of Procedural Fairness. This mutual agreement
to arbitrate is set forth more fully in the enclosed Mutual Agreement to Arbitrate EmploymentRelated Disputes (&#147;Arbitration Agreement&#148;),
the execution of which is a condition of your employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer letter, together with your Employee Confidential Information and Inventions Assignment Agreement and the Arbitration Agreement,
forms the complete and exclusive statement of your employment agreement with the Company. It supersedes any other agreements or promises
made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes expressly reserved to the
Company&#146;s discretion in this letter, require a written modification signed by an officer of the Company. If any provision of this
offer letter agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other
provision of this offer letter agreement and the provision in question shall be modified so as to be rendered enforceable in a manner
consistent with the intent of the parties insofar as possible under applicable law. This letter may be delivered via facsimile, electronic
mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act
or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and be valid and effective
for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
sign and date this letter, and the enclosed Employee Confidential Information and Inventions Assignment Agreement and return them to
me by June 25, 2021 if you wish to accept employment at the Company under the terms described above. If you accept our offer, we
would like you to start on July 1, 2021.</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
look forward to your favorable reply and to a productive and enjoyable work relationship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="bf002_v1.jpg" ALT="(SIGNATURE)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 65%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cuong
    Do</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
CONTRACT CONTAINS A BINDING ARBITRATION PROVISION WHICH MAY BE ENFORCED BY THE PARTIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Understood
and Accepted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    Reading</FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enclosures</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIAL
INFORMATION AND INVENTION ASSIGNMENT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of my employment with <FONT STYLE="font-variant: small-caps"><B>BioVie Inc.</B></FONT>, its subsidiaries, parents, affiliates,
successors and assigns (together &#147;<B><I>Company</I></B>&#148;), and the compensation paid to me now and during my employment with
Company, and the Company&#146;s agreement to provide me with access to its Confidential Information (as defined below), I hereby enter
into this Confidential Information and Invention Assignment Agreement (the &#147;<B><I>Agreement</I></B>&#148;) and agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
Information Protections</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 17.3pt; text-align: justify">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recognition
of Company&#146;s Rights; Nondisclosure</B>. I understand and acknowledge that my employment with Company creates a relationship of
confidence and trust with respect to Company&#146;s Confidential Information (as defined below) and that Company has a protectable interest
therein. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or publish
any of Company&#146;s Confidential Information, except as such disclosure, use or publication may be required in connection with my
work for Company, or unless an officer of Company expressly authorizes such disclosure. I will obtain Company&#146;s written approval
before publishing or submitting for publication any material (written, oral, or otherwise) that discloses and/or incorporates any Confidential
Information. I hereby assign to Company any rights I may have or acquire in such Confidential Information and recognize that all Confidential
Information will be the sole and exclusive property of Company and its assigns. I will take all reasonable precautions to prevent the
inadvertent accidental disclosure of Confidential Information. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b),
I will not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that:
(1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely
for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in
a lawsuit or other proceeding, if such filing is made under seal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential
Information</B>. The term &#147;<B><I>Confidential Information</I></B>&#148; means any and all confidential knowledge, data or information
of Company. By way of illustration but not limitation, &#147;<B><I>Confidential Information</I></B>&#148; includes (a) trade secrets,
inventions, mask works, ideas, processes, formulas, software in source or object code, data, programs, other works of authorship, know-how,
improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights
(as defined below) therein (collectively, &#147;<B><I>Inventions</I></B>&#148;); (b) information regarding research, development, new
products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts,
credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential
strategies, financial projections and business strategies, operational plans, financing and capital-raising plans, activities and agreements,
internal services and operational manuals, methods of conducting Company business, suppliers and supplier information, and purchasing;
(c) information regarding customers and potential customers of Company, including customer lists, names, representatives, their needs
or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties,
the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and
other non-public information relating to customers and potential customers; (d) information regarding any of Company&#146;s business
partners and their services, including names, representatives, proposals, bids, contracts and their contents and parties, the type and
quantity of products and services received by Company, and other non-public information relating to business partners; (e) information
regarding personnel, employee lists, compensation, and employee skills; and (f) any other non-public information which a competitor of
Company could use to the competitive disadvantage of Company. Notwithstanding the foregoing, it is understood that, at all such times,
I am free to use information which was known to me prior to my employment with Company or which is generally known in the trade or industry
through no breach of this Agreement or other act or omission by me. Notwithstanding the foregoing or anything to the contrary in this
Agreement or any other agreement between the Company and me, nothing in this Agreement will limit my right to discuss my employment or
report possible violations of law or regulation with the Equal Employment Opportunity Commission, United States Department of Labor,
the National Labor Relations Board, the Securities and Exchange Commission, or other federal government agency or similar state or local
agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National
Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including
but not limited to &#147;whistleblower&#148; statutes or other similar provisions that protect such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &#9679; Santa Monica, CA 90404</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third
Party Information</B>. I understand, in addition, that Company has received and in the future will receive from third parties their confidential
and/or proprietary knowledge, data or information (<B>&#147;<I>Third Party Information</I>&#148;</B>) subject to a duty on Company&#146;s
part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment
and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need
to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party
Information or unless expressly authorized by an officer of Company in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term
of Nondisclosure Restrictions</B>. I understand that Confidential Information and Third Party Information is never to be used or disclosed
by me, as provided in this Section 1. If a temporal limitation on my obligation not to use or disclose such information is required under
applicable law, and the Agreement or its restriction(s) cannot otherwise be enforced, I agree and Company agrees that the two year period
after the date my employment ends will be the temporal limitation relevant to the contested restriction; <B><I>provided, however</I>,
</B>that this sentence will not apply to trade secrets protected without temporal limitation under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Improper Use of Information of Prior Employers and Others</B>. During my employment with the Company, I will not improperly use or disclose
confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality,
and I will not bring onto the premises of Company any unpublished documents or any property belonging to any former employer or any other
person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignments
of Inventions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions</B>.
As used in this Agreement, the term <B>&#147;<I>Intellectual Property Rights</I>&#148;</B> means all trade secrets, Copyrights, trademarks,
mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country; the term &#147;<B><I>Copyright</I></B>&#148;
means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary,
musical, or artistic work) recognized by the laws of any jurisdiction or country; and the term &#147;<B><I>Moral Rights</I></B>&#148;
means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction
or country.</FONT></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Excluded
Inventions and Other Inventions</B>. Attached hereto as <B>Exhibit A</B> is a list describing all existing Inventions, if any, (a) that
are owned by me or in which I have an interest and were made or acquired by me prior to my date of first employment with the Company,
(b) that may relate to Company&#146;s business or actual or demonstrably anticipated research or development, and (c) that are not to
be assigned to Company (&#147;<B><I>Excluded Inventions</I></B>&#148;). If no such list is attached, I represent and agree that it
is because I have no Excluded Inventions. For purposes of this Agreement, &#147;<B><I>Other Inventions</I></B>&#148; means Inventions
in which I have or may have an interest, as of the commencement of my employment or thereafter, other than Company Inventions (as defined
below) and Excluded Inventions. I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of
my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any
Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any
rights assigned to Company under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise
in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not
I give Company notice as required above), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide
license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly
perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer
for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any
third parties have rights in any such Other Inventions, I hereby represent and warrant that such third party or parties have validly
and irrevocably granted to me the right to grant the license stated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment
of Company Inventions</B>. Inventions assigned to Company or to a third party as directed by Company pursuant to Section 2.6 are referred
to in this Agreement as &#147;<B><I>Company Inventions</I></B>.&#148; Subject to Section 2.4 and except for Excluded Inventions set
forth in <B>Exhibit A</B> and Other Inventions, I hereby assign to Company all my right, title, and interest in and to any and all Inventions
(and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with
others, during the period of my employment with the Company. To the extent required by applicable Copyright laws, I agree to assign in
the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such
Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment
of all Moral Rights. To the extent such Moral Rights cannot be assigned to Company and to the extent the following is allowed by the
laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and
all claims and causes of action of any kind against Company or related to Company&#146;s customers, with respect to such rights. I further
acknowledge and agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions (and any
Intellectual Property Rights with respect thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unassigned
or Nonassignable Inventions</B>. I recognize that this Agreement will not be deemed to require assignment of any Invention that I developed
entirely on my own time without using the Company&#146;s equipment, supplies, facilities, trade secrets, or Confidential Information,
except for those Inventions that either (i) relate to the Company&#146;s actual or anticipated business, research or development, or
(ii) result from or are connected with work performed by me for the Company. In addition, this Agreement does not apply to any Invention
which qualifies fully for protection from assignment to the Company under any specifically applicable state law, regulation, rule or
public policy (&#147;<B><I>Specific Inventions Law</I></B>&#148;).</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obligation
to Keep Company Informed</B>. During the period of my employment, I will promptly and fully disclose to Company in writing all Inventions
authored, conceived, or reduced to practice by me, either alone or jointly with others. At the time of each such disclosure, I will advise
Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the Specific Inventions Law;
and I will at that time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep in confidence
and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to
Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the Specific Inventions Law. I will
preserve the confidentiality of any Invention that does not fully qualify for protection under the Specific Inventions Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government
or Third Party</B>. I agree that, as directed by Company, I will assign to a third party, including without limitation the United States,
all my right, title, and interest in and to any particular Company Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership
of Work Product</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 51.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment
and which are protectable by Copyright are &#147;works made for hire,&#148; pursuant to United States Copyright Act (17 U.S.C., Section
101).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 51.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that Company will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment,
and I hereby irrevocably and unconditionally assign to Company all right, title, and interest worldwide in and to such work product.
I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected
by this Section, except as necessary to perform services for Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement
of Intellectual Property Rights and Assistance</B>. I will assist Company in every proper way to obtain, and from time to time enforce,
United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries. To that
end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may
reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights
and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Company
or its designee, including the United States or any third party designated by Company. My obligation to assist Company with respect to
Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my
employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company&#146;s
request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document
needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized
officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and on my behalf to execute,
verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with
the same legal force and effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever,
which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporation
of Software Code</B>. I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code
licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions
the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company <B>except
</B>in strict compliance with Company&#146;s policies regarding the use of such software.</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Records</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that
is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my
employment at Company, which records will be available to and remain the sole property of Company at all times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duty
of Loyalty During Employment</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. I agree that during the period of my
employment with Company, I will not, without Company&#146;s express written consent, directly or indirectly engage in any employment
or business activity which is directly or indirectly competitive with, or would otherwise conflict with, my employment with Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonableness
of Restrictions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that I have read this entire Agreement and understand it. I acknowledge that I have the right to consult with counsel prior to
signing this Agreement. I further acknowledge that I will derive significant value from the Company&#146;s agreement to provide me with
Company Confidential Information to enable me to optimize the performance of my duties to the Company. I further acknowledge that my
fulfillment of the obligations contained in this Agreement, including, but not limited to, my obligation neither to disclose nor to use
Company Confidential Information other than for the Company&#146;s exclusive benefit and my obligations not to solicit are necessary
to protect Company Confidential Information and, consequently, to preserve the value and goodwill of the Company. I agree that this Agreement
does not prevent me from earning a living or pursuing my career. I agree that the restrictions contained in this Agreement are reasonable,
proper, and necessitated by Company&#146;s legitimate business interests. I represent and agree that I am entering into this Agreement
freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>In
the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, I and Company agree
that the court will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum
extent allowed by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Conflicting Agreement or Obligation</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>I represent that my performance of all the terms of this Agreement and as an intern of Company does not and will not breach any
agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment with Company. I have not
entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
of Company Property</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. When I leave the employ of Company, I will deliver
to Company any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof,
and any other material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company.
I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return
it to Company. In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit
any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer-useable copy
of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems; and I
agree to provide Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed.
I further agree that any property situated on Company&#146;s premises and owned by Company, including disks and other storage media,
filing cabinets or other work areas, is subject to inspection by Company&#146;s personnel at any time with or without notice. Prior
to leaving, I will cooperate with Company in attending an exit interview and completing and signing Company&#146;s termination statement
if required to do so by Company.</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
and Equitable Remedies</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree that any
threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company, and
Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable
relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that if Company is successful in whole or in part in any legal or equitable action against me under this Agreement, Company will
be entitled to payment of all costs, including reasonable attorney&#146;s fees, from me.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice
is given, labeled &#147;Attention Chief Executive Officer,&#148; and to me at my address as listed on Company payroll, or at such other
address as Company or I may designate by written notice to the other. Notice will be effective upon receipt or refusal of delivery. If
delivered by certified or registered mail, notice will be considered to have been given five business days after it was mailed, as evidenced
by the postmark. If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected
by the courier or express mail service receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
of This Agreement to Subsequent Employer or Business Associates of Intern</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.1&nbsp;&nbsp;&nbsp;&nbsp;</B>If
I am offered employment or the opportunity to enter into any business venture as owner, partner, consultant or other capacity while the
restrictions described in Section <B>Error! Reference source not found.</B> of this Agreement are in effect I agree to inform my potential
employer, partner, co-owner and/or others involved in managing the business with which I have an opportunity to be associated of my obligations
under this Agreement and also agree to provide such person or persons with a copy of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
Provisions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.1&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law; Consent to Personal Jurisdiction</B>. This Agreement will be governed by and construed according to the laws of the State of California
as such laws are applied to agreements entered into and to be performed entirely within California between residents of California. I
hereby expressly consent to the personal jurisdiction and venue of the state and federal courts located in California for any lawsuit
filed there against me by Company arising from or related to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2&nbsp;&nbsp;&nbsp;&nbsp;Severability</B>.
In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions
of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained
in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively
broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable
to the extent compatible with the applicable law as it will then appear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3&nbsp;&nbsp;&nbsp;&nbsp;Successors
and Assigns</B>. This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, subsidiaries,
affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival</B>.
This Agreement will survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company
to any successor in interest or other assignee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At-Will
Status</B>. I agree and understand that nothing in this Agreement will change my at-will status or confer any right with respect to continuation
of my employment with Company, nor will it interfere in any way with my right or Company&#146;s right to terminate my employment at
any time, with or without cause or advance notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waiver</B>.
No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach. No waiver by Company of
any right under this Agreement will be construed as a waiver of any other right. Company will not be required to give notice to enforce
strict adherence to all terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Export</B>.
I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing
such data, in violation of the United States export laws or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts</B>.
This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will
constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission
method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advice
of Counsel</B>. <B>I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL
COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT WILL NOT BE CONSTRUED AGAINST
ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire
Agreement</B>. The obligations pursuant to Sections 1 and 2 (except Subsection 2.4 and Subsection 2.7(a)) of this Agreement will apply
to any time during which I was previously engaged, or am in the future engaged, by Company as a consultant if no other agreement governs
nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties
with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us<B>.</B> No modification
of or amendment to this Agreement will be effective unless in writing and signed by the party to be charged. Any subsequent change or
changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[signatures
to follow on next page]</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement will be effective as of July 1, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; width: 40%; font-weight: bold; text-align: justify; text-indent: 0">Employee:</TD>
    <TD STYLE="padding: 0; width: 60%; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-weight: bold; text-align: left; text-indent: 0">I have read this agreement carefully and understand its terms.&nbsp;&nbsp;I have completely filled out Exhibit&nbsp;A to this Agreement.</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(Signature)</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Name</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Date</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-bottom: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accepted
    and agreed</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cuong
    Do<BR>
    President &amp; Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Excluded
Inventions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FROM:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATE:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: -0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Excluded
Inventions Disclosure</B>. Except as listed in Section 2 below, the following is a complete list of all Excluded Inventions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Excluded Inventions.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
below:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.6in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
sheets attached.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Due
to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to the Excluded Inventions
generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; width: 0.3in; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 25%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Excluded
    Invention</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 40%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Party(ies)</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 25%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Relationship</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
sheets attached.</FONT></TD>
</TR></TABLE>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioVie
Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Mutual
Agreement to Arbitrate Employment-Related Disputes</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Mutual Agreement to Arbitrate Disputes (&#147;<B>Agreement</B>&#148;) is made and entered into as of July 1, 2021 (the &#147;<B>Effective
Date</B>&#148;) by and between BioVie, Inc., a Nevada corporation, (the &#147;<B>Employer</B>&#148;) and Chris Reading, an individual
(the &#147;<B>Employee</B>&#148;) (the Employer and the Employee are collectively referred to herein as the &#147;<B>Parties</B>&#148;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Intent
of Agreement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. It is the intent of Employee
and the Employer that this Agreement will govern the resolution of all disputes, claims and any other matters in question arising out
of or relating to the Parties&#146; employment relationship. The Parties shall resolve all disputes arising out of the employment relationship
in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Mandatory
Arbitration</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Employer and Employee agree
that any claim, complaint, or dispute that relates in any way to the Parties&#146; employment relationship, whether based in contract, tort,
statute, fraud, misrepresentation or any other legal theory, shall be submitted to final, binding and confidential arbitration conducted
by JAMS or its successor, under JAMS&#146; then applicable rules and procedures for employment disputes (available upon request and
also currently available at <U>http://www.jamsadr.com/rules-employment-arbitration/</U>). You can also call JAMS at (213) 620-0100 if
you have questions about the arbitration process. If the JAMS Employment Arbitration Rules are inconsistent with the terms of this Agreement,
the terms of this Agreement shall govern, except as otherwise required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Covered
Claims</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement to arbitrate covers
all grievances, disputes, claims, or causes of action (collectively, &#147;<B>claims</B>&#148;) in a federal, state or local court or
agency under applicable federal, state or local laws, arising out of Employee&#146;s employment with the Employer and the termination thereof,
including claims Employee may have against the Employer or against its officers, directors, supervisors, managers, employees, or agents
in their capacity as such or otherwise, or that the Employer may have against Employee. The claims covered by this Agreement include,
but are not limited to, claims for breach of any contract or covenant (express or implied), tort claims, claims for wrongful termination
(constructive or actual) in violation of public policy, claims for discrimination or harassment (including, but not limited to, harassment
or discrimination based on race, sex, gender, religion, national origin, age, marital status, medical condition, psychological condition,
mental condition, disability, or sexual orientation), claims for violation of any federal, state, or other governmental law, statute,
regulation, or ordinance, including, but not limited to, all claims arising under Title VII of the Civil Rights Act, the Age Discrimination
in Employment Act, the Americans With Disabilities Act, the California Fair Employment and Housing Act, the Consolidated Omnibus Budget
Reconciliation Act of 1985, and Employee Retirement Income Security Act. The parties to this Agreement specifically agree that all claims
under the California Labor Code, including, but not limited to, claims for overtime, unpaid wages, and claims involving meal and rest
breaks shall be subject to this Arbitration Agreement. (&#147;<B>Covered Claims</B>&#148;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Claims
Not Covered</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Claims not covered by this Agreement
are claims for workers&#146; compensation, unemployment compensation benefits, administrative charges for unfair labor practices brought before
the National Labor Relations Board, Excluded Claims (defined in Paragraph 5 below), or any other claims that, as a matter of law, the
Parties cannot agree to arbitrate. Nothing in this Agreement shall be interpreted to mean that employees are precluded from filing complaints
with the California Department of Fair Employment and Housing and/or federal Equal Employment Opportunity Commission and National Labor
Relations Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &#9679; Santa Monica, CA 90404</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Waiver
of Class Action and Representative Action Claims</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Waiver of Class Action and Representative Action Claims. Except for representative claims which cannot be waived under applicable law
and which are therefore excluded from this Agreement (&#147;Excluded Claims&#148;), Employee and the Company expressly intend and agree
that: (a) class action and representative action procedures are hereby waived and shall not be asserted, nor will they apply, in any
arbitration pursuant to this Agreement; (b) each will not assert class action or representative action claims against the other in arbitration
or otherwise; and (c) Employee and the Company shall only submit their own, individual claims in arbitration and will not seek to represent
the interests of any other person. To the extent that the Parties&#146; dispute involves both timely filed Excluded Claims and claims subject
to this Agreement, the Parties agree to bifurcate and stay for the duration of the arbitration proceedings any such Excluded Claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Waiver
of Trial by Jury</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Parties understand
and fully agree that by entering into this Agreement to arbitrate, they are giving up their constitutional right to have a trial by jury,
and are giving up their normal rights of appeal following the rendering of a decision except as California law provides for judicial
review of arbitration proceedings. The Parties anticipate that by entering into this Agreement, they will gain the benefits of a speedy
and less expensive dispute resolution procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Claims
Procedure</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Arbitration shall be initiated
upon the express written notice of either party. The aggrieved party must give written notice of any claim to the other party. Written
notice of an Employee&#146;s claim shall be mailed by certified or registered mail, return receipt requested, to the Employer&#146;s General Counsel
or Chief Executive Officer at 2120 Colorado Avenue, Suite 230 &#9679; Santa Monica, CA 90404 (&#147;<B>Notice Address</B>&#148;). Written
notice of the Employer&#146;s claim will be mailed to the last known address of Employee. The written notice shall identify and describe the
nature of all claims asserted and the facts upon which such claims are based. Written notice of arbitration shall be initiated within
the same time limitations that California law applies to those claim(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Arbitrator
Selection</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Arbitrator shall be selected
as provided in JAMS&#146; Rules and Procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Discovery</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The JAMS Employment Arbitration Rules regarding discovery shall apply to arbitration under this Agreement. The Arbitrator selected according
to this Agreement shall decide all discovery disputes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Substantive
Law</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Arbitrator shall apply the substantive
state or federal law (and the law of remedies, if applicable) as applicable to the claim(s) asserted. The Arbitrator shall conduct and
preside over an arbitration hearing of reasonable length, to be determined by the Arbitrator. The Arbitrator shall provide the Parties
with a written decision explaining his or her findings and conclusions. The Arbitrator&#146;s decision shall be final and binding upon the
Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Motions</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Arbitrator shall have jurisdiction to hear and rule on prehearing disputes and is authorized to hold prehearing conferences by telephone
or in person as the Arbitrator deems necessary. The Arbitrator shall have the authority to set deadlines for completion of discovery,
and for filing motions for summary judgment, and to set briefing schedules for any motions. The Arbitrator shall have the authority to
adjudicate any cause of action, or the entire claim, pursuant to a motion for summary adjudication and/or summary judgment, and, in deciding
such motions, shall apply the law of the State of California.</FONT></P>


<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Compelling
Arbitration/Enforcing Award</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Either party
may bring an action in court to compel arbitration under this Agreement or to otherwise determine the arbitrability of claims under this
Agreement, and to confirm, vacate or enforce an arbitration award, and each party shall bear its own attorney fees and costs and other
expenses of such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Arbitration
Fees and Costs</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Employer shall be responsible
for the arbitrator&#146;s fees and expenses. Each party shall pay its own costs and attorneys&#146; fees, if any. However, if any party prevails
on a statutory claim which affords the prevailing party attorneys&#146; fees and costs, or if there is a written agreement providing for attorneys&#146;
fees and costs, the Arbitrator may award reasonable attorneys&#146; fees and costs to the prevailing party. Any dispute as to the reasonableness
of any fee or cost shall be resolved by the Arbitrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Term
of Agreement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement to arbitrate
shall survive the termination of Employee&#146;s employment. It can only be revoked or modified in writing signed by both Parties that specifically
states an intent to revoke or modify this Agreement and is signed by the Employer&#146;s General Counsel or an authorized executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Severability</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
If any provision of this Agreement to arbitrate is adjudged to be void or otherwise unenforceable, in whole or in part, the void or unenforceable
provision shall be severed and such adjudication shall not affect the validity of the remainder of this Agreement to arbitrate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Voluntary
Agreement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. By executing this Agreement the
Parties represent that they have been given the opportunity to fully review, comprehend and negotiate the terms of this Agreement. The
Parties understand the terms of this Agreement and freely and voluntarily sign this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the Parties have executed this Agreement as of the Effective Date above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">BioVie Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Cuong Do</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: President &amp; Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EMPLOYEE</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 29%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
Chris Reading</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>4
<FILENAME>bivi-20210930_10qex10z15.htm
<DESCRIPTION>EXHIBIT 10.15
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="bf001_v1.jpg" ALT="(LOGO)"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
17, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Clarence Ahlem&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5305
Renaissance Ave&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San
Diego, CA 92122</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
&#9;Offer of Employment</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Clarence,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIOVIE,
INC.</B>, a Nevada corporation (the &#147;<B><I>Company</I></B>&#148;) is pleased to offer you the position of <B>Executive Vice President,
Product Development</B> on the following terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will be responsible for efforts to advance the development of the NE3107 and the portfolio with particular emphasis on launching the
Parkinson&#146;s clinical program, ensuring drug supply, and scaling up manufacturing to support clinical trials and preparing for commercial
launch. You will report to Cuong Do will work at our San Diego facility. Of course, the Company may change your position, duties, and
work location from time to time in its discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
the Company completes its fundraising round, your base salary will be <B>$120,000 </B>on an annualized basis, less payroll deductions
and withholdings, paid bi-weekly on the Company&#146;s normal payroll schedule. Upon completion of the fundraising, your annualized
salary will increase to <B>$240,000</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will receive a $500,000 retention bonus that increases by $10,000 per month for the period of time between your start date and the time
your monthly salary increases to the $240,000 annualized rate. This retention bonus will become payable when the Company completes its
fundraise and will be payable over the subsequent 24 months. Should you separate from the company before the bonus is fully paid, the
monthly payout will be reduced by one-half and continue until the full amount has been paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will also be eligible to earn an annual discretionary performance bonus that will be determined by the Company&#146;s CEO and the Board&#146;s
Compensation Committee. The amount of this bonus will be determined in the sole discretion of the Company and based, in part, on your
performance and the performance of the Company during the calendar year. The Company will pay you this bonus, if any, by no later than
March 15th of the following calendar year. The bonus is not earned until paid and no pro-rated amount will be paid if your employment
terminates for any reason prior to the payment date.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &bull; Santa Monica, CA 90404</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
your employment, you will be eligible to participate in the standard benefits plans offered to similarly situated employees by the Company
from time to time, subject to plan terms and generally applicable Company policies. Currently, the Company is pleased to offer an enhanced
benefits program. You will have a range of options to choose from for medical, dental and vision coverage. The Company will cover 80%
of the lowest cost plan, and you can pay for the difference between the company-supported amount and the actual cost of the plan you
select. The company will also provide Basic Life &amp; AD&amp;D coverage of 2X your basic salary. A full description of these benefits
is available upon request. You will also qualify to participate in the 401(k) plan, which matches your contributions dollar-for-dollar
up to five percent (5%) of your salary. Exempt employees may take a reasonable amount of time off with pay, as permitted by their duties
and responsibilities, and as approved in advance by their supervisor. As such, you will qualify for three (3) weeks of paid vacation
leave annually (prorated in the first calendar year of employment) plus any approved company holidays. The Company may change compensation
and benefits from time to time in its discretion. Additionally, you will be entitled to paid sick leave as provided by applicable state
law and/or local ordinance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to approval by the Company&#146;s Board of Directors (the &#147;<B><I>Board</I></B>&#148;), the Company anticipates granting you options
to purchase the Company&#146;s common stock at the fair market value as determined by the Board as of the date of grant (the &#147;<B><I>Option</I></B>&#148;)
when the Company has completed its fundraise and a compensation study has been conducted to determine market practices for such grants.
The anticipated Option will be governed by the terms and conditions of the Company&#146;s Inc. 2019 Omnibus Equity Incentive Plan (the
&#147;<B><I>Plan</I></B>&#148;) and your grant agreement, and will vest over five (<B>5</B>) year schedule, subject to your Continuous
Service (as defined in the Plan) as of each such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Company employee, you will be expected to abide by all Company rules and policies. As a condition of employment, you must sign and
comply with the attached Employee Confidential Information and Inventions Assignment Agreement which prohibits unauthorized use or disclosure
of the Company&#146;s proprietary information, among other obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any
former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information
which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry
or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring
onto Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation
of confidentiality. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities
on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Normal
business hours are from 9:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to work additional
hours as required by the nature of your work assignments.</FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
employment with the Company will be &#147;at-will.&#148; You may terminate your employment with the Company at any time and for any
reason whatsoever simply by notifying the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Likewise,
the Company may terminate your employment at any time, with or without cause or advance notice. Your employment at-will status can only
be modified in a written agreement signed by you and by an officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer is contingent upon a reference check and satisfactory proof of your right to work in the United States. You agree to assist as
needed and to complete any documentation at the Company&#146;s request to meet these conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, and in exchange
for the mutual promises contained in this Agreement and the sign-on bonus you and the Company agree to arbitrate all disputes relating
to your employment with the Company, the parties agree to arbitration administered by JAMS pursuant to its Employment Arbitration Rules
&amp; Procedures and subject to JAMS Policy on Employment Arbitration Minimum Standards of Procedural Fairness. This mutual agreement
to arbitrate is set forth more fully in the enclosed Mutual Agreement to Arbitrate Employment Related Disputes (&#147;Arbitration Agreement&#148;),
the execution of which is a condition of your employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer letter, together with your Employee Confidential Information and Inventions Assignment Agreement and the Arbitration Agreement,
forms the complete and exclusive statement of your employment agreement with the Company. It supersedes any other agreements or promises
made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes expressly reserved to the
Company&#146;s discretion in this letter, require a written modification signed by an officer of the Company. If any provision of this
offer letter agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other
provision of this offer letter agreement and the provision in question shall be modified so as to be rendered enforceable in a manner
consistent with the intent of the parties insofar as possible under applicable law. This letter may be delivered via facsimile, electronic
mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act
or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and be valid and effective
for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
sign and date this letter, and the enclosed Employee Confidential Information and Inventions Assignment Agreement and return them to
me by June 25, 2021 if you wish to accept employment at the Company under the terms described above. If you accept our offer, we
would like you to start on July 1, 2021.</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
look forward to your favorable reply and to a productive and enjoyable work relationship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cuong
    Do</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">THIS
CONTRACT CONTAINS A BINDING ARBITRATION PROVISION WHICH MAY BE ENFORCED BY THE PARTIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.9pt; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Understood
and Accepted:&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clarence
    Ahlem</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date<FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.9pt; text-indent: 34.6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.9pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enclosures&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIAL
INFORMATION AND INVENTION ASSIGNMENT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of my employment with <FONT STYLE="font-variant: small-caps"><B>BioVie Inc.</B></FONT>, its subsidiaries, parents, affiliates,
successors and assigns (together &#147;<B><I>Company</I></B>&#148;), and the compensation paid to me now and during my employment with
Company, and the Company&#146;s agreement to provide me with access to its Confidential Information (as defined below), I hereby enter
into this Confidential Information and Invention Assignment Agreement (the &#147;<B><I>Agreement</I></B>&#148;) and agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
Information Protections</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 17.3pt; text-align: justify">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recognition
of Company&#146;s Rights; Nondisclosure</B>. I understand and acknowledge that my employment with Company creates a relationship of
confidence and trust with respect to Company&#146;s Confidential Information (as defined below) and that Company has a protectable interest
therein. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or publish
any of Company&#146;s Confidential Information, except as such disclosure, use or publication may be required in connection with my
work for Company, or unless an officer of Company expressly authorizes such disclosure. I will obtain Company&#146;s written approval
before publishing or submitting for publication any material (written, oral, or otherwise) that discloses and/or incorporates any Confidential
Information. I hereby assign to Company any rights I may have or acquire in such Confidential Information and recognize that all Confidential
Information will be the sole and exclusive property of Company and its assigns. I will take all reasonable precautions to prevent the
inadvertent accidental disclosure of Confidential Information. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b),
I will not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that:
(1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely
for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in
a lawsuit or other proceeding, if such filing is made under seal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential
Information</B>. The term &#147;<B><I>Confidential Information</I></B>&#148; means any and all confidential knowledge, data or information
of Company. By way of illustration but not limitation, &#147;<B><I>Confidential Information</I></B>&#148; includes (a) trade secrets,
inventions, mask works, ideas, processes, formulas, software in source or object code, data, programs, other works of authorship, know-how,
improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights
(as defined below) therein (collectively, &#147;<B><I>Inventions</I></B>&#148;); (b) information regarding research, development, new
products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts,
credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential
strategies, financial projections and business strategies, operational plans, financing and capital-raising plans, activities and agreements,
internal services and operational manuals, methods of conducting Company business, suppliers and supplier information, and purchasing;
(c) information regarding customers and potential customers of Company, including customer lists, names, representatives, their needs
or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties,
the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and
other non-public information relating to customers and potential customers; (d) information regarding any of Company&#146;s business
partners and their services, including names, representatives, proposals, bids, contracts and their contents and parties, the type and
quantity of products and services received by Company, and other non-public information relating to business partners; (e) information
regarding personnel, employee lists, compensation, and employee skills; and (f) any other non-public information which a competitor of
Company could use to the competitive disadvantage of Company. Notwithstanding the foregoing, it is understood that, at all such times,
I am free to use information which was known to me prior to my employment with Company or which is generally known in the trade or industry
through no breach of this Agreement or other act or omission by me. Notwithstanding the foregoing or anything to the contrary in this
Agreement or any other agreement between the Company and me, nothing in this Agreement will limit my right to discuss my employment or
report possible violations of law or regulation with the Equal Employment Opportunity Commission, United States Department of Labor,
the National Labor Relations Board, the Securities and Exchange Commission, or other federal government agency or similar state or local
agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National
Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including
but not limited to &#147;whistleblower&#148; statutes or other similar provisions that protect such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &#9679; Santa Monica, CA 90404</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third
Party Information</B>. I understand, in addition, that Company has received and in the future will receive from third parties their confidential
and/or proprietary knowledge, data or information (<B>&#147;<I>Third Party Information</I>&#148;</B>) subject to a duty on Company&#146;s
part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment
and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need
to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party
Information or unless expressly authorized by an officer of Company in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term
of Nondisclosure Restrictions</B>. I understand that Confidential Information and Third Party Information is never to be used or disclosed
by me, as provided in this Section 1. If a temporal limitation on my obligation not to use or disclose such information is required under
applicable law, and the Agreement or its restriction(s) cannot otherwise be enforced, I agree and Company agrees that the two year period
after the date my employment ends will be the temporal limitation relevant to the contested restriction; <B><I>provided, however</I>,
</B>that this sentence will not apply to trade secrets protected without temporal limitation under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Improper Use of Information of Prior Employers and Others</B>. During my employment with the Company, I will not improperly use or disclose
confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality,
and I will not bring onto the premises of Company any unpublished documents or any property belonging to any former employer or any other
person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignments
of Inventions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions</B>.
As used in this Agreement, the term <B>&#147;<I>Intellectual Property Rights</I>&#148;</B> means all trade secrets, Copyrights, trademarks,
mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country; the term &#147;<B><I>Copyright</I></B>&#148;
means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary,
musical, or artistic work) recognized by the laws of any jurisdiction or country; and the term &#147;<B><I>Moral Rights</I></B>&#148;
means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction
or country.</FONT></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Excluded
Inventions and Other Inventions</B>. Attached hereto as <B>Exhibit A</B> is a list describing all existing Inventions, if any, (a) that
are owned by me or in which I have an interest and were made or acquired by me prior to my date of first employment with the Company,
(b) that may relate to Company&#146;s business or actual or demonstrably anticipated research or development, and (c) that are not to
be assigned to Company (&#147;<B><I>Excluded Inventions</I></B>&#148;). If no such list is attached, I represent and agree that it
is because I have no Excluded Inventions. For purposes of this Agreement, &#147;<B><I>Other Inventions</I></B>&#148; means Inventions
in which I have or may have an interest, as of the commencement of my employment or thereafter, other than Company Inventions (as defined
below) and Excluded Inventions. I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of
my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any
Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any
rights assigned to Company under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise
in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not
I give Company notice as required above), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide
license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly
perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer
for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any
third parties have rights in any such Other Inventions, I hereby represent and warrant that such third party or parties have validly
and irrevocably granted to me the right to grant the license stated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment
of Company Inventions</B>. Inventions assigned to Company or to a third party as directed by Company pursuant to Section 2.6 are referred
to in this Agreement as &#147;<B><I>Company Inventions</I></B>.&#148; Subject to Section 2.4 and except for Excluded Inventions set
forth in <B>Exhibit A</B> and Other Inventions, I hereby assign to Company all my right, title, and interest in and to any and all Inventions
(and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with
others, during the period of my employment with the Company. To the extent required by applicable Copyright laws, I agree to assign in
the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such
Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment
of all Moral Rights. To the extent such Moral Rights cannot be assigned to Company and to the extent the following is allowed by the
laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and
all claims and causes of action of any kind against Company or related to Company&#146;s customers, with respect to such rights. I further
acknowledge and agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions (and any
Intellectual Property Rights with respect thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unassigned
or Nonassignable Inventions</B>. I recognize that this Agreement will not be deemed to require assignment of any Invention that I developed
entirely on my own time without using the Company&#146;s equipment, supplies, facilities, trade secrets, or Confidential Information,
except for those Inventions that either (i) relate to the Company&#146;s actual or anticipated business, research or development, or
(ii) result from or are connected with work performed by me for the Company. In addition, this Agreement does not apply to any Invention
which qualifies fully for protection from assignment to the Company under any specifically applicable state law, regulation, rule or
public policy (&#147;<B><I>Specific Inventions Law</I></B>&#148;).</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obligation
to Keep Company Informed</B>. During the period of my employment, I will promptly and fully disclose to Company in writing all Inventions
authored, conceived, or reduced to practice by me, either alone or jointly with others. At the time of each such disclosure, I will advise
Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the Specific Inventions Law;
and I will at that time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep in confidence
and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to
Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the Specific Inventions Law. I will
preserve the confidentiality of any Invention that does not fully qualify for protection under the Specific Inventions Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government
or Third Party</B>. I agree that, as directed by Company, I will assign to a third party, including without limitation the United States,
all my right, title, and interest in and to any particular Company Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership
of Work Product</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 51.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment
and which are protectable by Copyright are &#147;works made for hire,&#148; pursuant to United States Copyright Act (17 U.S.C., Section
101).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 51.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that Company will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment,
and I hereby irrevocably and unconditionally assign to Company all right, title, and interest worldwide in and to such work product.
I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected
by this Section, except as necessary to perform services for Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement
of Intellectual Property Rights and Assistance</B>. I will assist Company in every proper way to obtain, and from time to time enforce,
United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries. To that
end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may
reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights
and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Company
or its designee, including the United States or any third party designated by Company. My obligation to assist Company with respect to
Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my
employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company&#146;s
request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document
needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized
officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and on my behalf to execute,
verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with
the same legal force and effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever,
which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporation
of Software Code</B>. I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code
licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions
the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company <B>except
</B>in strict compliance with Company&#146;s policies regarding the use of such software.</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Records</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that
is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my
employment at Company, which records will be available to and remain the sole property of Company at all times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duty
of Loyalty During Employment</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. I agree that during the period of my
employment with Company, I will not, without Company&#146;s express written consent, directly or indirectly engage in any employment
or business activity which is directly or indirectly competitive with, or would otherwise conflict with, my employment with Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonableness
of Restrictions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that I have read this entire Agreement and understand it. I acknowledge that I have the right to consult with counsel prior to
signing this Agreement. I further acknowledge that I will derive significant value from the Company&#146;s agreement to provide me with
Company Confidential Information to enable me to optimize the performance of my duties to the Company. I further acknowledge that my
fulfillment of the obligations contained in this Agreement, including, but not limited to, my obligation neither to disclose nor to use
Company Confidential Information other than for the Company&#146;s exclusive benefit and my obligations not to solicit are necessary
to protect Company Confidential Information and, consequently, to preserve the value and goodwill of the Company. I agree that this Agreement
does not prevent me from earning a living or pursuing my career. I agree that the restrictions contained in this Agreement are reasonable,
proper, and necessitated by Company&#146;s legitimate business interests. I represent and agree that I am entering into this Agreement
freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>In
the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, I and Company agree
that the court will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum
extent allowed by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Conflicting Agreement or Obligation</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>I represent that my performance of all the terms of this Agreement and as an intern of Company does not and will not breach any
agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment with Company. I have not
entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
of Company Property</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. When I leave the employ of Company, I will deliver
to Company any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof,
and any other material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company.
I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return
it to Company. In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit
any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer-useable copy
of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems; and I
agree to provide Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed.
I further agree that any property situated on Company&#146;s premises and owned by Company, including disks and other storage media,
filing cabinets or other work areas, is subject to inspection by Company&#146;s personnel at any time with or without notice. Prior
to leaving, I will cooperate with Company in attending an exit interview and completing and signing Company&#146;s termination statement
if required to do so by Company.</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
and Equitable Remedies</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree that any
threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company, and
Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable
relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that if Company is successful in whole or in part in any legal or equitable action against me under this Agreement, Company will
be entitled to payment of all costs, including reasonable attorney&#146;s fees, from me.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice
is given, labeled &#147;Attention Chief Executive Officer,&#148; and to me at my address as listed on Company payroll, or at such other
address as Company or I may designate by written notice to the other. Notice will be effective upon receipt or refusal of delivery. If
delivered by certified or registered mail, notice will be considered to have been given five business days after it was mailed, as evidenced
by the postmark. If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected
by the courier or express mail service receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
of This Agreement to Subsequent Employer or Business Associates of Intern</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.1&nbsp;&nbsp;&nbsp;&nbsp;</B>If
I am offered employment or the opportunity to enter into any business venture as owner, partner, consultant or other capacity while the
restrictions described in Section <B>Error! Reference source not found.</B> of this Agreement are in effect I agree to inform my potential
employer, partner, co-owner and/or others involved in managing the business with which I have an opportunity to be associated of my obligations
under this Agreement and also agree to provide such person or persons with a copy of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
Provisions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.1&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law; Consent to Personal Jurisdiction</B>. This Agreement will be governed by and construed according to the laws of the State of California
as such laws are applied to agreements entered into and to be performed entirely within California between residents of California. I
hereby expressly consent to the personal jurisdiction and venue of the state and federal courts located in California for any lawsuit
filed there against me by Company arising from or related to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2&nbsp;&nbsp;&nbsp;&nbsp;Severability</B>.
In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions
of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained
in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively
broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable
to the extent compatible with the applicable law as it will then appear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3&nbsp;&nbsp;&nbsp;&nbsp;Successors
and Assigns</B>. This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, subsidiaries,
affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival</B>.
This Agreement will survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company
to any successor in interest or other assignee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At-Will
Status</B>. I agree and understand that nothing in this Agreement will change my at-will status or confer any right with respect to continuation
of my employment with Company, nor will it interfere in any way with my right or Company&#146;s right to terminate my employment at
any time, with or without cause or advance notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waiver</B>.
No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach. No waiver by Company of
any right under this Agreement will be construed as a waiver of any other right. Company will not be required to give notice to enforce
strict adherence to all terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Export</B>.
I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing
such data, in violation of the United States export laws or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts</B>.
This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will
constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission
method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advice
of Counsel</B>. <B>I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL
COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT WILL NOT BE CONSTRUED AGAINST
ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire
Agreement</B>. The obligations pursuant to Sections 1 and 2 (except Subsection 2.4 and Subsection 2.7(a)) of this Agreement will apply
to any time during which I was previously engaged, or am in the future engaged, by Company as a consultant if no other agreement governs
nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties
with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us<B>.</B> No modification
of or amendment to this Agreement will be effective unless in writing and signed by the party to be charged. Any subsequent change or
changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[signatures
to follow on next page]</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement will be effective as of July 1, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; width: 40%; font-weight: bold; text-align: justify; text-indent: 0">Employee:</TD>
    <TD STYLE="padding: 0; width: 60%; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-weight: bold; text-align: left; text-indent: 0">I have read this agreement carefully and understand its terms.&nbsp;&nbsp;I have completely filled out Exhibit&nbsp;A to this Agreement.</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(Signature)</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Name</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Date</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-bottom: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accepted
    and agreed</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cuong
    Do<BR>
    President &amp; Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Excluded
Inventions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FROM:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATE:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: -0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Excluded
Inventions Disclosure</B>. Except as listed in Section 2 below, the following is a complete list of all Excluded Inventions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Excluded Inventions.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
below:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.6in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
sheets attached.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Due
to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to the Excluded Inventions
generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; width: 0.3in; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 25%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Excluded
    Invention</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 40%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Party(ies)</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 25%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Relationship</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
sheets attached.</FONT></TD>
</TR></TABLE>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioVie
Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Mutual
Agreement to Arbitrate Employment-Related Disputes</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Mutual Agreement to Arbitrate Disputes (&#147;<B>Agreement</B>&#148;) is made and entered into as of July 1, 2021 (the &#147;<B>Effective
Date</B>&#148;) by and between BioVie, Inc., a Nevada corporation, (the &#147;<B>Employer</B>&#148;) and Clarence Ahlem, an individual
(the &#147;<B>Employee</B>&#148;) (the Employer and the Employee are collectively referred to herein as the &#147;<B>Parties</B>&#148;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Intent
of Agreement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. It is the intent of Employee
and the Employer that this Agreement will govern the resolution of all disputes, claims and any other matters in question arising out
of or relating to the Parties&#146; employment relationship. The Parties shall resolve all disputes arising out of the employment relationship
in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Mandatory
Arbitration</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Employer and Employee agree
that any claim, complaint, or dispute that relates in any way to the Parties&#146; employment relationship, whether based in contract,
tort, statute, fraud, misrepresentation or any other legal theory, shall be submitted to final, binding and confidential arbitration
conducted by JAMS or its successor, under JAMS&#146; then applicable rules and procedures for employment disputes (available upon request
and also currently available at <U>http://www.jamsadr.com/rules-employment-arbitration/</U>). You can
also call JAMS at (213) 620-0100 if you have questions about the arbitration process. If the JAMS Employment Arbitration Rules are inconsistent
with the terms of this Agreement, the terms of this Agreement shall govern, except as otherwise required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Covered
Claims</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement to arbitrate covers
all grievances, disputes, claims, or causes of action (collectively, &#147;<B>claims</B>&#148;) in a federal, state or local court or
agency under applicable federal, state or local laws, arising out of Employee&#146;s employment with the Employer and the termination thereof,
including claims Employee may have against the Employer or against its officers, directors, supervisors, managers, employees, or agents
in their capacity as such or otherwise, or that the Employer may have against Employee. The claims covered by this Agreement include,
but are not limited to, claims for breach of any contract or covenant (express or implied), tort claims, claims for wrongful termination
(constructive or actual) in violation of public policy, claims for discrimination or harassment (including, but not limited to, harassment
or discrimination based on race, sex, gender, religion, national origin, age, marital status, medical condition, psychological condition,
mental condition, disability, or sexual orientation), claims for violation of any federal, state, or other governmental law, statute,
regulation, or ordinance, including, but not limited to, all claims arising under Title VII of the Civil Rights Act, the Age Discrimination
in Employment Act, the Americans With Disabilities Act, the California Fair Employment and Housing Act, the Consolidated Omnibus Budget
Reconciliation Act of 1985, and Employee Retirement Income Security Act. The parties to this Agreement specifically agree that all claims
under the California Labor Code, including, but not limited to, claims for overtime, unpaid wages, and claims involving meal and rest
breaks shall be subject to this Arbitration Agreement. (&#147;<B>Covered Claims</B>&#148;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Claims
Not Covered</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Claims not covered by this Agreement
are claims for workers&#146; compensation, unemployment compensation benefits, administrative charges for unfair labor practices brought before
the National Labor Relations Board, Excluded Claims (defined in Paragraph 5 below), or any other claims that, as a matter of law, the
Parties cannot agree to arbitrate. Nothing in this Agreement shall be interpreted to mean that employees are precluded from filing complaints
with the California Department of Fair Employment and Housing and/or federal Equal Employment Opportunity Commission and National Labor
Relations Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &bull; Santa Monica, CA 90404</FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Waiver
of Class Action and Representative Action Claims</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Waiver of Class Action and Representative Action Claims. Except for representative claims which cannot be waived under applicable law
and which are therefore excluded from this Agreement (&#147;Excluded Claims&#148;), Employee and the Company expressly intend and agree
that: (a) class action and representative action procedures are hereby waived and shall not be asserted, nor will they apply, in any
arbitration pursuant to this Agreement; (b) each will not assert class action or representative action claims against the other in arbitration
or otherwise; and (c) Employee and the Company shall only submit their own, individual claims in arbitration and will not seek to represent
the interests of any other person. To the extent that the Parties&#146; dispute involves both timely filed Excluded Claims and claims subject
to this Agreement, the Parties agree to bifurcate and stay for the duration of the arbitration proceedings any such Excluded Claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Waiver
of Trial by Jury</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Parties understand
and fully agree that by entering into this Agreement to arbitrate, they are giving up their constitutional right to have a trial by jury,
and are giving up their normal rights of appeal following the rendering of a decision except as California law provides for judicial
review of arbitration proceedings. The Parties anticipate that by entering into this Agreement, they will gain the benefits of a speedy
and less expensive dispute resolution procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Claims
Procedure</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Arbitration shall be initiated
upon the express written notice of either party. The aggrieved party must give written notice of any claim to the other party. Written
notice of an Employee&#146;s claim shall be mailed by certified or registered mail, return receipt requested, to the Employer&#146;s General Counsel
or Chief Executive Officer at 2120 Colorado Avenue, Suite 230 &bull; Santa Monica, CA 90404 (&#147;<B>Notice Address</B>&#148;). Written
notice of the Employer&#146;s claim will be mailed to the last known address of Employee. The written notice shall identify and describe the
nature of all claims asserted and the facts upon which such claims are based. Written notice of arbitration shall be initiated within
the same time limitations that California law applies to those claim(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Arbitrator
Selection</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Arbitrator shall be selected
as provided in JAMS&#146; Rules and Procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Discovery</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The JAMS Employment Arbitration Rules regarding discovery shall apply to arbitration under this Agreement. The Arbitrator selected according
to this Agreement shall decide all discovery disputes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Substantive
Law</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Arbitrator shall apply the substantive
state or federal law (and the law of remedies, if applicable) as applicable to the claim(s) asserted. The Arbitrator shall conduct and
preside over an arbitration hearing of reasonable length, to be determined by the Arbitrator. The Arbitrator shall provide the Parties
with a written decision explaining his or her findings and conclusions. The Arbitrator&#146;s decision shall be final and binding upon the
Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Motions</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Arbitrator shall have jurisdiction to hear and rule on prehearing disputes and is authorized to hold prehearing conferences by telephone
or in person as the Arbitrator deems necessary. The Arbitrator shall have the authority to set deadlines for completion of discovery,
and for filing motions for summary judgment, and to set briefing schedules for any motions. The Arbitrator shall have the authority to
adjudicate any cause of action, or the entire claim, pursuant to a motion for summary adjudication and/or summary judgment, and, in deciding
such motions, shall apply the law of the State of California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Compelling
Arbitration/Enforcing Award</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Either party
may bring an action in court to compel arbitration under this Agreement or to otherwise determine the arbitrability of claims under this
Agreement, and to confirm, vacate or enforce an arbitration award, and each party shall bear its own attorney fees and costs and other
expenses of such action.</FONT></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Arbitration
Fees and Costs</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Employer shall be responsible
for the arbitrator&#146;s fees and expenses. Each party shall pay its own costs and attorneys&#146; fees, if any. However, if any party prevails
on a statutory claim which affords the prevailing party attorneys&#146; fees and costs, or if there is a written agreement providing for attorneys&#146;
fees and costs, the Arbitrator may award reasonable attorneys&#146; fees and costs to the prevailing party. Any dispute as to the reasonableness
of any fee or cost shall be resolved by the Arbitrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Term
of Agreement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement to arbitrate
shall survive the termination of Employee&#146;s employment. It can only be revoked or modified in writing signed by both Parties that specifically
states an intent to revoke or modify this Agreement and is signed by the Employer&#146;s General Counsel or an authorized executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Severability</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
If any provision of this Agreement to arbitrate is adjudged to be void or otherwise unenforceable, in whole or in part, the void or unenforceable
provision shall be severed and such adjudication shall not affect the validity of the remainder of this Agreement to arbitrate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Voluntary
Agreement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. By executing this Agreement the
Parties represent that they have been given the opportunity to fully review, comprehend and negotiate the terms of this Agreement. The
Parties understand the terms of this Agreement and freely and voluntarily sign this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the Parties have executed this Agreement as of the Effective Date above.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">BioVie Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Cuong Do</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: President &amp; Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">EMPLOYEE&nbsp;</P>

<P STYLE="margin: 0 0 0 17.3pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 29%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
Clarence Ahlem</FONT></P>




<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>5
<FILENAME>bivi-20210930_10qex10z16.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<IMG SRC="bf001_v1.jpg" ALT="(LOGO)"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
19, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wendy
Kim<BR>
501 Beale Street 20B&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San
Francisco, CA 94105</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employment
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Wendy,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>BioVie,
Inc.</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, a Nevada corporation (the &#147;<B><I>Company</I></B>&#148;)
is pleased to offer you the position of <B>Chief Financial Officer</B> on the following terms. You will be overseeing the company&#146;s
financial operations and ensuring we are in compliance with all required SEC and NASDAQ regulations. You will report to Cuong Do will
work remotely. Of course, the Company may change your position, duties, and work location from time to time in its discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
base salary will be <B>$225,000 </B>on an annualized basis, less payroll deductions and withholdings, paid bi-weekly on the Company&#146;s
normal payroll schedule. You will also receive an $10,000 annual healthcare supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will receive a $131,250 retention bonus that will become payable when the Company completes its fundraise and will pay out over the subsequent
24 months. Should you separate from the company before the bonus is fully paid, the monthly payout will be reduced by one-half and continue
until the full amount has been paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will also be eligible to earn an annual discretionary performance bonus that will be determined by the Company&#146;s CEO and the Board&#146;s
Compensation Committee. The amount of this bonus will be determined in the sole discretion of the Company and based, in part, on your
performance and the performance of the Company during the calendar year. The Company will pay you this bonus, if any, by no later than
March 15th of the following calendar year. The bonus is not earned until paid and no pro-rated amount will be paid if your employment
terminates for any reason prior to the payment date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
your employment, you will be eligible to participate in the standard benefits plans offered to similarly situated employees by the Company
from time to time, subject to plan terms and generally applicable Company policies. Currently, the Company is pleased to offer an enhanced
benefits program. You will have a range of options to choose from for medical, dental and vision coverage. The Company will cover 80%
of the lowest cost plan, and you can pay for the difference between the company-supported amount and the actual cost of the plan you
select. The company will also provide Basic Life &amp; AD&amp;D coverage of 2X your basic salary. A full description of these benefits
is available upon request. You will also qualify to participate in the 401(k) plan, which matches your contributions dollar-for-dollar
up to five percent (5%) of your salary. Exempt employees may take a reasonable amount of time off with pay, as permitted by their duties
and responsibilities, and as approved in advance by their supervisor. As such, you will qualify for three (3) weeks of paid vacation
leave annually (prorated in the first calendar year of employment) plus any approved company holidays. The Company may change compensation
and benefits from time to time in its discretion. Additionally, you will be entitled to paid sick leave as provided by applicable state
law and/or local ordinance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &bull; Santa Monica, CA 90404</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to approval by the Company&#146;s Board of Directors (the &#147;<B><I>Board</I></B>&#148;), the Company anticipates granting you options
to purchase the Company&#146;s common stock at the fair market value as determined by the Board as of the date of grant (the &#147;<B><I>Option</I></B>&#148;)
when the Company has completed its fundraise and a compensation study has been conducted to determine market practices for such grants.
The anticipated Option will be governed by the terms and conditions of the Company&#146;s Inc. 2019 Omnibus Equity Incentive Plan (the
&#147;<B><I>Plan</I></B>&#148;) and your grant agreement, and will vest over five (<B>5</B>) year schedule, subject to your Continuous
Service (as defined in the Plan) as of each such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Company employee, you will be expected to abide by all Company rules and policies. As a condition of employment, you must sign and
comply with the attached Employee Confidential Information and Inventions Assignment Agreement which prohibits unauthorized use or disclosure
of the Company&#146;s proprietary information, among other obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any
former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information
which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry
or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring
onto Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation
of confidentiality. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities
on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Normal
business hours are from 9:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to work additional
hours as required by the nature of your work assignments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
employment with the Company will be &#147;at-will.&#148; You may terminate your employment with the Company at any time and for any
reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with or without cause
or advance notice. Your employment at-will status can only be modified in a written agreement signed by you and by an officer of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer is contingent upon a reference check and satisfactory proof of your right to work in the United States. You agree to assist as
needed and to complete any documentation at the Company&#146;s request to meet these conditions.</FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, and in exchange
for the mutual promises contained in this Agreement and the sign-on bonus you and the Company agree to arbitrate all disputes relating
to your employment with the Company, the parties agree to arbitration administered by JAMS pursuant to its Employment Arbitration Rules
&amp; Procedures and subject to JAMS Policy on Employment Arbitration Minimum Standards of Procedural Fairness. This mutual agreement
to arbitrate is set forth more fully in the enclosed Mutual Agreement to Arbitrate Employment-Related Disputes (&#147;Arbitration Agreement&#148;),
the execution of which is a condition of your employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer letter, together with your Employee Confidential Information and Inventions Assignment Agreement and the Arbitration Agreement,
forms the complete and exclusive statement of your employment agreement with the Company. It supersedes any other agreements or promises
made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes expressly reserved to the
Company&#146;s discretion in this letter, require a written modification signed by an officer of the Company. If any provision of this
offer letter agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other
provision of this offer letter agreement and the provision in question shall be modified so as to be rendered enforceable in a manner
consistent with the intent of the parties insofar as possible under applicable law. This letter may be delivered via facsimile, electronic
mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act
or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and be valid and effective
for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
sign and date this letter, and the enclosed Employee Confidential Information and Inventions Assignment Agreement, and the Mutual Agreement
to Arbitrate Employment-Related Disputes and return them to me by July 1, 2021.</FONT></P>




<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
look forward to your favorable reply and to a productive and enjoyable work relationship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cuong
    Do</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
    CONTRACT CONTAINS A BINDING ARBITRATION PROVISION WHICH MAY BE ENFORCED BY THE PARTIES.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Understood
and Accepted:&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wendy
                                            Kim</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enclosures&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIAL
INFORMATION AND INVENTION ASSIGNMENT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of my employment with <FONT STYLE="font-variant: small-caps"><B>BioVie Inc.</B></FONT>, its subsidiaries, parents, affiliates,
successors and assigns (together &#147;<B><I>Company</I></B>&#148;), and the compensation paid to me now and during my employment with
Company, and the Company&#146;s agreement to provide me with access to its Confidential Information (as defined below), I hereby enter
into this Confidential Information and Invention Assignment Agreement (the &#147;<B><I>Agreement</I></B>&#148;) and agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
Information Protections</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 17.3pt; text-align: justify">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recognition
of Company&#146;s Rights; Nondisclosure</B>. I understand and acknowledge that my employment with Company creates a relationship of
confidence and trust with respect to Company&#146;s Confidential Information (as defined below) and that Company has a protectable interest
therein. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or publish
any of Company&#146;s Confidential Information, except as such disclosure, use or publication may be required in connection with my
work for Company, or unless an officer of Company expressly authorizes such disclosure. I will obtain Company&#146;s written approval
before publishing or submitting for publication any material (written, oral, or otherwise) that discloses and/or incorporates any Confidential
Information. I hereby assign to Company any rights I may have or acquire in such Confidential Information and recognize that all Confidential
Information will be the sole and exclusive property of Company and its assigns. I will take all reasonable precautions to prevent the
inadvertent accidental disclosure of Confidential Information. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b),
I will not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that:
(1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely
for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in
a lawsuit or other proceeding, if such filing is made under seal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential
Information</B>. The term &#147;<B><I>Confidential Information</I></B>&#148; means any and all confidential knowledge, data or information
of Company. By way of illustration but not limitation, &#147;<B><I>Confidential Information</I></B>&#148; includes (a) trade secrets,
inventions, mask works, ideas, processes, formulas, software in source or object code, data, programs, other works of authorship, know-how,
improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights
(as defined below) therein (collectively, &#147;<B><I>Inventions</I></B>&#148;); (b) information regarding research, development, new
products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts,
credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential
strategies, financial projections and business strategies, operational plans, financing and capital-raising plans, activities and agreements,
internal services and operational manuals, methods of conducting Company business, suppliers and supplier information, and purchasing;
(c) information regarding customers and potential customers of Company, including customer lists, names, representatives, their needs
or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties,
the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and
other non-public information relating to customers and potential customers; (d) information regarding any of Company&#146;s business
partners and their services, including names, representatives, proposals, bids, contracts and their contents and parties, the type and
quantity of products and services received by Company, and other non-public information relating to business partners; (e) information
regarding personnel, employee lists, compensation, and employee skills; and (f) any other non-public information which a competitor of
Company could use to the competitive disadvantage of Company. Notwithstanding the foregoing, it is understood that, at all such times,
I am free to use information which was known to me prior to my employment with Company or which is generally known in the trade or industry
through no breach of this Agreement or other act or omission by me. Notwithstanding the foregoing or anything to the contrary in this
Agreement or any other agreement between the Company and me, nothing in this Agreement will limit my right to discuss my employment or
report possible violations of law or regulation with the Equal Employment Opportunity Commission, United States Department of Labor,
the National Labor Relations Board, the Securities and Exchange Commission, or other federal government agency or similar state or local
agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National
Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including
but not limited to &#147;whistleblower&#148; statutes or other similar provisions that protect such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &#9679; Santa Monica, CA 90404</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third
Party Information</B>. I understand, in addition, that Company has received and in the future will receive from third parties their confidential
and/or proprietary knowledge, data or information (<B>&#147;<I>Third Party Information</I>&#148;</B>) subject to a duty on Company&#146;s
part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment
and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need
to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party
Information or unless expressly authorized by an officer of Company in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term
of Nondisclosure Restrictions</B>. I understand that Confidential Information and Third Party Information is never to be used or disclosed
by me, as provided in this Section 1. If a temporal limitation on my obligation not to use or disclose such information is required under
applicable law, and the Agreement or its restriction(s) cannot otherwise be enforced, I agree and Company agrees that the two year period
after the date my employment ends will be the temporal limitation relevant to the contested restriction; <B><I>provided, however</I>,
</B>that this sentence will not apply to trade secrets protected without temporal limitation under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Improper Use of Information of Prior Employers and Others</B>. During my employment with the Company, I will not improperly use or disclose
confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality,
and I will not bring onto the premises of Company any unpublished documents or any property belonging to any former employer or any other
person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignments
of Inventions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions</B>.
As used in this Agreement, the term <B>&#147;<I>Intellectual Property Rights</I>&#148;</B> means all trade secrets, Copyrights, trademarks,
mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country; the term &#147;<B><I>Copyright</I></B>&#148;
means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary,
musical, or artistic work) recognized by the laws of any jurisdiction or country; and the term &#147;<B><I>Moral Rights</I></B>&#148;
means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction
or country.</FONT></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Excluded
Inventions and Other Inventions</B>. Attached hereto as <B>Exhibit A</B> is a list describing all existing Inventions, if any, (a) that
are owned by me or in which I have an interest and were made or acquired by me prior to my date of first employment with the Company,
(b) that may relate to Company&#146;s business or actual or demonstrably anticipated research or development, and (c) that are not to
be assigned to Company (&#147;<B><I>Excluded Inventions</I></B>&#148;). If no such list is attached, I represent and agree that it
is because I have no Excluded Inventions. For purposes of this Agreement, &#147;<B><I>Other Inventions</I></B>&#148; means Inventions
in which I have or may have an interest, as of the commencement of my employment or thereafter, other than Company Inventions (as defined
below) and Excluded Inventions. I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of
my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any
Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any
rights assigned to Company under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise
in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not
I give Company notice as required above), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide
license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly
perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer
for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any
third parties have rights in any such Other Inventions, I hereby represent and warrant that such third party or parties have validly
and irrevocably granted to me the right to grant the license stated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment
of Company Inventions</B>. Inventions assigned to Company or to a third party as directed by Company pursuant to Section 2.6 are referred
to in this Agreement as &#147;<B><I>Company Inventions</I></B>.&#148; Subject to Section 2.4 and except for Excluded Inventions set
forth in <B>Exhibit A</B> and Other Inventions, I hereby assign to Company all my right, title, and interest in and to any and all Inventions
(and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with
others, during the period of my employment with the Company. To the extent required by applicable Copyright laws, I agree to assign in
the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such
Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment
of all Moral Rights. To the extent such Moral Rights cannot be assigned to Company and to the extent the following is allowed by the
laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and
all claims and causes of action of any kind against Company or related to Company&#146;s customers, with respect to such rights. I further
acknowledge and agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions (and any
Intellectual Property Rights with respect thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unassigned
or Nonassignable Inventions</B>. I recognize that this Agreement will not be deemed to require assignment of any Invention that I developed
entirely on my own time without using the Company&#146;s equipment, supplies, facilities, trade secrets, or Confidential Information,
except for those Inventions that either (i) relate to the Company&#146;s actual or anticipated business, research or development, or
(ii) result from or are connected with work performed by me for the Company. In addition, this Agreement does not apply to any Invention
which qualifies fully for protection from assignment to the Company under any specifically applicable state law, regulation, rule or
public policy (&#147;<B><I>Specific Inventions Law</I></B>&#148;).</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obligation
to Keep Company Informed</B>. During the period of my employment, I will promptly and fully disclose to Company in writing all Inventions
authored, conceived, or reduced to practice by me, either alone or jointly with others. At the time of each such disclosure, I will advise
Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the Specific Inventions Law;
and I will at that time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep in confidence
and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to
Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the Specific Inventions Law. I will
preserve the confidentiality of any Invention that does not fully qualify for protection under the Specific Inventions Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government
or Third Party</B>. I agree that, as directed by Company, I will assign to a third party, including without limitation the United States,
all my right, title, and interest in and to any particular Company Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership
of Work Product</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 51.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment
and which are protectable by Copyright are &#147;works made for hire,&#148; pursuant to United States Copyright Act (17 U.S.C., Section
101).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 51.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that Company will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment,
and I hereby irrevocably and unconditionally assign to Company all right, title, and interest worldwide in and to such work product.
I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected
by this Section, except as necessary to perform services for Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement
of Intellectual Property Rights and Assistance</B>. I will assist Company in every proper way to obtain, and from time to time enforce,
United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries. To that
end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may
reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights
and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Company
or its designee, including the United States or any third party designated by Company. My obligation to assist Company with respect to
Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my
employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company&#146;s
request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document
needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized
officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and on my behalf to execute,
verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with
the same legal force and effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever,
which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporation
of Software Code</B>. I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code
licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions
the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company <B>except
</B>in strict compliance with Company&#146;s policies regarding the use of such software.</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Records</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that
is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my
employment at Company, which records will be available to and remain the sole property of Company at all times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duty
of Loyalty During Employment</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. I agree that during the period of my
employment with Company, I will not, without Company&#146;s express written consent, directly or indirectly engage in any employment
or business activity which is directly or indirectly competitive with, or would otherwise conflict with, my employment with Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonableness
of Restrictions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that I have read this entire Agreement and understand it. I acknowledge that I have the right to consult with counsel prior to
signing this Agreement. I further acknowledge that I will derive significant value from the Company&#146;s agreement to provide me with
Company Confidential Information to enable me to optimize the performance of my duties to the Company. I further acknowledge that my
fulfillment of the obligations contained in this Agreement, including, but not limited to, my obligation neither to disclose nor to use
Company Confidential Information other than for the Company&#146;s exclusive benefit and my obligations not to solicit are necessary
to protect Company Confidential Information and, consequently, to preserve the value and goodwill of the Company. I agree that this Agreement
does not prevent me from earning a living or pursuing my career. I agree that the restrictions contained in this Agreement are reasonable,
proper, and necessitated by Company&#146;s legitimate business interests. I represent and agree that I am entering into this Agreement
freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>In
the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, I and Company agree
that the court will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum
extent allowed by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Conflicting Agreement or Obligation</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>I represent that my performance of all the terms of this Agreement and as an intern of Company does not and will not breach any
agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment with Company. I have not
entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
of Company Property</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. When I leave the employ of Company, I will deliver
to Company any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof,
and any other material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company.
I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return
it to Company. In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit
any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer-useable copy
of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems; and I
agree to provide Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed.
I further agree that any property situated on Company&#146;s premises and owned by Company, including disks and other storage media,
filing cabinets or other work areas, is subject to inspection by Company&#146;s personnel at any time with or without notice. Prior
to leaving, I will cooperate with Company in attending an exit interview and completing and signing Company&#146;s termination statement
if required to do so by Company.</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
and Equitable Remedies</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree that any
threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company, and
Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable
relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that if Company is successful in whole or in part in any legal or equitable action against me under this Agreement, Company will
be entitled to payment of all costs, including reasonable attorney&#146;s fees, from me.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice
is given, labeled &#147;Attention Chief Executive Officer,&#148; and to me at my address as listed on Company payroll, or at such other
address as Company or I may designate by written notice to the other. Notice will be effective upon receipt or refusal of delivery. If
delivered by certified or registered mail, notice will be considered to have been given five business days after it was mailed, as evidenced
by the postmark. If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected
by the courier or express mail service receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
of This Agreement to Subsequent Employer or Business Associates of Intern</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.1&nbsp;&nbsp;&nbsp;&nbsp;</B>If
I am offered employment or the opportunity to enter into any business venture as owner, partner, consultant or other capacity while the
restrictions described in Section <B>Error! Reference source not found.</B> of this Agreement are in effect I agree to inform my potential
employer, partner, co-owner and/or others involved in managing the business with which I have an opportunity to be associated of my obligations
under this Agreement and also agree to provide such person or persons with a copy of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
Provisions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.1&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law; Consent to Personal Jurisdiction</B>. This Agreement will be governed by and construed according to the laws of the State of California
as such laws are applied to agreements entered into and to be performed entirely within California between residents of California. I
hereby expressly consent to the personal jurisdiction and venue of the state and federal courts located in California for any lawsuit
filed there against me by Company arising from or related to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2&nbsp;&nbsp;&nbsp;&nbsp;Severability</B>.
In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions
of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained
in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively
broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable
to the extent compatible with the applicable law as it will then appear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3&nbsp;&nbsp;&nbsp;&nbsp;Successors
and Assigns</B>. This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, subsidiaries,
affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival</B>.
This Agreement will survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company
to any successor in interest or other assignee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At-Will
Status</B>. I agree and understand that nothing in this Agreement will change my at-will status or confer any right with respect to continuation
of my employment with Company, nor will it interfere in any way with my right or Company&#146;s right to terminate my employment at
any time, with or without cause or advance notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waiver</B>.
No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach. No waiver by Company of
any right under this Agreement will be construed as a waiver of any other right. Company will not be required to give notice to enforce
strict adherence to all terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Export</B>.
I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing
such data, in violation of the United States export laws or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts</B>.
This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will
constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission
method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advice
of Counsel</B>. <B>I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL
COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT WILL NOT BE CONSTRUED AGAINST
ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire
Agreement</B>. The obligations pursuant to Sections 1 and 2 (except Subsection 2.4 and Subsection 2.7(a)) of this Agreement will apply
to any time during which I was previously engaged, or am in the future engaged, by Company as a consultant if no other agreement governs
nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties
with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us<B>.</B> No modification
of or amendment to this Agreement will be effective unless in writing and signed by the party to be charged. Any subsequent change or
changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[signatures
to follow on next page]</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement will be effective as of July 1, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; width: 40%; font-weight: bold; text-align: justify; text-indent: 0">Employee:</TD>
    <TD STYLE="padding: 0; width: 60%; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-weight: bold; text-align: left; text-indent: 0">I have read this agreement carefully and understand its terms.&nbsp;&nbsp;I have completely filled out Exhibit&nbsp;A to this Agreement.</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(Signature)</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Name</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Date</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-bottom: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accepted
    and agreed</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cuong
    Do<BR>
    President &amp; Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Excluded
Inventions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FROM:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATE:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: -0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Excluded
Inventions Disclosure</B>. Except as listed in Section 2 below, the following is a complete list of all Excluded Inventions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Excluded Inventions.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
below:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.6in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
sheets attached.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Due
to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to the Excluded Inventions
generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; width: 0.3in; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 25%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Excluded
    Invention</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 40%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Party(ies)</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 25%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Relationship</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
sheets attached.</FONT></TD>
</TR></TABLE>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioVie
Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Mutual
Agreement to Arbitrate Employment-Related Disputes</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Mutual Agreement to Arbitrate Disputes (&#147;<B>Agreement</B>&#148;) is made and entered into as of July 1, 2021 (the &#147;<B>Effective
Date</B>&#148;) by and between BioVie, Inc., a Nevada corporation, (the &#147;<B>Employer</B>&#148;) and Wendy Kim, an individual (the
&#147;<B>Employee</B>&#148;) (the Employer and the Employee are collectively referred to herein as the &#147;<B>Parties</B>&#148;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Intent
of Agreement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. It is the intent of Employee
and the Employer that this Agreement will govern the resolution of all disputes, claims and any other matters in question arising out
of or relating to the Parties&#146; employment relationship. The Parties shall resolve all disputes arising out of the employment relationship
in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Mandatory
Arbitration</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Employer and Employee agree
that any claim, complaint, or dispute that relates in any way to the Parties&#146; employment relationship, whether based in contract,
tort, statute, fraud, misrepresentation or any other legal theory, shall be submitted to final, binding and confidential arbitration
conducted by JAMS or its successor, under JAMS&#146; then applicable rules and procedures for employment disputes (available upon request
and also currently available at <U>http://www.jamsadr.com/rules-employment-arbitration/</U>). You can also call JAMS at (213)
620-0100 if you have questions about the arbitration process. If the JAMS Employment Arbitration Rules are inconsistent with the terms
of this Agreement, the terms of this Agreement shall govern, except as otherwise required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Covered
Claims</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement to arbitrate covers
all grievances, disputes, claims, or causes of action (collectively, &#147;<B>claims</B>&#148;) in a federal, state or local court or
agency under applicable federal, state or local laws, arising out of Employee&#146;s employment with the Employer and the termination thereof,
including claims Employee may have against the Employer or against its officers, directors, supervisors, managers, employees, or agents
in their capacity as such or otherwise, or that the Employer may have against Employee. The claims covered by this Agreement include,
but are not limited to, claims for breach of any contract or covenant (express or implied), tort claims, claims for wrongful termination
(constructive or actual) in violation of public policy, claims for discrimination or harassment (including, but not limited to, harassment
or discrimination based on race, sex, gender, religion, national origin, age, marital status, medical condition, psychological condition,
mental condition, disability, or sexual orientation), claims for violation of any federal, state, or other governmental law, statute,
regulation, or ordinance, including, but not limited to, all claims arising under Title VII of the Civil Rights Act, the Age Discrimination
in Employment Act, the Americans With Disabilities Act, the California Fair Employment and Housing Act, the Consolidated Omnibus Budget
Reconciliation Act of 1985, and Employee Retirement Income Security Act. The parties to this Agreement specifically agree that all claims
under the California Labor Code, including, but not limited to, claims for overtime, unpaid wages, and claims involving meal and rest
breaks shall be subject to this Arbitration Agreement. (&#147;<B>Covered Claims</B>&#148;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Claims
Not Covered</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Claims not covered by this Agreement
are claims for workers&#146; compensation, unemployment compensation benefits, administrative charges for unfair labor practices brought before
the National Labor Relations Board, Excluded Claims (defined in Paragraph 5 below), or any other claims that, as a matter of law, the
Parties cannot agree to arbitrate. Nothing in this Agreement shall be interpreted to mean that employees are precluded from filing complaints
with the California Department of Fair Employment and Housing and/or federal Equal Employment Opportunity Commission and National Labor
Relations Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &bull; Santa Monica, CA 90404</FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Waiver
of Class Action and Representative Action Claims</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Waiver of Class Action and Representative Action Claims. Except for representative claims which cannot be waived under applicable law
and which are therefore excluded from this Agreement (&#147;Excluded Claims&#148;), Employee and the Company expressly intend and agree
that: (a) class action and representative action procedures are hereby waived and shall not be asserted, nor will they apply, in any
arbitration pursuant to this Agreement; (b) each will not assert class action or representative action claims against the other in arbitration
or otherwise; and (c) Employee and the Company shall only submit their own, individual claims in arbitration and will not seek to represent
the interests of any other person. To the extent that the Parties&#146; dispute involves both timely filed Excluded Claims and claims subject
to this Agreement, the Parties agree to bifurcate and stay for the duration of the arbitration proceedings any such Excluded Claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Waiver
of Trial by Jury</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Parties understand
and fully agree that by entering into this Agreement to arbitrate, they are giving up their constitutional right to have a trial by jury,
and are giving up their normal rights of appeal following the rendering of a decision except as California law provides for judicial
review of arbitration proceedings. The Parties anticipate that by entering into this Agreement, they will gain the benefits of a speedy
and less expensive dispute resolution procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Claims
Procedure</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Arbitration shall be initiated
upon the express written notice of either party. The aggrieved party must give written notice of any claim to the other party. Written
notice of an Employee&#146;s claim shall be mailed by certified or registered mail, return receipt requested, to the Employer&#146;s General Counsel
or Chief Executive Officer at 2120 Colorado Avenue, Suite 230 &bull; Santa Monica, CA 90404 (&#147;<B>Notice Address</B>&#148;). Written
notice of the Employer&#146;s claim will be mailed to the last known address of Employee. The written notice shall identify and describe the
nature of all claims asserted and the facts upon which such claims are based. Written notice of arbitration shall be initiated within
the same time limitations that California law applies to those claim(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Arbitrator
Selection</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Arbitrator shall be selected
as provided in JAMS&#146; Rules and Procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Discovery</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The JAMS Employment Arbitration Rules regarding discovery shall apply to arbitration under this Agreement. The Arbitrator selected according
to this Agreement shall decide all discovery disputes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Substantive
Law</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Arbitrator shall apply the substantive
state or federal law (and the law of remedies, if applicable) as applicable to the claim(s) asserted. The Arbitrator shall conduct and
preside over an arbitration hearing of reasonable length, to be determined by the Arbitrator. The Arbitrator shall provide the Parties
with a written decision explaining his or her findings and conclusions. The Arbitrator&#146;s decision shall be final and binding upon the
Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Motions</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Arbitrator shall have jurisdiction to hear and rule on prehearing disputes and is authorized to hold prehearing conferences by telephone
or in person as the Arbitrator deems necessary. The Arbitrator shall have the authority to set deadlines for completion of discovery,
and for filing motions for summary judgment, and to set briefing schedules for any motions. The Arbitrator shall have the authority to
adjudicate any cause of action, or the entire claim, pursuant to a motion for summary adjudication and/or summary judgment, and, in deciding
such motions, shall apply the law of the State of California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Compelling
Arbitration/Enforcing Award</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Either party
may bring an action in court to compel arbitration under this Agreement or to otherwise determine the arbitrability of claims under this
Agreement, and to confirm, vacate or enforce an arbitration award, and each party shall bear its own attorney fees and costs and other
expenses of such action.</FONT></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Arbitration
Fees and Costs</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Employer shall be responsible
for the arbitrator&#146;s fees and expenses. Each party shall pay its own costs and attorneys&#146; fees, if any. However, if any party prevails
on a statutory claim which affords the prevailing party attorneys&#146; fees and costs, or if there is a written agreement providing for attorneys&#146;
fees and costs, the Arbitrator may award reasonable attorneys&#146; fees and costs to the prevailing party. Any dispute as to the reasonableness
of any fee or cost shall be resolved by the Arbitrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Term
of Agreement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement to arbitrate
shall survive the termination of Employee&#146;s employment. It can only be revoked or modified in writing signed by both Parties that specifically
states an intent to revoke or modify this Agreement and is signed by the Employer&#146;s General Counsel or an authorized executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Severability</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
If any provision of this Agreement to arbitrate is adjudged to be void or otherwise unenforceable, in whole or in part, the void or unenforceable
provision shall be severed and such adjudication shall not affect the validity of the remainder of this Agreement to arbitrate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Voluntary
Agreement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. By executing this Agreement the
Parties represent that they have been given the opportunity to fully review, comprehend and negotiate the terms of this Agreement. The
Parties understand the terms of this Agreement and freely and voluntarily sign this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the Parties have executed this Agreement as of the Effective Date above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">BioVie Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Cuong Do</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: President &amp; Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EMPLOYEE&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 29%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Name: Wendy Kim&nbsp;</P>




<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>6
<FILENAME>bivi-20210930_10qex10z17.htm
<DESCRIPTION>EXHIBIT 10.17
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><IMG SRC="bf001_v1.jpg" ALT="(LOGO)"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
21, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan
Adams<BR>
25 West 15th St, Unit B&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chicago,
IL 60605</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employment
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Jonathan,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>BioVie,
Inc.</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, a Nevada corporation (the &#147;<B><I>Company</I></B>&#148;)
is pleased to offer you the position of <B>Executive Vice President, Cirrhosis Programs </B>on the following terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will be responsible for efforts to advance the development of BIV201 with emphasis on completing the clinical trials and preparing the
program for commercial launch. You will report to Cuong Do will work remotely from the Company&#146;s facilities. Of course, the Company
may change your position, duties, and work location from time to time in its discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
base salary will be <B>$260,000 </B>on an annualized basis, less payroll deductions and withholdings, paid bi-weekly on the Company&#146;s
normal payroll schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will also be eligible to earn an annual discretionary performance bonus of up to $78,000 that will be determined by the Company&#146;s
CEO and the Board&#146;s Compensation Committee. The amount of this bonus will be determined in the sole discretion of the Company and
based, in part, on your performance and the performance of the Company during the fiscal year. The Company will pay you this bonus, if
any, by no later than September 15<SUP>th</SUP> after the closing of the Company&#146;s fiscal year. The bonus is not earned until paid
and no pro-rated amount will be paid if your employment terminates for any reason prior to the payment date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
your employment, you will be eligible to participate in the standard benefits plans offered to similarly situated employees by the Company
from time to time, subject to plan terms and generally applicable Company policies. Currently, the Company is pleased to offer an enhanced
benefits program. You will have a range of options to choose from for medical, dental and vision coverage. The Company will cover 80%
of the lowest cost plan, and you can pay for the difference between the company-supported amount and the actual cost of the plan you
select. The company will also provide Basic Life &amp; AD&amp;D coverage of 2X your basic salary. A full description of these benefits
is available upon request. You will also qualify to participate in the 401(k) plan, which matches your contributions dollar-for-dollar
up to five percent (5%) of your salary. Exempt employees may take a reasonable amount of time off with pay, as permitted by their duties
and responsibilities, and as approved in advance by their supervisor. As such, you will qualify for three (3) weeks of paid vacation
leave annually (prorated in the first calendar year of employment) plus any approved company holidays. The Company may change compensation
and benefits from time to time in its discretion. Additionally, you will be entitled to paid sick leave as provided by applicable state
law and/or local ordinance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &bull; Santa Monica, CA 90404</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to approval by the Company&#146;s Board of Directors (the &#147;<B><I>Board</I></B>&#148;), the Company anticipates granting you 124,167
options to purchase the Company&#146;s common stock at the fair market value as determined by the Board as of the date of grant (the
&#147;<B><I>Option</I></B>&#148;). Twenty percent (20%) of the option grant will vest immediately and the remainder will vest in five
equal installments on the anniversary of the grant, subject to your Continuous Service (as defined in the Plan) as of each such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Company employee, you will be expected to abide by all Company rules and policies. As a condition of employment, you must sign and
comply with the attached Employee Confidential Information and Inventions Assignment Agreement which prohibits unauthorized use or disclosure
of the Company&#146;s proprietary information, among other obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any
former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information
which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry
or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring
onto Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation
of confidentiality. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities
on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Normal
business hours are from 9:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to work additional
hours as required by the nature of your work assignments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
employment with the Company will be &#147;at-will.&#148; You may terminate your employment with the Company at any time and for any
reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with or without cause
or advance notice. Your employment at-will status can only be modified in a written agreement signed by you and by an officer of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, and in exchange
for the mutual promises contained in this Agreement and the sign-on bonus you and the Company agree to arbitrate all disputes relating
to your employment with the Company, the parties agree to arbitration administered by JAMS pursuant to its Employment Arbitration Rules
&amp; Procedures and subject to JAMS Policy on Employment Arbitration Minimum Standards of Procedural Fairness. This mutual agreement
to arbitrate is set forth more fully in the enclosed Mutual Agreement to Arbitrate Employment-Related Disputes (&#147;Arbitration Agreement&#148;),
the execution of which is a condition of your employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer letter, together with your Employee Confidential Information and Inventions Assignment Agreement and the Arbitration Agreement,
forms the complete and exclusive statement of your employment agreement with the Company. It supersedes any other agreements or promises
made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes expressly reserved to the
Company&#146;s discretion in this letter, require a written modification signed by an officer of the Company. If any provision of this
offer letter agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other
provision of this offer letter agreement and the provision in question shall be modified so as to be rendered enforceable in a manner
consistent with the intent of the parties insofar as possible under applicable law. This letter may be delivered via facsimile, electronic
mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act
or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and be valid and effective
for all purposes.</FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
sign and date this letter, the Employee Confidential Information and Inventions Assignment Agreement, and the Mutual Agreement to Arbitrate
Employment-Related Disputes and return them to me as soon as possible since your option grant will not take effect until these agreements
have been signed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cuong
    Do</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
    CONTRACT CONTAINS A BINDING ARBITRATION PROVISION WHICH MAY BE ENFORCED BY THE PARTIES.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Understood
and Accepted:<BR>
</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan
                                            Adams</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enclosures</FONT></P>




<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIAL
INFORMATION AND INVENTION ASSIGNMENT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of my employment with <FONT STYLE="font-variant: small-caps"><B>BioVie Inc.</B></FONT>, its subsidiaries, parents, affiliates,
successors and assigns (together &#147;<B><I>Company</I></B>&#148;), and the compensation paid to me now and during my employment with
Company, and the Company&#146;s agreement to provide me with access to its Confidential Information (as defined below), I hereby enter
into this Confidential Information and Invention Assignment Agreement (the &#147;<B><I>Agreement</I></B>&#148;) and agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
Information Protections</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0 0pt 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 17.3pt; text-align: justify">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recognition
of Company&#146;s Rights; Nondisclosure</B>. I understand and acknowledge that my employment with Company creates a relationship of
confidence and trust with respect to Company&#146;s Confidential Information (as defined below) and that Company has a protectable interest
therein. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or publish
any of Company&#146;s Confidential Information, except as such disclosure, use or publication may be required in connection with my
work for Company, or unless an officer of Company expressly authorizes such disclosure. I will obtain Company&#146;s written approval
before publishing or submitting for publication any material (written, oral, or otherwise) that discloses and/or incorporates any Confidential
Information. I hereby assign to Company any rights I may have or acquire in such Confidential Information and recognize that all Confidential
Information will be the sole and exclusive property of Company and its assigns. I will take all reasonable precautions to prevent the
inadvertent accidental disclosure of Confidential Information. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b),
I will not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that:
(1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely
for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in
a lawsuit or other proceeding, if such filing is made under seal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential
Information</B>. The term &#147;<B><I>Confidential Information</I></B>&#148; means any and all confidential knowledge, data or information
of Company. By way of illustration but not limitation, &#147;<B><I>Confidential Information</I></B>&#148; includes (a) trade secrets,
inventions, mask works, ideas, processes, formulas, software in source or object code, data, programs, other works of authorship, know-how,
improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights
(as defined below) therein (collectively, &#147;<B><I>Inventions</I></B>&#148;); (b) information regarding research, development, new
products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts,
credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential
strategies, financial projections and business strategies, operational plans, financing and capital-raising plans, activities and agreements,
internal services and operational manuals, methods of conducting Company business, suppliers and supplier information, and purchasing;
(c) information regarding customers and potential customers of Company, including customer lists, names, representatives, their needs
or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties,
the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and
other non-public information relating to customers and potential customers; (d) information regarding any of Company&#146;s business
partners and their services, including names, representatives, proposals, bids, contracts and their contents and parties, the type and
quantity of products and services received by Company, and other non-public information relating to business partners; (e) information
regarding personnel, employee lists, compensation, and employee skills; and (f) any other non-public information which a competitor of
Company could use to the competitive disadvantage of Company. Notwithstanding the foregoing, it is understood that, at all such times,
I am free to use information which was known to me prior to my employment with Company or which is generally known in the trade or industry
through no breach of this Agreement or other act or omission by me. Notwithstanding the foregoing or anything to the contrary in this
Agreement or any other agreement between the Company and me, nothing in this Agreement will limit my right to discuss my employment or
report possible violations of law or regulation with the Equal Employment Opportunity Commission, United States Department of Labor,
the National Labor Relations Board, the Securities and Exchange Commission, or other federal government agency or similar state or local
agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National
Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including
but not limited to &#147;whistleblower&#148; statutes or other similar provisions that protect such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &#9679; Santa Monica, CA 90404</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-right: 0pt; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="margin-right: 0pt; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third
Party Information</B>. I understand, in addition, that Company has received and in the future will receive from third parties their confidential
and/or proprietary knowledge, data or information (<B>&#147;<I>Third Party Information</I>&#148;</B>) subject to a duty on Company&#146;s
part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment
and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need
to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party
Information or unless expressly authorized by an officer of Company in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term
of Nondisclosure Restrictions</B>. I understand that Confidential Information and Third Party Information is never to be used or disclosed
by me, as provided in this Section 1. If a temporal limitation on my obligation not to use or disclose such information is required under
applicable law, and the Agreement or its restriction(s) cannot otherwise be enforced, I agree and Company agrees that the two year period
after the date my employment ends will be the temporal limitation relevant to the contested restriction; <B><I>provided, however</I>,
</B>that this sentence will not apply to trade secrets protected without temporal limitation under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Improper Use of Information of Prior Employers and Others</B>. During my employment with the Company, I will not improperly use or disclose
confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality,
and I will not bring onto the premises of Company any unpublished documents or any property belonging to any former employer or any other
person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignments
of Inventions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions</B>.
As used in this Agreement, the term <B>&#147;<I>Intellectual Property Rights</I>&#148;</B> means all trade secrets, Copyrights, trademarks,
mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country; the term &#147;<B><I>Copyright</I></B>&#148;
means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary,
musical, or artistic work) recognized by the laws of any jurisdiction or country; and the term &#147;<B><I>Moral Rights</I></B>&#148;
means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction
or country.</FONT></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-right: 0pt; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="margin-right: 0pt; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Excluded
Inventions and Other Inventions</B>. Attached hereto as <B>Exhibit A</B> is a list describing all existing Inventions, if any, (a) that
are owned by me or in which I have an interest and were made or acquired by me prior to my date of first employment with the Company,
(b) that may relate to Company&#146;s business or actual or demonstrably anticipated research or development, and (c) that are not to
be assigned to Company (&#147;<B><I>Excluded Inventions</I></B>&#148;). If no such list is attached, I represent and agree that it
is because I have no Excluded Inventions. For purposes of this Agreement, &#147;<B><I>Other Inventions</I></B>&#148; means Inventions
in which I have or may have an interest, as of the commencement of my employment or thereafter, other than Company Inventions (as defined
below) and Excluded Inventions. I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of
my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any
Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any
rights assigned to Company under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise
in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not
I give Company notice as required above), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide
license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly
perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer
for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any
third parties have rights in any such Other Inventions, I hereby represent and warrant that such third party or parties have validly
and irrevocably granted to me the right to grant the license stated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment
of Company Inventions</B>. Inventions assigned to Company or to a third party as directed by Company pursuant to Section 2.6 are referred
to in this Agreement as &#147;<B><I>Company Inventions</I></B>.&#148; Subject to Section 2.4 and except for Excluded Inventions set
forth in <B>Exhibit A</B> and Other Inventions, I hereby assign to Company all my right, title, and interest in and to any and all Inventions
(and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with
others, during the period of my employment with the Company. To the extent required by applicable Copyright laws, I agree to assign in
the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such
Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment
of all Moral Rights. To the extent such Moral Rights cannot be assigned to Company and to the extent the following is allowed by the
laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and
all claims and causes of action of any kind against Company or related to Company&#146;s customers, with respect to such rights. I further
acknowledge and agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions (and any
Intellectual Property Rights with respect thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unassigned
or Nonassignable Inventions</B>. I recognize that this Agreement will not be deemed to require assignment of any Invention that I developed
entirely on my own time without using the Company&#146;s equipment, supplies, facilities, trade secrets, or Confidential Information,
except for those Inventions that either (i) relate to the Company&#146;s actual or anticipated business, research or development, or
(ii) result from or are connected with work performed by me for the Company. In addition, this Agreement does not apply to any Invention
which qualifies fully for protection from assignment to the Company under any specifically applicable state law, regulation, rule or
public policy (&#147;<B><I>Specific Inventions Law</I></B>&#148;).</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-right: 0pt; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="margin-right: 0pt; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obligation
to Keep Company Informed</B>. During the period of my employment, I will promptly and fully disclose to Company in writing all Inventions
authored, conceived, or reduced to practice by me, either alone or jointly with others. At the time of each such disclosure, I will advise
Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the Specific Inventions Law;
and I will at that time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep in confidence
and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to
Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the Specific Inventions Law. I will
preserve the confidentiality of any Invention that does not fully qualify for protection under the Specific Inventions Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government
or Third Party</B>. I agree that, as directed by Company, I will assign to a third party, including without limitation the United States,
all my right, title, and interest in and to any particular Company Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership
of Work Product</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 51.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment
and which are protectable by Copyright are &#147;works made for hire,&#148; pursuant to United States Copyright Act (17 U.S.C., Section
101).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 51.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that Company will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment,
and I hereby irrevocably and unconditionally assign to Company all right, title, and interest worldwide in and to such work product.
I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected
by this Section, except as necessary to perform services for Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement
of Intellectual Property Rights and Assistance</B>. I will assist Company in every proper way to obtain, and from time to time enforce,
United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries. To that
end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may
reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights
and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Company
or its designee, including the United States or any third party designated by Company. My obligation to assist Company with respect to
Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my
employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company&#146;s
request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document
needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized
officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and on my behalf to execute,
verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with
the same legal force and effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever,
which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporation
of Software Code</B>. I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code
licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions
the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company <B>except
</B>in strict compliance with Company&#146;s policies regarding the use of such software.</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-right: 0pt; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="margin-right: 0pt; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Records</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that
is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my
employment at Company, which records will be available to and remain the sole property of Company at all times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duty
of Loyalty During Employment</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. I agree that during the period of my
employment with Company, I will not, without Company&#146;s express written consent, directly or indirectly engage in any employment
or business activity which is directly or indirectly competitive with, or would otherwise conflict with, my employment with Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonableness
of Restrictions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that I have read this entire Agreement and understand it. I acknowledge that I have the right to consult with counsel prior to
signing this Agreement. I further acknowledge that I will derive significant value from the Company&#146;s agreement to provide me with
Company Confidential Information to enable me to optimize the performance of my duties to the Company. I further acknowledge that my
fulfillment of the obligations contained in this Agreement, including, but not limited to, my obligation neither to disclose nor to use
Company Confidential Information other than for the Company&#146;s exclusive benefit and my obligations not to solicit are necessary
to protect Company Confidential Information and, consequently, to preserve the value and goodwill of the Company. I agree that this Agreement
does not prevent me from earning a living or pursuing my career. I agree that the restrictions contained in this Agreement are reasonable,
proper, and necessitated by Company&#146;s legitimate business interests. I represent and agree that I am entering into this Agreement
freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>In
the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, I and Company agree
that the court will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum
extent allowed by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Conflicting Agreement or Obligation</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>I represent that my performance of all the terms of this Agreement and as an intern of Company does not and will not breach any
agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment with Company. I have not
entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
of Company Property</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. When I leave the employ of Company, I will deliver
to Company any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof,
and any other material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company.
I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return
it to Company. In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit
any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer-useable copy
of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems; and I
agree to provide Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed.
I further agree that any property situated on Company&#146;s premises and owned by Company, including disks and other storage media,
filing cabinets or other work areas, is subject to inspection by Company&#146;s personnel at any time with or without notice. Prior
to leaving, I will cooperate with Company in attending an exit interview and completing and signing Company&#146;s termination statement
if required to do so by Company.</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-right: 0pt; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="margin-right: 0pt; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
and Equitable Remedies</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree that any
threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company, and
Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable
relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that if Company is successful in whole or in part in any legal or equitable action against me under this Agreement, Company will
be entitled to payment of all costs, including reasonable attorney&#146;s fees, from me.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice
is given, labeled &#147;Attention Chief Executive Officer,&#148; and to me at my address as listed on Company payroll, or at such other
address as Company or I may designate by written notice to the other. Notice will be effective upon receipt or refusal of delivery. If
delivered by certified or registered mail, notice will be considered to have been given five business days after it was mailed, as evidenced
by the postmark. If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected
by the courier or express mail service receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
of This Agreement to Subsequent Employer or Business Associates of Intern</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.1&nbsp;&nbsp;&nbsp;&nbsp;</B>If
I am offered employment or the opportunity to enter into any business venture as owner, partner, consultant or other capacity while the
restrictions described in Section <B>Error! Reference source not found.</B> of this Agreement are in effect I agree to inform my potential
employer, partner, co-owner and/or others involved in managing the business with which I have an opportunity to be associated of my obligations
under this Agreement and also agree to provide such person or persons with a copy of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
Provisions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.1&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law; Consent to Personal Jurisdiction</B>. This Agreement will be governed by and construed according to the laws of the State of Illinois as such laws are applied to agreements
entered into and to be performed entirely within Illinois between residents of Illinois. I hereby expressly consent to the personal jurisdiction
and venue of the state and federal courts located in Illinois for any lawsuit filed there against me by Company arising from or related
to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2&nbsp;&nbsp;&nbsp;&nbsp;Severability</B>.
In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions
of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained
in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively
broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable
to the extent compatible with the applicable law as it will then appear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3&nbsp;&nbsp;&nbsp;&nbsp;Successors
and Assigns</B>. This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, subsidiaries,
affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-right: 0pt; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="margin-right: 0pt; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival</B>.
This Agreement will survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company
to any successor in interest or other assignee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At-Will
Status</B>. I agree and understand that nothing in this Agreement will change my at-will status or confer any right with respect to continuation
of my employment with Company, nor will it interfere in any way with my right or Company&#146;s right to terminate my employment at
any time, with or without cause or advance notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waiver</B>.
No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach. No waiver by Company of
any right under this Agreement will be construed as a waiver of any other right. Company will not be required to give notice to enforce
strict adherence to all terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Export</B>.
I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing
such data, in violation of the United States export laws or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts</B>.
This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will
constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission
method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advice
of Counsel</B>. <B>I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL
COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT WILL NOT BE CONSTRUED AGAINST
ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire
Agreement</B>. The obligations pursuant to Sections 1 and 2 (except Subsection 2.4 and Subsection 2.7(a)) of this Agreement will apply
to any time during which I was previously engaged, or am in the future engaged, by Company as a consultant if no other agreement governs
nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties
with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us<B>.</B> No modification
of or amendment to this Agreement will be effective unless in writing and signed by the party to be charged. Any subsequent change or
changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[signatures
to follow on next page]</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-right: 0pt; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="margin-right: 0pt; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement will be effective as of August 21, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; width: 40%; font-weight: bold; text-align: justify; text-indent: 0">Employee:</TD>
    <TD STYLE="padding: 0; width: 60%; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-weight: bold; text-align: left; text-indent: 0">I have read this agreement carefully and understand its terms.&nbsp;&nbsp;I have completely filled out Exhibit&nbsp;A to this Agreement.</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(Signature)</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Name</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Date</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-bottom: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accepted
    and agreed</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;&nbsp;Cuong
    Do<BR>
    Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President &amp; Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-right: 0pt; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="margin-right: 0pt; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Excluded
Inventions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FROM:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATE:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-indent: -0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Excluded
Inventions Disclosure</B>. Except as listed in Section 2 below, the following is a complete list of all Excluded Inventions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Excluded Inventions.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
below:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.6in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
sheets attached.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Due
to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to the Excluded Inventions
generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; width: 0.3in; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 25%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Excluded
    Invention</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 40%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Party(ies)</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 25%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Relationship</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
sheets attached.</FONT></TD>
</TR></TABLE>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-right: 0pt; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="margin-right: 0pt; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioVie
Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Mutual
Agreement to Arbitrate Employment-Related Disputes</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Mutual Agreement to Arbitrate Disputes (&#147;<B>Agreement</B>&#148;) is made and entered into as of August 21, 2021 (the &#147;<B>Effective
Date</B>&#148;) by and between BioVie, Inc., a Nevada corporation the &#147;<B>Employer</B>&#148;) and Jonathan Adams, an individual
(the &#147;<B>Employee</B>&#148;) (the Employer and the Employee are collectively referred to herein as the &#147;<B>Parties</B>&#148;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Intent of the Agreement</U>. It is the intent of Parties to resolve all disputes, claims, and any other matters arising out of or
relating to the Employee&#146;s employment by the Employer or termination of employment by binding private arbitration in accordance with
the provisions of this Agreement. The Parties understand that by entering into this Agreement <B>THE EMPLOYEE AND THE EMPLOYER ARE GIVING
UP THE RIGHT TO A JURY TRIAL OR TO FILE A LAWSUIT IN COURT AGAINST THE OTHER, AND THE RIGHT TO BRING A CLASS OR COLLECTIVE ACTION AGAINST
THE OTHER IN COURT OR IN ARBITRATION,</B> regarding any claims covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties acknowledge the right of the Employee or prospective Employee to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
report any good faith allegation of unlawful employment practices to any appropriate federal, state, or local government agency that
enforces anti-discrimination laws;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
report any good faith allegation of criminal conduct to any appropriate federal, state, or local official;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
participate in a proceeding with any appropriate federal, state, or local government agency that enforces anti-discrimination laws;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
make any truthful statements or disclosures required by law, regulation, or legal process; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
request or receive confidential legal advice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Mandatory Arbitration</U>. In exchange for the mutual promises contained in this Agreement, and as a condition of Employee&#146;s employment
with Employer, and Employee&#146;s sign-on bonus, Employer and Employee agree that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
any and all &#147;<B>Covered Claims</B>&#148; (as defined in Section 3 below) shall be submitted to and resolved by final and binding
arbitration to be held in Chicago, Illinois, before a single arbitrator and administered by JAMS or its successor, under JAMS&#146; then
applicable rules and procedures for employment disputes (available upon request and also currently available at <U>http://www.jamsadr.com/rules-employment-arbitration/</U>).
The Employee can also call the JAMS at (312) 655-0555 with any questions about the arbitration process. If the JAMS Employment Arbitration
Rules are inconsistent with the terms of this Agreement, the terms of this Agreement shall govern;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the Arbitrator, and not any federal, state, or local court or agency, shall have exclusive authority to resolve any dispute relating
to the interpretation, applicability, formation, or enforceability of this Agreement, including but not limited to the arbitrability
of any dispute between the parties, except for a dispute regarding the enforceability or scope of the waiver in Section 5, which shall
be determined by a court of competent jurisdiction; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &bull; Santa Monica, CA 90404</FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the Arbitrator&#146;s decision shall be final and binding only on the Parties to this Agreement and the Parties agree that awards deciding
issues for similarly situated employees will have no preclusive effect in any arbitration between the Parties; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
nothing in this Agreement shall preclude the Parties from seeking provisional remedies, such as an injunction or temporary restraining
order, in aid of arbitration from a court of competent jurisdiction or from the arbitrator; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the Arbitrator shall have no power to award punitive damages to either party, except where an applicable statute allows for punitive
damages; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the arbitration shall be conducted on a confidential basis and there shall be no disclosure of evidence or the award or Arbitrator&#146;s
decision beyond the arbitration proceeding, unless otherwise provided by this agreement or allowed by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Covered Claims</U>. Except as provided in Section 4, Covered Claims under this Agreement shall include all past, current, and future
grievances, disputes, claims, or causes of action that otherwise could be brought in a federal, state, or local court or agency under
applicable federal, state, or local laws, arising out of or relating to the Employee&#146;s employment with the Employer, including claims
arising out of or related to the Employee&#146;s hiring, recruitment, and termination of employment, and including claims the Employee may
have against the Employer or its officers, directors, supervisors, managers, employees, or agents in their capacity as such or otherwise,
or that the Employer may have against the Employee. Covered Claims include, but are not limited to, claims for breach of any contract
or covenant (express or implied), tort claims, claims for wages, or other compensation due, claims for wrongful termination (constructive
or actual), claims for discrimination, harassment, or retaliation (including, but not limited to, harassment or discrimination based
on race, age, color, sex, gender, gender identity, transgender status, sexual orientation, national origin, alienage or citizenship status,
creed, religion, marital status, partnership status, familial status, domestic violence victim status, military status, predisposing
genetic characteristics, medical condition, including pregnancy, psychological condition, mental condition, criminal accusations and
convictions, disability, or any other trait or characteristic protected by federal, state, or local law, claims for violation of any
federal, state, local or other governmental law, statute, regulation, or ordinance, including, but not limited to, all claims arising
under Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Family and Medical Leave Act, the Fair Labor
Standards Act, the Equal Pay Act, the Employee Retirement Income Security Act, the Civil Rights Act of 1991, Section 1981 of U.S.C. Title
42, the Worker Adjustment and Retraining Notification Act, the Age Discrimination in Employment Act, the Fair Credit Reporting Act, the
Uniform Services Employment and Reemployment Rights Act, the Genetic Information Nondiscrimination Act, the Illinois Human Rights Act,
the Right to Privacy in the Workplace Act, the Illinois Health and Safety Act, the Illinois Worker Adjustment and Retraining Notification
Act, the Illinois Union Employee Health and Benefits Protection Act, the Illinois Employment Contract Act, the Illinois Labor Dispute
Act, the Victims&#146; Economic Security and Safety Act, the Illinois Whistleblower Act, the Illinois Wage Payment and Collection Act, Minimum
Wage Law, Equal Pay Act of 2003, One Rest in Seven Act, the Illinois Biometric Information Privacy Act, all of their respective implementing
regulations, antitrust laws, and any other federal, state, local, or foreign law that governs the Parties&#146; employment relationship or
termination thereof that can be arbitrated under applicable law. Covered Claims under this Agreement include claims arising out of or
related to acts or omissions that occurred before entering into this Agreement and those that may occur in the future.</FONT></P>


<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Claims Not Covered</U>. Notwithstanding anything to the contrary in Section 2 or Section 3 of this Agreement, this Agreement does
not cover:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
claims for workers&#146; compensation benefits; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
claims for unemployment compensation benefits; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
claims for sexual harassment or abuse or claims of discrimination that are based on the same facts and circumstances or otherwise related
to excluded sexual harassment and abuse claims if any applicable federal, state, or local law prohibits mandatory arbitration of those
claims; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
whistleblower retaliation claims under the Sarbanes-Oxley Act (SOX) or the Dodd-Frank Act that cannot be arbitrated as a matter of law;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
administrative charges for unfair labor practices brought before the National Labor Relations Board; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
administrative charges brought before the Equal Employment Opportunity Commission, the Illinois Department of Human Rights and Illinois
Human Rights Commission, or other similar administrative agency; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
any other claims that, as a matter of law, the Parties cannot agree to arbitrate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything to the contrary in Section 2 or Section 3 of this Agreement, nothing in this Agreement prevents or shall be interpreted to mean
that the Employee is precluded from filing charges or complaints with or seeking relief from the National Labor Relations Board (NLRB),
the Equal Employment Opportunity Commission (EEOC), the Illinois Department of Human Rights and Illinois Human Rights Commission, or
any equivalent state or local agency, or testifying or participating in any proceedings before those administrative bodies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Waiver of Class and Collective Actions</U>. Employee and Employer expressly intend and agree that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
class and collective action procedures shall not be asserted and will not apply in any arbitration pursuant to this Agreement; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
each party will not assert class or collective claims against the other in court, in arbitration, or otherwise; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
each party shall only submit their own individual claims in arbitration and will not seek to represent the interests of any other person;
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
any claims by the Employee will not be joined, consolidated, or heard together with the claims of any other employee without the mutual
consent of the parties to the proceedings; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
no decision or arbitral award determining an issue with a similarly situated employee shall have any preclusive effect in any arbitration
between the Parties, and the Arbitrator shall have no authority to give preclusive effect to the issues determined in any arbitration
between the Employer and any other employee; and</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
notwithstanding anything to the contrary in the JAMS Employment Arbitration Rules, and the general grant of authority to the arbitrator
in paragraph 2 to determine issues of arbitrability, the arbitrator shall have no jurisdiction or authority:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
to compel any class or collective claim, consolidate different arbitration proceedings, or join any other party to an arbitration between
Employer and Employee; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
to determine the enforceability or scope of the class and collective action waiver, which shall be determined by a court of competent
jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Waiver of Trial by Jury</U>. The Parties understand and fully agree that by entering into this Agreement to arbitrate, they are giving
up their constitutional right to have a trial by jury, and are giving up their normal rights of appeal following the issuance of the
arbitrator&#146;s award except as applicable law provides for judicial review of arbitration proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Claims Procedure</U>. Arbitration shall be initiated by the express written notice of either Party. The aggrieved party must give
written notice of any claim to the other Party. Written notice of Employee&#146;s claim shall be mailed by certified or registered mail, return
receipt requested, to Employer&#146;s General Counsel or Chief Executive Officer at 2120 Colorado Avenue, Suite 230, Santa Monica, CA 90404
(&#147;<B>Notice Address</B>&#148;). Written notice of Employer&#146;s claim will be mailed to the last known address of Employee. The written
notice shall identify and describe the nature of all claims asserted and the facts supporting the claims. Written notice of arbitration
shall be initiated within the same time limitations that applicable federal and state law applies to those claim(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Arbitrator Selection</U>. The Arbitrator shall be selected as provided in the JAMS Employment Arbitration Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Discovery</U>. JAMS Employment Arbitration Rules regarding discovery shall apply to arbitration under this Agreement. To the extent
not provided for in the JAMS Employment Arbitration Rules, the Arbitrator has the power to order discovery upon a showing that discovery
is necessary for a Party to have a fair opportunity to present a claim or defense. The Arbitrator shall have the authority to set deadlines
for completion of discovery. The Arbitrator shall decide all discovery disputes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Governing Law; Substantive Law</U>. The Agreement and any arbitration shall be governed by the Federal Arbitration Act (FAA) to the
exclusion of any state law inconsistent with the FAA. If it is determined by a court that the FAA does not apply to the Parties&#146; dispute,
then the Illinois arbitration law shall apply. The Arbitrator shall apply the substantive state or federal law (including the applicable
statute of limitations) as applicable to the claim(s) asserted in arbitration. Claims arising under federal law shall be determined in
accordance with federal law. Common law claims shall be determined in accordance with Illinois substantive law, without regard to its
conflict of law Illinois substantive law, without regard to its conflict of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Compelling Arbitration: Enforcing Award</U>. Either party may ask a court to stay any court proceeding to compel arbitration under
this Agreement, and to confirm, vacate, or enforce an arbitration award. Judgment on the award rendered by the arbitrator may be entered
in any court of competent jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Arbitration Fees and Costs</U>. The Employer shall be responsible for the arbitrator&#146;s fees and arbitration expenses and any other
costs unique to the arbitration hearing, except that the Employee shall be responsible for paying the initial filing fees as provided
by the JAMS Employment Arbitration Rules. Each Party shall pay its own deposition, witness, expert, and attorneys&#146; fees and other expenses
to the same extent as if the matter were being heard in court. However, if any Party prevails on a statutory claim that affords the prevailing
party attorneys&#146; fees and costs, or if there is a written agreement providing for attorneys&#146; fees and costs to be awarded to the prevailing
party, the Arbitrator may award reasonable attorneys&#146; fees in accordance with the applicable statute or written agreement. The Arbitrator
shall resolve any dispute as to the reasonableness of any fees or costs awarded under this paragraph.</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Term of Agreement; Modification in Writing</U>. This Agreement to arbitrate shall survive the termination of Employee&#146;s employment.
It can only be revoked or modified in a writing that specifically states an intent to revoke or modify this Agreement and is signed by
both Employee and Employer&#146;s General Counsel or an authorized executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal; color: black; vertical-align: baseline; background-color: white"><U>Successors and Assigns</U></FONT>.
Employer may freely assign this Agreement at any time. This Agreement shall inure to the benefit of Employer&#146;s successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Severability</U>. If any provision of this Agreement to arbitrate is adjudged to be void or otherwise unenforceable, in whole or in
part, the void or unenforceable provision shall be severed and that adjudication shall not affect the validity of the remainder of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Voluntary Agreement</U>. By executing this Agreement the Parties represent that they have been given the opportunity to fully review
the terms of this Agreement. The Parties understand the terms of this Agreement and freely and voluntarily sign this Agreement. <B>EACH
PARTY FULLY UNDERSTANDS AND AGREES THAT THEY ARE GIVING UP CERTAIN RIGHTS OTHERWISE AFFORDED TO THEM BY CIVIL COURT ACTIONS, INCLUDING
BUT NOT LIMITED TO THE RIGHT TO A JURY OR COURT TRIAL AND THE RIGHT TO BRING ANY CLAIM AS A CLASS OR COLLECTIVE ACTION</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the Parties have executed this Agreement as of the Effective Date above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">BioVie Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Cuong Do</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: President &amp; Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EMPLOYEE</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 29%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Name:
    Jonathan Adams</P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>7
<FILENAME>bivi-20210930_10qex10z18.htm
<DESCRIPTION>EXHIBIT 10.18
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="bf001_v1.jpg" ALT="(BIOVIE)"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
23, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Penelope Markham<BR>
6405 Woodland Run Ct<BR>
Clifton, VA 20124</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employment
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Penny:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>BioVie,
Inc.</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, a Nevada corporation (the &#147;<B><I>Company</I></B>&#148;)
is pleased to offer you the position of <B>Executive Vice President, Liver Disease Research and Development,</B> on the following
terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will be responsible for leading the scientific for our liver disease programs and will report to Cuong Do. You will work remotely
and will travel as needed to fulfil your duties. Of course, the Company may change your position, duties, and work location from
time to time in its discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
base salary will be <B>$220,000 </B>on an annualized basis, less payroll deductions and withholdings, paid bi-weekly on the Company&#146;s
normal payroll schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will also be eligible to earn an annual discretionary performance bonus of up to <B>$66,000</B>. The amount of this bonus will
be determined in the sole discretion of the Company and based, in part, on your performance and the performance of the Company
during the calendar year. The Company will pay you this bonus, if any, by no later than September 15th after the closing of the
Company&#146;s fiscal year. The bonus is not earned until paid and no pro-rated amount will be paid if your employment terminates
for any reason prior to the payment date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
your employment, you will be eligible to participate in the standard benefits plans offered to similarly-situated employees by
the Company from time to time, subject to plan terms and generally applicable Company policies. Currently, the Company is pleased
to offer an enhanced benefits program. You will have a range of options to choose from for medical, dental and vision coverage.
The Company will cover 80% of the lowest cost plan, and you can pay for the difference between the company-supported amount and
the actual cost of the plan you select. The Company will also provide Basic Life &amp; AD&amp;D coverage of 2X your basic salary.
A full description of these benefits is available upon request. You will also qualify to participate in the 401(k) plan, which
matches your contributions dollar-for-dollar up to five percent (5%) of your salary. Exempt employees may take a reasonable amount
of time off with pay, as permitted by their duties and responsibilities, and as approved in advance by their supervisor. You will
qualify for three (3) weeks of paid vacation leave annually (prorated in the first calendar year of employment) plus any approved
company holidays. The Company may change compensation and benefits from time to time in its discretion. Additionally, you will
be entitled to paid sick leave as provided by applicable state law and/or local ordinance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &#9679; Santa Monica, CA 90404</FONT></P>
<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to approval by the Company&#146;s Board of Directors (the &#147;<B><I>Board</I></B>&#148;), the Company anticipates granting
you an option to purchase 124,167 shares of the Company&#146;s common stock at the fair market value as determined by the Board
as of the date of grant (the &#147;<B><I>Option</I></B>&#148;). The anticipated Option will be governed by the terms and conditions
of the Company&#146;s 2019 Omnibus Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;) and your grant agreement. Twenty
percent (20%) of the option grant will vest immediately and the remainder will vest in five equal installments on the anniversary
of the grant, subject to your Continuous Service (as defined in the Plan) as of each such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Company employee, you will be expected to abide by all Company rules and policies. As a condition of employment, you must sign
and comply with the attached Employee Confidential Information and Inventions Assignment Agreement which prohibits unauthorized
use or disclosure of the Company&#146;s proprietary information, among other obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets,
of any former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use
only that information which is generally known and used by persons with training and experience comparable to your own, which
is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by
the Company. You agree that you will not bring onto Company premises any unpublished documents or property belonging to any former
employer or other person to whom you have an obligation of confidentiality. You hereby represent that you have disclosed to the
Company any contract you have signed that may restrict your activities on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Normal
business hours are from 9:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to
work additional hours as required by the nature of your work assignments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
employment with the Company will be &#147;at-will.&#148; You may terminate your employment with the Company at any time and
for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with
or without cause or advance notice. Your employment at-will status can only be modified in a written agreement signed by you and
by an officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer is contingent upon a reference check and satisfactory proof of your right to work in the United States. You agree to assist
as needed and to complete any documentation at the Company&#146;s request to meet these conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, and
in exchange for the mutual promises contained in this Agreement and the sign-on bonus you and the Company agree to arbitrate all
disputes relating to your employment with the Company, the parties agree to arbitration administered by JAMS pursuant to its Employment
Arbitration Rules &amp; Procedures and subject to JAMS Policy on Employment Arbitration Minimum Standards of Procedural Fairness.
This mutual agreement to arbitrate is set forth more fully in the enclosed Mutual Agreement to Arbitrate Employment-Related Disputes
(&#147;Arbitration Agreement&#148;), the execution of which is a condition of your employment with the Company.</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer letter, together with your Employee Confidential Information and Inventions Assignment Agreement and the Arbitration Agreement,
forms the complete and exclusive statement of your employment agreement with the Company. It supersedes any other agreements or
promises made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes expressly
reserved to the Company&#146;s discretion in this letter, require a written modification signed by an officer of the Company.
If any provision of this offer letter agreement is determined to be invalid or unenforceable, in whole or in part, this determination
shall not affect any other provision of this offer letter agreement and the provision in question shall be modified so as to be
rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This letter
may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN
Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to
have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
sign and date this letter, the Employee Confidential Information and Inventions Assignment Agreement, and the Mutual Agreement
to Arbitrate Employment-Related Disputes and return them to me as soon as possible since your option grant will not take effect
until these agreements have been signed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
look forward to your favorable reply and to a productive and enjoyable work relationship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cuong
    Do</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
    CONTRACT CONTAINS A BINDING ARBITRATION PROVISION WHICH MAY BE ENFORCED BY THE PARTIES.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Understood
                                         and Accepted:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penelope
                                         Markham</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enclosures</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIAL
INFORMATION AND INVENTION ASSIGNMENT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of my employment with <FONT STYLE="font-variant: small-caps"><B>BioVie Inc.</B></FONT>, its subsidiaries, parents, affiliates,
successors and assigns (together &#147;<B><I>Company</I></B>&#148;), and the compensation paid to me now and during my employment with
Company, and the Company&#146;s agreement to provide me with access to its Confidential Information (as defined below), I hereby enter
into this Confidential Information and Invention Assignment Agreement (the &#147;<B><I>Agreement</I></B>&#148;) and agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
Information Protections</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 17.3pt; text-align: justify">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recognition
of Company&#146;s Rights; Nondisclosure</B>. I understand and acknowledge that my employment with Company creates a relationship of
confidence and trust with respect to Company&#146;s Confidential Information (as defined below) and that Company has a protectable interest
therein. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or publish
any of Company&#146;s Confidential Information, except as such disclosure, use or publication may be required in connection with my
work for Company, or unless an officer of Company expressly authorizes such disclosure. I will obtain Company&#146;s written approval
before publishing or submitting for publication any material (written, oral, or otherwise) that discloses and/or incorporates any Confidential
Information. I hereby assign to Company any rights I may have or acquire in such Confidential Information and recognize that all Confidential
Information will be the sole and exclusive property of Company and its assigns. I will take all reasonable precautions to prevent the
inadvertent accidental disclosure of Confidential Information. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b),
I will not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that:
(1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely
for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in
a lawsuit or other proceeding, if such filing is made under seal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential
Information</B>. The term &#147;<B><I>Confidential Information</I></B>&#148; means any and all confidential knowledge, data or information
of Company. By way of illustration but not limitation, &#147;<B><I>Confidential Information</I></B>&#148; includes (a) trade secrets,
inventions, mask works, ideas, processes, formulas, software in source or object code, data, programs, other works of authorship, know-how,
improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights
(as defined below) therein (collectively, &#147;<B><I>Inventions</I></B>&#148;); (b) information regarding research, development, new
products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts,
credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential
strategies, financial projections and business strategies, operational plans, financing and capital-raising plans, activities and agreements,
internal services and operational manuals, methods of conducting Company business, suppliers and supplier information, and purchasing;
(c) information regarding customers and potential customers of Company, including customer lists, names, representatives, their needs
or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties,
the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and
other non-public information relating to customers and potential customers; (d) information regarding any of Company&#146;s business
partners and their services, including names, representatives, proposals, bids, contracts and their contents and parties, the type and
quantity of products and services received by Company, and other non-public information relating to business partners; (e) information
regarding personnel, employee lists, compensation, and employee skills; and (f) any other non-public information which a competitor of
Company could use to the competitive disadvantage of Company. Notwithstanding the foregoing, it is understood that, at all such times,
I am free to use information which was known to me prior to my employment with Company or which is generally known in the trade or industry
through no breach of this Agreement or other act or omission by me. Notwithstanding the foregoing or anything to the contrary in this
Agreement or any other agreement between the Company and me, nothing in this Agreement will limit my right to discuss my employment or
report possible violations of law or regulation with the Equal Employment Opportunity Commission, United States Department of Labor,
the National Labor Relations Board, the Securities and Exchange Commission, or other federal government agency or similar state or local
agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National
Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including
but not limited to &#147;whistleblower&#148; statutes or other similar provisions that protect such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &#9679; Santa Monica, CA 90404</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third
Party Information</B>. I understand, in addition, that Company has received and in the future will receive from third parties their confidential
and/or proprietary knowledge, data or information (<B>&#147;<I>Third Party Information</I>&#148;</B>) subject to a duty on Company&#146;s
part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment
and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need
to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party
Information or unless expressly authorized by an officer of Company in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term
of Nondisclosure Restrictions</B>. I understand that Confidential Information and Third Party Information is never to be used or disclosed
by me, as provided in this Section 1. If a temporal limitation on my obligation not to use or disclose such information is required under
applicable law, and the Agreement or its restriction(s) cannot otherwise be enforced, I agree and Company agrees that the two year period
after the date my employment ends will be the temporal limitation relevant to the contested restriction; <B><I>provided, however</I>,
</B>that this sentence will not apply to trade secrets protected without temporal limitation under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Improper Use of Information of Prior Employers and Others</B>. During my employment with the Company, I will not improperly use or disclose
confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality,
and I will not bring onto the premises of Company any unpublished documents or any property belonging to any former employer or any other
person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignments
of Inventions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions</B>.
As used in this Agreement, the term <B>&#147;<I>Intellectual Property Rights</I>&#148;</B> means all trade secrets, Copyrights, trademarks,
mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country; the term &#147;<B><I>Copyright</I></B>&#148;
means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary,
musical, or artistic work) recognized by the laws of any jurisdiction or country; and the term &#147;<B><I>Moral Rights</I></B>&#148;
means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction
or country.</FONT></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Excluded
Inventions and Other Inventions</B>. Attached hereto as <B>Exhibit A</B> is a list describing all existing Inventions, if any, (a) that
are owned by me or in which I have an interest and were made or acquired by me prior to my date of first employment with the Company,
(b) that may relate to Company&#146;s business or actual or demonstrably anticipated research or development, and (c) that are not to
be assigned to Company (&#147;<B><I>Excluded Inventions</I></B>&#148;). If no such list is attached, I represent and agree that it
is because I have no Excluded Inventions. For purposes of this Agreement, &#147;<B><I>Other Inventions</I></B>&#148; means Inventions
in which I have or may have an interest, as of the commencement of my employment or thereafter, other than Company Inventions (as defined
below) and Excluded Inventions. I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of
my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any
Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any
rights assigned to Company under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise
in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not
I give Company notice as required above), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide
license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly
perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer
for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any
third parties have rights in any such Other Inventions, I hereby represent and warrant that such third party or parties have validly
and irrevocably granted to me the right to grant the license stated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment
of Company Inventions</B>. Inventions assigned to Company or to a third party as directed by Company pursuant to Section 2.6 are referred
to in this Agreement as &#147;<B><I>Company Inventions</I></B>.&#148; Subject to Section 2.4 and except for Excluded Inventions set
forth in <B>Exhibit A</B> and Other Inventions, I hereby assign to Company all my right, title, and interest in and to any and all Inventions
(and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with
others, during the period of my employment with the Company. To the extent required by applicable Copyright laws, I agree to assign in
the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such
Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment
of all Moral Rights. To the extent such Moral Rights cannot be assigned to Company and to the extent the following is allowed by the
laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and
all claims and causes of action of any kind against Company or related to Company&#146;s customers, with respect to such rights. I further
acknowledge and agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions (and any
Intellectual Property Rights with respect thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unassigned
or Nonassignable Inventions</B>. I recognize that this Agreement will not be deemed to require assignment of any Invention that I developed
entirely on my own time without using the Company&#146;s equipment, supplies, facilities, trade secrets, or Confidential Information,
except for those Inventions that either (i) relate to the Company&#146;s actual or anticipated business, research or development, or
(ii) result from or are connected with work performed by me for the Company. In addition, this Agreement does not apply to any Invention
which qualifies fully for protection from assignment to the Company under any specifically applicable state law, regulation, rule or
public policy (&#147;<B><I>Specific Inventions Law</I></B>&#148;).</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obligation
to Keep Company Informed</B>. During the period of my employment, I will promptly and fully disclose to Company in writing all Inventions
authored, conceived, or reduced to practice by me, either alone or jointly with others. At the time of each such disclosure, I will advise
Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the Specific Inventions Law;
and I will at that time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep in confidence
and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to
Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the Specific Inventions Law. I will
preserve the confidentiality of any Invention that does not fully qualify for protection under the Specific Inventions Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government
or Third Party</B>. I agree that, as directed by Company, I will assign to a third party, including without limitation the United States,
all my right, title, and interest in and to any particular Company Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership
of Work Product</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 51.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment
and which are protectable by Copyright are &#147;works made for hire,&#148; pursuant to United States Copyright Act (17 U.S.C., Section
101).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 51.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that Company will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment,
and I hereby irrevocably and unconditionally assign to Company all right, title, and interest worldwide in and to such work product.
I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected
by this Section, except as necessary to perform services for Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement
of Intellectual Property Rights and Assistance</B>. I will assist Company in every proper way to obtain, and from time to time enforce,
United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries. To that
end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may
reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights
and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Company
or its designee, including the United States or any third party designated by Company. My obligation to assist Company with respect to
Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my
employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company&#146;s
request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document
needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized
officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and on my behalf to execute,
verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with
the same legal force and effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever,
which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporation
of Software Code</B>. I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code
licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions
the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company <B>except
</B>in strict compliance with Company&#146;s policies regarding the use of such software.</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Records</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that
is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my
employment at Company, which records will be available to and remain the sole property of Company at all times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duty
of Loyalty During Employment</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. I agree that during the period of my
employment with Company, I will not, without Company&#146;s express written consent, directly or indirectly engage in any employment
or business activity which is directly or indirectly competitive with, or would otherwise conflict with, my employment with Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonableness
of Restrictions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that I have read this entire Agreement and understand it. I acknowledge that I have the right to consult with counsel prior to
signing this Agreement. I further acknowledge that I will derive significant value from the Company&#146;s agreement to provide me with
Company Confidential Information to enable me to optimize the performance of my duties to the Company. I further acknowledge that my
fulfillment of the obligations contained in this Agreement, including, but not limited to, my obligation neither to disclose nor to use
Company Confidential Information other than for the Company&#146;s exclusive benefit and my obligations not to solicit are necessary
to protect Company Confidential Information and, consequently, to preserve the value and goodwill of the Company. I agree that this Agreement
does not prevent me from earning a living or pursuing my career. I agree that the restrictions contained in this Agreement are reasonable,
proper, and necessitated by Company&#146;s legitimate business interests. I represent and agree that I am entering into this Agreement
freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>In
the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, I and Company agree
that the court will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum
extent allowed by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Conflicting Agreement or Obligation</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>I represent that my performance of all the terms of this Agreement and as an intern of Company does not and will not breach any
agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment with Company. I have not
entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
of Company Property</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. When I leave the employ of Company, I will deliver
to Company any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof,
and any other material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company.
I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return
it to Company. In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit
any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer-useable copy
of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems; and I
agree to provide Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed.
I further agree that any property situated on Company&#146;s premises and owned by Company, including disks and other storage media,
filing cabinets or other work areas, is subject to inspection by Company&#146;s personnel at any time with or without notice. Prior
to leaving, I will cooperate with Company in attending an exit interview and completing and signing Company&#146;s termination statement
if required to do so by Company.</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
and Equitable Remedies</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree that any
threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company, and
Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable
relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that if Company is successful in whole or in part in any legal or equitable action against me under this Agreement, Company will
be entitled to payment of all costs, including reasonable attorney&#146;s fees, from me.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice
is given, labeled &#147;Attention Chief Executive Officer,&#148; and to me at my address as listed on Company payroll, or at such other
address as Company or I may designate by written notice to the other. Notice will be effective upon receipt or refusal of delivery. If
delivered by certified or registered mail, notice will be considered to have been given five business days after it was mailed, as evidenced
by the postmark. If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected
by the courier or express mail service receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
of This Agreement to Subsequent Employer or Business Associates of Intern</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.1&nbsp;&nbsp;&nbsp;&nbsp;</B>If
I am offered employment or the opportunity to enter into any business venture as owner, partner, consultant or other capacity while the
restrictions described in Section <B>Error! Reference source not found.</B> of this Agreement are in effect I agree to inform my potential
employer, partner, co-owner and/or others involved in managing the business with which I have an opportunity to be associated of my obligations
under this Agreement and also agree to provide such person or persons with a copy of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
Provisions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.1&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law; Consent to Personal Jurisdiction</B>. This Agreement will be governed by and construed according to the laws of the Commonwealth of Virginia as such laws are applied to
agreements entered into and to be performed entirely within Virginia between residents of Virginia. I hereby expressly consent to the
personal jurisdiction and venue of the state and federal courts located in Virginia for any lawsuit filed there against me by Company
arising from or related to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2&nbsp;&nbsp;&nbsp;&nbsp;Severability</B>.
In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions
of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained
in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively
broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable
to the extent compatible with the applicable law as it will then appear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3&nbsp;&nbsp;&nbsp;&nbsp;Successors
and Assigns</B>. This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, subsidiaries,
affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival</B>.
This Agreement will survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company
to any successor in interest or other assignee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At-Will
Status</B>. I agree and understand that nothing in this Agreement will change my at-will status or confer any right with respect to continuation
of my employment with Company, nor will it interfere in any way with my right or Company&#146;s right to terminate my employment at
any time, with or without cause or advance notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waiver</B>.
No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach. No waiver by Company of
any right under this Agreement will be construed as a waiver of any other right. Company will not be required to give notice to enforce
strict adherence to all terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Export</B>.
I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing
such data, in violation of the United States export laws or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts</B>.
This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will
constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission
method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advice
of Counsel</B>. <B>I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL
COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT WILL NOT BE CONSTRUED AGAINST
ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire
Agreement</B>. The obligations pursuant to Sections 1 and 2 (except Subsection 2.4 and Subsection 2.7(a)) of this Agreement will apply
to any time during which I was previously engaged, or am in the future engaged, by Company as a consultant if no other agreement governs
nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties
with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us<B>.</B> No modification
of or amendment to this Agreement will be effective unless in writing and signed by the party to be charged. Any subsequent change or
changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[signatures
to follow on next page]</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement will be effective as of August 23, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; width: 40%; font-weight: bold; text-align: justify; text-indent: 0">Employee:</TD>
    <TD STYLE="padding: 0; width: 60%; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-weight: bold; text-align: left; text-indent: 0">I have read this agreement carefully and understand its terms.&nbsp;&nbsp;I have completely filled out Exhibit&nbsp;A to this Agreement.</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(Signature)</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Name</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Date</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-bottom: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accepted
    and agreed</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:<BR>
    Title:</FONT></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Excluded
Inventions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FROM:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATE:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: -0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Excluded
Inventions Disclosure</B>. Except as listed in Section 2 below, the following is a complete list of all Excluded Inventions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Excluded Inventions.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
below:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.6in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
sheets attached.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Due
to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to the Excluded Inventions
generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; width: 0.3in; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 25%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Excluded
    Invention</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 40%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Party(ies)</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 25%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Relationship</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
sheets attached.</FONT></TD>
</TR></TABLE>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioVie
Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Mutual
Agreement to Arbitrate Employment-Related Disputes</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Mutual Agreement to Arbitrate Disputes (&#147;<B>Agreement</B>&#148;) is made and entered into as of August 23, 2021 (the &#147;<B>Effective
Date</B>&#148;) by and between BioVie, Inc., a Nevada corporation, (the &#147;<B>Employer</B>&#148;) and Penelope Markham, an
individual (the &#147;<B>Employee</B>&#148;) (the Employer and the Employee are collectively referred to herein as the &#147;<B>Parties</B>&#148;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-weight: normal; color: black; vertical-align: baseline; background-color: white"><U>Intent of Agreement</U></FONT>.
It is the intent of Employee and the Employer that this Agreement will govern the resolution of all disputes, claims and any other matters
in question arising out of or relating to the Parties&#146; employment relationship. The Parties shall resolve all disputes arising out
of the employment relationship in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Mandatory
Arbitration</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Employer and Employee agree
that any claim, complaint, or dispute that relates in any way to the Parties&#146; employment relationship, whether based in contract,
tort, statute, fraud, misrepresentation or any other legal theory, shall be submitted to final, binding and confidential arbitration
conducted by JAMS or its successor, under JAMS&#146; then applicable rules and procedures for employment disputes (available upon request
and also currently available at <U>http://www.jamsadr.com/rules-employment-arbitration/</U>). You can also call JAMS at (213) 620-0100
if you have questions about the arbitration process. If the JAMS Employment Arbitration Rules are inconsistent with the terms of this
Agreement, the terms of this Agreement shall govern, except as otherwise required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Covered
Claims</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This Agreement to arbitrate covers
all grievances, disputes, claims, or causes of action (collectively, &#147;<B>claims</B>&#148;) in a federal, state or local court or
agency under applicable federal, state or local laws, arising out of Employee&#146;s employment with the Employer and the termination
thereof, including claims Employee may have against the Employer or against its officers, directors, supervisors, managers, employees,
or agents in their capacity as such or otherwise, or that the Employer may have against Employee. The claims covered by this Agreement
include, but are not limited to, claims for breach of any contract or covenant (express or implied), tort claims, claims for wrongful
termination (constructive or actual) in violation of public policy, claims for discrimination or harassment (including, but not limited
to, harassment or discrimination based on race, sex, gender, religion, national origin, age, marital status, medical condition, psychological
condition, mental condition, disability, or sexual orientation), claims for violation of any federal, state, or other governmental law,
statute, regulation, or ordinance, including, but not limited to, all claims arising under Title VII of the Civil Rights Act, the Age
Discrimination in Employment Act, the Americans With Disabilities Act, claims of discrimination or retaliation under Virginia law, any
and all similar or employment laws of the Commonwealth of Virginia, such as the Virginia Human Rights Act, Virginians with Disabilities
Act, Virginia Payment of Wages Law, to the extent that such claims may be waived and released; and the human rights and fair employment
practices laws (whether statutory or common laws) of the state or states and localities in which you have provided services to the Company
(each as amended). The parties to this Agreement specifically agree that all claims under the Labor Code of Virginia, including, but
not limited to, claims for overtime, unpaid wages, and claims involving meal and rest breaks shall be subject to this Arbitration Agreement.
(&#147;<B>Covered Claims</B>&#148;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Claims
Not Covered</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Claims not covered by this Agreement
are claims for workers&#146; compensation, unemployment compensation benefits, administrative charges for unfair labor practices brought
before the National Labor Relations Board, Excluded Claims (defined in Paragraph 5 below), or any other claims that, as a matter of law,
the Parties cannot agree to arbitrate. Nothing in this Agreement shall be interpreted to mean that employees are precluded from filing
complaints with the Virginia Office of Civil Rights and/or federal Equal Employment Opportunity Commission and National Labor Relations
Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2120
Colorado Avenue, Suite 230 &#9679; Santa Monica, CA 90404</FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Waiver
of Class Action and Representative Action Claims</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Waiver of Class Action and Representative Action Claims. Except for representative claims which cannot be waived under applicable law
and which are therefore excluded from this Agreement (&#147;Excluded Claims&#148;), Employee and the Company expressly intend and agree
that: (a) class action and representative action procedures are hereby waived and shall not be asserted, nor will they apply, in any
arbitration pursuant to this Agreement; (b) each will not assert class action or representative action claims against the other in arbitration
or otherwise; and (c) Employee and the Company shall only submit their own, individual claims in arbitration and will not seek to represent
the interests of any other person. To the extent that the Parties&#146; dispute involves both timely filed Excluded Claims and claims
subject to this Agreement, the Parties agree to bifurcate and stay for the duration of the arbitration proceedings any such Excluded
Claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Waiver
of Trial by Jury</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Parties understand
and fully agree that by entering into this Agreement to arbitrate, they are giving up their constitutional right to have a trial by jury,
and are giving up their normal rights of appeal following the rendering of a decision except as Virginia law provides for judicial review
of arbitration proceedings. The Parties anticipate that by entering into this Agreement, they will gain the benefits of a speedy and
less expensive dispute resolution procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Claims
Procedure</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Arbitration shall be initiated
upon the express written notice of either party. The aggrieved party must give written notice of any claim to the other party. Written
notice of an Employee&#146;s claim shall be mailed by certified or registered mail, return receipt requested, to the Employer&#146;s
General Counsel or Chief Executive Officer at 2120 Colorado Avenue, Suite 230 &bull; Santa Monica, CA 90404 (&#147;<B>Notice Address</B>&#148;).
Written notice of the Employer&#146;s claim will be mailed to the last known address of Employee. The written notice shall identify and
describe the nature of all claims asserted and the facts upon which such claims are based. Written notice of arbitration shall be initiated
within the same time limitations that Virginia law applies to those claim(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Arbitrator
Selection</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Arbitrator shall be selected
as provided in JAMS&#146; Rules and Procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Discovery</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The JAMS Employment Arbitration Rules regarding discovery shall apply to arbitration under this Agreement. The Arbitrator selected according
to this Agreement shall decide all discovery disputes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Substantive
Law</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Arbitrator shall apply the substantive
state or federal law (and the law of remedies, if applicable) as applicable to the claim(s) asserted. The Arbitrator shall conduct and
preside over an arbitration hearing of reasonable length, to be determined by the Arbitrator. The Arbitrator shall provide the Parties
with a written decision explaining his or her findings and conclusions. The Arbitrator&#146;s decision shall be final and binding upon
the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-weight: normal; color: black; vertical-align: baseline; background-color: white"><U>Motions</U></FONT>.
The Arbitrator shall have jurisdiction to hear and rule on prehearing disputes and is authorized to hold prehearing conferences by telephone
or in person as the Arbitrator deems necessary. The Arbitrator shall have the authority to set deadlines for completion of discovery,
and for filing motions for summary judgment, and to set briefing schedules for any motions. The Arbitrator shall have the authority to
adjudicate any cause of action, or the entire claim, pursuant to a motion for summary adjudication and/or summary judgment, and, in deciding
such motions, shall apply the law of the Commonwealth of Virginia.</FONT></P>

<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Compelling
Arbitration/Enforcing Award</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Either party
may bring an action in court to compel arbitration under this Agreement or to otherwise determine the arbitrability of claims under this
Agreement, and to confirm, vacate or enforce an arbitration award, and each party shall bear its own attorney fees and costs and other
expenses of such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-weight: normal; color: black; vertical-align: baseline; background-color: white"><U>Arbitration
Fees and Costs</U></FONT>. The Employer shall be responsible for the arbitrator&#146;s fees and expenses. Each party shall pay its own
costs and attorneys&#146; fees, if any. However, if any party prevails on a statutory claim which affords the prevailing party attorneys&#146;
fees and costs, or if there is a written agreement providing for attorneys&#146; fees and costs, the Arbitrator may award reasonable
attorneys&#146; fees and costs to the prevailing party. Any dispute as to the reasonableness of any fee or cost shall be resolved by
the Arbitrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Term of Agreement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
This Agreement to arbitrate shall survive the termination of Employee&#146;s employment. It can only be revoked or modified in writing
signed by both Parties that specifically states an intent to revoke or modify this Agreement and is signed by the Employer&#146;s General
Counsel or an authorized executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Severability</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
If any provision of this Agreement to arbitrate is adjudged to be void or otherwise unenforceable, in whole or in part, the void or unenforceable
provision shall be severed and such adjudication shall not affect the validity of the remainder of this Agreement to arbitrate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Voluntary Agreement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
By executing this Agreement the Parties represent that they have been given the opportunity to fully review, comprehend and negotiate
the terms of this Agreement. The Parties understand the terms of this Agreement and freely and voluntarily sign this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the Parties have executed this Agreement as of the Effective Date above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioVie
                    Inc.&nbsp;</FONT></P>

</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Cuong Do</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: President &amp; CEO</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EMPLOYEE</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>8
<FILENAME>bivi-20210930_10qex10z19.htm
<DESCRIPTION>EXHIBIT 10.19
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="bf001_v1.jpg" ALT="(BIOVIELOGO)">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
3, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Joseph M. Palumbo</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">616
Brookside Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saint
Davids, PA 19087</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Updated
Offer of Employment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Dr. Palumbo:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>BioVie,
Inc.</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, a Nevada corporation (the &#147;<B><I>Company</I></B>&#148;)
is pleased to offer you the position of <B>Executive Vice President and Chief Medical Officer</B>, on the following terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will be responsible for overseeing the clinical development efforts for all of the Company&#146;s assets and will report to the
Company&#146;s Chief Executive Officer. You can work remotely and are expected to travel as needed to fulfill your duties. Of
course, the Company may change your position, duties, and work location from time to time in its discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
base salary will be <B>$500,000 </B>on an annualized basis, less payroll deductions and withholdings, paid bi-weekly on the Company&#146;s
normal payroll schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will also pay to you a one-time cash bonus of up to <B>$165,000</B>, less payroll deductions and withholdings, as follows:
<B>$50,000</B> as part of the first payroll following the start of your employment with the Company, followed by three (3) equal
quarterly installments of <B>$38,333.33</B>, each payable on the next following payroll date, provided you are still employed
by the Company on those dates. If, however, your employment with the Company is terminated by the Company for cause or by you
without Good Reason (as defined below) within 18 months of your start date, you shall promptly repay in full all of the foregoing
bonus amounts previously paid to you, with the Company having the right to the extent legally permitted to set off any such amount
you are obligated to repay against any amounts owed by the Company to you as of the termination of your employment, and you will
forfeit payment of any remaining bonus installments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will also be eligible to earn an annual discretionary performance bonus of up to <B>$150,000</B>. The amount of this bonus will
be determined in the sole discretion of the Company and based, in part, on your performance and the performance of the Company
during the calendar year. The Company will pay you this bonus, if any, by no later than September 15th after the closing of the
Company&#146;s fiscal year. The bonus is not earned until paid and no pro-rated amount will be paid if your employment terminates
for any reason prior to the payment date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the termination of your employment by the Company without cause or by you for Good Reason (as defined below), you shall the right
to receive&nbsp;severance payments in the form of a continuation of your cash base salary as in effect immediately prior to such
termination for a&nbsp;period of twelve (12) months following the effective date of such termination so long as you execute a
binding and enforceable general release containing terms reasonably satisfactory to the Company. For purposes of this Agreement,
&#147;<B><I>Good Reason</I></B>&#148; means (i)&nbsp;any breach by the Company of any of its material obligations under this
offer letter agreement, (ii)&nbsp;any material reduction in your duties, authority or responsibilities without your consent other
than for cause, or (iii)&nbsp;any assignment to you of duties or responsibilities materially inconsistent with your position and
duties contained in this offer letter agreement without your consent; provided, however, that you may not terminate your employment
for Good Reason unless you first provide the Company with written notice specifying the Good Reason and provide the Company with
30 days in which to remedy the stated reason.</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
your employment, you will be eligible to participate in the standard benefits plans offered to similarly-situated employees by
the Company from time to time, subject to plan terms and generally applicable Company policies. You will have a range of options
to choose from for medical, dental and vision coverage. The Company will cover 80% of the lowest cost plan, and you can pay for
the difference between the company-supported amount and the actual cost of the plan you select. The Company will also provide
Basic Life &amp; AD&amp;D coverage of 2X your basic salary. A full description of these benefits is available upon request. You
will also qualify to participate in the 401(k) plan, which matches your contributions dollar-for-dollar up to five percent (5%)
of your salary. Exempt employees may take a reasonable amount of time off with pay, as permitted by their duties and responsibilities,
and as approved in advance by their supervisor. You will qualify for four (4) weeks of paid vacation leave annually (prorated
in the first calendar year of employment) plus any approved company holidays. The Company may change compensation and benefits
from time to time in its discretion. Additionally, you will be entitled to paid sick leave as provided by applicable state law
and/or local ordinance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to approval by the Company&#146;s Board of Directors (the &#147;<B><I>Board</I></B>&#148;), the Company anticipates granting
you a non-qualified option to purchase 124,167 shares of the Company&#146;s common stock at the fair market value as determined
by the Board as of the date of grant (the &#147;<B><I>Option</I></B>&#148;). The anticipated Option will be governed by the
terms and conditions of the Company&#146;s 2019 Omnibus Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;) and your
grant agreement. Twenty percent (20%) of the option grant will vest immediately and the remainder will vest in five equal installments
on the anniversary of the grant, with any unvested portion of such Option vesting in full upon the occurrence of a Change of Control
(as defined in the Plan), in all cases subject to your Continuous Service (as defined in the Plan) as of each such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Company employee, you will be expected to abide by all Company rules and policies. As a condition of employment, you must sign
and comply with the attached Employee Confidential Information and Inventions Assignment Agreement which prohibits unauthorized
use or disclosure of the Company&#146;s proprietary information, among other obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets,
of any former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use
only that information which is generally known and used by persons with training and experience comparable to your own, which
is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by
the Company. You agree that you will not bring onto Company premises any unpublished documents or property belonging to any former
employer or other person to whom you have an obligation of confidentiality. You hereby represent that you have disclosed to the
Company any contract you have signed that may restrict your activities on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Normal
business hours are from 9:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to
work additional hours as required by the nature of your work assignments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
employment with the Company will be &#147;at-will.&#148; You may terminate your employment with the Company at any time and
for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with
or without cause or advance notice. Further, the Company may change your compensation and benefits from time to time in its discretion.
Your employment at-will status can only be modified in a written agreement signed by you and by an authorized officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer is contingent upon a reference check and satisfactory proof of your right to work in the United States. You agree to assist
as needed and to complete any documentation at the Company&#146;s request to meet these conditions.</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, and
in exchange for the mutual promises contained in this offer letter agreement and the Option grant you and the Company agree to
arbitrate all disputes relating to your employment with the Company, including the terms of this offer letter agreement, pursuant
to arbitration administered by JAMS pursuant to its Employment Arbitration Rules &amp; Procedures and subject to JAMS Policy on
Employment Arbitration Minimum Standards of Procedural Fairness. This mutual agreement to arbitrate is set forth more fully in
the enclosed Mutual Agreement to Arbitrate Employment-Related Disputes (&#147;Arbitration Agreement&#148;), the execution of
which is a condition of your employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer letter agreement, together with your Employee Confidential Information and Inventions Assignment Agreement and the Arbitration
Agreement, forms the complete and exclusive statement of your employment agreement with the Company. It supersedes any other agreements
or promises made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes expressly
reserved to the Company&#146;s discretion in this offer letter agreement, require a written modification signed by an authorized
officer of the Company. If any provision of this offer letter agreement is determined to be invalid or unenforceable, in whole
or in part, this determination shall not affect any other provision of this offer letter agreement and the provision in question
shall be modified so as to be rendered enforceable in a manner consistent with the intent of you and the Company insofar as possible
under applicable law. This offer letter agreement may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other
transmission method and shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. This
offer letter agreement will be governed by and construed according to the laws of Pennsylvania as such laws are applied to agreements
entered into and to be performed entirely within Pennsylvania between residents of Pennsylvania. Subject to the parties duty to
arbitrate as set forth above and in the Arbitration Agreement, you hereby expressly consent to the personal jurisdiction and venue
of the state and federal courts located in Pennsylvania for any lawsuit filed there against you by the Company arising from or
related to this offer letter agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
sign and date this offer letter agreement, the Employee Confidential Information and Inventions Assignment Agreement, and the
Mutual Agreement to Arbitrate Employment-Related Disputes and return them to me by September 10<SUP>th</SUP> if you wish to accept
employment at the Company under the terms described above. If you accept our offer, we expect you to start on November 1st.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
look forward to your favorable reply and to a productive and enjoyable work relationship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cuong
    Do</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
&amp; CEO&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
    OFFER LETTER AGREEMENT CONTAINS A BINDING ARBITRATION PROVISION WHICH MAY BE ENFORCED BY THE PARTIES.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Understood
and Accepted:</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    M. Palumbo</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enclosures</FONT></P>



<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIAL
INFORMATION AND INVENTION ASSIGNMENT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of my employment with <FONT STYLE="font-variant: small-caps"><B>BioVie Inc.</B></FONT>, its subsidiaries, parents, affiliates,
successors and assigns (together &#147;<B><I>Company</I></B>&#148;), and the compensation paid to me now and during my employment with
Company, and the Company&#146;s agreement to provide me with access to its Confidential Information (as defined below), I hereby enter
into this Confidential Information and Invention Assignment Agreement (the &#147;<B><I>Agreement</I></B>&#148;) and agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
Information Protections</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 17.3pt; text-align: justify">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recognition
of Company&#146;s Rights; Nondisclosure</B>. I understand and acknowledge that my employment with Company creates a relationship of
confidence and trust with respect to Company&#146;s Confidential Information (as defined below) and that Company has a protectable interest
therein. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or publish
any of Company&#146;s Confidential Information, except as such disclosure, use or publication may be required in connection with my
work for Company, or unless an officer of Company expressly authorizes such disclosure. I will obtain Company&#146;s written approval
before publishing or submitting for publication any material (written, oral, or otherwise) that discloses and/or incorporates any Confidential
Information. I hereby assign to Company any rights I may have or acquire in such Confidential Information and recognize that all Confidential
Information will be the sole and exclusive property of Company and its assigns. I will take all reasonable precautions to prevent the
inadvertent accidental disclosure of Confidential Information. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b),
I will not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that:
(1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely
for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in
a lawsuit or other proceeding, if such filing is made under seal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential
Information</B>. The term &#147;<B><I>Confidential Information</I></B>&#148; means any and all confidential knowledge, data or
information of Company. By way of illustration but not limitation, &#147;<B><I>Confidential Information</I></B>&#148; includes
(a) trade secrets, inventions, mask works, ideas, processes, formulas, software in source or object code, data, programs, other
works of authorship, know-how, improvements, discoveries, developments, designs and techniques and any other proprietary technology
and all Intellectual Property Rights (as defined below) therein (collectively, &#147;<B><I>Inventions</I></B>&#148;); (b) information
regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements,
licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods of obtaining
business, forecasts, future plans and potential strategies, financial projections and business strategies, operational plans,
financing and capital-raising plans, activities and agreements, internal services and operational manuals, methods of conducting
Company business, suppliers and supplier information, and purchasing; (c) information regarding customers and potential customers
of Company, including customer lists, names, representatives, their needs or desires with respect to the types of products or
services offered by Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and
services provided or sought to be provided to customers and potential customers of Company and other non-public information relating
to customers and potential customers; (d) information regarding any of Company&#146;s business partners and their services, including
names, representatives, proposals, bids, contracts and their contents and parties, the type and quantity of products and services
received by Company, and other non-public information relating to business partners; (e) information regarding personnel, employee
lists, compensation, and employee skills; and (f) any other non-public information which a competitor of Company could use to
the competitive disadvantage of Company. Notwithstanding the foregoing, it is understood that, at all such times, I am free to
use information which was known to me prior to my employment with Company or which is generally known in the trade or industry
through no breach of this Agreement or other act or omission by me. Notwithstanding the foregoing or anything to the contrary
in this Agreement or any other agreement between the Company and me, nothing in this Agreement will limit my right to discuss
my employment or report possible violations of law or regulation with the Equal Employment Opportunity Commission, United States
Department of Labor, the National Labor Relations Board, the Securities and Exchange Commission, or other federal government agency
or similar state or local agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted
by Section 7 of the National Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions
of law or regulation, including but not limited to &#147;whistleblower&#148; statutes or other similar provisions that protect
such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third
Party Information</B>. I understand, in addition, that Company has received and in the future will receive from third parties their confidential
and/or proprietary knowledge, data or information (<B>&#147;<I>Third Party Information</I>&#148;</B>) subject to a duty on Company&#146;s
part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment
and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need
to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party
Information or unless expressly authorized by an officer of Company in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term
of Nondisclosure Restrictions</B>. I understand that Confidential Information and Third Party Information is never to be used or disclosed
by me, as provided in this Section 1. If a temporal limitation on my obligation not to use or disclose such information is required under
applicable law, and the Agreement or its restriction(s) cannot otherwise be enforced, I agree and Company agrees that the two year period
after the date my employment ends will be the temporal limitation relevant to the contested restriction; <B><I>provided, however</I>,
</B>that this sentence will not apply to trade secrets protected without temporal limitation under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Improper Use of Information of Prior Employers and Others</B>. During my employment with the Company, I will not improperly use or disclose
confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality,
and I will not bring onto the premises of Company any unpublished documents or any property belonging to any former employer or any other
person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignments
of Inventions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions</B>.
As used in this Agreement, the term <B>&#147;<I>Intellectual Property Rights</I>&#148;</B> means all trade secrets, Copyrights, trademarks,
mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country; the term &#147;<B><I>Copyright</I></B>&#148;
means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary,
musical, or artistic work) recognized by the laws of any jurisdiction or country; and the term &#147;<B><I>Moral Rights</I></B>&#148;
means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction
or country.</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Excluded
Inventions and Other Inventions</B>. Attached hereto as <B>Exhibit A</B> is a list describing all existing Inventions, if any, (a) that
are owned by me or in which I have an interest and were made or acquired by me prior to my date of first employment with the Company,
(b) that may relate to Company&#146;s business or actual or demonstrably anticipated research or development, and (c) that are not to
be assigned to Company (&#147;<B><I>Excluded Inventions</I></B>&#148;). If no such list is attached, I represent and agree that it
is because I have no Excluded Inventions. For purposes of this Agreement, &#147;<B><I>Other Inventions</I></B>&#148; means Inventions
in which I have or may have an interest, as of the commencement of my employment or thereafter, other than Company Inventions (as defined
below) and Excluded Inventions. I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of
my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any
Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any
rights assigned to Company under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise
in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not
I give Company notice as required above), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide
license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly
perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer
for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any
third parties have rights in any such Other Inventions, I hereby represent and warrant that such third party or parties have validly
and irrevocably granted to me the right to grant the license stated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment
of Company Inventions</B>. Inventions assigned to Company or to a third party as directed by Company pursuant to Section 2.6 are referred
to in this Agreement as &#147;<B><I>Company Inventions</I></B>.&#148; Subject to Section 2.4 and except for Excluded Inventions set
forth in <B>Exhibit A</B> and Other Inventions, I hereby assign to Company all my right, title, and interest in and to any and all Inventions
(and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with
others, during the period of my employment with the Company. To the extent required by applicable Copyright laws, I agree to assign in
the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such
Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment
of all Moral Rights. To the extent such Moral Rights cannot be assigned to Company and to the extent the following is allowed by the
laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and
all claims and causes of action of any kind against Company or related to Company&#146;s customers, with respect to such rights. I further
acknowledge and agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions (and any
Intellectual Property Rights with respect thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unassigned
or Nonassignable Inventions</B>. I recognize that this Agreement will not be deemed to require assignment of any Invention that I developed
entirely on my own time without using the Company&#146;s equipment, supplies, facilities, trade secrets, or Confidential Information,
except for those Inventions that either (i) relate to the Company&#146;s actual or anticipated business, research or development, or
(ii) result from or are connected with work performed by me for the Company. In addition, this Agreement does not apply to any Invention
which qualifies fully for protection from assignment to the Company under any specifically applicable state law, regulation, rule or
public policy (&#147;<B><I>Specific Inventions Law</I></B>&#148;).</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obligation
to Keep Company Informed</B>. During the period of my employment, I will promptly and fully disclose to Company in writing all Inventions
authored, conceived, or reduced to practice by me, either alone or jointly with others. At the time of each such disclosure, I will advise
Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the Specific Inventions Law;
and I will at that time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep in confidence
and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to
Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the Specific Inventions Law. I will
preserve the confidentiality of any Invention that does not fully qualify for protection under the Specific Inventions Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government
or Third Party</B>. I agree that, as directed by Company, I will assign to a third party, including without limitation the United States,
all my right, title, and interest in and to any particular Company Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership
of Work Product</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 51.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment
and which are protectable by Copyright are &#147;works made for hire,&#148; pursuant to United States Copyright Act (17 U.S.C., Section
101).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 51.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that Company will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment,
and I hereby irrevocably and unconditionally assign to Company all right, title, and interest worldwide in and to such work product.
I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected
by this Section, except as necessary to perform services for Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement
of Intellectual Property Rights and Assistance</B>. I will assist Company in every proper way to obtain, and from time to time enforce,
United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries. To that
end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may
reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights
and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Company
or its designee, including the United States or any third party designated by Company. My obligation to assist Company with respect to
Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my
employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company&#146;s
request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document
needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized
officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and on my behalf to execute,
verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with
the same legal force and effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever,
which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporation
of Software Code</B>. I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code
licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions
the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company <B>except
</B>in strict compliance with Company&#146;s policies regarding the use of such software.</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Records</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that
is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my
employment at Company, which records will be available to and remain the sole property of Company at all times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duty
of Loyalty During Employment</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. I agree that during the period of my
employment with Company, I will not, without Company&#146;s express written consent, directly or indirectly engage in any employment
or business activity which is directly or indirectly competitive with, or would otherwise conflict with, my employment with Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonableness
of Restrictions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that I have read this entire Agreement and understand it. I acknowledge that I have the right to consult with counsel prior to
signing this Agreement. I further acknowledge that I will derive significant value from the Company&#146;s agreement to provide me with
Company Confidential Information to enable me to optimize the performance of my duties to the Company. I further acknowledge that my
fulfillment of the obligations contained in this Agreement, including, but not limited to, my obligation neither to disclose nor to use
Company Confidential Information other than for the Company&#146;s exclusive benefit and my obligations not to solicit are necessary
to protect Company Confidential Information and, consequently, to preserve the value and goodwill of the Company. I agree that this Agreement
does not prevent me from earning a living or pursuing my career. I agree that the restrictions contained in this Agreement are reasonable,
proper, and necessitated by Company&#146;s legitimate business interests. I represent and agree that I am entering into this Agreement
freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>In
the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, I and Company agree
that the court will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum
extent allowed by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Conflicting Agreement or Obligation</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>I represent that my performance of all the terms of this Agreement and as an intern of Company does not and will not breach any
agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment with Company. I have not
entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
of Company Property</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. When I leave the employ of Company, I will deliver
to Company any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof,
and any other material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company.
I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return
it to Company. In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit
any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer-useable copy
of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems; and I
agree to provide Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed.
I further agree that any property situated on Company&#146;s premises and owned by Company, including disks and other storage media,
filing cabinets or other work areas, is subject to inspection by Company&#146;s personnel at any time with or without notice. Prior
to leaving, I will cooperate with Company in attending an exit interview and completing and signing Company&#146;s termination statement
if required to do so by Company.</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
and Equitable Remedies</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree that any
threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company, and
Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable
relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>I
agree that if Company is successful in whole or in part in any legal or equitable action against me under this Agreement, Company will
be entitled to payment of all costs, including reasonable attorney&#146;s fees, from me.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-variant: small-caps">.
</FONT>Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice
is given, labeled &#147;Attention Chief Executive Officer,&#148; and to me at my address as listed on Company payroll, or at such other
address as Company or I may designate by written notice to the other. Notice will be effective upon receipt or refusal of delivery. If
delivered by certified or registered mail, notice will be considered to have been given five business days after it was mailed, as evidenced
by the postmark. If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected
by the courier or express mail service receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
of This Agreement to Subsequent Employer or Business Associates of Intern</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.1&nbsp;&nbsp;&nbsp;&nbsp;</B>If I am offered employment or the opportunity to enter into any business venture as owner, partner, consultant or other capacity within
two years following the termination of my employment with the Company, I agree to inform my potential employer, partner, co-owner and/or
others involved in managing the business with which I have an opportunity to be associated of my obligations under this Agreement and
also agree to provide such person or persons with a copy of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
Provisions</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.1&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law; Consent to Personal Jurisdiction</B>. This Agreement will be governed by and construed according to the laws of Pennsylvania as such laws are applied to agreements entered
into and to be performed entirely within Pennsylvania between residents of Pennsylvania. I hereby expressly consent to the personal jurisdiction
and venue of the state and federal courts located in Pennsylvania for any lawsuit filed there against me by Company arising from or related
to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2&nbsp;&nbsp;&nbsp;&nbsp;Severability</B>.
In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions
of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained
in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively
broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable
to the extent compatible with the applicable law as it will then appear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3&nbsp;&nbsp;&nbsp;&nbsp;Successors
and Assigns</B>. This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, subsidiaries,
affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival</B>.
This Agreement will survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company
to any successor in interest or other assignee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At-Will
Status</B>. I agree and understand that nothing in this Agreement will change my at-will status or confer any right with respect to continuation
of my employment with Company, nor will it interfere in any way with my right or Company&#146;s right to terminate my employment at
any time, with or without cause or advance notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waiver</B>.
No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach. No waiver by Company of
any right under this Agreement will be construed as a waiver of any other right. Company will not be required to give notice to enforce
strict adherence to all terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Export</B>.
I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing
such data, in violation of the United States export laws or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts</B>.
This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will
constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission
method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advice
of Counsel</B>. <B>I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL
COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT WILL NOT BE CONSTRUED AGAINST
ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.3pt">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire
Agreement</B>. The obligations pursuant to Sections 1 and 2 (except Subsection 2.4 and Subsection 2.7(a)) of this Agreement will apply
to any time during which I was previously engaged, or am in the future engaged, by Company as a consultant if no other agreement governs
nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties
with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us<B>.</B> No modification
of or amendment to this Agreement will be effective unless in writing and signed by the party to be charged. Any subsequent change or
changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[signatures
to follow on next page]</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement will be effective as of October 1, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; width: 40%; font-weight: bold; text-align: justify; text-indent: 0">Employee:</TD>
    <TD STYLE="padding: 0; width: 60%; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-weight: bold; text-align: left; text-indent: 0">I have read this agreement carefully and understand its terms.&nbsp;&nbsp;I have completely filled out Exhibit&nbsp;A to this Agreement.</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">(Signature)</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Name</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Date</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-bottom: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accepted
    and agreed</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;&nbsp;Cuong
    Do<BR>
    Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President &amp; CEO</FONT></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Excluded
Inventions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FROM:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATE:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: -0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Excluded
Inventions Disclosure</B>. Except as listed in Section 2 below, the following is a complete list of all Excluded Inventions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Excluded Inventions.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
below:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.6in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
sheets attached.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Due
to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to the Excluded Inventions
generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; width: 0.3in; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 25%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Excluded
    Invention</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 40%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Party(ies)</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 25%; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Relationship</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-top: 8pt; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&#9;</B></FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 8pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#9744;</FONT></TD><TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
sheets attached.</FONT></TD>
</TR></TABLE>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioVie
Inc.</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Mutual
Agreement to Arbitrate Employment-Related Disputes</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Mutual Agreement to Arbitrate Disputes (&#147;<B>Agreement</B>&#148;) is made and entered into as of October 1, 2021 (the &#147;<B>Effective
Date</B>&#148;) by and between BioVie, Inc., a Nevada corporation, (the &#147;<B>Employer</B>&#148;) and Joseph M. Palumbo, an
individual (the &#147;<B>Employee</B>&#148;) (the Employer and the Employee are collectively referred to herein as the &#147;<B>Parties</B>&#148;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal; color: black; vertical-align: baseline; background-color: white"><U>Intent of Agreement</U></FONT>.
It is the intent of Employee and the Employer that this Agreement will govern the resolution of all disputes, claims and any other
matters in question arising out of or relating to the Parties&#146; employment relationship. The Parties shall resolve all disputes
arising out of the employment relationship in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Mandatory Arbitration</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Employer and Employee agree that any claim, complaint, or dispute that relates in any way to the Parties&#146; employment relationship,
whether based in contract, tort, statute, fraud, misrepresentation or any other legal theory, shall be submitted to final, binding and
confidential arbitration conducted by JAMS or its successor, under JAMS&#146; then applicable rules and procedures for employment disputes
(available upon request and also currently available at <U>http://www.jamsadr.com/rules-employment-arbitration/</U>). You can also call
JAMS at (215) 246-9494 if you have questions about the arbitration process. If the JAMS Employment Arbitration Rules are inconsistent
with the terms of this Agreement, the terms of this Agreement shall govern, except as otherwise required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Covered Claims</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
This Agreement to arbitrate covers all grievances, disputes, claims, or causes of action (collectively, &#147;<B>claims</B>&#148;)
in a federal, state or local court or agency under applicable federal, state or local laws, arising out of Employee&#146;s employment
with the Employer and the termination thereof, including claims Employee may have against the Employer or against its officers,
directors, supervisors, managers, employees, or agents in their capacity as such or otherwise, or that the Employer may have against
Employee. The claims covered by this Agreement include, but are not limited to, claims for breach of any contract or covenant
(express or implied), tort claims, claims for wrongful termination (constructive or actual) in violation of public policy, claims
for discrimination or harassment (including, but not limited to, harassment or discrimination based on race, sex, gender, religion,
national origin, age, marital status, medical condition, psychological condition, mental condition, disability, or sexual orientation),
claims for violation of any federal, state, or other governmental law, statute, regulation, or ordinance, including, but not limited
to, all claims arising under Title VII of the Civil Rights Act, the Age Discrimination in Employment Act, the Americans With Disabilities
Act, claims of discrimination or retaliation under Pennsylvania law, any and all similar or employment laws of Pennsylvania, such
as the <FONT STYLE="color: #252525">Pennsylvania<FONT STYLE="background-color: white">&nbsp;Human Relations Act, the&nbsp;</FONT>Pennsylvania<FONT STYLE="background-color: white">&nbsp;Whistleblower
Law, the&nbsp;</FONT>Pennsylvania<FONT STYLE="background-color: white">&nbsp;Public Employee Relations Act, and the Philadelphia
Fair Practices Ordinance</FONT></FONT>, all as amended and their respective implementing regulations, to the extent that such
claims may be waived and released; and the human rights and fair employment practices laws (whether statutory or common laws)
of the state or states and localities in which you have provided services to the Company (each as amended). The parties to this
Agreement specifically agree that all claims under the Labor Code of Pennsylvania, including, but not limited to, claims for overtime,
unpaid wages, and claims involving meal and rest breaks shall be subject to this Arbitration Agreement. (&#147;<B>Covered Claims</B>&#148;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Claims Not Covered</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Claims not covered by this Agreement are claims for workers&#146; compensation, unemployment compensation benefits, administrative
charges for unfair labor practices brought before the National Labor Relations Board, Excluded Claims (defined in Paragraph 5
below), or any other claims that, as a matter of law, the Parties cannot agree to arbitrate. Nothing in this Agreement shall be
interpreted to mean that employees are precluded from filing complaints with the Pennsylvania Human Relations Commission and/or
federal Equal Employment Opportunity Commission and National Labor Relations Board.</FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Waiver of Class Action and Representative Action Claims</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Waiver of Class Action and Representative Action Claims. Except for representative claims which cannot be waived under applicable
law and which are therefore excluded from this Agreement (&#147;Excluded Claims&#148;), Employee and the Company expressly intend
and agree that: (a) class action and representative action procedures are hereby waived and shall not be asserted, nor will they
apply, in any arbitration pursuant to this Agreement; (b) each will not assert class action or representative action claims against
the other in arbitration or otherwise; and (c) Employee and the Company shall only submit their own, individual claims in arbitration
and will not seek to represent the interests of any other person. To the extent that the Parties&#146; dispute involves both timely
filed Excluded Claims and claims subject to this Agreement, the Parties agree to bifurcate and stay for the duration of the arbitration
proceedings any such Excluded Claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Waiver of Trial by Jury</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Parties understand and fully agree that by entering into this Agreement to arbitrate, they are giving up their constitutional
right to have a trial by jury, and are giving up their normal rights of appeal following the rendering of a decision except as
Pennsylvania law provides for judicial review of arbitration proceedings. The Parties anticipate that by entering into this Agreement,
they will gain the benefits of a speedy and less expensive dispute resolution procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Claims Procedure</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Arbitration shall be initiated upon the express written notice of either party. The aggrieved party must give written notice of
any claim to the other party. Written notice of an Employee&#146;s claim shall be mailed by certified or registered mail, return receipt
requested, to the Employer&#146;s General Counsel or Chief Executive Officer at 2120 Colorado Avenue, Suite 230 &bull; Santa Monica,
CA 90404 (&#147;<B>Notice Address</B>&#148;). Written notice of the Employer&#146;s claim will be mailed to the last known address
of Employee. The written notice shall identify and describe the nature of all claims asserted and the facts upon which such claims
are based. Written notice of arbitration shall be initiated within the same time limitations that Pennsylvania law applies to
those claim(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Arbitrator Selection</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Arbitrator shall be selected as provided in JAMS&#146; Rules and Procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Discovery</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The JAMS Employment Arbitration Rules regarding discovery shall apply to arbitration under this Agreement. The Arbitrator selected
according to this Agreement shall decide all discovery disputes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Substantive Law</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Arbitrator shall apply the substantive state or federal law (and the law of remedies, if applicable) as applicable to the
claim(s) asserted. The Arbitrator shall conduct and preside over an arbitration hearing of reasonable length, to be determined
by the Arbitrator. The Arbitrator shall provide the Parties with a written decision explaining his or her findings and conclusions.
The Arbitrator&#146;s decision shall be final and binding upon the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal; color: black; vertical-align: baseline; background-color: white"><U>Motions</U></FONT>. The
Arbitrator shall have jurisdiction to hear and rule on prehearing disputes and is authorized to hold prehearing conferences by
telephone or in person as the Arbitrator deems necessary. The Arbitrator shall have the authority to set deadlines for completion
of discovery, and for filing motions for summary judgment, and to set briefing schedules for any motions. The Arbitrator shall
have the authority to adjudicate any cause of action, or the entire claim, pursuant to a motion for summary adjudication and/or
summary judgment, and, in deciding such motions, shall apply the law of Pennsylvania.</FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Compelling Arbitration/Enforcing Award</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Either party may bring an action in court to compel arbitration under this Agreement or to otherwise determine the arbitrability
of claims under this Agreement, and to confirm, vacate or enforce an arbitration award, and each party shall bear its own attorney
fees and costs and other expenses of such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal; color: black; vertical-align: baseline; background-color: white"><U>Arbitration Fees and Costs</U></FONT>.
The Employer shall be responsible for the arbitrator&#146;s fees and expenses. Each party shall pay its own costs and attorneys&#146; fees,
if any. However, if any party prevails on a statutory claim which affords the prevailing party attorneys&#146; fees and costs, or if
there is a written agreement providing for attorneys&#146; fees and costs, the Arbitrator may award reasonable attorneys&#146; fees and
costs to the prevailing party. Any dispute as to the reasonableness of any fee or cost shall be resolved by the Arbitrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Term of Agreement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
This Agreement to arbitrate shall survive the termination of Employee&#146;s employment. It can only be revoked or modified in writing
signed by both Parties that specifically states an intent to revoke or modify this Agreement and is signed by the Employer&#146;s
General Counsel or an authorized executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Severability</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
If any provision of this Agreement to arbitrate is adjudged to be void or otherwise unenforceable, in whole or in part, the void
or unenforceable provision shall be severed and such adjudication shall not affect the validity of the remainder of this Agreement
to arbitrate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: black; vertical-align: baseline">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Voluntary Agreement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
By executing this Agreement, the Parties represent that they have been given the opportunity to fully review, comprehend and negotiate
the terms of this Agreement. The Parties understand the terms of this Agreement and freely and voluntarily sign this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the Parties have executed this Agreement as of the Effective Date above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioVie
                    Inc.&nbsp;</FONT></P>

</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Cuong Do</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: President &amp; CEO</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EMPLOYEE</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>bivi-20210930_10qex31z1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO SECTION 302 OF
THE SARBANES OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AND RULE&nbsp;13-A14 OF THE EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>CERTIFICATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR>
    <TD COLSPAN="3" STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">I, Cuong V Do, certify that:</FONT></TD></TR>
<TR>
    <TD STYLE="width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="width: 98%; line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">I have reviewed this quarterly report on Form 10-Q of BioVie Inc.;</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a &ndash; 15(f) and 15d &ndash; 15(f)) for the registrant and have:</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">a)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">b)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">c)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">d)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">5.</FONT></TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">a)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">b)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date:  November 10, 2021</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">/s/ Cuong V Do</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 21%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 6%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 36%; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%"><BR>
Cuong V Do<BR>
Chief Executive Officer <BR>
<I>(Principal Executive Officer)</I></FONT></TD></TR>
</TABLE>
<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>bivi-20210930_10qex31z2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CERTIFICATION PURSUANT TO SECTION 302 OF THE
SARBANES OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>AND RULE&nbsp;13-A14 OF THE EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>CERTIFICATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR>
    <TD COLSPAN="3" STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">I, Joanne Wendy Kim, certify that:</FONT></TD></TR>
<TR>
    <TD STYLE="width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="width: 98%; line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">I have reviewed this quarterly report on Form 10-Q of BioVie Inc.;</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a &ndash; 15(f) and 15d &ndash; 15(f)) for the registrant and have:</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">a)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">b)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">c)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">d)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">5.</FONT></TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">a)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">b)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: November 10, 2021</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">/s/ Joanne Wendy Kim</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 21%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 6%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 36%">
        <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0">
        Joanne Wendy Kim</P>
        <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0">Chief Financial Officer<BR>
        <I>(Principal Financial and Accounting Officer)</I></P></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>bivi-20210930_10qex32z1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report
of BioVie Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2021, as filed with the Securities and
Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Cuong V Do, Chief Executive Officer of the Company
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to
my knowledge:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">(1)</FONT></TD>
    <TD STYLE="width: 99%; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">(2)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: November 10, 2021</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">/s/ Cuong V Do</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 21%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 6%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 36%; line-height: 106%">
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Cuong V Do</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Chief Executive Officer </FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%"><I>(Principal Executive Officer)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>bivi-20210930_10qex32z2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report of
BioVie Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2021, as filed with the Securities and
Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Joanne Wendy Kim, Chief Financial Officer of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my
knowledge:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">(1)</FONT></TD>
    <TD STYLE="width: 99%; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">(2)</FONT></TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: November 10, 2021</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 20%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 6%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 36%; border-bottom: black 1pt solid">/s/ Joanne Wendy Kim </TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 106%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">
        <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0">
        Joanne Wendy Kim</P>
        <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0">Chief Financial Officer<BR>
        <I>(Principal Financial and Accounting Officer)</I></P></TD></TR>
</TABLE>
<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>bf001_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bf001_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ -P#Z P$1  (1 0,1 ?_$ ,4   (" P$! 0$
M       )" H%!@<# 0($ 0 !! ,! 0               0($!P,&"0@%$
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MB=N[ZH/7B[TJ_P#XB?&*WX@<:/X$T\]HT5I& 6,#&'\F9V@>.X 8'<HV%IY
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MUFKQN!N?I\X_!J@'(J300'Q ,3V%AH4H-14+K]-2KX(@4!,80*4H"(B(@
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,K4*8M;(J'10A?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>bf002_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bf002_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ *@ \ P$1  (1 0,1 ?_$ &T   ,! 0$!
M       '" D&! H! 0                     0   & @$!!08& P
M  $" P0%!@<( !$2$Q06"2$Q(B,5-C-591<W.$%C9Q$!
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M&H4^.%%N G2;NIA^3OEA^!!$IE#?"4> V1.0HB G* @43B F ! @>P3B CU
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4_KGY#^B]WP-0^ < X!P#@' __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,, EL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !2,"RD!BI(ZCJ*6B@#GY/"-F[Z7.MS/'>:?-YXO(XX1+.Q1D;S#LP0P=LX
MY.>"!44W@JSN'EEEOKYKB6VGMGFS&&9969LD!-I9-\@4XX$C9SG-=+10!S\/
MA5(+RSNH]6U!9;2P-A&<0G*$J2Q'E_>^1?;CI4S^&K6XTZ[L+VXN;VUN8HXV
M2X*DJ44 .&"AM^0&W$DA@",5M44 83>&$&H07T.J7\$\%B;&,H(B A*DM\T9
MRV57V]JAM?!ME8W&GS6=Y>PM90S1)\R.9#,RO([EU)9V9 2<^M='10!SR^%=
ME[)>QZWJB74EHEH\P,)8JK,V[F,X8EV)QQSP  *MQ>'K2T\/KHE@TEE:*FP&
M':S8)RV2X;);+9)!)W$YSS6M10!@7/A*SEOI[NUN)[!KBS:SE2T2)4=220Q!
M0Y9=QP>G)XY-6GT&W;54U1994OUM6M6G3:"ZD@@L,8+*02.,#<W&#BM6B@#G
M;+P;96B:/%+=WEW;Z/$B64%P4V1LJ;%D(55W.%) )R!G( /-.U3PC::OJ%U=
MW-Y> W%HEKLC9%$>QS(DB';N$BN=P.< @<<5T%% &$WAMFU0:E_;.H"[%G]C
M\P+!RN[=OQY>-V?PXZ4QO"-I+)";F\O;F&&[AO(X9V1PLL:JJL&*[QRH8X;D
MYSPQ!Z"B@#+71537[O6$O;E9KFUCM6C^38BH792ORYR#(_4D<].!5-_"-FSZ
M7.EQ/#=Z?+YHNHXX1+<$H482DI@A@QS@#GG@@8Z"B@#+M]$2VUS4-66\N3->
MQ11-&VS9&(]VW;A<Y^=NI/6L^W\'16VAQZ.FL:G]DC@D@49B!^<$;CB,9(#-
M@'Y><D$@8Z2B@##L_"]M;7>G7$MW=W9TZ'RK1)RFV+Y=I<!57+%>,G. 3C&3
MG<HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,ZZUFVM-1
MCL&CN)+F2![A$CB+;D0JK$'U!=..OS"H;+Q+IFH7EI;6LLCM>6S74#&)E5T4
MA6&2!AE) *'YAGD"J.LZ?=7/BBPO!97<UK;V%U"[6UP(F+R/ 5 .]3TB;/;E
M?PR3X:U"W\$:1IS62SWEG>QNJP2(/*@\X[UW'8&)MV:-CCYBQ)ZD@ ["RU&*
M_P!/6\ACF$;*657C*NP_W3SSV]:;I.JVNM:7;ZC9%VM;A!)$SH4+*>AP>>:B
MN;6_.IPW<5^XM(D/F6*PH?.;#8.\\@Y([@<>YK$\-1ZUH?@[2-,.CN]S962Q
MS SQA69(\!4(8\EL<D 8R?0$ WHM8LIY;^&"0RSV!"W$2(2RDH'  [Y![9YR
M.H(JI8^*=,U*6TCM&GD:\L3?VY\E@)(05&03QG++\O4;AD5G6ND:CI?BFROH
M4EN8+FS-M?L3&FQE;?&Y&<D[GFSC/W\YXYS'\%ZE%<JUO/'Y4%]*D,9; ^PW
M!+3I[$-)\H]((_4B@#I(O%.ES^7Y<DYW+ 6_</\ N_/($0?CY2<C@\J""V 1
M6T#D9KC-9\/:C=^(UU+3X?L=['<0!+R*4>5/;#:9([B,_?QF380,@[?F7DUV
M8Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC0,[.0H&!RQ)/XF@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD:2WC$<I:<R,WS9. &D+  #E4R3@YZ6B@#'TW0(M/UB^U5I?,O+V.**9UC5
MZQ[MK,!U?YSEO8   8K8HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K$U+Q/::=?7%EY%Q<W-O9F^FB@"EEBR5!
M 9@6)*MPN>G.,KG;KDO%'AJ^UV\$L/V6.2")3I]Z)6CGLIR7#N,*=ZE2F4)
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MXTK5M3N=(GU%;)3ILC702&5R)Y_+:->2HV)\[DCYCG;V!R 1'QM;CPU_;_\
M9&I_8/[/_M$-B'/E8!QCS.&VDG!ZA3CD8JW=>)Q97UI:3Z1J*O=72VL;?N2N
MYD9\D^9T 1L]^G'(SAP^"[JW^&$^@PP:?'K$^DKITLJ2L(G*HR!R=F?XF/W<
M\XSWK2U'P]<23:))IUK90+;:D+ZZC\YE7_5/&=F$.3\^>BYV]B: +<'BBUNH
MDN;:UNYK%[D6R7B!#&[;_+R!NW;=_P N=N.XR,&ETWQ(NJ2[(=,OD07<UH\C
M^5M1H]P8G#D[<K@''5E]:I>&=%U?PY8PZ$ALY=)M25M[MI6\_P K.0C1[-I(
M!V[@_. =O:H-%\/:EI=W/=?8M+^U37MU*;@3N6$,LGF;,>6,DE4&2>.2,XP0
M#KZR==UU-!LY[R:PO+BW@MIKJ:2W"$(L8!(.YEY()P!G.T]*DOK"[U32HH7O
MKC3;DA6DDL)%)5L<J&=#E<]RH/ Z5#XGTV[U;PCJVEV1B-S>6<MLC3N54%U*
MY)"D\9STY]J ([?Q+%)X@DT>XL+NRE2+S5EN3&$E!95&TJY))+8Y Y!%;(FB
M:9H1*AE4!F0,-P!Z$BN*\6>$=2\127DJ1Z>'GT9[)/-E8^7,T@;(.S[HQUZY
M X':_I.@:C:^(YKV^^RSQ))/):W(GE,RK,0S1%#\@ ( W \A$^4$9H Z-[NV
MC,@DN(D,:[G#.!M'J?0<C\Z5KJW1XD:>(/*"8U+C+X&3CUXKBW\'ZC!/J=]8
MKI\5Y-JYOHAO=!-"8T1XI'10R$E=^1N&X*3G%8^IZ6VGZC;V$>E1S0QV=F#9
M032J)7AFDE1(BT+!PA.,[TX8[\#&T ]&AOT<LLX%N_FM$BR2(3)CN,$]1SCJ
M.X%1V.MZ9J5FMY9W]O-;M,T"RK(-K.&*E0>YR./7M7)1>#-36Z$R264+)J<]
MVCHQ<&.2=)=K1LFUON \8964%7'-,?P=K7V"*S8Z?<6OGZBEQ:RW,R)-!<S>
M:KDHH.]>1LY!#'YAUH [B2]M8A(9+F%!$ TA:0#8"2 3Z<@C\*HZSKUMHILU
MF1I'NKJ*V5(V7<ID<('()!*@D9QD\]*YA?!NI6=K)+8Q::MX=7GO&3S7B6Y@
MDW_NWD1-RD;\]&&5[YX9)X(U&.Y@BMAIILH[G3KB-I'D\RW%ML4Q("&RA56(
M)8$%VSG<30!W<D\43(LDJ(9&VH&8#<?0>IKFKSQWIEK>S0 >8D-XE@\PE0*L
M[!"H()SM_><L <;6XX&3Q#X9N]7N;XQ2P&&^L%LR920]HRNS+-%@'+9?=CY>
M8H^>.*5QX7UB22_9?L.+C7[?5$S</Q'&L(*G]W]X^5].>O% '2V6K>=:-/?6
MS::RR>68[F:(G. 1RC,.<\#.?:KPFB,Y@$J>:%W&/<-P'KCTKAQX2UBWU"\N
M((])FMKN\O#-97#/Y<D-P(@6.$^^#&<K@AA(PW#.:T=-\.W]KXDDN[H6D]O'
M)+):W/G2^<BR!<Q>7]P*,<,#T51MR-U &MK6O6NB:;<WD@:X^S;/,AA92XW,
M #@D<?,#].F>E7OM=L(A+]HB\LML#[Q@MG&,^N>,>M<3K/@S5+\:N+>6T$=Z
ML@6"9RR[VEB;<"4+1Y6/YE!*LVT@+R37U3P+JMW:ZW:VZZ5'#J$]X\>68-$)
M;98D((3CYE)91U#?>QN5@#I&\6VR7CVS6=T'355TLGY,;VB64/\ >^X58>^>
MH':\NMVIUZXTB0-%/###*'D90LHE,@4+SDG]T^1BN=?PSJ\VH/=.+%?,UZ'4
MRHG<XC6V2(KG8,ME"1VP>HJ77_"5QK6KWLX-LL-W:6MN)BQ$UNT,TDF]!MZ_
MO!@Y&"H/- '5K/$\LD22HTD>-Z!@2N>F1VS2&ZMU,P:>(&%0TH+C]V,9RWH,
M ]?2N=T+0+VPUVZO+X6TNTSK;72SRM*T<LHDV,A^1-N .,YQGY>0<R3P?J5Q
M+J N_LDY::1K.[%W/',L<ERDY7 &V,IL&UESDHN0!N! .L36-.DU&33TO8&N
MXXA,\0<$HA. Q]!P:KOXBLTUVVTMLC[3:FZBN=Z>4X#JFT'.2Q+J1Q@YX)KF
M3X1UN*6Y=7TRY,UC#;GSAL&Z.YDE&56,IDI)]_: '7/ED':*DGP^U"XM9[:<
MZ>T<UKJ=IN>1Y#&+FX\U)!E<LR@D$9'('S<\ '8P:ZMS?7=K%9S;K2]6SF9F
M10"8EE#CYN5PZC YR>G%.OM?L[&YL(7.];RX>W$J,I2)ECDD._G@8B<=^1SB
MN>?PGJ1UO[6&M7B76X=05I)F,GE+:+;MGY/OY7/7!!ZBJUAX)U*T;1TD-C+:
MV5W'.T$DC/L5;>6+8KE-SJ#(NT/D@*?G/  !W/VF#?&GG1[Y06C7<,N!U(]1
M5"WUVUNO$%QH\09IK>W6=Y 5*?,S+MX.0P*G((':N2T+P5J^GKI=O?-8SV]M
M%#ATN)=UK)$K+F)=H5P0?XMNTLWW@<5H>$_#.J:+J4,U\;'RH-)@TT-;NS-*
M8G<B1@5&-P;)&3@YY/6@#K!<0&21!-&7BP)%W#*9Z9],U0UC7['1M!NM8E<2
MV]O$\N(G4F38"2%R0"<*>,]C7$ZAX$UR^GO))%TAO/(& [HK!;[[0"4\L@$J
M6!Z_-DDMN)#[SP'J[PZS';?V;LU"/4;=(WE95A2YV,L@PA^8,GS+C!R"&R,$
M ]%C<21JX& P!YIU16RR):Q)+M\Q4 ;:<C..<>U2T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 0W=PMI9SW+*SK#&TA5,9( S@9QS7-6
M_CRSN$@<:?J")-]B8,RQ_+'=-MA<@29P7&TC[P/.,<UTUS MS:S0.6594*$K
MU (QQ6"G@W3(XUC22Z54BM(E^8<+;/OAZC^%B3[]#D<4 5-4\:64<&K0;=0M
MI[&(2LZ0QE]OG-%E0Q(ZKGY@,JP(SFBZ\?6D'VM4TZ]=X#=QH6"*DLMNI9D!
MW$C(!(8C&!Z\5/)X$T-HKA MVHN(VBD_TEVRK2F4C#$@?.6_,^U2GP9I4CYE
M-S(#-<3,K/@,TZE9,X ."">F,9X[4 -MO%L,DVDVES:7$=SJ,<97"KL#M$\N
MW.[)&(VY (!P"<],VP\?V*:=:L\&J7 :WM9Y+B2&)2J3RM&K.%8#(92"%!/0
M@'G&G!X,T>VN;>XC:\\ZW:)XW:Z<X>.-HU;!."=CE3Q@CM44?@32(K,VJR70
MB,$%OCS!D)#(9(QG'9F;GOGG- %B?Q=8PR2*8;IT#B**5(P4FE,HA\M3GAM[
M ?-M!Y()"L17\/:Y=W&AZM?WT<\CVE[>((8X@9/+C=@J!5)W-@8ZG)J23P3H
ML@NT/VT1W,OG^6+R4+#+YGFEXAN_=MY@#97'/L2#:C\,:9'HVH:5MG>UU!Y7
MN0\[LSM)]\@DY7/H,#OW- &?9^-(]2UO3["RLY6CN'NDEE=D_=F':,##$,#O
M4@@GC'&2=NO+K42Z@;.&VN;ADE2&>2% RP,R[AOYSC!7) .-P)P,D5+;PCI5
MIJ,=_#]J%PD\DX8W,ARTBJ'SD\@[%./4>G%33>&M-GU=]3Q<QW,B!)?)N)(T
MDP,*S(I"LR@G#$9'']U< %&;Q;::=!<3W(FECA1;J=X4!6WMI'98Y&R02"$9
MC@,0 <CI4_B2\N]+_LZ_CN/+L4NTCOTVK_JW.P,"1QAV3/\ L[CP1FK%WX=T
MR]F\V2(@-"MO(B,52:)3N6-U'!4$G'L6'1F!O7UE;ZEIUS8W<8DMKB)H94/\
M2L,$?D: .9NM9O8M7TO2XKG]YK%S<-%*\:D06\*Y.W  8MQM)R &S\V,%UUJ
M>KV?B'3M!>6!CJ$L\B76SYDMHHXR1MZ&4N^,_=P"<?PUN7NB6.H6=O;2I(HM
MB&MY8I&22%@-H*N#D'!(/J"0<@D5%)X=L9DMBYG:XM9/.ANFE)F23!!8,?4$
M@K]T@XQCB@#D]1\4:I:ZE=:5Y[++9:G91-<QP!C-;W!Z;<']XN&&0,'@XY*B
M>3Q%JK>$;'55FV+<:I!#!.D0)N;.6=4239@[6*-D#UP=HSM&]/X3TV6-06N%
MD^V)?23+)\\LZ8VLQ(.0,#"_=   & !4?_"*:8UH;>":YCM&O%U".**3*),'
M\S<N0<*7^?;]W/;DY (K;4?$+^#;VZ%G$^KQ^>ME'.IB%P S"%G0D%"PVY4D
M<G^'.!AOXKN;G1DO+'4)<#4[.TDBFM EU )'1)(Y8R.)!N)!  Z<-C)[B^LK
M?4K&2SN0QAEP&V.R'@YX92"#QU!S67/X4L+H,TLMR9WN8;J2XW#>\D6/*SQC
M"X!"@ 9R2"2<@&1K&MWFG6FC7)O[F.VN]0>*9WM!YJP"&63E-I(8&+^[T)R,
M]$&M:M'X3TK7;N9(X!<@W9CC4"6S>0HDV/FV?*8Y&&>%WC@XV[DOARTFGMII
M;F[::"[^V+(7 +2^7Y8)&,8"97: !R3C/-2VV@:=:Z3/I*1L=-G#I]D?F-$?
M.Y%'9>3A>@' P!B@#&U>_P!3M19RP7S+'=ZS':A&A0[822K <=2RD@^A'6G:
M%JFJ>)=&BURSGBBAFNB([5XOE%NDQ1LM][S"JL0> ,@8.-QU;SP_97=KI]J7
MGBBT^6.6W$;XPT8PF2<[L>AZ]\T0^';"VO9;B W$:32&5[9)G$#2'DMY><9/
M)(Z$\D$\T 86A:OJ5_+.KW<TDEO=WR%9+8+ \<,C1H#(%&')*$D$_=?@=K'@
M_7[O6)9H+^3R=0MX4%[I\T'E2V\^3N*\X:$\;&!;@'+$GB_'X6LHX'MC<7;V
MTDTMP\#. KR2%BS' !/S.3C. <8' PDOAFV\J3R+F\CNGBCMTNO.8RQ0H^X(
MK=>N<DY+<;BV * %UZ[N[;5/#\-O.8H[R_-O, JG<@@EE[C@YB ^A/?!#;Z^
MND\:Z/I\<Y6TN;.ZFE38IRT;0A<$C(_UIS]!TYS?U#2X=2GLIGGFCDLY3-"8
M\?*Y1DS@@Y^5W&.GS$]<$4QX:MAJ,>HK>7@O4$@\[*DGS-F_(*D<B.,=. @Q
MCG(!5BU:\U?Q5J^E6DZVL6E)"KMY8=I99%WC.>B!<<#DDGE<<VM6O=3T[P5=
MWQ-L-3M;!IG.PO%YJIN; R"1D''(H_X1;3UE2>*2\AN NR6:&Y=&G7<6(DP?
MF^9F(/5=QVD9-7[W3;:_TJ?37W);3Q&%Q&<$HPP1GW!(SUYH YS4/%36Y@@9
MS!'%IR:CJ%VL)D\B%C@;5Z9)#DDYVA/NG/$B>*X;GQI:Z3:W-I+;/;W>[$JE
MWFB:$8&#P/GD&.I*-V&3I7/A?3;J.-)UD?%L;.0[L&: XS&X P5X],C)P1N;
M,\^B:?<W\5ZT16XB@F@1XB4*K)LW8*X(/[M<$<B@#+\(W^JWL=_;ZX'AU*"8
M;[?RT58T9<J4921(IYPQP>"" 0:BTV_U&XFN=*N+YO[1M=1*/(L:?-;E?,1M
MNWH4(0G^_NP<#%=#8:=#IT16-I9';EY9G+NYQC)8_P#ZJ!IMH-5;5!%B\>!;
M=I,GF,,6 QTZL3^- '&1:YK#RVJM?Y$GB2;3F_<I_J%60@=/O?(.?<\=,;VI
M7UY!XOT*QAN"EK=QW#3Q[%.XQA2N"1D?>.?H.E-7PEIZ-&%N[P.E\^HH3(I/
MGL"K-RO3YVXZ#/3IB9O#-K_:,6HF]O!>1&1A-O7JX56)4KM^ZB#I@;>.220!
MOBW6+C2-&EEL/L[7X5I(8[A@JR;!N9>2.H&T>A8'IFJO_"1C5_$.GZ5I=P%@
MN--_M1KH1Y9HF8+&$W< G)))!P  !DY76L=*@LYS)#<W#MY9!$D@899RY?D<
M$L3TP.@QA1BE9>$]-L[2SBM9;E&L2XM9EE^>)6.6C!Q@ID?<8%1@8 VK@ PY
M?$MR\^FK#J$KQ2:K<V%P\%BX=E2*60 (Z$EU,84E05/)XSA=;5=9O-)\*P74
M>R>]N9H+>!KA-BAII51&D5?[H<$@8SM(!&<BS_PBUA&UK)%+<Q26US+>(ZL"
M3/*&#N00020[C&,#=P!@8L2:'IUYHUQI-TGVNUF+&<2MEF9FWDY'*G)R,8V\
M;<8& #+\0S:SHGAK6;^*^67[)ILES%(\2AUFC4M@@#!1@ ,8!&#R<C:R_NM8
M73;NYTFZDFG@N(8XH;^W$0F8LH92=H(5@X ; P03R*T)?"]G/I%UIMQ<WT\5
MS ;>1YKAG<Q$890QSC(X)')XR<@8FDT-)I3++>WCREHSO+*.(V+*N N -QR<
M#)P 20 * ,S2]4G\2S-<Z??S6UL$C\VWD@3S() TJRQG(X8,@!SD<'&<@C#A
MUW6V\):%K4FI-G4+BUBEC2V0[?,D*N5P">A&!@X([YQ7:KIEE9WE_J$0^SW%
MXJ?:)@W78I"L0>,@'&<<@#.<"LZ/PGIT>B:?I<4]T+2PE2:WQ("P9#N3)(.X
M \\Y]\T 9FK:U<Z=9:)=R:C<Q6MW>2+/(]H/-6 032\IM)# Q =.A.1GI9B\
M37EA\.9_$>IVZRSV]M+<!$Q&)T4L8FX+;-Z!&(R=NX^F*TG\.6TL]M.]Q=--
M;W9O!(7&6E\LQY/&,;"5P !@],\U-9:'8V.ERZ7''YFGN&46LH#QJC9S& 1]
MSDC:<@#@8  H @AMM:C6'[1?Q2L\3BX,<(01R$ JT6<_*""-K;B<@YX(/%OX
MOU2'3-!NIK]EDU'0/MP"VRN&NV:!8TQ@81FGV\E?X?F')KL[#P]9:9 MK;75
M[M2,I LUTTOD+T^3>3T!P"<D XS@XJO'X+TE8;:!Q--;V^GOIB0RL"IMFVY0
M\9/W$YZ_*.>N0""QUC4M7U^72F"Z?)I]E;7%XJ 2$S3!\(K'C8NPY.,L2,%<
M'<MO>ZJGBW2],O;B,K)I<UQ<)%& KRQO$FY<Y(4^83C)Q@<]<W&\*V3/:3&Y
MOA=VT/D"[6Y99I8LY"2,/O@=06R023G)),K^'K<ZG#J$-S<P7$-NUM&R,K (
MS*S<,#DEE4ECD\=>M &1=:I?CQ;J.F)>W"(EO:26PCM5D57E>56WG;PG[M3R
M0>3@G@5:\5ZS=:(EC<K%,=-WL;^>VB\Z6",+PX3G*@XW$!B!VYR)8_"EE&]P
MT5U>K]IMH[6?][DO&@; +$;@<R.2P(8EB<],7[^PM9KBVNI)Y+:>$-%#+')L
MQOVY7!^5L[1P0?4<X- '.7&HZK'!X=N%U>"5-4N8(':TB0QE3 [LR$[B<NF0
M<D;3CGK3GO\ 5+?7[G2I=2G>2.RLWBDALU93++)-&Q<;?E3]TK8W#JV#T UI
M/#6F"RTFTB\RVM]*D22T2-\;652BY)R6X8CD\[N<FG76AVMQJ%W.U]=137UN
ML$JQR*I:)-V IQN7!E?YE(.7Z], ">)+^[T[3[6XM&B7=J%I!()$+;HY9XXF
M Y&#A\YYZ=.XS]7;7;?7K$0:O EM=72HEH+,,1$JEY"TA;/(1@"!@%D'N=O4
M=)@U*SCM9))(XHY8YE$6T8:-PZ=0>C*IQ[8/&09GL8)-1BOV!-Q%$\*'/"JY
M5FX]S&G7TXZG(!S?AOQ'=ZE/I2780KJ^EG5(E1<>0 T?[LG^+Y9H^<9RK'H0
M%O\ AZ]N[K4?$,-S.94LM0%M"-BC">1%)V')S*1] /<FWIV@V.ER[[5'!$8A
MC#.6$40)(1 ?NKDG_P ='15 @3PU;1RWC"ZN]E[<BZN8]Z[97 48/RYV[412
MH(! P<Y.0"F_B1D\:V^E[[8V=S'+"A!S(+E 'Q@'[I3S.W!C([BJ>C>(KZ[\
M22:7J+K:7B2SL;1X<+-;@_N9;>3.'&TKO')W$\(!@[<_AVVN+"SM)+BY/V2<
M7,4VX>9Y@)(8G'/4Y_O D'.3DM?#EA:74$Z><YMC(;999"XA,ARY7/<].<[0
M2%V@D4 :]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (ZAT
M9& *L,$$9!%<5H&CV]GJ,GAY].B%GH]TU[9N81MV2Y,>WME2TZ>O[I2>O/;4
MF!0!Y9H_E)H-VVBOI3:FTNK+I,<$:"83^=.8\-G;LV@XSA1\O7C&G8RZ0A\*
MG2X[7SEE9;AI 1<P8MI"[3<ALY!5M_\ &ZL>0,^@8!HP* .#_M>.T\6Z7K;O
MLL=;1K%9FF3RFQF2V9<-GD>:#P/FF ]*J>!UCAURVB0PZA%)93S6VH)A;F..
M22-VCO%'!EW8 ;.6V/D Y->CX'6H)[N&!F0DO,(FF$*<NRKC.!WY('U- '$Z
MC"EAK&N:MID-O=QB01:UI\:AWFA,2$2!.\BY<X(^=2PY(3#[S31HU_I.JZ=8
MP@WED-)G,<((0E08'.!PJL"A[8D7/"BNXB<21))M9-P!VN,$9[$=C3NU ',>
M*M/M;#P#<6%JC6MM$D4<0@0;(@'4 R C'DCK)D8\O?G-<.]I=SZ1<_NH9M0G
MCNK2&P1CL^U,P*W-F0#LBS@[CMVD9+;@Q/K4$XN/,_=2Q^7(4_>+C=CN/4>]
M2\?Y- '&L;>#XDQBXN(C-_8+K-*"$9L2J<G'(X!/M6?I"SV&H:ZV@:?#=V%Y
M+;313Z0\:QB-D<-A'8(91L7+!N1+&Q'R[3VMMJEK=ZE?:?$7\^Q\OS@R%0-Z
M[EP3UX]*N\4 <;\.-2MF\':/ISL(+X6?FBUED0RF(-M\S 8G;DXR>_6L;Q!X
MZU#3;W48[2^M L27"()X<&.6*2W 7:6#$E99#DD;L!E7:,OZ1Y,?G><5S)MV
M;B>@SDX].V?7 ]!3CM49)P![XH \XNO%%U--?:/?WELMI]MNK(WSPJ4<B&-X
MX6!^7<QE=?<1%?O-FM/3="A\1_"#1]-E6-9&TJV,#RQ[A#,L2E'P>NU@.._(
M/!-=)8ZW8ZCJ%Q9VLC/)!!#.S;2$*2[BA5NC [#R*T<#\Z //-2:XU7PG)KZ
MZ:UM/=26L6H1QQM]HCM(Y%^T1?* S8/G#CJO3M3]:CTFX\/W=YX5,4D3"VAO
M3I)!#6J3 NJ[.-XC:7@?-ACWVUZ!P*J:AJ-OIL<3S$EII5ABC7[TCMT49[\'
MK@  DT >=^+ELV:^DT;[&-+.@WQU(P@>0QVK]GR1\I?/F8[XSZC.;.;&+PIX
MR6<6-HT^@)]FM8-OE7$:POLN%/ =RQV' !7RT'(VL?6[.X2]LX+I(YHUE0.$
MFC:-UR.C*W*GU!J;'^<T <[X9T9-/DO]1AG@\C4FBF2WM1B&/"!=P/\ $S<$
ML  <+QQD\'IQM5T#5()A:7MG_8,\MOJ2A5D:)PI\N\7H)]W1OXL.< @UZ]@8
MI<4 >1ZJ-(C^&NHQW#:/)/)96K?N8E4+&OE[!+DD!O,:7'J,XZ&M?3-#LM>T
M_P 5Z+?"VM;J\NFE^PQA6CMAM40SQC^,-A9"V "VY2 0V?1<4F!0!YMKS6^J
M?#'Q%KNI:=;VE[+I4EJR2HN8WC4@H">3B;>!Z[5([58C&@MKVMVWB+[%B["1
MZ8LV/+DL3"@"V_J=^_<J<Y*]MM>@X&*,"@#S2-=*A\;:Y-<R::88OL3W NH@
MUP[+&Y&T@Y\W>(SC!)[<XIUH]O9^-1=/+;7MK+J5S+YDA"7FGR)%(C^8?XK?
M:IVDX*AHQR-M>DXI'0.C(=P!&.&(/X$=* .0^(4VGW_P\GG9[:XM)VMGB=BK
M)(&E0@C/!R#Q57QCJ&AWKZ);^?8S&VU>T<Y*LJ E\8/0'"G@<@>Q%=RD:1HJ
M(H55&% X %.Q0!PWB+5-/N]?T:>YN(IO#MM)/'>2DAK=+K;&8?-)XV@,^"?E
M#E<D-BM1Y;;3O#%_>:!);(DLGF0NS$0%VVC*D @*3SNP0"23D9KI,4N* /(]
M1\174%_<^(;=UM[V#1)9"MU"@=Q'=E5C;:Q!!Y&Y3AL[EQG%7?%7B5[RU\2Z
M6]U;RVCZ3J:JC1A&26%(MJ@$DG(E9LG[P *@*-S>G8I<4 <;X/:!_$GB0Q-&
MVX63$H0=V;=<'CKTZ^U<QX?UZ_\ #_AFR6)TETV*U;[0JQ;?[.87*Q_,0#@;
M'D8@J=OE$XQD5ZQBC H XC6=4O\ _A6XU(ZK&LAGAW7EI@(\!N%7?EEQ@QG)
M8 #J1\N*QDURXT'6=;ETSR;E+C7)T-E&HW3N--64%2/XC)$%X')=LY.,>HXI
M,4 <KH_B"74/#VJZG#J-G=01*TEK.JL0F(P2LG"9*MG(X(! /()K%M/%FK>5
MHT-S?VR76HVEM>0R2Q%([@N0)8$"@Y=1R,,#^\4\A6SZ+BDQZ4 >:WOBZ\G@
M\11_;=*E%G::COM)&CDRT3%8@(PV\J5R)-X'S ;?E/,>O>)=4;1M<BMKMHDC
MTN2XMY[)4*IM2(D$GYHS\S\X*E2"K*5Q7=6GA^RM+I)PUS,8V9X5N+AY5A9L
M@E Q.#AF&>H!(& 2*U,4 >=ZKXTOX3K)LKVS5].L[B5;><%WF18M\4ZA5 *,
MV!G=M.[:,,.;@\1:E%K>FZ7)J-H9KA8;B-Y(RJWD<CMYB1JH;)1,$$,,<%LC
M)KN,"C H \X\+:I_;?CFTU*66,WDFB2I<P"+:UI()T)@8]<KNQ\W/5APP ??
M^-M0MM1U:*VNK*5+>QOYD$R^7Y4MO(BA2,Y^ZY)W$;L @(I!/HF!5>^L8M0L
MWM9C*(WP<Q2M&P((((92""" >* //W\:WJQ;(]5TYH[B:=+.]:19$5T6(QPS
MF(.N]R\GRJ5+*@P0QQ3Y_%6L/JLUJFH0*KZG=Z>B0PKO14M3*C L6RX=0O((
M.X\=,=S8:7!IYD:-I9)9<>9--(7D?'0$GL,G '')/4G-S% '&:?KEQ!\/_#E
M\EPUPMREK'=WS$/Y*LH#R''!PWRY/ )RV0#6=9W,FN>)]'MM9EBDCDLM3B\E
ME0QWD:SPI')L8'B1 QXX(R5X)SZ+28% 'FOB*[8ZSK-O=:@#]GU/1I+2&?9M
MA!N8R64  XSOR<^HSQPZV\4WLUTP>YTUKRWM=8BBN)HL,&@N(D0L5R0K+AF"
MCG:#C@ >DXHQ0!D>&M1FU314N+A95F$DB,)%4'AR!@H2K#&/F4X/7"G*C7HH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M"KJ45S/I=W#9SBWNI(76&8C/EN5(5L=\'!KC[?1M1DBL[F;1HK:,3AM1TU+K
MS5N@(7CW#<=A^8H<-@L%!8[E45W5% 'D6L>';[2O#6O7NK/+))%86L=O>&Z.
MY74L'56W;APZ*2<;]N3S71+X;O8KF9_L7FZ+->3R-H_FJ-J/#&@89.S_ %B2
MOM# ?OBWWEQ7=,JN,, 1Z$4 !1@=* /.;?PMK-O%J$MY =3U!;"R@AN)+ME\
MV1$*SE3N#+N!Z':'(&XCK4$/A+5H9=18V 9YM.O[."=9HU==\\DD(R""HV.J
M@# 7!' QGTZB@#A(= UDW%N\JLDL5S:SPW2S M#"D*)-;D9YW%9.F5S+NZK2
M>"= U31;RR>\MI(Q_9$=O=N9P^^X1S@M\Q+$*>#Z8''2N\HH \RN_"NKW=[>
M>=8R2VLDFILJO<J5;S5C\DD;_53C/W3CIVZ"^M-:.@:$%M%OYK8Q_P!HV4\X
M!N%\ED;YCE6(<J^&X.WKG%=;10!YS)X7U./5_M-O8,IBN],:&1;H,4BB7;,
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M%*<\'/)P<U4\4V]WJ^J0:C86]XL%GI-\D[&VD5IO-11'$$(#,=R[N <;1W-
M'5GQ'H84,=9T[:Q0 _:DP2^0G?\ BVMCUP<=*>FO:/)-##'JUB\L[M'%&MPA
M:1E^\JC.21W Z5QMS9W</@72U=M0N9I+S3'""R)EMXXY("ZE53("['?YAWQZ
M5<UVPOEU?0(;>6YDN"]X6OA;$B-GA=4:0JNT8)4<XSC@=@ =0-:TIKAK==3L
MS,KLAC$Z[@R@EAC.<@ DCMBFV^O:/=J&MM6L9U,33 Q7",#&N-S\'[HR,GH,
MCUKG?";1P>'M&TB\TF]BO](A1)0]JX1)$0HTB2 ;7W MC:22'Y YQBZ+9.?
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MD;F<+Y1*Y+XSC!Q@ [JBN&%QK2ZQIMF'U=;-EBFM[I[7>S#S7\R.<@A4_=;
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M2$L6"@?3 '.,FA=^%-3NF:Z_T!+J2;3FE2)F2)A:R^9N'RDAFSMQSM"KR<4
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MVN5\L1"/%[,-@C=GC ^?@*7?&.@)'3B@"&U\51^9>P10ZC>7<<]WBW=85?9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI6@U&/3_ #@;F2)YD09.41E5SGIP748Z\T 6Z*,CUIDLJPQ-(YPJ@L3Z =:
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MPO>:7%I_E7,=Y>/9R,7*M"X@>897&>0@ZXX8$9!% '*^'K+Q';6N@V%Q;:A
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MQ&)H4=%DC99-R-B3.0WJ.AP-!O"%P^JM?'4U.=5BU+:UOR=EN("A(8#D#=D
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M""H*ELP.#@E1D88G.-S1/$2ZVX>&UD6SE@CN+:Z((69&[88 AAP3C(PPYZ@
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M -)Y/)#;>2N 1DG:"-H +D>G>'O#&CRVQ6SL=/DR'6XD C(V\J=YQMVC&WH
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M"9XPP1I8PQ4,,,!D<9'!]:QK.STGP]K15Y6:^UJ[EDB=X<DML#-&'5>%"QY
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MVMK9?+ =TC5!L08 )'8#IZ"@#SKP_P"+;S1=)T^TN!'/!/%(\<\LC%XC]N2
MM(S$[U F5NQ 0@DYR+]SJU_>>(]*2:/;/9W]]:MY<CK!<[;8NK8Y]0#U*L'
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MA=48'(5MF"IR"O!!(W5V%% &)JOAY=4U6SOS<M#):,CQM&FV1=K;F4.,'8^
MK*<@@= >1CVW@2:TCLQ%K#*UK;&W!6# D!G68AANY4[=A'<$\\UV=% '#_\
M"NP-->Q35"(CIU[IRDVXR$N9 Y/! RH4 <8ZGT Z74M+DU!],G6X2.YL+C[0
MC&(LC,8I(B"NX'&)&(YX('7OIT4 <E9>!8--U.SNK.^D6**-$GBEB20S,C,X
M<,1F-BSG=MX(P %QFNMHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH BN;:&\M9K6YB2:"9#')&XRKJ1@@CN"#5"?PYH]RP:XT^"=OGR
MTR[RV]0CAB<[@5"J0<\*H[#&I10!DP^&=%MWB>'3H$>*59D91@B14\L-GUV?
M+GN.M10^$/#UO9-9P:/9Q6[3"X\N.,*%D'1EQ]TCMC&.U;=% &:?#^E?V.=(
M6QACTX_\NT:[$^]N/"X_BY^M)#X>TNWNH[F*U"S1S23HV]CB208=NO4]ZTZ*
M ,R?P]I-S=2W4ME&9Y98II'!*EWCQL8X/)&%Q_NK_=&(AX5T/[1;W!TR!Y[:
M5IH9'&YD=FWL03SR_P W^]SUYK8HH S;_0=,U2622]M5F:6W-L^68;HB<E"
M>A(&?6GC1M/%R]S]EC,S_?8C.X[=FX@\%MH"[CR0,9QQ5^B@#$/A#P^;1K5M
M+@>V>V2U:%P60Q(VY%P3CY6)(/4$DBI?^$7T/S[&;^RK3S+ 8M6$0S$,YP/Q
MY^O/7FM:B@"G=Z58W\J2W5M'+(@*JQ'.TD$J?5254E3P2H)' IUKIUM93W,T
M",LETXDF)=FWL %SR>N !]% Z 5:HH Q/^$0T 0/ NFQ+"\)@:-2P4QEMQ3
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-VTDTD:.UO- \:%'0L,@,YW8/( VM@[A<UCQE9Z3'K(CMYKJXTJW:>>)"JX
MC,@SDY"D#[V-N<@$L"*LVWABSM-2M+^*299K=9QU7$AF97E9OEZLRJ>, 8P
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M,96VIA@VT<X^\5X(/3FF6_@'2;:.WBBEO$BA6U!C$V%E-N5,+-@?>4(HR,9
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MV\C:,,LUE)"=K1N0WW_FP"-NUHGX/;L;"[TAFU&6RA"OI\AMKG9:E6#*BOM
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M%C+E67R=P/#$!AG!PQ!QGC.T58_&5UIJS6%_)80%)X+>"Z8;8XQ);M*HD#.
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M@@CA3=L10J[F+' XY)Y)]SS4 TRQ7R<6=N/).8L1+\ASG*\<<\\5:H ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !3))HHF19)40N<*&8#<<9X]>!3Z\Z\<6\O]K75U:1+=2_V:L%Q
MIUU 3'?PM(Y\J%P"4F!!Z9!W)D8&0 =VVI6*3^0U[;K-NV^695#9],9ZU*US
M MPMNT\8F8;A&7&XCUQUQ7#//'#XW\0RR2P?9L6ADMVAWR7)5),)'SRP8Q]
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MFTJ7"KM974X41X^7:0.^:]DFTV>>PC6YGC,D:1N3"KR(Q4J20<#<",X/J,T
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MZRRZAJ*?;)+1IRDBW/[B,JL9RKQMD#C( "LORT >C27$,4D4<DT:23,5B5F
M+D D@#N< GCL#4E<WKU]=6^M>'8DG$,-Q<3+<Y13M46\C!LG.W#A1GOG!SGG
M-\$ZQJ]_=11ZG>/<>=HEC>,KQ(GEW#;UF4;0.ZH2#D@MV! H [:BO-AXPUF'
M4[HRK?/IIVEI/[/8/;(+B5)&"A3G:HB!!+$ A\#)6M*#6M3.K6>FS7NH)N2"
M:WN3I1Q>*97$JR?+B,B,)GE"-V[&#L !V],DFBB:-9)40R-L0,P&YL$X'J<
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MJ3R6[31/&)HCAXR01N4^HSD5QC>#]5\D2(-/CN -,C:&*5TA<6DXE,GW"0S
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M\!&PQW*!PN*CC\%S2>+8=:O+?3W@:>>>6V+&00L\42#R\H,DF(LQ^7EN^,D
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MF=BECR0,MUY)9B2223FOX+TA[-;0"988UC2 "3)@1)!(J(3G"[U4X]%4?=4
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M "22 /7K0!YW<>/=0MD'GBWM9?LU\6CNHMK+/#'$\: K(5?<'9OD8Y&,;2&
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MN"26V\C@&O5)6"PNS(7 4DJ!DGVQWK(MO$VESVEK/!(QAN889K<B)AYBRDA
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M5$\PJVX#:2GS#/WAR,U6UGQ')9V.BWUHFZ"]O(HG#P.SF)U8Y50<AN!U!^E
M&-?>'/$-P\[6LBV^HI+>LM^9R%N(95?RH6V_,NUFC&<?*(LJ<MBJ]_X?UJYN
M=/O;'18K$HMU)+9-<J\9+K$/*;!PH?RV'[O@%@QSE@>GA\8:-<?9 ES(!=.L
M<9:!UP[,Z!&R/E;=&ZX/(*X..,Y&B^+KN::V?5'LH;4V^IRW$JHR!/LETD0;
M)8X4HQ)SW'7'% %"X\.ZK-KLVI6NFR6C'4;.6!O-C#10K%Y<@PKXQC@J/O#
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MER0(_P"$%0,9&<\G< 3R_#W3WL[JTBO[Z&"ZT\:>Z*48+$)'=0NY25V^:Z@
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M[<'F_"7BVZE\-:0GER7IMK*U_M&629?-!DMQ() &;<^20N,?,=V#E<$ V)/
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MQ+Z"("66YP=YWNH&X,=Q 0$GN&4Y.<T =%1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[.QM-/MUM[
M*VAMH%)(BAC"*"3DX &.3D_C5BB@ HHHH **** "H!9VPOC>BWB^UM&(C/L&
M\H"2%W=<9)..F2:GHH **** "BBB@ HHHH **** "BBB@ HHHH *0@$$$<&E
MHH KV=C:Z?;);6=O%;VZ#"10QA$7G/  P.2:L444 %%%% !1110 4444 %%%
M% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ***,B@ HHS29% "T49HH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&^
MX<C<,=/6N(M/#-Y%::'\C12V%A%!.BS 9,:.H2(C[FXM\S9&5"C&?N]I<?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,, EL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK**Y@^*$U;29[G1EEDMS%C[6FT- SVXG1RCCIM>/L3EAE2,D8UMXIU&[\/\
MA2\MIC*US=06UR59-UP_D.9%8$?)AU'3!X/&,9 /0**Y&/Q[:2Z.^I+8W(CM
M[1+R]0E=UO$7=">OSD&*0X'\*'') -2#Q)>I>:_IGG3W5[]NN5LP/+0PPQV\
M+D@E=IVM* ,@DEAGC) !W-%<3HOC1V\,:7<36MYJ,RV,+7TT$?*2FV68DY 4
M @KW&"Z\8R1>L/&:7EWIUM-IL]I)J$*3V_GR(!(K#/R$'#,H&64'< 5.""2
M#J**QK[Q"EIJB6$-G<7<X\EID@0LT:2NR(YXQC*L3DC !/.,5SD_Q%>;2DNK
M'2G22>WM;F$74J@&.:819.S=R"0<=P>O:@#O**Y"/Q)=?V\ME# [++K;Z?/]
MIE4>5BS\\&((IRI"Y^8YR3TS\L'AGQ9/+H]C#<K=:E?E@;EXXLNJ/<21(Y"J
M%P/+8GI@*2 >E ';45R6G>(;C5O%^G&W,B:1=Z;=S1!BA$ICFA19,8W+P['!
M.,,O .0%L?%MS/>WMC)8Q->+?36UI#',?G6*-69F8J,?> X!Y8#H"U '645S
M\GBRV/A:T\16\$CV,_E._F?(T,;L%+L,' 3.6[ *QR<<PW_C"*PBO'>S>0V<
M$EY.L;C*VR.R^8,XR3M=@HZA3SG (!TU%<?;>,YFDU1)+%99H;QX+."V9W:9
M$ACD)/R\'#CMC+ 9P"U;&J:^NFZ+%J/V.9_,0N(7PCIB-I,,#SG"D8 )R1T&
M2 #8HKG?#_B*?7-1U%!;QQVENL#0-O)=Q)&),L,8'# 8!.,=3FN;3QOJ<1AU
M>[MB;6.QU6:XLK:164"UN8DWAF526V%QCH3C@9. #T:BL6'Q$ESK*V,%G<RQ
M;VB>Y1"4BD50Q#'& ,'&<_>&,#@FEJ_C.#2?M[C3[R[M[!)?M,ENA(C:.'SB
M&)PH!7C.?O$#'(- '3T5R=WXZM[&.]-S8RPM:7*V\AEE14&Z(2H3)G:NX$*-
MQ W$ G!!JU'XK5]3^Q?8G+#4Y--R''+K;&X##.."HQR1@^HYH Z*BN)T_P =
M0+IE@WV34)XFMM/E:YG:+>5NW,:,P4C+;U^; '<CMG7L?%,-_KITM+24-NN%
MWY!\LPNJ-YB]4W%E9.NY2#Q0!OT5QOBCQ9+;Z-K?]EQ70DM;*[*7T<6Y(9XH
MRV&W+C&1@'GD$8'!-VX\7VUB)3-!<S06:'[;<11,1 RP"<EN,8*$<@YRRC&#
MD '2T5S5YK^IVVNZ5IYTN-$N[F2)W:?.Y5A,@,8 ]1@[L<J1@@AJIV/C6U3P
MU!?+'>W44&G0ZC=R3%/-CMW+ .VT ,V(W8A1T0XY*@@'8T5SFF^+HM1U:"Q^
MP7$'GM=I')(R$%K:7RI 0"<<D$'Z^V='6]6_L:Q%S]F:<DL JL%QA&?G/)SM
MP  3DCC&2 #2HKC)/B' (+BZ@T;4)K6".U=I%>%2?M 4Q@ N/[X!]#TR.:FU
M3QTFBY&H:5=1NL4KLB21N=T<#3$<'&"J, 2021TQD@ ZVBN7'C2+?/#)8303
MQW4%L/-=?+S,@=&9UR%'.WG^+ &=PRMIXT@OHK)X--OBT\<,LL)CS)#'*[(C
MG;E=N49B=P^49&>E '3T5Q^B>(KK6?%<;(9$TJYT>.]MHFVG<&D(#G W E<9
M4D@9'?-+'XO\JZ:UAL=0NYY]0NK6,2R0J$:)"^,@C"G'R]3ZX.!0!U]%4])U
M*'6=&L=4MUD6"]MX[B-9  P5U# '!(S@^IJY0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5'+<0P&,2RHAD?8@9@-S8)P,]3@'CVIE[*
MUO87$RJ[M'$SA8XR[$@9P%'WC[=Z\U@U+4M5GTL:@9Y/)URUDMY9;;RB8GL\
MEONJ,>8SCIP>,GB@#TV>XAMH_,GE2)-P7<[!1DG &3W)('XU)7CG]JZWK'A&
MPN+F_-_!<VVG74[M;(HMKC[7$V%V 9!3>S YVA <@,,ZEWXE\0VMM+'%<W<\
MUK>3@R_8 _G0I<Q ;BB8R(V?A0N5.[(*\@'I<,\-PK-#*DBJQ0E&# ,#@CCN
M",$5']BA%\UY^]\YHA$?WK;=H)/"9V@Y/4#/3G@5YOI]SKVD-?MID=Q<E;O5
MI9M,>V "C?))#(#M#;G8H I)#*Y('RDB]9:E>77B?1[E]5U"73)$OE5WLF@4
M,!#M#AHQDC]]ABJX"D<X8L =-9^'M N/#!TRWB6ZT:Z0NJFX>9'5SNRKEB<9
MY!!XZC%%SX>T&.WMHKJ(;5#6Z--<OOE$A&Z-F+;I Q495B<X&<XKF/#^O:K>
M1:):7DEY;7,ME9SAH]/#Q7+$8N%<A=L97&,90J<'YL[:RCJ^J:M<V,=^+EXD
MOM+NH3/9F%D9GD$H(V@#&T97+;<L-S"@#T(>&M*%Z;SR)?M!NS>[_M$G^N,7
ME;L;L?ZOY<=,=JR[+P78V6J,RPC^S$L[6VM[8W$C;3#)(ZE@3\XS*,!B<;!Z
M\1^*]2UFSN+F.PWQ%; SV3+$'6ZNE;B!L@XR-HP"K$,Y!&W(RSJ^N17-]=27
MUVUE%K/V218K:-Q:VVQ6\P80LWSCRRQ) #$D97( .@C\+>'-0MX7BA,L<5Q/
M/'+%=R9#R.3,-ZODJS9W)G:2.14L_@_1+B-T>VF7==/>!H[N:-HY7!#LC*P*
M;MQR%(!R<CFN*\/WNJZ9IUAI 6]L4:XF:"=].+BX8WDI>-U" )F/80?D&'8Y
M 4XZ3P?JMQ)IUF^KZI/<7NHO*(8W@1%7RV;@;$&,H%/S'GMZ4 =#=:18WHLA
M-!Q8S+/;A'9!&Z@J#A2,C!(P>.>E9UGX=\/V5S#:V\0\ZV19$@>Y=RJAW96*
MLQSAG?#$=>_ QC^(KSQ'IVK7S6+7EQ:B*&^A2*"-@$B8BX@!V$EG79M&=VYC
M@@*167XFN]:CN)K7[9=JJVUC<2^1$N]<WH\X95<E5C.".FT9.<G(!V5GHVB_
MV"V@V\:RZ?;@6Y@:=I#%M (7<6+*5^4CG*_+C&!39M%T6VN+*ZG4QRP7)D@D
MDNG!::0;.26^=B#M ;/& .,"N5TBYNK+Q7<FWG=+:\\0S1S0&-0KH;)6$ARN
MX'S45<@@98@@G&*OB1;AO$]_%++=/']OT:6V5TRB 7&79#MQP-Q//KGIP =M
MJ/AC2=6N)+B\@E>22*.)RES)&&6-_,3(5@"58D@]1D]C4,W@W0;B3S9+-_-^
MTR77F+<RJV^0 /\ ,&SM8 93[IP.*Y9/$.M^1;6CW5R':XN(H;\6(G$[1W3*
MB2*B@+OB"-D; P9B&7&:U?&VM:KI1M_[*-SN6)IG$=H94<++$""P!(^4O\H
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M$]I)]MBD2QO4%DUB?*EB:,B!UE(^\QVX 8G)9=N5R #M;KP_IEYJT&J30/\
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MK*4V%D(;Y"5)!VXSGG-<=%>7UCXMO9[*XD\BZUV&.2%HE FC:PC&YB5RO[Q
M,C W9!ST&]X0U>[U>VN+F\FN%.R+S+>XLF@-K-M/F("RKN X_O8Y.XA@  =
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M8;F4@=\=1R,5]J5KK<^HQR7,$TS:,ES%/;HKRAR5E\P8.UE1BQV$;2.25XH
MZ77/"]FEN;BUE2T=IX7F>>\GC$FQ#$BAUD!0_,.1G=C!!SD2:?X=TE/)O[R[
M-Y>V!>-[O[5)\JARXCD^<[U0G@2%B.O!KD-3UC4]5T[5(;L73VI^Q3VXGLC"
M4=;YED'W1C:J1Y!+$=<\FNATJ R:!XQ@2$NTU]>;(PN=^Y!T'?)S]: -O1O#
M6AZ7*M[I=OMWP^7&PN'D01%MX5 6*JF>0%P!VXIR^%='2Y6X6WE$JW$MR&%S
M+Q+*NQV^]W4D>@[8KA]/UC6-*TBTC:XOI-)-K:(UZMF&>R<Q2^8@58SE59(1
MEE8J9""?[O7WM]J%OI&BN[R 321I?W4=OM:%#&Q\SRVW;!Y@0'(.U68G&"P
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MI_M%N8UQ)&=ZJ%.WB)1N*_,9K/X?B'^R6FT;2V,%Y?37:[$/F0R^?Y4?W?F
M\X#!X&#CMD ]%+* 22 !U/I2[AUSUKSO3O!FJV%I'&EM8&5M/TJ"Y9GQYDUM
M(QDDR%.6P4VLP.=F",5GQ?#W5X].\I[:P:XAT^UMK>03D['AN7DW E01\C*
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MKKRK;R#%/N7S5,+J\9^[MX*+_#@XZ4 5[SQKI%B+MI&F=+9"Q>%/-#;9!&P
M4D@JS*,,!G)(R 2+EMXBL)]/U&]D,EM'ILDD=X)UP82BAB3@D$;2&R">#ZY
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MO(&36K-9QK>_;WEN&$<?RP+R@(W?,% SN(8CWXXSBH7UZP26"$F;S94B?RQ
MY>-9&VH77&4RV1R!C!S@ X .&?4[_6[KP??3-;V>H&\N(098MPAE2SE688W
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M_D2(<EBI'#-'D9ST[4 <NGC?4U6VM+B72H+V268037)>*&_6.X,6V(#<=[*
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M2 >E>A,BM]Y0?J*S;;6=/NI9HK<3.T-X;.4+;/\ )*%#G/R\+@CY_N\CGD4
M8WBOQ!J.E7]I:V,UE%Y]G>7!:XB+D&%588 =>.3D?J.]*W\8:A?I"T26\<CS
M64?V7:3)-%<1HQGC/HA=ST(Q;R9/.4[25H%>-93&&D8H@;&6."<#UX!/T!I+
MB6&TMI+B4$1PHSL50L0H&3@ $GIT'6@#S>P\836N@>']5G:UU&5_#LMW/<"/
M=-&ZO;"3+*?NC>690,_NO;C2OO&DUNL,=KK&B3+<^<]G?2NRV\^PQ@1 KNW.
M=[#Y,_=X!(91V=C<VNHV-MJ%J0\%Q$LT3E<$JPR#@\C@_K5*\\1:3I\\]O=3
M-&]M]G,@\AR%\YRD1! P064C(Z8YQ0!5\1:U<Z==V]I#+:V@GM;F9;N[4F,2
M1!"L9Y7J&=CSG;$V/487A23^W?$FJZEJ5N([VW:UDBMI<-)9,]JI:,-P1@R.
M",#)).,UWA 88(!'7FJEE?6=[/>I;$F2TG^SW ,90J^U7QR!D;74Y'!S0!Y?
M+K-VFIP7RZE:SZE8QZ^N^X4-L6*X38C*K+_"@[C@YKJ=,\7S:IX@M[))].AX
MC:2UDE/GRQO;K*)8@!RH9MI)XX;D$8/8LB'EE4^Y%5;34;.\N[RUMW)FL76*
M=3&R[&*AP!D<_*0>,B@#D-2\6ZM;>(KJRAETX00ZE9681XF+D3IW._J"<C Y
M QQ]ZJUIX\OIUL[66XTJ"]DDD5)+DO%'?>7=/"Z1 ;COVHK;06.95P" <^A&
M-"<E%SG.<4!%4 *H 'H* /-Y_&5[J>G&\@U*PM8([RQ%Q#'(3<69:[2.6*<$
M84;3CG!.U\94\2V_B2]34OL=@^CV@NM8O[>21;4G/EPF19"!(-S\#<2>?]GI
M7HF!SP.>M4EOK"35IM,!!O(H5G=#$1A') .[&#DJPX/;F@#BM*\<:GJUSI$:
MOI<,EW#93R0M("2DT1>3'SAE8':%7#9!'7)V=Y9WMKJ-I'=V5S#<VT@RDT,@
M=&&<<,.#6=/X=MKF_DN);BY:"5TEDM"RF)G3;M;E=PP40[58*2.0<G.I!!';
M0K%"NU!D]2223DDD\DDDDD\DF@"2BJEAJ=KJ1NA:NS&UN&MIMT;)MD7!(^8#
M(Y'(X/8U;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O?QW,N
MG74=E,L%V\3K#*R[@CD':Q'< X.*X";0-?F2W9+:_MX6FT[[1:KJ')=';[3*
M6$GS*R%0><L1DKGD^BR.L4;2.P5%!9F8X  [DUB+XPT22-'2[=]\IA14MY69
MG\GS@H4+DDQ_,..>V3Q0 JR/=Z#J-E:VMY$ULDEI"6G'F2[4P&20.3R3C<S!
M@0<X(K%\+Z+J%IX@AO=1TUT?^P;*U>XD>-V\^,R>8"0Q8G#J,]#CK5S4_&=G
M'::=-I<D=T;RYLD!".0(;B54#9 PIP20&(Z?0&Y=:^UGXK&F31J+4V/V@.BL
M\C/Y@3:% .1@YX!/7TH YB30_%']KRW%G]M@F?4KXI<378DCC@>W(B)0R'*>
M;L(7&1MZ 8ILGAW5Y=3TF^;293;V]U:226LMQ'*Z2+',DTRLSX(.^'/(9BC-
MMS][KM0\5:/I;2B]O!#Y4,D[$QN1LCQO((&&*[AD#)'I4">,-,FU:TTV#[1)
M//<26[?Z.Z^4R1^8=VX @%2I!Z$-D''- %?5K#5Y?%%G=V:.]JBPK*LD@"8\
MPEBI#!D8#!/#+(-JD#:&$7AC3=;M;VUEU RQE-/\B_+S"1+NY#C$R8)(X$G4
M*2'08^0!=N[U_3;'48["XN0EU)MVQA&;[P<KD@$ MY;X!ZE<#)K-_P"$SL3X
M0@\2"VN_LMP8Q''Y1\SYW")D=N2,GD>F>,@'*ZM9ZS8Q2/=&[2WGU>Q\HI=M
M',VZZ(:,E)-K#:^ V$.-H.=@(MQZ'XAA6TM)H]1EL&EE>'[/>1"6P/V@O$'=
MR2RB,JIV%B I4!@W.S;>(K*\U:_TW5XH%:WU%H+0O$S(P6WCGW,Q&U7VNYP2
M.%.,X)K7CU[3YK:^FAD>3["2+B,1.)$.T/C80#RI!''.: .0N=,\1W&AWH.F
MWL>L@I%)<07RHEX!<!MZ .,?(#G=M(!V ,.BPZ%JUO<SR6VF3V_F^)4NW,4T
M:>9;;0"6VO\ ,N0?E.3R#C-;,?C733!:7UQ=):VD^GQWIBEA?S$5W55)(XQE
M@/UZ5=M_%NC7-REO'=D2L\L066&2/#QC<Z,64!6"C=M."5^8 CF@#E5TWQ0(
MS//8W\US'/$M_"MW (M0C61OFA (P2-I82%,J/+^8=-OP;'<:39KHMSIUQ _
MFWETKM+'(JH]U(R*2'+;BK@Y(QP><C%;EEK%CJ#726\^7M6"SHZLC1Y4,,A@
M#@@Y!Z&L]/&6A2QH\=X7$DHA0+#(6=S%YR@*%R<Q_,,#GH,GB@#C_%?A_P 0
MZQ/JT4>E32V]Q;W<*JUU&\<AQ T#8=^,%),# "LQ_O,YZC7--FO+OPQ>1:49
M19:@)9(_W6^"-K>5.[ <.T>0I/3(S@4W4/&5F+#3[C2Y4NC=SV0&(W(6&XF6
M,,2!\AP6P&QRN/:M'6/$VE:"X34;AXF,$EQA8))/W:%0[?*IX7<I/H#GH#0!
MP=IH/BK3K6W>QL+J.3[/<?:86O(RLA-\DBH 79 QA\X XP"^">3C8U^&YT_X
M87:;]2MI RLBR78$\:M.#LWQ$  !MH ) 7 R16S;>*8!+JQO7C6&UOA;6YA#
M2-,IMHY\@*"6.'8\#HOXU/+KN@WJP02SV]Q%=8\LLF^)CY?G %L;0?+&_!(.
M.: .<?0]:BO;.:VLYY((M6N+N&&:\!:WC:S>(!G+,1NF9F&W=M#]!C K6.G^
M);6-Q<Z/>W5BUW'))9-=1,[QFT5&"EI2,K,&8[FY)W;F;)KN++5["]^U+;S
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MNCR@#_52 &,AP02S %7!4X5LJ5S6S_PD6EFZ2U%T&ED#^7L1F$A0!F5& PS
M'.T$G ;CY3BOX6U:]US1;;5;B.&."]MXKB!$#AH]Z!BC;OO8R,.,!L]!CD X
M_3/#^O6%K:6K:9?-;-8Z=#/']N4A)4CF69@ADPP&8 1P#@$!]FTM.@^)9]'4
M76FW,MZVFZ+%*TEQ$S/-;W+R3Y8OR<-NR3S]:[2[\6Z)8_:OM-Z$%K')+,WE
MN0JQE5<@@8;:74$#)&1FH[SQ7IT5C>202L]S;M+'Y#0RA_,1-Y!7;NV[2IW
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M% !1110 4444 %%%% !1110 C*KH48!E88((R"*S4\.Z(B;$T?3U3;&NT6J
M8C.8QTZ*>1Z=JTZ* ,+4_"UC?QVL44-O;1P7<=TRI N)2F<*PXXY-7Y-%TN9
MK-I=.M':RQ]D+0(3;XQC9D?+T'3'05>HH SCX?T8Q7,1TFQ,=U();A/LR8F<
M'(9QCYF!&<GG-*=#TDO>N=,LBU\-MV?LZ9N!@C$G'S]3US6A10!3MM*TZRM)
M+2UL+6"VDSOABA54;(P<J!@\ #Z"J]QH=L]BMC:JEI9L2)X((4"S1E"I0C'
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M^=79Q(V.!A" <@Y(ZU+I&JZKK]A/JUG-!'$;R2*VM63(>**4QN7;KO;8Y!&
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M9Y8IDDO61(;=@!(792VS&<9"AB>?X36=;^"M+M)FFMI+V.1D,9873GY?,:0
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M[2=6O]9\2:DD4IAL=.N4BVA$=;A&MTD!SG<K;I 0>FT8(R<C3U/0K#5IO,N
MPD,#VTA1]OF0OC=&WJ#CKU'.",G+M/TFUTV_OIX)G\R^E666,E<;E14&T #
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M9I<NX:\G%M#M0MER"0"1TX4\FI8A;)<301L/.XFD7=EOFR QSV.T@?[N!TH
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M'!JDEH83 08X!:B83,=_16*@G@')'!*X[6SL(K*-U1YI"[EF>:0R-R20,GG
MS@"J]K8V>CSWDPF96U&Z$TGF,.92JH O_ 448]L^IH X>+Q?KH\-6E[-<6WV
MBZT==3M2+?"7$^Q#]E'S')R3TPQWKC[C9UI]<OF\0G2SJL5JETQ6VG5$D$5P
M(P6M7'=AN$@.1N&5X(W'JH+^&<JG[R*5C(%BE7:[!&VLP!YVYP0>X93W%+>B
M$VKPSSO$LX\D,DA1\L,#:PY#>A'(ZT 8.A:_)+9P7&L7*6<CLFGF&<K'YEZI
M82",G&\$C"XZ[2<5#XF\0W^F75U#;>7&\-B+NT21-QOY0[!K=?1L! ,9;,JD
M A2&Z2.PMXX(H=K,L3;QN8G+9)W'U.3GGOSU JQB@#C_  Y%;7/B3Q1=23I=
M3VFJ8B=PC- #:0 [2!D#[RX_V?7)K(LO$NH7UUX<>]U!K?=JOV>?R@@@G#6D
MCJ%?G>I<?*#L89 9=P#'T?'&*,>YH \^'C6_BM+>]N&C$$MM')J"I'AM)D\^
M.-U?/8*\ARPZP.W*G"TI-=CM?&D=Y+J,#Q7&F1QR:G B@)";J01R$'(*G*J7
M&5!?=@*>/3L48]S0!Y/;>)+S0I=1;2/LUVESJ6JE+../<TDB1^:I4J<DDC!
M'(;UQ6CJVK-?W^G1RS6UW9P:[9-9WZ%<2%T8LG'&Y<]1U5P.H)/H^/K4<\T-
MN@>:18U+*@+' +,P51]22 /<T >3VWBW_B;_ /"1N\4UR=&C%W#''AK$FZ19
M$? +?N@Y)W#/RL>AP-IO%.LO<QPP:QHK1KI=U?B98FDCE$4P5"6!!VE#R47J
M&*Y& /0NV>:Q8O%&E3ZC%8I).9Y+R6R4- X'FQ)O<9(P!@<'^+MD<T <[K&I
MOJWPH\427R$216-S&RRA" PAR,.I*/R00RXYXPI! >GBJ^&KWFG2WEM]GBU-
M+9[]%"B")[43(3DD#,A" G@YQR2,]SBC'N: /+K;Q)=6]YJ>L7,5O;WTFE:9
M]H*@E40W5Q&UQMZ[1&PDP3PN 3WJGI6MIIE[>&SETV8FXUBYBN9(5)W(L3J5
M*L/E8'+;<;L9R*]9GEBMH6FFD"1KR68X IL4XFFGB$<RF%PI9T(#Y4-E3W'.
M,CN".U 'G</CF^C?9?:E8)"ZZ?*\XV1-$MQ%(S!=[%208P1N_A9L;CM!Z$>(
M;B'P+8ZM?WMDEQ.T"2SV@$D*F254.#N*C[V-Q8J&Y^8#!W=1TR/4HXE>>Y@>
M%_,CDMY2C*V"OT(PQ&"".<]0#4EE86^GVHM[9"L89G.6)+,S%F8D\DDDDGWH
M S/!^KSZYX7M+ZZ:)KEB\<OE=-R.R'CL?EY'\JW*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH JZE%)-I5Y%$',CP.J!'V,25.,-D8/OD?6O
M/+3POK=K!;D6%QYL46COQ=*?W\,I^U.,O]XQ80G^(#'2O2I9$AB>65U2-%+,
M[' 4#J2>PKG=2\86L&GO)9!Y;@3VD7E20NK!+B58UDVD LOS$C'!*E<@@X .
M*URTUFT76'NHGM)-0MVC@ABOM[33+=,ZE!NWOF-U[< ,N$4*IWM2\/ZY<"[\
MM)/M8>^/VN.X"_:;>6.3RH>H*E6:+&1@>22#\Q!U=1UVXTM;.RN[>.;4KF.Y
MFBECB80IY2EE+ DL"05&,_WN>F31/&5A?Z-!/<SK%=BVMYIX_)=!F5-P\O</
MG4[7P02/E//!H Y?6/!FHW&G1VUMIKR(=&V2Q2W"LK77FQ/T9R-YV/\ -T)(
MRWIOZ7I\+^*[QK0VSZ<9%NYHE=6:VO0IC9"!D %<-C.0RD_Q5MKXCTJ32K/4
MXKM9+6]94MW16)D9NBA<9W<'(QD8.>E5+7Q7I\]_>6ZQS1^08 '>(@SO*FY0
MJXW9QC.0",'( &: *&J:+J]WKLLJ$E3=6L]E=K(!]EC0CSHBN03O4/R,[O,P
MV H-3:!H;0^&-1T^YTV.V:YNKUO*<(5=)9Y'3.TD8VNHP>F,5H_\)/I)LX[I
M;AVB<9;;"Y:/Y]AWKC<F&RIW 8*MG&TXP;KQ?>6_@O5-2"VQU"RDNUQY3^3M
MAN7B!;YN"53/WN3DC@4 8MCX7UF"SL6_LB6&>UL]&A4+/$"KV\\C7&,/CF-V
M&>X8CN:Z7PYIFJV^MWESJD4HE >(W(G0Q72F3<C"-1D%5X._D9PN1S6DOBC2
MW24I).TD4SP/ +67SMZ*'8"/;N/RE2"!@AEQG(S3B\56[:S=*US;OI@LK*XM
M9H@6:5KB29 H()W9,:XP/XC0!SB^%M9\S3Y;BPCNDM=0M[D"5T,X&V42!FSM
M?:74^9A789W E06L7.@>*%0RVKJ;Z$3_ &B5Y@J:DK3JZ1\9*?NPZY(^3=M7
M*DFM73O&EDNBF_UFYAM<WES"#Y;IB..X:%793DKP%W$X R2< '%R/QEHTIPD
MUP3F0 &RF!8QLRR!04^8J48$#)'&>HR <W>:%K!O]/O=/T7R88K:Z:>PEN4=
M7\V:!S 3N^4L(Y" OR!MH)*E@>BUJPN[PZ:ZVC3V"%Q=Z=E T@9"%ZG:=I_A
MR!SD'*@'>?S#$PC*K(0=I89 /8D9&?IFN2T?QY8RZ#IMUJ\RPWEU90WLB0VT
MI2))3A26 ( !X))XZG - $?A?P_J>F>(!<ZI']IF&CVEJ]^65C)-&TI?DG>>
M'0;B 6VG-4HO"UU'J:HVC@VG_"0S7TK1M&%D@>UE3)&X$_-( 01SD\$=>RU/
M6+/2(FDNY&4+$\Q5(VD;RTQN;:H)P,C) [CUJK<^*=(M+B:&XNC&T*.[%HG"
MD(R*V&QAB&D08'=OK0!R?A[0_$<,NB1:O;7#+:Q0E)UNX\V[(A61).K.&ZC!
M(.X!L;16[>Z?J4_BP/+8BYL3Y,EM=+<>6;-D)+@@')#9'3(;E7^4"K]QXITB
MS$)NKKR/-D$0$D;*58R>6-P(RH+\ G@]<XYJQ?ZYI^F3PPW4S(\S(JXC9@"[
MK&N2!A<NR@9]?0' !PMSX8\1OI42A)Q=);6T%]Y5T%^W31W$;-.&W#!V++UP
M3Y@!^Z,-MM"FN/$NL6VCM+:26&K6Y@NC*72UA%G$6C6,MR&W$;<8Y!S\@QW>
MJZ]IVC)(U[.4$<#W,@6-G*1)C<Y"@G R*K?\)'HL%S,CSI!(MT]I*[QE%$J0
MF<AF(QCR\MN)QC/.>* .4E\-:Y);0_Z/.@W:<MS;I=#$TL4P:>?.X9#1C;D_
M,_&Y1M%5M<\(ZQ>S:I:VNF;;.33[VQA4W8DC<-#"+=CO;<,-&PQ@!6((!RSG
MLKCQAHUJA,\\Z.)8XO*^R2F0M("8_D"[L-@@'&,@K]X$4S_A--$$(E:XF52T
MZX:UE#!H4WR KMR"%!.,9.,#GB@#%?1];DU*_N;>UFM[23^SW%H\R?O(X]WF
MP@!BJ<%>.%8@C.&+5CW_ (1\0M#J AAN7S8RC3T%V%^RR&Y\R%!\^ R+CYAP
M -H) %=E%XTT.:5(TN9MSR0Q@FUE !E_U1)*X"N>%8\$\ YXK0GU>TBU'^SC
M*?M91'VK$SA Y94+8X )5AR1T^E &)XMT_5K^2R6SMGN+)TECN88ITBEC=MG
MERJS*<;,.,J0PW KDC%8[^&=5EUB:62SEDCFU:Y9WEN%=6M'M#'M*EC\AF"'
M9CC:#@8%;'ASQK9ZIX?L;F\D\N_DLK6XGBCMY N9L*OEY!W OE>"<'J:HZKX
MWF$&IW>D-:S6MOH4NIP/+$^6EC9@589!Q\N,<$'/- &&OA+66TG3[>71W9+7
M3=*1K9I8F'G6]R'F"@OM#,F<'@'."16KJ>C:Z]WK#QZ=)/8W>H^9);1SQ*\T
M1M88@Z%L@%7C;@[3@@CD 5UVJ:[8Z/-;0W;3>9<[Q"D-O)*TA12[ !%/.T$X
MZG!QFH%\5:.Z6TD=X'BN%A9)5C8H!*,Q;FQA=W&-V.2HZL,@'+2^'-<;Q#9O
M-:?:EM]2MKF.^>Z#>7 MOY;Q'.&)\S<_3#;\\'BKVM:'J3^)-3O].LDS<VEB
M/.#(GF^3<2/-"3G<#)&RJ#C;Q@D8%3WWB^5_A_JOB/3K;RY;1+DI%=H>3"[(
M=P!'78>A[^U7V\7Z+%:W4\ET\:VDK13I);R)(K*@<_(5#'Y2&! Y!&,YH CT
MK06_LK5+"_1A8WEQ*8;5F!-O"P V @G'S;V&#\N\ 8P*RK;P_K,.GZ6]Y'#=
M30SK%J,*;1]LMXXY(HSSA3\S+*5;&,D9^4 ]'>>(=,LH;&9YWECOCBU:V@><
M3?(9/E\L'JBDCU .*J6WC/0[O88+MY$:W2Z\P6TNQ8G#E69MN%!\MQR1\PV]
M>* .3M?"_B/3/[1EMX$GO9["R59WE0&013R,\#NVXEC"R1[V!!VY)KH'T:]D
M\$&PBBO+>>217$7GQM)"IF#E<X\LJ!G]W]TJ-F<<UH6WBS1[R1(K>Z,LSRO%
MY<<3LRLCHC;@!D &6/D\8<-G;S4<WC/0H+O[*]\#/OC0(D3ON+R>6I&T'(WX
M4GH"RYQN7(!R=WX9UV6:>X.GYN5MK!8)+><* \5W+(Y :0E6\N0<9(&64,1R
M8[SP[XCN5UO_ (ELBB]@15B6\5T,B7;OD%FR<QLI!;'"D80!5KL+'Q99:EJU
MG8VD=PXNK>XG65X6C"F&58G1E8!@P9B""!C'N*36_&.E:$EY]I>5Y;:*60Q)
M$V7,<7FLJL<*6V$-C/3Z&@"OIFEZI!;^*$0?8[B]O9IK.9RK 9B1%? )Z,I.
M#^59UMH^J20V=S+HHM4\\'4=-%V)1= 0O'N&3L(W%&Y(+!<M\R@'JY-4AAL(
M+J=9$\[8%C$;,Q9NBX SG\/RK.7QGH<A@V74K+.MJ\;BUEVE;DD0L6VX 8@C
M)X!X.#0!R;>%_$4<9\Q;F\N88=-\F<W*G:\5S(\H&YQEA"RIN."^&Y^8YD3P
MOK/G:=)<V*74=KJ,%P/-:,SA=LHDW-G;)M+H?,PKL,[@2H+=II^O6.J) ]JT
MS+/YNW? Z$&)]D@8, 5(;C!P<Y]*I-XTT1;B2 3W#2I)+%L2RF8M)%]]%PGS
M,!S@9) )&1S0!R4GA#5KFV5&T_%Q)9ZS:+//,C-"9YQ);LS;BV H(R-Q!/3D
MFI!X<UFZUFVU*YT<^7'?V=P(9)HGD55MWCD/WMH(9E)PQ) R,D 5V#>*M&4V
M'^GQ[;\1-;L <.)/]62?X=V,#.,G ZD53?QOI!N[:UM)'NII[N.UVQ*?DWHS
MJYS_  %4;!&<D$<8; !!X/TW5[22>;6()([SRTAFE%PCQ73J3^^1% VYSR6&
M[D#D*"8O"VF:Q9Z]?7-_9O;P7-N@*BY$J+*LTQ8@EBS;D>/#$ X&,( J"TGC
M;2+:P^T7E\[C9<SEHK"=<10S>7)E<$Y0E0WXM@#IH+XETMM22P6X+SO,;=2D
M3LAE""0IO V[MAW8ST!]#@ X.^TG6KOS=&GB*ZM<Z/JRB=IE*W4GG6YBD!!R
MH 8  @;.0. "=;^QM7GU>_N[K2Y)-)N[EY7TX7""0A[6!0_#;=R/'("-W60L
M"=H)[*]N+6R1;JX7G>L:%8RS%F.T 8&>I_4YXS57_A(],.C6.KK<E[&]:%8)
MDB=@QE(6/( RN2P'(&"><4 <1+X/UV6QU1KI7N]42TL5M[EKKB66)!YVS+?(
M6([A0203ZA\WAG6KO49Y;G3Y?LD]S?3>0+I<;9((Q&&4,!G>K>H!YSSFNJM_
M&>A7()2ZE4"*>8^;:RQX$+;90=RCYE/5?O=\8IK>*=.EN;1([](5>ZFMI5GM
MI =\<3.R%C@1D ;LMD%0<=<@ H>$-)U73;V9[^&=%FTVQ65Y)Q)YETBR"9C\
MQ)8@Q@MWV^PK E\,ZW<+,]SHQD!FT^Y\@W$<H$D-Y(TVQG;+%HF7#,06 P=N
M @[&7QCHMO%OEGG4[X4"?9)2Y\[B(A0N2K'(#8QN!7J"*K)XQM?[1@ME6XG^
MU7C6R@6<D36Y6U$^V17^8L1R,*.& QE22 4_&FF:WJ+VHTVS:3RD$@EBN@C)
M(LT3[=K$#E%<!NN>,HI;=6M-!U:/Q):W3V+"!-=N[QG\Q,")[9HU;&[/+-TQ
MGUQ75:?K=EJL4$EG(\D=Q!YZ-Y; ;<XYR/E.<_*<'@\<'&8GC#2[:$M=7K2L
MTMTL8@L)LX@?#J5PQ++T)XW8) QT ,G6M!U6Z\27][!:W+QF72VMW6Z"[?+F
M8W!4%QMS$VT],Y([DFG_ ,(]KZVD-B;.<V'VN\5(HKJ.-K96N"\$JMSA50@8
M7#+C@$$UV-_K$$-GIUQ%>1)%>W$,<4A@>59!)T VD;2PZ,>!D9!Z5E7/Q!T6
M/2I;ZU:XNMD(G2-;>2,R*9!'D;P. Q ;NOIR 0#!U?PWKFI+JJW>FFYE2Y$E
MO(MQ%Y=S#]J25%V$*?,2-2@+G Y .'.+LN@ZI/XEDEGL9Y--?5Q.4^T*4-N;
M Q,I7?R/-Q\N.AZ<FMZ^\8Z%ILLT=W?K&T,,DS@1NWRQX,F-H.2H.2!SPW]T
MX=<>+M%M#$+N\^S&1R@%Q$\9!RP&X, 5!*'!/#<8SN7(!YW,UUIT.DV&L_:V
MNK33+(W$<<\$LZO'*Q/EAIE;,@4JVT2&0%5P"N&[KPEIFIZ<UV+]!Y;K&8F=
M@TN[+EU=E.U\$C$F%9LG<,C)F'BC3Y]5TJUAMYYGO3)Y4Q@950+&KDY8 \AE
MY''7)XQ5V]U_3=.NOL]S<"-@T:NVQBL9D)";V PNXC SCG'J* -.BN?T#6;W
M7+N[G$<45A!<7%KL:-A+OCDV!@Q."#M<D8!&0.>:Z"@ HHHH **** "BBB@
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M84GL6,;$N%<"X4_-U52C#IG?CG!R 5?&GA>75M-U.YT^6X&I3:5<6 B1D"W
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M@*B)8MR8&\2E5')7 R1N91@]?92SO9Q"[:,7FQ3,D8P%8CIC)]^]<#/XDO\
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M9$VD9&W);/;%36],U22ZEMW_ +1NK:!=)F!1Y2K21WA>X9<'D[-K8Z\#'*\
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M)/+EB<74C1M+OQE#%Y6,@K@,I4D@4 =M#H^EVRPK!IUI$(%980D"KY8;[P7
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MB*,ASNV"7SQM7[I*<!!P =C!IUK;W]U?)$BW-T$$TH4!G" A02.N,MUR>?3
M"#2=- C T^U BD$L?[E?D?IN''!]ZX-8?%\<L*78OY;MCI$LKP2@195P+O&"
M% (ZJ!@YR!P2*UM_PE5I#:S(FLW3M!.;N*1FW.JWL94)O(57-N9@,%2?ER<A
M< 'H7]B:2$C3^S++;&-J+]G3"C<'P..!N ;Z@'K3X=)TVW>)X+"UB>$,(FCA
M52@;[VT@<9[XZUQTPUSS[*"&+6DL9\2PS,X>>"3SF8I,=^/+V% -P<A0P/S8
MK,NK3Q!+;S^7-KH9[75P-LDJG>+C=9X_NG83@C!(PK9 "T >B?V3IHF$WV"U
M\T2^?YGDKN\S&-^<9W8XSUIL>EZ99PO'#86D,4B")U2%5#*,X4@#D?,W'N?6
MN,EF\27-S>++!JD+K9N]M-;KB.16M@-K#=\L@F)X"!Q@8.W<*SH;#76US2)+
MF/5[BUM[BRN)?,>0[9&MITE(R1QO,.0/E&2< %Z /2I+&SENX;N2UA>YA!$4
MS("\8/4*W49[XJ@-'L_[>N-<D*22M!' -ZJ1$(FD(*GJ#F1\\^GISC^*7UD:
MO9G3H=1,4)MY6:!AY;K]IC$RE002WE;OO9!!.T9!(SCHET_PO\3:0MK>?:Y#
MJ?DQO(VZ0O+*T6UB<D$,G?!R<Y.: .PM9=+FU2^2U\@WT.Q;HHH#C*@J&/?Y
M<?ABKBPQ(5*1H"BE5('W0<9 ]!P/R%>>W5KJL?B6[U#3XM2C#WVG^7\L@5X=
MFV7>/X@%)SNR0<$8:MSP;)JTUK<SZQ!?VUP4C$T%Q@JLP!\PQ?,Q*GY>F%.!
MM4'=D W(M&TJ#RO)TVSC\J1I8]D"C8YZL,#ACW(YJ>2SM9KF.YDMXGGB5ECE
M9 60-]X ]0#@9]<5Y6EMXL30A)YVO-?_ -C1RX9Y"?MJ2X48Z?=ZK]UARP;K
M6]++XHDO=4EAM;P74"S"",D+:W,1D!BVDOQ+Y8P,!,-NW$C&0#M8HK33K810
M0Q00J"1'$@4#N< ?B>*DMYX[JVBN(23%*@="5()!&1P>1^->>166IMJFGZD8
M];,9M-11#-N\RW9_)9 5W,0/EEV[BQX _N 5K!/% %G/.^L^?$^D@HQDVX*A
M;O*]&&-Q.<\X(YQ0!ZA17G&CZQ<6-[)J&IW6IS1B&X:.%(9G6Z43%ED48\L;
M8SP$+!@<_P (KT<'- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% #)I4MX))I6VQQJ78XS@ 9-9C>)M#0(7U6UC$@A*%Y H<2Y\LJ3UW;6
MQC^Z?0UHW,*W-K+ Q(61"A(ZX(Q7$VO@&\@2S$FLQ2&W33HSMLBH9;.1W7'[
MPX+!P"><$$]\  T8/$7AZW-VNCM8J[6LFH/,%\JW;YF!:24+@$N'W'D@ALC/
M!T-+UUM0U75+-[>-%L1"PDCD+^:)(]^<;1C'3OGKQTK!'@.Y$>IH-6C_ .)A
M9WEK(39GY?/FEE##]Y_"9B,'K@<BMO1-!FTK4[^[ENTG%W';KL6$IL,4>PG.
MXYSUQQCISUH SH?'^ERW]L7>.VTNXM);E;RZ8PG*3+%@HP& =P.2?7(&*Z7^
MT+07XL3.@NBA=8B>6 QG'KC<N<=-PSU%<4?AY<G39[+^V(MCZ7=Z:C"R.56>
M0/N/[SD@#&.,]>.E;6F^&9=/UV>]:YMI[=YI+B)&LE$\3R?> FW'Y,EB%VY&
MX#=@8(!I+X@TB2[GM(]1MY;J#=YL,;AW4J5!&T<Y!=!CKE@.]*->TEE@9-0M
MV2<1F-E<%6$C;8^1Q\S9"^I! S@UBWGA*XNO[1D348TGN=3CU&$M:[XXRL4<
M7ENA;]XI5#GE3\V1@@5EZCX5O=-3SK2:*6*YO--DN+2WL2H5X;E'>2/:WR)L
M!.PAC\OWB2<@'37'B73182W%O>VA<6\TT9N)#%&?*;8^YL':%<A6X)7/2G7W
MB"PM+*[?[;9)/! \N+B?RXP5"YW/@X4%T!(!(W#C) /.2^ +F2SN[3^V$$,U
MMJ=K'_H9W(EY(LA)/F?,R,IYX!!' QDV;SP3-=V^KH-3\AM3LIK6810,(V:1
M542LGF8+JJX!&"00&)P* -RU\0V%VVI!#,O]GW'V:??"P^?8K_*,9;AAT^O3
M!-J74[".RBO&NXOLTX7R94;<)=WW=F/O$]L9SVKFKOP;=3W%Y<0ZI DLNIIJ
M42RV7FQJXMQ Z.N\;U*C(P5*G')Q6M<:-.=*TVSM+J&V%I)&SJMJ!'*B@@QA
M%9=@.>,'L =RD@@%2PU#P7I,Y73KC1+62Y*%C;&)/,+KO3)7KN7YAGJ"".M:
M/_"1:,;*"\&I6QMI\F.4."I 8*23V 8A23T) .":Y;3?A[=V%G;V[ZQ#*()=
M.8,+(KE;0  ?ZP\MM'/;G@]IQX"E^RWD)U4'[=#=VUT?LW#13S/+\H+_ "LO
MFN W(.1D<4 =(VOZ3&[K)?PQE)G@<N=H61$\QE)/ (0%N?X1GI5)_&6A?Z.+
M>_CNVGFAA1;8&4YE&Y"=O12H8@G@[2!DC%9S>#+A=4DN;?4XX[?[>;Z*%K4L
M58VC6Q4MO&1@AAP.A!SG(K0> KBW_LPQZM'OT^WT^!"UF2&^R^:,D>9_%YQ[
M\8'6@#K;W5+'345[VZB@!&<N<8 (!8^B@LH)/ R,GD5G6NORW_B&\TZUL\Q6
M$X@NI92R$$Q"0%!MPP^9%QD'DGH!F+7?#!U>XEFCO/(^T6$NGW"/%Y@>)SG(
MY&UAS@\CGD' Q/H>@MHU]JLXN%DAO98Y(XA$5,02%(@"Q8[N(P<X')- #IO%
M.DQ2V427)F>\F6"$0HSY+*S D@<*55F!Z$#(R*MQZQITLD\<=Y"[P*'D ;.%
M)(!]QE67([J1U!%<S:^!IK,Z>;?5$06=Y'=K#]F/D@B.5'")YG[L,)2<*=BE
M1A>6RC^ Y&TVTM4U9HY--MEMM-G6W&Z)5FBE3S 6Q)@V\(XVY ?^\, &I_PE
M=J=>BL4$;V;V<TYN5<EEDCE2)HC'MSG+XZYR",5L7E_:Z?;-<W<RPPJ"S._
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MDZAX[O!>-9V>GQ+(EW:1^9)/N5XY;MH&^Z",_+G@G&XY^92M;NN^()M&O;.
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M=C1AY]Y;M=V]JER7=X4*!\G9@-EP "=IR,LO;H=*T'2=$CGBTK3X+-)VWR+
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M-\5Z;JE[Y$$JB)[>WN()V=0LZS>9M"<YW?NFR" ?:M5KZU5YD:YA#0)OE4N
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MG8VEXWV_3S#):7ESEV\V/ W/CD[AN5O4.U0CQI!+J\FEVVDZC<722SQ[8_)
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MR+*,,<QD X/7((QD&HQJ-SJ&KZG9V<ZP1:>(XI7\O>QE=1(0!Z+&R$=<L_\
MLD$ ET32IK&\U6^N#&DNHW"SM!"Y:.,K&D?!(&2=F2<#L.V3L5YYIOBO5M1A
M6SCN EY##J$TDLUOM;-O(J1))'QM++(C-C'&,8W<='H^OO?WUDDB%8M3TY=0
MM 1\R ;!(C?3S8\'ON/IR =!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%%  >1BL@^&M+^RRVZVVQ);PWQ*.P83EM_F*<\'=SQQU&,$@WM0N
M9+/3+JZAMWN9887D2!/O2$ D*/<XQ^->:Z5XGM_[?O\ 4HM7TZ5]1M-)0SP1
MC:&:2X5Q][ 8<@%S\ORJ0Q # '9R^#-$N%E6:U:19[:2VF4S.!*CNSMN /+%
MF9MW4%B1VQ:3P[8#0;C1I/M%Q:7*.DYN+F2220,,',C$MTX'/  QTKF/#_BK
M6-7CTB29H"FLV,,UN]O"2D,R$?:48Y./E.5SW# Y(&=#PUXL-\'35;FUAE9H
MDAPRB.=I-Y7RGW?-N"'"$*XVG<.02 :%GX2TJQU-=0@6Y%R'D<NUU(VXR! ^
M06Y!\J,X]5I;GPII=UJ,E^ZW"W#S"X)2YD51((C#O"YVY\L[3QR ,UG^(_$E
M]I=W=PVR0B2WLH[NVBE!SJ#F1E>",_W@ @&,G=,G&.&N>%]0U'5K6[N[R[M)
M(UNKBVC2" IL\J>6/<27;.Y50XP,<]<T 07'A.UATYK"QCC,%S9QZ7.MQ*Q
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M0@<_,3U\J,_\!]SF%/!>D11P)&LRK!!;6\8$IXCMY/,A'_ 6YSU/0Y%9VO\
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MGYFW3)UQM;K_  [J>I:S<ZRUQ=VGV:UOIK**." ATV$89F+L"<'D;1SSQTH
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M+(QX&50%1CYFHZ?J=NNO71M9--U-+GQ+#B98U?AM/1A)&0V%8[2-W0Y;IG@
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M(.!\Q:NA\+::EG#<RPM,+.24M90S0M$T$+?.4V, 5^=G ! PH08^45T-&,4
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MD9=S-^\D9SEB6/+$G&2<#H!@#  %2T44 %%%% !1110 4444 %%%% !1110
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MAC5M9@.GWB6$"2$12D#?MWO&W7&%:,@]]W08Y2X\$231WL?]K,1=Z2=,D=X
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M-"\0S:W<>8EHJZ?-$TEO/YR;BROL=&0$G(XR>Q)4@$ MJOIMC)>_;7L[=KK
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MI-$@CCD6%0R* 0 #C( #$8]SZTLNE:?/J,&HS6-K)>VZE8;EX5,D8.<A6(R
M<GIZT <KI_CF2]U&+3W@MXI;HP?9IUD,D1\V*:0<X&X?N& 88#;@1QUI0>(]
M2L?$M[/+"LL-S-ID,L/VQI$@:<%#Y7&" Q!)&T$ G&375'PIX=^S/ =!TK[.
MZA7C-G'M8 E@",8(!)/U)-.73-!N;VXC%CI\EU&T,DW[A"P90?*8\=5&=I[=
ML4 :U% X%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M356G31[UK9I4N!;R&)H8Q(X;:<%5/#'/0'@UY^Z>)7U"PG6UNOML-O?0P,SS
M/;//Y41A8A@&1"?,'[SD$,-S#:3Z1++'!"\TKK''&I9W<@!0.223T%4H-=TF
MZBEEM]3LIHXBHD>.X1@F[!7<0>,Y&/7(H Y-]0UFU<W*6VLW.C.]L;E'B;[7
M"6243;% #%0PMR=F?O2;>F!6MO[3L?&+32VVKW.G/96$-Q<M$PF+*UP59MBX
M< N@<+R-X)^4.*[&W\0Z7>:FFGVMY%/.]J+M?*8,K1$X5@PX.>>F>!GN,PV_
MB&W,^LB]:&SATNY6!YII@%8&&.7<2<!>),?A0!PFC_\ "3Z9IUM#8PZEAK"6
M26&6W(",+L?<W* )#$TI4$_,0N<\5JW@UK[38/;07=TD&L3RZ>US$^1$;"51
MYI(!5?/<H"^#MV\D<GLWU;3XYI87OK598D,DB-,H9% !+$9X #*<_P"T/45!
M?^(=+T[26U2>[B-FKB,21L&#.6V!01WW<>W.<8- '"6MSK$%Q=:G%9:S()[#
M3X[QKBUD\Y2KW(FV*-I)5G0D(>C$ID;:V_#,>L3:_-]OU#5I+6WL[9H#<6X@
M25F$H<,-O)QY3$9R#UQRHV-/\36EWJM_IT\D%M<V]TUO#&]PI:X588Y2ZKP<
M 2C.,XQG/-6&\2:(D7FMK&GB,EAO-TF,JF]AG/9?F/H.>E '&^([[Q,?[>%F
M=5M[RVMY_LJ6MDTD4Z%1Y3*YW+OW8! &_EOX0&$DL6HR>*+-IQJ\UI:>(&\N
M0QRX$,E@3D@ !D$[,,D$+G;D+Q77WVOZ9IUE:WEQ=QBWNY8HH)%;<LC2, A!
M'&#D'/3'-2RZSID#RI-J%I&T)02*\Z@H78J@.3QN8$#U((% 'F%U;:W?:#++
M?V^L7%[<^%KZWP\,OS7!. I0#:K,,8X&[ QG QT%W>>)9+[418)>QW5O:S-9
M0FT;[/<(8<Q;I&(4.)<97A^N?EY'8)K&FR::^I)J%HUC&&+W*SJ8E"G#9?.!
M@@@\\8IJ:UI<D$TZ:C9M#!(8II!.I6-QC*L<X#<C@\\T <UX1@DFU?7YS#JL
M=K=);>7)?(\4K8B*N,G# @YZ=">.,5BZ3_PD<'A&PM8H]3ANX](@^R;XI.;]
M682I/N&=A_=C)PNTN0> 1WRZ[I+W,%LNIV33SJK0Q"X3=(K E2HSD@A6(QU
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M >1=K '. 0O)%_6O&'E136D$4\,L]K,;:Y4HQ21;?SE)7D 8S][G*_=*_-0
M2>$+N;2;FPDG@'F7]S?QS*/GBD=R\1&01\K,0>,,!@\$J67>A7<=AK2ZC-Y\
MFL2PR(;"W?=!=+#&BNIR=JAX4<%N%)&XX&39\,ZA>7FK217-T\L?]C:==*K
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MWUVT>WE,:H3%)9[MW' &]G7@G&-N6QD@'8)X-\-2JSQ68V.W_+*YD"\3>:
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M@>KL=?TK4[QK6RO$FF6,2E5!YC.-K@XP5.1@C@\XS@U//IEA<W"W-Q9V\LR
M!9)(E9E .1@D9X//UH Y$^>WC;75DGN!I\ M)I7.I2QK;+LD9F5,[<$HNX<
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M+D/-<221@(I(C*)YC;ST3Y2IYY(8'IS4MOK=B]C8SW-W8QM=I&R>5<"2-BY
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M2%S@9.6 '')QQS0!PUN_BB:Y@24:W%;RW&GR.'!W 'S%N%9@./NIG:$7@,H
M;)N:3;:Z(=-:YGU%EO3<:;.D\[QO"BR.T4RYP0WDJ5+?>)*$]&)ZT>)-",EK
M%_:]AYETJM GGKF0%@@*C/.6(7Z\=:+B^T&QOY[NYGL(+N.+9-/(45UC7Y]K
M,><#<&QGC<#W&0##\;RZTD:+H\>HF5())E>V&Y/,5XB%91R6V^80"=I 8%7)
M4##NCXF26ZFADUDO)/J<0&URJQ;"T&U<8'S[=K8SU&2.*[R/7=(GM)KN'4;6
M6WA;;))'('"G:&YQ_LD-].>E2/JNFH\*O>VX,XS$2XP_REN#T/RJS?0$]!0!
MPEG_ ,)#!K5FTAUF6Q6>UDN V\D^9:S)+UP2!*8"5'"') 7#5'8S>*DL_#WG
MP:PMS$+/[49,.'#22)-NP>NTH3O+<%2H4JS5V]GKMA<162RWEB+FZCC=(X+@
M2(V\,5V-@;@=C[3@;@C8'!Q!I'B2VOO#D6L:A]GTZ-I7B;S)P45EE:,#>0N<
ME1C@=<4 8VE0:S;?#^_CT^"2+5/M-])"DR[&(>YD=2-V!DHP*YXR1GO57[-K
M-UXFM(1<:Q%H3W,K1X:1'">2A_>,1O \[=M#'U'*8%=;:^(-&O;F.VM=4LYI
MY=^R..92S;#A\#/8]:<VM:6L%Q.U];B.W.)F+C]W\N_)]!M^;/3;STYH Q]8
M&KCQ39M9_:9;/;"LD2DQJN9&W2*XRK$ #<D@Y7&QMV0>/T*Z\3-X>TW5K6;4
M]0AGTR!]06<LSNY<9:W&5.0F[<%(R-N,MDUW4GB?3Y+F:UAEM_-AO(;.474A
MA5GD 8*A*G>VQ@0!P?4=1)I^K^&H+;[)IU_ID5O;PO*(H)45(XD8J[ #@*K9
M!/0&@# L3K"WVGVEW'KDMLT,$EM=!E0JRRN9%N!GO'Y0^?<2-V#OR3E3S>)Q
M96PB36S-#=S2^85.)(AJ PI7 )/V<Y&[Y=N0%+?=]$L]0LM0$AL[F*;RG,<@
M1@3&XZJPZJ1Z'FJT^OZ+:WILY]4LHKI71&A>=0RLP)4$9X) ./6@#ET@U2V\
M%^,/LL5Y!J,ES?R68CC82,S9,93CG)QR*K^5K</B-Y(9M9>V36(/*$GF,AMY
M(!YQ((P5\S/!X0CY0HZ]@OB#19(+>=-3LVBN21"XE4A\.$./H[*A]&8#J0*F
MMM5T^\6%K:ZBE$S.D94YW%"0P'T((/H010!PMM>^*!I#75S8ZGYYEBCU&U\L
MY0['$CV^)=S#<8S\C*NT?*-Q85#=66MVBZG<VYUB2^GTG3UBG*L9&9)Y=X(7
M*JVQDR!S\S$?Q&NNTKQ19W^KW^EW#6UM>V][);0P_: SSJL:2;P" <X?D<XV
MGDUIIJ5C-#<20SQRK;G$HC^8J=H;! YR5((]001G(H X2ZFUZUU&[NQ<ZK'&
MNIW:AVC+QQVOV,LK!#A"!,JX)QW&<%JUO!L]P\E['>7=T;LPP2?9;E;C$7R[
M2P:95+!G5N .,=>16M;^(-$U?3[0F>W:/4[=)(K>XP#(DJG:&4_W@&&.^UL9
MP:J>$+[29M MKFTTVSTHSP^?);6Z@*@W%020JY^Z<<#]* .3U:R\1W_ABYBN
M8M1DEETM$O;=M[;KX2+\T.W^ @2$[3MQY> #FO3H0H@C";]H4 ;R2V/?/.?K
MS69-XH\/P*'FUG3XP4,GSW"J0H?82<G@!_E.>AR#T-:_TH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH K:A;&]TVZM 8P9X7C!EB$B#<"
M/F0\,.>0>O2N2D^'WFK% VJR&S6&ZMFA=6=E@GCC0HDC.6!!CR"V_&[&, 8[
M*X:5;:5K>-9)@A,:,^T,V. 3@X&>^#]*Y71_&QUB[M+:.Q"275I!<QJ9CG+'
M$\9^3&Z$8+#/\2C@F@ N/".H3W46J+K44>KPFW"3K:9A81+,N'CWY.X7$N<,
M,?)C[N2^/PE>0^(SKD.J1I=>1!!L6V*Q,B&0N&0/R&,N5[J47E@6#<S<^+=2
MN_#6L"S\RTC@T"YOXIGG\RX657E49)7&!Y?;L?85U"^+)I-4N])CT]3J<4\L
M44+7&(Y%2**7<7V_*2)XP1@X)."0,T 9L?P[F6VM(7U=<VMJ\*.EL5_>&Y2X
M1R"YX#1J"O\ $,\C-7[KP8;Z8RSWX#37TEY<^5$5W;K0VH5/F.W"$-D[LL#T
M!P*]OX_CO(DN+:P<V\C::4:24*Q2\8*I*A2 5)Y&2#V-7M&\1W=UX-FUJ]MH
M?.1[@"**8*I"2N@&Y]H'W1R?K[4 9@\"ZFRQR2ZY:O<PV]I#&PT[]V?L[2D;
MT,AW!EF92 5YP01C%64\#X34DDN+(QWUO;0M#'9>7&GE2/(Q50_R[C(VW!#)
M@'<S<U8;Q?M\&:GXA^PN?[/-R)+??@L8'9&PQ X.PGD ^U1MXQEM]5^QW6G"
M.-=1;3Y9EGW;6^S_ &A&"[1D%/O#C:>!O'- &GH]CJ6F/'9RW8NK*.$XDE0^
M<7,C$#?N.X!2!EAN. 2S$G&/?^!3>V<]H=0581+>SVK&#+Q272R!]QW ,H,T
MI PI.4&?E):>'QD)X(I$L9 +PQ_8&.\I<!XGD&<(64A8G)PK+]W#')VYMWXN
MO6DU%;JPEM[>!--=8XI]LZ//,58.0,<$8(!/ /\ >X .DO-'NI] M]/@OD@F
MA\C,WD[E;RV4D;=P(#;2,A@1G(/%<LOPWN4TVYLQK$&);$V:,+(C8/M#39QY
MG/#;<<= ?:M!/'+FY='T>X,6S4#']G<2RR/:2[&58\#[W&WG.<C'0G6\/:\^
MN?;&-O&D4#HJ3PS>;'.&17RC;5R & ^H/X@$6C::%US4]31)X(;AL"WE0+B8
M';)(/]EQ'%C_ '2P^\2<S7_ ]QK^HSS3:NL=O(9-D:VWSQK):M;N V_!/S;P
MQ7/ !R H%C7_ !B^@7E[#/8JR6\,-S&WG$&6%G*S,!L/^J #L!GY2#D51\0^
M*[O3TO[FUMO](@T6\OK=GN"8'6.10K%0.25(8>QQGG( -0>'M3EOM+U"ZU6S
MEO+*>221HK$QI,K1^7C'F$AL ?,2?IC%9\/@ QZ&NE/J*R0RZ1#I%X3;\R1Q
M%MKI\WR/B20<[ADJ<?*0S+?Q)>:=XDU"UO(FFMI=86S602@_9LV,<VU5V_,N
M0^3P?F'!YQ)_PGPSIK?V<WE:DEI/;/YP^:&>5(LL-O#J9$)7H0W#'!H M6/A
M">SUBVOFU"-UAO[R\,8MR"PG'"YW'[N>N.?04[7/!D>L7UW>)?RVLD\,6T(@
M(2XA<O#/ZEES@C.",9Z"H]+\47VI^);.Q^R00VLD.H&3]Z7??;72P9'R@8.<
M_P# O]GYDN_&4]MK-U:#2'>VM;^&PDN!<*&\R:-&C(3'(W2(IY&-P/(S@ =<
M^#FEU"YGAOHXH97TXI%Y))1;27S0,[N=QXSCCWJ&S\&7UA]G-OK$.0+J.Y66
MSWI+'/.9CM4O\K#)7)W CJIZ57B\:!X=/UC4+&:UMIM'N=418;GS 842!SN3
M:,O^\('I@\_-Q<N_%U]:ZPNC#1U?4GD18U^U@1LKPS2(V_9D<V\BD;>, \Y%
M %C2_"TVG:I9WK7T<OV<Z@600E=WVJX6<X.XXVE=O?(.>*;'X4GCUDZA]OC/
M_$W?4]GD'O:FV$>=W8'=G\,=Z?XF\43:!(8XM.^U,-/N;\DSB,!8#'O7H>2)
M...H X!)$1\8J[H;>TWP2W+V4<DDFT_:%B,@#*%.$^5EW DY X*G< #.M? -
MY:V^BP#6H7CTI+145K,_,8"X)&)!C<K]\X(X."16UX:TT6WVZ[1+B&"\G,\%
MM<)M:W#X>08Z@F5I&//<8X K"TGQF7M["]U&)TGN='L;H[)OW+27$FQ0%(^4
M[F&6/0''.,UKR>*;F&\>R?2G-[ Z-<0Q2[]L#R,JRAMNW&$9B&*$ 'KQD I3
M> A=6\]O<:B?*,U_- T4.UXVNMX.220P42/@8&?E)Z<Z</AV8^'=1TVYN+/S
M[^.1))[.R%NN6C$8;9N8D@ <ENP'  %+K_B7^PKJTB:T:9)Y(D9UE4%-\R1#
M"\D\R DG XQG) K)D^("6JRS7NG216R0W\@:.4.[-:3^2Z[< #=N4@[NI(.
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M)YK[Q($\O<&SE3L&TD$97@Y%9'AG5]1U/6+Q;LW$/DJT<]C-9E1!()"%*2X
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MVK&"5RVWYOF8#(TH[66X^%_C"UAMWEFEEU<10HA9G+RS% H')R&4C'7(QUH
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MVRVC1LORF)3E5*]."20>HR<$9I]EH-CIUY!-:1F%8+8VT<:NVW:S!B2"<$Y
MYZ\MDG/'#W>I:[=*IN;B^6*'5K1O,MH<(86F?AAL#JP&S<C;@!L.Y@U-E\4:
M^;J[\N>YBA:6V,+3V'E[ ;YHIEY7&!%C.6)  ;(R< ';3:!HL+->S0B/R[EK
M]I6G=0LNS:9"=V!\O'H!D=*+C2M!UVZ>>6&VNKB)4B=T?YE *RH&VGL=KKGI
MG(^\<\#JVKZS=^']1TJ[GNYH7BU:W%TEFKO/)&P$$;[4VC<C.<A5W;5P>N;=
MKJ^KK)':0W4MM&=5M+;FV4.MNUDA;(9<Y$F1EAD%=IZ$4 =U?:%I>I75K<WE
ME#-/:DF%W7E,]1[C@'!XR >PJ*X\,Z-=1W4<MBA2[#B958J'#D%^ >-Q +8Q
MNQSFN#A\5:U):V27.KQV;"&*22YEB1$(%S(DK2EDP,Q("-F,-DL I6NIUW4-
M3M?$&G06CR?9)61)HX8P9 6D W#<I#J%#;@"K*N7^;&  :C^&M(DEN)9+,2/
M<EC,7D9O,W*JL&R>051 1T(4 CBJUYX9\-QIJ=W=6-M"EXA^W2EO+5UX+%B"
M ,[1N/&<#.:Y#2]3URW\.VEN;F_B<P7S-=RVWFR?:TE'EQ,&3D,"_'5B-H((
MP37=3U;5/#'B&SU".[M;]--NDET];/? X: ^6R38Y8OP &))++MXR #MW\/:
M0)S>/; RBX^U^:TC$B7R_+W9)_N?*1TP .U-FT71M9#WCQ+<+=Q1 RI,VV1$
M;S(\%3C )+ CU/K46B:D+Z"]^W2!)XG*SV[%3'&FT$,C8&^-E(;<?4CY2"J\
M3X=U35=-T"PLOM-R8TTC2#$@M5<V\C,8YDX7( 54W%MQ0MG'1: /2;/3K33O
MM!MHS']HE:>7YB=SGJW)XZ=JJ6NEZ(\6VRM[4)$DUI_H^!Y89@9$!7[OS*,C
MJ"*Y+1=3\37D>D_:IKT#4+=H)7%FL9M+B*3YG8-'QOCW=1M#)@ ;N,^[U[Q
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MX@!!VY/.>!SG- #8O$D27^J6HBOKJ[ANWB2T"1!L)!%(?+.X KB13ER#N?'
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ML0(2=4<J) #G&<=,GD'!Q6N54YR!R,'B@*% "@ #@ 4 +1110 4444 %%%%
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M,TF10 M%&:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:LK5O#6B:\\3ZMI=K?-$"L9N(P^T'KC/3.!^0H TT8,H96#*>00<@BG4=**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,, EL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4K^[.[Y203R<XS3K'PVVF3S1V.HS0:9+*TYLE1<1NY+.$?&55F)..Q)VE1@
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M.S4>:\TCB-1F0@JS$_WL9!/7&0: //\ 1Y+Z;3O C?;;Z>6Z%QY_FW\R^?\
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M+).9G$DBRW.S 8'.,1MN)SNW8]34EIXEOCKK:99:=;AIM0O%=YKN1@%A\K)
MVGE@_P!T8"GIGOUEYH^EZC-'-?:=9W4L8PCSP*[(,@X!(XY /X"DCT?2X;L7
M<6G6<=R'>03) H<,^-[;L9RV!D]\<T <U8^-7O(;&<QPPVNJ-;K87#R*1F59
M&VR*K$@CR]H.1N9PN 0:A'BK5;35KM+[[(\8@TY$BM\LD<UQ/+"S>8?O*"@/
M0=AP<D[VH:?X;TO1-2FO=-T^+37#7-\#:J4DQR7=0/F/&>035YM'TQG:1M.M
M"[6_V4L85R8>OEYQ]S_9Z4 <PGBW59M4738].M5FC-UYTTT[)&PMWA!9/E/#
M+,.I^5@P.=N3?TWQ+<7OA[5+XVJ_;;%6#6<C& K((E?8[/\ *O+8#@LA7# X
M.!L#2-,#Q.-.M T2/'&PA7**_+*.. >X[]Z@D;1[*2'2'AMHO[0WHEL(AMF
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M"@Y/4E6 ]2#Z&KEO<0W=M%<V\J302H'CDC8,KJ1D$$<$$<YH DHHHH ****
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M8)*X8[V^0+D!1RS$$GCL+=;E9)S.\3(9,Q!$*E4P.&R3DYW'(P,$#'&3/10
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MPPW8(;*DU4A\(ZK)I^GRWFE:8=2M+FS,\JW3/]L$.\-*2R##'>6Y!8\@DX%
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M=74_,"#R@SD<\T 5$\4V$5U<PSW3RNM[):11PV$VY72$2F,\'>VW<P(P&&
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M$+9W:%A^[P2-[*<@A@3D=ZN3^#X[EYI)M3O)99A:!I9 A8FVF:=#PH'+N<@
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M-Q;B!=GF8&-JC)W!LYZ@D"6T\',\&^\N5CN'6R4I;QJL<:VDS2P@ #'<!L
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M-'"[H9%+*"!D9 (R/Q%>?0>+;^TTQ;][>VN;\:'IMR\SNR>;YTKJ00,@8Y/
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M'&0%V/E)#YV>'.!&6[X%M=4O+?1O XM;J,17\D,-PS+O+I]FDDX;/',?7_\
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M%G&\4%Y+8>3(663>MN9A(2/X"!TQG:0^?X3U$&EZ?:O$]O86L+Q*RQM'"JE
MQRP&!P">3ZT^6PLYI7EEM())'C,3.\8)9#U4GNOMTH I^'[J]O\ 1;6]OQ;B
M6YC295@#;55E# ?-R2,D9XSC.!T&I3(H8X(4AAC2.) %1$4!5 Z  =!3Z "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (;P.;*X$<22R>6
MVV-_NN<< ^QKS^ST?Q%I.GW-OI$%T+&." VUG>31M-!^]!EMX9<G*>6"%+\
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MN(%GO+"Y:Z:UT(3%W0L\EO=-+/R&QD*<^^<#)XK8\9:=JVH7).F_;]G]DWJ
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M/)Z>]+7G7CF/_B<7-Q'Y-VRZ:(KG3+I!_I4+N_\ QZO]Y9\J00 0V8LX(4T
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ML$-S:SM'YI&XK:S02-PG+;I$()^\%Y(XH [F^OK33+4W-Y/%!"I +R-@9)P
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M V&]#@@_C5C>G'S#YNG/6N%MO"&I6+7*6T5A%;_;;.ZBA21MDD<4$430L"O
M!C+J<GD+G'-5U\ N;L27%CI]S$MA>Q11R,RB%Y9Q+%&I"[E2,#:&7!7JH'8
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M5)]H?<CLA'!(ZJ>AZ5C>%?#USH6H7TLD-O%!<6UH@6!LYEC0K(S# Y)(YY)
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M'=M+LP7  Y)YR ":I3^";:>[^T'4]2!>6VN)T#QE9YH&5DE;*'#?(H(7:I
MQP,-U7PW+K'BJ:2X\Q=+GTO['/Y;J/-S)EHSD%@I4D9&#R<$'F@"U?\ C+0]
M,:Z^TW3 6T,LSF-#)\L9 D&%R<J6&00.YZ*V)(O%FE2-=!FGA%H&-RTT+1^0
M K-EP>57:I(8C!'0FJESX*MKBTU>R_M/4X['5!,9+59$*1-*<R-'E"1N)8X)
M(!8D &I]0\(Z=JM])=:AYMPSQO$58JO[MXC&\>Y0&V$$MMW8W?-C(% #I/%V
MEQ78LW%V+QI/+6V^S.9&)C:53@#HRH^">ZL."K %YXHMHM T[6;*"6]M;^:V
MCB,>$.V9U16(8C'+CCKGTY(8OA.W_M&SU&6^OIKVVD1A/(T>YPD4L:JV$ (
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MD<93H5^;'0-D@#)!N:'X8MM!DB:VN;J01Z?;Z>%F*$>7!OV'A0=W[QLGI[4
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M72(X5GM[>-(P9XT+/M "EL* 3@ 9QVJ_]@LS#+#]D@\J5BTB>6-KD]R.YX%
M'G=_XFDU?5=&CFN+*V-KK5I#)!'*6,C26WF!U;(S&2^U<KSL)SS@;6J^)+C1
M/$>L&YN$:QMM/LI8X?+YC,LTT;R$YY50H9NP5>V"3UQMX&G$YAC,RC:)"HW
M>F>O>@P0M+YK1(9-A3>5&=I[9]/:@#CK?Q%KEY?V=K;S:.RS07<_GQH\J.L,
MT*@#:^ 2LI!P6 9>IP16=!XXUQ]-MKZ2/3BLEKI%XZ+$X.R\D,3Q@[SR"I8-
MZ?*5/WJ[T:=8@+BSMQL0QK^Z7Y4/51QTY/%,.DZ:5*G3[4@J%(\E>0.@Z=*
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ML<DA8R%9%8.-Q=LC.#FDMO#N@_;'EMH_W]O>FY<1W3_NIVA"<J&PO[I@ N,
M,"!S7)ZSXBUNTM-:MK&]N9[J"[N%LI4LTD,BBS655)5=O^L9E'RDMLVYR&:K
MUOKM_)<7C>:4LSJ\4,US' NZVA>QBE#?=(QYK*I9@<*W. ,@ W1X9T#3+.%S
M (;:QMXXPTER^Q8HB60.2V&"')&[.WGI5R70]*NC?R26<4G]I0K#=D\B=%#
M ]CPQ&>N,>@K@FU?Q+)I.NR7&H.D]EHQN((5M8L7$A-TJEE92<LJ6\A3(P7
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M)ZJUUO43K%OIOGVT\-Y;PW%C=1Q%E=4(%P&(<C(!0JW _>#@[3GJ!!"I4B)
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M #@QCE@,X!7D YH ZBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 4444 %%%% $5Q<0VD$D]Q*D,,:EWDD8*JJ.I)/ %8VG>+=-U/46MH9
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M@;JX69#C:,[0H5AD9!X-=+X=TVXTZQF-Y%:QW=S,9YQ;.[J6P%SN?YF.%')
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MWC5I9"BJ5VEF XR>,\_7@SV?B^QU"1TM8+F0>5:W$+;543PW!PDB98' P<Y
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M3ZK)87D<BJQR+22<8921VC/![X.""*FN?!&EWAG$\ERR3W,MTZ"0*"\D)@8
M@9 \MB!@^_7FI+?PI86U[%=+<W9F6\%[EY0V^40>02<CO'D8&.O&,# !T%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*!@MST*Y.5.1%J6N6=M=(\6KW+IY3P3FTF.^R>7YF*  _:%!(91AMH!4 Y
M/0ZAEN[>&>&"6>-)IR1%&S ,Y R<#O@<UP(G\4F6<6U[JER;;1WN;026 MTN
M9]\H1)-RDAMGE@J6!Z$A3G$\^I:H]Q83:;+KRV4YNF>.XTUBT6+<%<AT#<2
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M">6"N=PW9QD8.?3!KS_5?!,VB^$M?AAB6]6XL;6WBCA@9W+1LQ/R*#\O[P@
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MYO+GR'N!;VJ!I#&A4,0"1GE@  <GL#4!\*:3_9UMIRV[+8VR[$MA(WE[=RN
M5S@X95(/48P" 2#-JGAW3]8N[6ZNUG$]LK(KP7$D)9&P61MC#<I*J2IR.* ,
MJ^\>Z986\MR\%W);+%=21S1(A6;[/GS53YNHVL1NP"%.":KZGXQE<K:65G=P
MW*ZK#83^8L>Y5=!('3YBOS*1C/(YR!6K<>$=(N;>ZMY(G,-RLZM&)#M7S_\
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ML4:QAY7+NP QEF/+'U)Y- $M%%% !1110 4444 %%%% !1110 4444 %%%%
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M0MM#$ G&<''UP:Y/3O'%S>0Q^?I,,$\]K97<$:WA<,EP6 !/E@[U\M_E4-D
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M,K)"6VR)C!SO).<D%5QTS6./$^MO-I5^R1/*IU=7MH[AHH95@EVJ6^4G("D
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M7REV!2!\S ,=^ .1GI0!J3^%4E\'R^'5O)5BD4J)7)D* ONVKDYVC[J@DX4
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M533O'=Y_8+7-U9P3W<-I<7\ZI*8U\B.9D(3*G+;5/!P,@98;LCNH9!-"DH!
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M[;R"04O;3PMK=F-;OH-,N[983F[G1&41*VXAF/\ "K*20>A!Z'-<OK%OJ%]
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MR#9ER.>&&TDY(!Y.#3-?BD_X2KPLT5M.\<5W.\KQ0,RH#;R*"S 87+,!R>]
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MQD.VY[E%&$;:_4_PMP?0\&J*^'[K_A&+[3_.TZ"^O%<R36MB$A#L,9\LDEN
M,Y8D^W &(/ %XLT[#4;9ED34%7]RP*FZ"<DECDJ4Z]P>W< [ :MIY>9!>VQ:
M"1(I5$HS&[D!%;T+;EP.^1CJ*BN9-'CUFW>=[--49/*@,C*)2K9.U<\X.T_D
M?>L;3-%,?B"VE4S)]CLH[2[S"5CN710864GJ%$DW3N0"?E%.USPM>:KK=O?1
M:A!%##):R+"]N6.8I6<_,&&<AL#(.W!QC<U $_A_Q?IVM:1'>27-I;7&T--:
M_:5=H<N44-T/)&!P,GBM4ZQIRI;R&_M0ERH:!C,N)05+ J<\C:">.P)KE8?
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MU@V5923A@=W)&<5HS:'I]QIUO8RQ2-!;R)+&?/?>'4Y#;\[BV>22<G)SG)H
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MK)J.H6ACA6)H (#/M+Y7S!A(&/RGD@9P.#NP^#M$@B:*.WFV-+;SD-=2MEX
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M$F/+EFC#@* !M",W/4 <GC-8$'B;Q#:RDBY?4W1M4@2U,"*TQ@):$Y0 [V
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M=;N8IKIW:3Q';HT4\:L(X7M(S\G'RC?N (S]T\YW$^@"XBVKO=48KG:S#(P
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MMEMM-@OK&#1Y1#%*WD-Y$DQ*A_+RORD?PG&5'?-=JWBNP&HMIZ1W4EP+EK0
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M7( .QAR1C'.,C(!:U:PO;Z_T"YC6W"V-XUQ<!Y6Z&"6+"?+R<RYYQP*YG2/
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M8QFX9GNKHO>FVMX8+%]X86RS[/\ :RN6#< YP.!DW$\6Z5+>R6<4K23  QA
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MZ(4U"<W%[(#&UPZ$,Z+\D98'G<4 9A_>9NF<5R5KX&UG^S].M[N/2G-K;:1
M<3.X_P!#G=V89C_C1\#I@DCD<GL7\4:9%J,MC*\L4R1O(HDB(\P(ZHVT=3\S
MHHX^8GY=V#B&[\7Z9I]L\MZMQ;-&SB2*6/#HJD;G S\ZC<IRF[(/&<' !S%W
MX)UEM,2SMH])1(KBYFB'F.A0/?+<HH81G PH!  P5!^8<",^ +_^S+FWCM])
MAEGL-6M#L=MH-U.)81GRQE4 P>.,\"NYU+6K72R%F6624Q23^5"F]_+CQO8
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M CN(5N;:6!VD59$*%HW*, 1C(8<@^XY%<=_PA;:;>:6VFW5VR1WJ3W$CF$%
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M)"L6&57+84DCD 4 =AJ>BP:E?6%W)//%)9&0Q>5MP2Z%"3E3G )Q[]<UD1^
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M322D;I& QN;: "Q[MC)[DX%9EMX%TVVTZ*Q6YO'@6S6PE5F3]_;*25B?"X(
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M*,CUHH **** "BBB@ HHHH **,T4 %%%)D>HH 6BBB@ HHHH **** "BBC-
M!1110 449 [T4 %%%% !1110 449'K10 449HH **** "BBB@ HHHH ****
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MA=H,@9B)&"DC<P+8XS3;/PIINF):Q:>L]O#;S"55%S*>BE0G+_< ) 0Y49X
M/- %2;Q3-9^(-6L[NVC^S6B62P-'(2\DEQ(T:@@@ #<%'4XZY.< O?%4D/A;
MQ!J4%H!?:,LXGMY7^7?'&).& Y4HRL.!]X [3G&G=>'=*O;J[N;BU\R6[A2"
M?,C .J,60[0<!E))# ;AV-$VGZ0EE+I-P(Q#J/FQO%+*=UP64EQDG<QVY[Y
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M! 4C&36KJLD%QH5U(N;F+R68"&Y\DOCTE##9T^]D8]:M0SV<;I9130+(BD+
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M/E/+Y4;2;(\;FP,X&2!GZFN0TKQM/-?K+?6[I9W-GIDL21H";=[IY4^=MWS
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M(\<:1[5!E9XC* I+8^XK$[B/NGVSE6OC)E\0745Y#<)82?84MPUMY;V[7 8
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ML)[B68SW8:22TD(\P'FV;='R5)/S<G))/K7144 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&10 449I,B@!:*
M,T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,, EL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,;OW1WX;Y-OS 'J :Y'^W?$KKI;K=S1QW)L!=B2T17MYG<K-" 5X 4%N<E<
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MK-E?FVA0=V?7++?P+?+-'-+#9+=1745RMQ%*VX*MBENT(;:& 9T.>VTY^]P
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MS'",2RQ#<R*21U7+!CA2 ><\4D?CS1YGB\E;N6&06C><L!" 7.?)/."=QPO
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MWYB&./FYP<C!*_=)%/7PQ;6D_P!MMGE:Y2WN8P&90)6G97D9_E^\61>F  ,
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MDMQ 91-:1Q;IH_**[\KGDC>A 4DL'!7<#5/7?&UIHXNX5L[J6Z@C,B1E1&)
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MD8RLH7YRH0;N%[CGH!R0" 4/"VLWNO6][+)<VCP+Y:V\D 7>"8P6W@.P&')
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MEN&:3;G=([2-T XW,Q'UJ[Y:<?(O!R..AH \PU+QU=R7\EHFJ6<,4=U"3-&
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M-[?(TA&S;OR%5B1C(VG/2H%\5:.[*J7>_?<"U4QQ.P:4PB<*"%YS&0P(X.<
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M+:"SO9H 1')D11A27=2NY0-W)( ''U-V'Q=H<]VULE^F]3,I9E98P8O]8-Y
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M@+-IELEA+I9N9IX)WF=9HED<R%#'M(?#,V&WKD$9''(!8B\4^;J'V$:/J:W
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MRM.$WB(,-Q'3.#VSQGI3+6[%Q! [KY,LL:R>2[J67(S@[20<=,@D>AKBM/\
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MVDC'O0 ^Z\36=I>&!HKAT2ZCLY9XT!2&:0*41N<\[XQD C,BY(YQSHU_6IO
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M:[CM[R0R/%]J8QQL9!(Q16R$W. Q [],9H 2R\7KJ/B.WTB'3KF-B+H7#3%
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MU_%-RNIW.EWE]9BV&JFS>],:A$C:U29%8$E1N=R@)ZA=OWB#7=X]S^=&/<T
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MXX(8X'J!SGK7?[?<T8^M 'G=IX\N)M)&I37-I':3200SMN(?2Y'63>LY,>$
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M#8%.M/#6I:=/?);Z>OV9M3M[J:,3JWVV 6J1.F]CN9A*K2'?C?CD_,Q'?44
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M+$'!3/0'C&27WUQJEIJ&N^1!J,%G=ZH"]U;V,LLB+]B@5'1%&YE\Q&!(!P0
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M:FKRS3I]=_M:._>SU=I)=/L(M3EDM75U832_:%C! !P67[F?D)*<XK5AO/$
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M)*$@;6'<X8=^M=1I.GH_B;4KZ!I%L7<.8'@9 +P!HY)%+ $@H$' VG)8$DT
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MR,K2 $(.K$9X'O6?J?B.QTZWM91(D_VFZBM4$4B$DO*L6[KR%9AG&2*X_7O
M.L:H;U(YM/E22"XMXI)V9799+:.)7DPI#.K1@[N201RH4+6IJ/A/4)M2N);(
M6"6]S-8W&'W V[V\XE*J N&5OG/\)#,QYW' !UL]Y;6K*MQ<11%L!1(X7.2
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MM981L3]Y'<2+&CCYN@9E!!^89'!%7X_"FE131RQ1-'Y=VMXB(VU5D$/D# '
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M0 ZB@G IHD1G*!@64 E<\@'I_*@!U%%% !1110 4444 %%%% !1110 4444
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M+(VLZI#*]W&K/"J"8Q\C;M&T(2.,AQR 0#WQU"$RF*$/<,L_D2^3AO);9O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW[ E&)7SV1E^88. 4(9?NG(8Y*@5OZ-IVW7M1OHC*MK*P;R9(&C47/W)74,
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M=PCW4CDK*RF4[&8@AF"$\8S]:ETKPQI.B7!GT^"6)_(6V&ZYED"Q*S,J ,Q
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M(7+A3M/R%XPVTCY.,CG:>N* *C^+K5)Y@;>Y-LC/$MT(SY9F680F(L0 &,C
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M&Y1G.5S\I_$8/MFK-( %& ,#TI: "BBB@ HHHH **** "BBB@ HHHH ****
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M:P/.XC&6*JI8X'<\5E:/<:9/XBU,VMO<1WLMK:W-Q)*QV2(X<1[06(!&Q@<
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MK;4(M7U61(-WAC33<R>7M EWRAQM4<$%E! 'RY'2O2<4R2))D*2*&4XR#WH
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M<Q1)#/+ODA*AO)E$,B@==P<J,$#.X8Z'&II6KV^J_:Q#'-'):3FWGCE4 HX
M;'!(/#*<@XP10!RFH^&-776-8NK*UL)8+N]ANC!+,8_M48M_*:)R$.W#XD!.
M02!ZG$<_A?6;=I&TR"V1$L;"W2WENG*.()96>$R$%\;90%<CDIRH'%='?>*[
M'3[RYMKB&Y5K>2U1VVJ%(N'*1L"6Y7>"I/8@]@36=J_C*/3)Y&2*XF*P(RVO
ME*N=]QY*R>86P5)(X&3@@]Z .4UO3K:RGL=/N[:"-([%"FGK>EWR)S(([7S
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MH3)*X+H#@]=9?%7B!Y;S9-HCBUM+*8I$K[9WG+IMCE9U'+(I0LH#;@"0#OH
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M=/RJ,]K,S,/D;!$H0')&TJ 5P3GO;C6K**Y-G%*EQ?&V:ZCM(I%\R1!CD9(
MR2 "2![X!(2PUB&_U'4;)898Y;!HUE+A<-O0.-I!/8X.<<CTYH P?!>H:O=S
ME=4N9Y]^E6-R?.A6/9.XD\Y!M5>FV,E3DJ6]P*/"6L:GJ.L7B7HO1;-:Q2PB
MYLS"4D\V=9%^X " L7RY;U!.2:ZY9$<L$=6*G:V#G!]#^=,-Q K%3-&&!VD%
MAD'CC]1^8H \UO/$/B:2RFCMWO8=6_LK4;AK46@.RXAFA$8CRAWC:[#@L&#
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M@22W:-3(JE@!(%#?.ASG*;NC#&5($?B'7[K3;R2PM;8AWTJ[O8[IB"J/#Y8
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MFTLP ;#C;(C80LQW8 +9 NZ;K\6JWE];V]E>!;.9X'FD151I$(RJ_-D]0<X
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MI61CMV@X3CH:ZN#7;U_!]]J45]I-W*CNMI=13$V\@R FZ0+C()VEE&W(/3D
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M44 5KZS%];& SSP_,K;X7VMP<X]"#T(/8T^TM(+"R@L[6)8K>"-8HHUZ(BC
M ]@ *FHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHS4/VNW^V"S\^/[28_-\K<-^S.-V.N,\9H FKB/%^L:II6HS2+-<1Z4MC\]
MQ9A9'L)2S8GFC():+:.HR%V.2#P5[>L^[T33;^=Y[FU21Y(Q%)DD"2,$D(X!
MPRY9N#D<GUH YS[9>R>--7LS/>_9(3:NLD<J".U!1V<L"<E6* '@XW=NHDT.
M[U#7=*O-6.IO;3K?S1I 541V\<,S)Y;J<\LJ98GD;SMV@"MN7P]I<UU=7,D#
MF2[VBX_?N!*%Z!EW8(QGC&.3ZTXZ%I9U-]2^R(+IRK2."0)&7[K,H.UF QAB
M"1@<\"@#"@BO?^$RGTEM7O6A@TZVN0Y<9:0S2!R1C&&5 I&, =,'FLW0-8U*
M^\0P:)/=7'V;.I7#W!/S3"&\-O'$&QP%7#''S$[<G!.[I[(Z#>:P-3LKFWGO
MKJU&V2*YW^9 K<$ -@J&8\@=6/<U+%X=TJ"WCACMV"QS//&WG.721\[V5\[E
M+;FS@\[CGJ: .3_M'Q'(]VFG70N[K2=8>V6-]JK?P>0)C$QX"R -M#C RHW<
M$UTOAO48M7@O+^WGG>"6<>6DQP8?W:;HR/X2KEP0>0<CL +R:181?9O*@$8M
MG>2)8V*KN?.YB <,3N8DG/+$]S4]O9VMH9S;P1Q&>0RR[%QO<@ L?<@#GVH
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M$V?]6S K^>[GOQVQ5Q;^S:%)ENH#%(P1)!(-K,3@ 'H3GC% 'GW]H^))-/\
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M7L=H;Q;:.9 SQXX.20H![$D#J>@J_P#:H!,L!FC$S$A8]PW' !.!UX!!_$4
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M0K@EWD7&P_\ 7,]CU/H,WV\9VD9NXC8:@UW:RR1R6B(CRD(L;%E"L0PVS1'
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M/5_)FTYM40X@)-LHC+/CS>PD'R]>#@'C-^Y\::=;IYWD74MLQN$BN(U4I+)
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MY0HRL2/N!<<9.2%Z;!GH:* ,75_"VF:W=+<7JSF18Q&/+N'C&!(LBG"D#(=
M0:LV.BVFGW<MU$KM/)&L3222%VV*695R>2 78C.<9QT  T:* "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEY_+&YBHPI/J0  ">1B@#G[>TG_X36?2SJFHF"#3;:Y5C<L2TGG2AB1TPP0
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MH+-)<&1D4;BBYY90.2.G3VH R;V"X37?#]LVJWDJ:@)S</#<,B-MA!78 ?E
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MPRJ^/K@^QH \[O+_ %Z/3;>T6XU6.0/J4:2FTN)'CVSXMI6\N-F?$>,*PVR
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M=P"Y<E5A,B[V(4,0%SDX4@_0@U)+=VT,\4$L\2339$<;. SX!)VCJ> 3QZ4
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M3SN9RA=3,%! PVS?M'8X'M6$]G?S>(]"DF349K.WUF=[>5TE#QVYM7 \S@$
M3,R@MR5VYR"2>[M[NVNQ(;:>*81R-$YC<,%=3AE..A!X([5"VK:<EO/.]_:K
M# Q6:0S*%C8 '#'. <$'!]: .9\17NL1>(K-;&+4O(CEM&=HX2\+1M*R2_='
M4*5SN)P,%0,,U86GV_BJ_MH;=K[5XKJ;3)93+<H\:"YCG'E!B%&T,NX,!C*\
M]0#7HLFI64-REM+=P1W#L%2)Y%#L2"0 ,Y)(5B/]T^E5KV;1KZTGCOI+*>VM
MW5IA*ZLD;*V06R< AE[]Q0!G?:-5F\'7>J6,$HU*[@:Y@M9'!,9*#8@SE0<
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ME@H7#;-V&8=N:FD\7-'<PVO]B:EY\]P]M"KHL:R,(6F!!<C((5ESV92#Q@D
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M"78T?3.UAPP^]G[I7I0!W*Z#I]M=S7^CJC:G"\V!)=RF)'F*/*K(&(7<0K$
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MTV%06<G&W@#HO48-7&T#3'\/KH4EJLFFK MN()&+?NU  &2<\8'.<\9K3HH
MRI?#FF3^?OM\&>[BO92CLN^:/9L8X/;RT..F1DCDYCF\+Z5<7,MQ)#+YTMVE
MZSK<2*?.1!&K###'R *0."!R#6S10!ST?@G08I+>2*UFC>W+["EW,,J[!VC;
M#_-&6&?+;*]>.35JV\-:9:7D%W!%(L\#7#1L9G.#.^^7@M@[F ;GH>F*UZ*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M .WR#17/>&/[6#72:OYAN1';%R0?+\SR5\SR^V-X/"\?G70T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7&_$+Q!<Z/H=S'9/=
M6\XA\TW,5J\@4;@ H8*5!//7D 'H2IKLJAN[2WOK62VNX8YX)!AXY%RK#W%
M$D;B6-74, P! 92IY]0>1]#3J** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,, EL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!@?V[<WVO:EI.F10&334C-Q+<%@IDD7<D:@?[."7YQD *W.W$@
M\>/?R:>T7V2QBN[&>?\ TS+&.>&9(6B^4C=EV(!&?N\ YKH7T 1:Q=:I8736
MEQ>QI'=8C#B3;PCX/1P"0#R",94X&*FG>#[;2M0L)K6<_9[2RFM!#(FXR>:Z
MR2.S9Y8L@)XQRW'/ !!:>);VXUN[TR1].BN;>]BMA;L6W2AH4F<J<]55G[88
MIU&>([#Q5?WTUG8);VYO[FXO59^1'##;3>2SD9RS,VW"C'WCD_+\VSIVBFPU
M35;UK@2G4+A;C88\>4RQK$,'//RHN??/K@9<7@QH$MIX=4EAU&UN+F:.ZBC
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M10 4444 %%%% !1110 4444 %%%% !145TL[VDRVTBQW#(PB=UW*K8X)&1D
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M*+(58#J-H*CDE1C/)Q;WQHU[IFF7FE1SQ":_MX95E1&.UKAH7CX8@-E&Y&0
M.H[ $]_X8U*\M?&< :T4:Y'Y=NQD;]W^X$.7^7VW<9]/>HKWPIJ\EY?W=I/:
M1M/?"Y6V>20121FVC@9'*!2"/+W C(Y((YS5X>.=-_L][OR+O]S%+-=0[4,E
MM''(T<C. V"%9'^Z6SL.W/&6?\)W9O<-!#IVHS-YEQ#&42,"62'EU4EQU7+
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M4A,D)D*D.1\V%).[&,'TK0B\50W,$,EMIVHSLZQ-)$L #P>82JAU8C'(.<9
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M-<0QN8Q*D6]HRH&QR<G//W3QGF@#T"TT!-/^QI:7=TL,%Q/<.A<8E:4LS!@
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MMU;PW$Q$27$BD,P."1NR1G#;0S;0 2#;T32H=(L6BCB2)III;B1$8E0\CEF
M)[#..@Z=!TK@;G6Y]2\1:!#JD]M%>VNL0*+6-",J]D[&4!OGVF1F4$X&% (W
M UT7Q!N;&\^%>NW(FMYK6;39'AD+*R.2F4*GH23C&.^,4 2+X T9;!K)'O!;
MFS^P[3-G;"'WA02,\=/I[\UJ6'AVQTW4I[VW:Y#3.TC0M.QB61CEW6/.U68Y
M)('<]-QSS">*+J'Q'%90W=@=/_MI=,CBBC _<M9"=2#NZAOE&!@\\=,3>)/%
M]SI/B2WL;:2*3#PK+:LFUY!(LV-K$\DM'&HP  202Q8!0#8N?"UA>2:J)KF[
M,>J8^VPK(%$BA0FW( 91M&.",\^IHD\*Z)*)87C/D3&9_LRRE45Y%*2.@!RK
M%68':1C<Q&"Q)XBR\4"/4KO5UOK5WO+#2?MERB!5M TUPLQ8?P[,[?GSL^7?
MG:<T9-8DT_P]/#IUQ;+.L/B&:&YBB7S4>.X+KY9Y 5@02 .0!@\4 >AVOA+2
M[;4(;N*:Z:X@G%U\\V_,GD"#<P/K&,<8'Y#$NG>$]+TJ^BNK19T:%)8X(S,Q
MCA21E9T5<X"[D! [=L  #FQXD:VUG4Q;26=Q;J--5KZ)5+K#*6#2R,IPX Y!
MP%4."1@$G,O_ !QKUG;Z@YNK!5L;&:[B=HLF[6.Y,:.?F&%=0!P.N2#@@  [
MP>';&.[:ZB\R)O.>Y15(*QSNI1I5!! 8J2/3YF.,LQ+!X>L3X6_X1H2S?8?L
MGV,C<-_D[=NW./[ORYZ^^>:DOM1AO-$U5]*OXWGMDEC,ELR2-#,JYVD$$;AD
M<$=^E>;Z+KCV>H'4[74;662>TT&.[>3:[7'FRR1/E@1\RJ^<]?E&>,Y /0KS
MPM8ZC'=_;Y;FYDNK5[1I9'&4A<8=4  5-V.2!DX&3P,(WA73Y;*_M9I+F1+Z
M6.>5O,V.LL:HJ.K( 58>5&01W4'US0\,>(KK7-3N@\]J$B0K-9 L9[24.5VO
M\HP"!QGD[25)4\<;.UC$^MSVLECYL7B>)XHK:-?M;D>3N$+ _>/S@C:<C>"1
MDD 'H$7A'38;ZVO5EOS<0QK&[M>RG[0%8LOFC=A\,S$9Z9(Z<5&G@G1X[8P(
MLX0I-"P\XG=#*VYXCGJA/3N.<$9.<"3QGJ4*37,AB2-+2[DNXC"7.G212!8P
MP# L&#'.2H.TN&"9PS2_%FKZEJ]MIT5]9E@^H;PL8>286\\011\R@%XWZX_V
M@,= #J5\-V*F\599U^UW!N95##:S&(1$%<;638 -K C@'KS4TOA[3WT_3;%$
MEAM]-:-K413,I38I51G.2-I(YSUSUP:Y'P7JBZOXPN+Y[F&:YN="LI)UB4#R
MI/-GWQD=04)QAOF'0U1\2^)=3NO#&LH\BVX?3-1^U0@A9+%XR5B&3_ST! Y^
M]D,A H Z>Q\$:+;V\26D]R88Y+:2,"4. ;<8C&<=!@#WQS5S3/"NDZ'=1W5J
M9T,$3P0K)<,4AB9E8HH)P%RHQZ=!@8 QO'-II=KX#N6"VOE3W=M*9"J 2N9H
M_G.  20.OI6'XAOH--U'5[K04LGTI-/7[<K1J]H;DSQA.,@>9L,N<=/D+ _*
M* .\NO#&D7EW<W,]HKRW,D$DI+'#-"<H<9]@#_>  .14$WA+3KFYEGG,LGFW
M;7DD;[2CNT'V<@C'*F(E<?CUYKFF\7W\5M=7EWJ-G'9'5YM,$RIY:6:IO*22
M.2XY(13D 98=,U>M/$5[?ZG'I<^I0V.HK'"QAB@+"[C>'+RP[^0%<D#((79\
MP.X8 .CTW1;33&=X#*\C1QP[YG+L(H\[$R>2%W-R<D[B223FJ<7A'3H;R"[C
MDN1<PRK*)F<,[LL31*7)!+D1NR[FRQSR20,<?H_BW5?^$6TN2&=+JY&E6-Q$
M)64G49G8K-$&'\2X XY5F!;(X,\OBS6H],N-1^W6LR)>WEOY%O OF*L$DJ!E
M#/B0G]V2FY21G:<]0#H;?P'HUM'9HAN\6:6Z1?Z0PP(&9H\@8!QO8>X///-6
M]-\+V6EW%M/!-<%K=+A$#LI&)Y!+)G '5U4^V,#C-;*,&0,,X//(P:=0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F!5;4X3<Z5>0*F
M]I('0)D?-E2,<UYY:>"KVU@MA_9L(E@BT=@RLF?/MI"9Y <_>:/"!NK 8.!0
M!Z9@4$#O7FLWA67S]7FU_P"P65A?P-"9UN"WE3FY=H9 &7ELRJ1DG#9 P,"N
MG&G:G/X.O!$;:TUZ_@,LDBJRH+AD  )QNP %3/7"CO0!JW.JV]KK%CIDBRF>
M]65HF"_*!& 6R>WWABKV!7GR>&-8>2TEM[6'1Y2E]DP7/G+;231HJNO"C[RE
MB% &3GJ6-(OAG5_*$CZ+I;Q3M)'?:6]\Y@F+(B"=6\O"D!6&T)DJQ));B@#O
M(;FWN))XX94=K>3RI0K9\M]H;:?0[64_0BIL"N?\.:--H^HZZ[PP+%>74<\4
ML9^9@((HR&!YSN1SR3][/))K.\%Z#JNC:A>S7T-K%'<VELI6WG+KYR>8'(RH
M)!!3#,68@#<2>@!KQ>*-.G431>?):-<_9%ND0F)I=VS:#Z;OEW8VYX!S@&[H
M^J6^MZ/9ZI:B06]W$LL8D&&VD9&1V-8/A?3-7\.:3;: ]K;SVECE8KP3<R1!
MB5S&1Q)C Z[>,Y_AKG-)\%ZOINGV\4=C;"7^R[2VN@TV%FEBG#,21]X^7G;N
M!7HK#;D4 >D><1>"W\B7:4W^=QLSG&WKG/?IC ZU-@5Y3+X%UM]'O[%[6W9Y
M-*N[&$K."H+W)DB'(&%52.@&,  =AJ7G@QO[:N[JPTBV@@:YTZ:W$8C3R_*F
M9[@@ _*65V7C[VX@\'- 'H6!1@8KS.Z\':R^E065E8V<*6MQ<S6P,_EF(->K
M/$B!054"-0.,%64 $+G,]IX>U/1=436(=,B>>*?4Y'"S &6.:3S(4R,G&>V#
M@\@'J0#T7 HP/\FL'7=.N=2;3)O(2XM896:\L)MI$R-$RXY^4E68'!.T\\Y
MKDSX*U*)4WPI=W,,>E;+EI 6#V]Q))(59CNSY4GEJQP3@@X!Y /2L#_)HP.*
MY3PWHVIVFM7MWJ<%L93YD:WL-PQ-U&9"Z;X]H"E0<<EL$G:0"<X.N^"=5U'3
M=0@"PR7C)?H+KS!FZ2<DPQOTP(RRGG./*7;G<0 #TG HP*YS7="CN- L[+3M
M.BB6+4;:[$*!$";+A99".<9(#].I;W)KED\$:G" FG11Z;*8-5MDN(G5?)CG
ME\RW4;3D(@_A'W3T'>@#TS H.!S7GTG@Q[OQ!9W=QI5HNGF[\VXT\E)(D'V:
M2)V . =[NG '(B#'#';6OX5T/4=.O[FXU.*W-SY8@:\AG8F\ 8D.\> %89.<
M[CEFP0.H!I1^(K>:&_=+2\W6-R+66,HH<R':0%!;G(="#W##&:TH)S-+.C6\
MT0B<*&?&),J&W+@GCDKSCE3VP3D2Z+./%HU*.9!93PK]JA/5I8B?*8#IT=LG
M_IG'^&%>Z!J_]J:C<VNGV5U:W.J?:)+&ZE"1W$1M8X<DA6Y5T+8*D$-G[P&
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MXF$JVZR 0;U9< 2^5A5;J"8\ \'@DT =9BJ&I:K;:4UDLZRL;NY6UC,:YP[
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M0<;6"8*D,-I .^NYC;6LDRP2W!49$4.-[^PR0/UHNKJVL;5[JZF2&%!EG=L
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MX;A-0N_]?=SK&RH0K7 ^<#Y0< DD9- %V;QAH4!M@;X2&Y4-"(8VD,F8S(H
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MMI"JF=F2(E@NT!F4KG. >"133XLT,7DUH=0B\^)=Y4\;AOV?*>APV <=,C.
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MD4EFUP,$D$<KU(!(()5>05\>:EJ"Q>++ 7?EVMOX?6ZA6+='()&:4$[PV?\
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M42V]E;0R!2@>.)5(4L6(R!T+$G'J<U:H **** "BBB@ HHHH **** "BBB@
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ML\276I&2(W0</"6W6ZA7DV\\!<X(Z$J*[_K110 4444 %%%% !1110 4444
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M5U?B/)=0&7;QG=D,,FK6C^%;[3O$=GJ+0VJA;C4FGD1SO9+B?S8A]WG'0C.
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MQ'&8QD&/WW>S $8QB@#7U?7++0[ WM[YH@5&=BD3-M55+LQQT 52>>IP!DD
MUE\6:2VI+8B2;S3<_9-Y@<()?*$H7<1CE#D'I^F6ZYX7MM=L(+.>ZO8XHHI(
MCY<H)=7C,;;BX;)PQPWW@<\\D&JG@JU6=)6O[Z5EOH[X[S%AY$@%O@@(/E*
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MO3?&%4@,""<^U.A\&:5:E([7SX;-3;,UFLF8W:W"B)CD%LKY<?1AGRUSGG(
MZW\8:==>0(HKHO/#-,D;1A6/DR".1<$\.'*C:>>?K@E\::'#+)&;EW*&(#RH
MVEWB23RT*[ <@O@?B#T9257PAI:ZB+T)*)5OS?J-_"R%"A '9269R.[L34$7
M@RWAL/L"ZIJ9LH[B*>V@:2,K;>7,)E1"4R5W*H^8L0  "!G(!HZ7X@LM8D=+
M5;@,F0XDA9?+8!"4?/W6 D7Y6P3DD9 -5=4\8Z/I$US'?27$9MX7F8BW=@RI
MLW[<#+ >:F2..3S\K;;%MX>M;?79-8+RO>/&\19MH^1F#;20 6 (^7<3M!(&
M,FLC5?A_8ZM/=RRZGJ<?VD3*XC>(X641AU!:,G'[I,9)QT&!Q0!HMXIL9EFA
MMFG^V)/):B!K9]XD6,2$[#@E=C*V<C(8 '<0*@T_Q7"O@[0=9U;>LNIPVORV
MUN\@\Z5 < *"0,D\GV&<T2>#[9]5?5([^^AO6NS=^;&T?&8DB:/!0@H5C3.0
M3D9!!JOJ/AF>#PYH&CZ8\TD>FW5IB1V3>(HB.3P 3@#M0!<'C/1#:07)N&1)
M9/+970J\3>88B'0_,,2 J>.,$] 2*%QXVCNTTS^QK>ZD2_OC9B:6V:(+A)6)
M42;=QS"PQVZGL#<A\'VUK>0W5GJ&H6LH#BX,4J@7@:5I6\P%2!\[R$%-I&]@
M"!P"#P?;6]GI-LE]>E=,O'O(F)CW.[>9D-\F",2N. .W/% #/^$TTNQLHVU*
MZ)D$&\S06TACN"KK&[1*-S$!V QSPP.2OS4__A-]'^T"!A?)+YZ6SH]C*I25
MUW*IRO4CH>G(YJO<> =,N++[)]HO(X4#K;JK(?LRO*LK+'E3P611\V[ &!@5
M9G\(6MQJDU^]Y>"26^@OF13'M#PIL51\F=I &><^A% %I/$VF/X=_MWSF2QS
MM+2J4*L'\LJP;&TA_E.< >N.:@NO%^F61N1<+=1FWA6>0-"00AD,><'_ &E/
MX<C(-2V?AN"R\/-H\=U=-"TKRM(Y0N=\ID93\NTJ2Q!!'W2165<?#S2YK0VT
M5S?6T+6YMF2!T 9/-,J@ H0H5B=H7  .,8   )O$GBLZ;IDTVGKOD214$CPL
M\38G2*5<J1AAO( /4@X#;2!JVWB'3KG3+W4/.:&WL6D2Z:>,H8C'RV01G '.
M?0BLN?P3;S6]_:C4]3CM+RX^U?9UDC*0R&42L4W(3\SC)#$@;FP!FKJ>&+(:
M;K6GS///;:O)-)<+(P&/,7:RJ5 P,#C.3[T 9UCXO+^(;VPOH7AC-U#;6:^2
M5?<\!EP_)'16Y& .AYS4-QX^LY+2]EMA/!;P:9]O^VR6_FJBEF09B5M[8*-G
MIP.N.:LKX(@%P;J35M3FO#<0W(N9&AW"2.-HP<",+RC,#E3UR,'FJX^'6G+I
MT]@E_J*P3Z<VFR_/&2T1=WSDH?F'F. ?0\@D T :E[XPT33[B>&YO%4PQ22,
MP(*_NR XSV(R.N._]UL:+:G"FGM>O'<*BL4*>2Q?<&VX"@9//0C@CD''-9<7
MA9()[QH=4U)+>ZD:9K421F))&(+NH*$_,0Q*DE,NQVY-/7PM9P^&7T&UFN+6
MU+EU:$J&3,GF$ %2FS/&S;MV_+C'% "V?BS2K^:&&VDDDED#$HJ$E-LIA.1W
M D5E+#(&,DX()GN]:@COY=,A9OMX@\T?NBZ1[@Y0O@C"GRWYR!D8R"RYSH?!
M-C'+$\EU=S^3=M>1"0Q_NI&F:9MI" J"SD'!Y7Y3D5<U#PU::EJ\&I323"XM
M@1 5V?NB5925)7(R&Y&=IVC(- &?X=\90:KX?M+FYCF%^;*SN)X8[=P&-POR
ME,_PEPXR3@;220.:RM:\=W26=U?Z+):R6?\ 8?\ :=LTT#DEO, PWS#@KVP"
M#SSTK5@\"V=M!;PPW^HH(+:RM4(>/[EJS-'D;,,27;.1@\8 (!J _#K3SIK6
M']H:EY+:>VG9W1;A$9-_7R_O=LGM[\T :/B'7+G1M5T.../S;:\FFCGC2%I)
M6VPO(NS!X.4P<@YSVJ2T\7Z)?36$=K>K*+\*;=E[EH_,52.JDI\W('IU(!L:
MEHR:E<:=<O<3PSV$K30O$4R6:-HSD,I!&'/;KBJ6D^$+/0[U9=-N[Z"U*1J]
MD)089&CC$:N<J6W;54'# ':"030!#XC\3OIUQ:VU@!)-_:-I;71:%G2-9I N
MTL"-K[3D=<?+D?.N2\\;Z=#\MFCWL@GMHRL+)@I/*(ED#$X(W'&.O0X (:I+
M_P '6E]JTM]]MOH!-<6]U-!$Z>7)- RE'.Y"P.$53@@$#IGFHX_!<$6DMIB:
MKJGV1)8I;1&DC;[)Y4HE18\H<J"JCY]V%& 0* )KOQMH5C+<I/=-FW0R-Y4;
M2[@)%C; 3)R'95(('4'IS3?^$WT<7 @87R2B=+9T>QE4I*Z[E4Y7J1T(XR1S
M44O@JWEL;VP_M/4UL[J0RK )(RL#&02MLRA/+#^+=@$A<9J:X\(6MQJDU^]Y
M>"2:^M[YD4Q[0\*[54?)G:0!GG/H10!7F\<Z1%%'J#74R60LKBYDC-C*7Q%*
MD;'('!1B59<$\@Y '-R7QAI$-M=S223(;29X98GB*2!E57.%."PV.K#&<A@!
M\QQ6=-\/;"?36L7U#4?+:VN[8L&BW%;F599#_J\9W* ..![\U;N/!\,M_-J$
M.IZC:WTET;D7$#1;D)B2)D 9"I0K&G# \J""#0!%?^+5.HZ3;Z64GAN+^.UN
M)3&2H#PM* IR,-MV'H1AO6F:[XJGTK6KJV9/(LK&R2_N;DPF;,9D(8!58,/E
M1N<'!()^4'-A_!MHVJI?)>WT2K>1WQMU=#&TRQ^5N)92YRF ?FYQGJ22_5_"
M5MK-SJ4L]Y>1C4-/_LZ5(C& L66.5RA(;YFY)/7I0!*WBS2T8"4W$0$J0RM+
M R>2SN4CWY *[F'!]"I. RDTC\0M %LUSOO/(6W-UO\ L4H'DA]KOC;G"G[W
M&1GI5VZ\+V=W?RW<DDX\\P-<PAE\N=H6W1LPVYR"!G:1D  Y K+/P\T]M-:Q
M;4-1,3:=-II):+<8Y7WL?]7][L#TQVSS0!MZIK)TW4](L_LDLW]HW#0"1&4"
M,K$\F3DY/"'H/7O@'(MO'>D1V$4ES>RW#&*.9YHK"5%$<DC1JY4Y*C<I!!.1
MC)Q6UJ6CIJ,^FSM<3Q3:?<?:(GB*_,QC>,A@5(P5=NF#Z$5SZ?#K3TL9+0:C
MJ6Q[2*T+;HMP6.9IE/\ J\9W,1Z8[9YH TI/&FBQ65Q=2SR1BVDECFCDC*R)
MY>"YV'D@!E/&20PP"3BMY'61%="&5AD$'((KF7\%6_\ :$E_;ZIJ=K>/<RW'
MG021@@2JBO%@H04/E1GD%@5!#5TZ*$0*,X P,G- "T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!4U.6:'2[N6W=4E2%V1W7< 0"02,C/YU
MP^E>,]2;1+)\0W4T-GITLX93ON_M#;"8R&P"&]CE@PPO!'H=0)9VL?D[+:%?
M(R(<1@>7D8.WTX]* .8UW4[VV\6K9)/ ;1]%N[C[-(G^LD1HP,G.>C'@=L^N
M1BZ=XRU7R+)(+?3HK4-ID B$;Y N8EZ'=P$8@@8.0,9!^:O0YK6WN"#-!%(0
MK*"Z X#<,.>Q[^M0C2]/7[MA:C!5N(5ZKT/3J.U '&0^.KUTM[606$6H>9*I
M,^8XKKRKIX'$66)#8C!VC>09$&#UJ3Q=>7NE^)XM1L)H$FMM!O[AEN0S1NL<
MENV" PVDY(W<XST/2NR2PLXU14M(%6-_,0+& %;^\..#[U));PS-&TL,;M&V
MY"R@E3ZCT- '-6>NZK+X@DTFYA@ADD\N[MR86&;4KAU;+\R)( IQP/,C..<#
M$\1W][+XBU"QENT,%M<Z)+;P*-A4O>[6)(/.0 #QCITQSW4%EY-U-<//+.\A
M^3S0N(5XRB8 XR,\Y)]<  /FL;2Y??/:P2O@#<\88X!R.OH2: .'_P"$[O8[
M>&VG;3H]2,MV@>;,,%S]GN3$53+$JS 9Q\Y7(X;FM3Q;'YFN^%46**5I;^6-
MHI6PLB?99FPW!R-RJ>AY KHUL+-%55M( JR>: (Q@/\ WNG7WZT7-C9WA4W5
MK!.5R%,L8;'TS0!YWI?BJ]T^RU#3X6A,UF=0N ;EC)#MA=#Y$4@;+*%DQN/W
M2"-GR[1+K?Q$OK"2^%M%8_N;.YE6*;=OBEBMXYMDG(R?G8$ 8Y4[L[E'H)M+
M8Q11&WB\N$J8TV#"%>A [8[4V6QM+C=YUK!)N.6WQ@Y.,9.?;B@#@_$FN79N
M&TR^N[*!K#4-,F=@C1F9)+Q>5R_"JH"DG<"0_"\5N>)?$MWI$]U#:PQ%[;39
M-1'GJ2+@1L T28(PV,9/.-Z<'I71&TMR8R;>(F(;8R4'R#(.!Z<J/R'I3I8(
M9MGFQ1R;&#IO4':PZ$>A]Z .5T&%K_Q/KMY>G<]EJ"):Y#*\*M9PDIG=@K^\
M8E<8W9;KC',W4KV/@K4-0T]S'KJ:W=P::$8AIV%VZI!M!_>)M&-IR%49^7:"
M/3HK2V@DDDAMXHY)3F1D0 N>N21UZFH[?3;&UD\RWLK>&3&W='$JG'ID#IP*
M .+@U_5#XEFTJPATRW,^K7,,DKQ.^1'!%(&(#C+$':>0!QQQ@K:?$$7,=K<O
M<:;!9WKQ1K))(-UB[)*Q2=0^ <QA!DH2S$;?EY[1=/LDG\];.W6;<7\P1*&W
M'J<XZFGFSM625#;0E9CNE4H,.?5O7H.M '!0^+M3MM8NQ=W5C.C0Z8B?9U/D
MQ-/(Z-*&)RR$@8/?*#./F-N/Q3KDM\EKMTV$117SS33(XCE^RS1(64[OD5ED
M;KNVL#]X#GLVMH'=W>&-G=/+9BH)9?[I]N3Q[TT6-H&C86L :-/+0^6,JG3:
M/0>U &/X:U]]5MI%OC%!?),8FMRGELI$:.1C<P;APP9&8;67G.16_426UO'L
MV01+L)*;4 VYZX],]ZEH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKB
M_%NNZGI&I8^T-::6]J56]BB61;6X);:]R""5A.% 9< '?N(X( .THKCQ?ZI-
MXTU335O;T6\36IB\N&%DAW*[,'RN[:?+QG)(+=1VET>]U;7].N-5AOVM?].E
MC@M&B38L<,S(RN2I;<X1LD'Y=PP.#D ZNBN1@.L'Q=-H[Z]<M'!I]M=%_(A&
M]S-('!&SA2J 8SD9ZYYK.T#7M6O]?BT*;4)FYU&XDNFBCWLD-V;>.-<*%' #
M,<$YQTS0!W]%<$^M>(_,N5M)#=7&DZJUI+;A$ U"#R!-UP-LH5AC!"EEY #?
M+T7A[4TUBVO-0M-0:[M)I0;8LB@1J8T.T  'ABV0V6!R#C&* -NBN8\.ZA?M
MXEUS2;^]FN/LH@EA%Q L;[7#992@"M&2N%S\P*L&[$OO]5NY_&]IX>MYWM(_
ML#W\TR(I9\2*BHNX$ ?,2QQG[N,9- '245Q\UYK-CXKT6PFOIKF*>"^DECAC
MB'F!)(_*+$J""$DP=I ) .,4S1M9OYO!DL]UJ96_GO;NT@N;I8E$12:6-"0H
M53M6/<1W((SR* .SHKB9_$E[J/A?PWJ5K<M:3W=_;V]XD2HX#%RDT>64\!E8
M9'IUJMX?UW5KOQ!;V)U&>Z(O-16ZCGMXT06T4TD4;(P52SAEC!V[AAFW8)6@
M#OZ*XJUU_4[>/7]/N;I9K^"2273Y7C4;X69T7<JXSY;1ONP/NA2>33CKFICX
M=Z9=6]Y$^M7>GQW$<EUY:+))Y8<@CY5^8X3C&-P/8T =G17'ZEX@OVBTG7]$
M,U[IDMH;J>P6-=\L!V'?'QN\Q0^[;G#;2N Q!K<T&[%_I[WD=^;V">5W@E^3
M;Y9/RA=H&1CUR?4T :E%48M9TV?5I]*AOK=]0MU#S6JR R1J<8)7J!\R_F*Y
MYO[8/BLZ-_;]TJ'33<^:L$&1)YN. 4/RXXP<G'?/- '7T5PWAGQP9O#^F_VK
M'.;^33;.Y,S*N+AISL! 3)'S@\8Z$8'8:.M>*+BR\$RZU#9/;77F);I#>J5$
M<C3"$,PX)0%MPZ;EQTS0!U%%<CXCDUK1+*"YM]7FGB^T6D+K)%%YC%[J*-L8
M0+AD=P>F#C!I;CQW;6NE/?RZ?<JD,L\5PNY"4,,@C<#!^8G=N&.,*V2N,$ Z
MVBN0'B_R-9N=/BT[4[RX?49;1$+0*J%+>.7"G</E93D9R<DY*\ 0'XCVXLI+
MS^Q=0$264U_@M%N\J&39+QO^\,@@9YSUH [:BN7U;QO:Z-=WT%Q8W+"TM;BY
MW1E"7$*1NX W<?+*N,X)VMP!M+:.G^((;U]426WEM6TV0+-YI4C:8UD# J3Q
MM89]"#0!KT5P^L>.9!HTK:?;M!=RVUM=VS3XPT$TBQ[N 0'4MRIXY!^;D5IW
MM_J6EWVB:6'\_P#M*XGBDN9)!YD($4D@" )AMNW +#G:,@DD@ Z6BN(\.>-F
MG\/Z>NI0S'46TVPN-Y (N6N%8 @)DCYHW)&W@<@'I5[Q#K=X/AQJFM6:W6F7
ML%G+,B3Q*)(W0'@JP(()7TY!R.N: .IHKCAXCN=*\2WMGJ$L[VI@MVMHIUC$
MSRR3>3B/8 I3<T8)8Y4MSP1B:Z\=6MG%*9K*?S+:Y:VNT5E_=,&B&5YRX(GC
M<$#[N<[6 4@'5T5S$/C%;JY%O%IMRC2WLNGV[RO&!)-'YADZ%B%"Q,<D<],9
MJ/P_XCD7P)H^IZI))/=W9BASM4-)+))L7(7"CD\XX !H ZNBN)N?$E[J^KZ?
MI5@SV)EEN[>[;(\V&6)1]W*LK#YU<?WOE!Q\PJ]<S:E-XV.E1ZK<6]NVE^>!
M''$<2"3;N^9">G;./I0!U%%>>6OC][>U%UJ-O>3S6]M<^:EGY0@G:*[%N70,
M0P.<-@M@!B/F(KH3XNABF=+FPNXEMV9+UPAD6T81>;\Y7*[2FTY!)RZC')P
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M[C*Y],CUH [^LN^\/:9J5Q/-=02.UQ MO,!/(JRQ L0C*& 89=^HY#$=#BN
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M!/=*5V0$$'[PZ*,,V3M(*YH LMX?\/JL>ES23R.S)-'%<:E-)+^[8.I4LY8
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MHG@M$CDNI+IAG]](%#,"21G8 O3C@#I0!8HHHH **** "BBB@ HHHH ****
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MGC&JWEXZL3EXYHBJJ?W?7<<L.G&>35]?#6I1>#?#6F(;5KS2&LS+F1A')Y(
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MLDR!2Y0?[84;MO7'.,563Q1H\JVYCNS)]H=XX0D3L9&3.\* ,DK@YQTP?0T
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M F-^Y3R,;E)R. 0>G-6KG6],LY-ES?0P_NVDW2-M7:J[F^8\<+\Q&<XYZ<T
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MG;2HBQ.2CYR)#B/'KN/RC&<G@<\4?\)+HOE0RG4K?RIE5EDW_* Q*KN/1=S
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M<H<-M8$'!['!K!A\.:EY6FS7FL)<ZCITFZ*X^R;4=?+:,AT#Y9B')W!ASC
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M7/E.\CE7C4P22@@ $$_N^_';OD<_X8\<2?V#IZZO'*]S)86]PMR2#Y[2R^2
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M^4$G=P< 97 RS+3HO$US/JXMKN%H5776T^'[--D,!;&3]YN4$@\G [X&>,D
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M&K#;(%( (&2">5QR8],\73/8F":P=KV".UR6F7;()H]RL2.<Y5@54,<XQG/
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M21OLWV=0HW_* O)R22?0=)[;PY=6GAC1=&AU(*=.6WC>7R/EN$C4*59=V0&
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M0R.[,IS%Y1."?O&/*ENI!//)J"+0?#K:LACBBEO[&!(G4W#.XC.[9YJECO\
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M2.T9A_>0A_FSD;]PSUW9.<U2U'P8);B!M-N?LL*";CS[E7#2R>9(P>.9"0S
M$J<\C((YSGRZAKEYXCDM(=0O;:SDU984D2UC!6W:Q+Y!>,])P%R>A.TYZ5G3
MZGXF6TE>+5+\O]CU9DQ:1$^9!<?Z*0/+^\\9/&,,!D#/- '>:?HEGIS1RH'E
MN41D\^5MSG>0TA] 78!FV@ D=.*:?#VE-+<2?90K7&\R;)&49?&\@ X4MCDC
M!//J:XO4_$/B$7[?9OMZ1-#(IQ8$HK&S$B,AV$$"0$98]2RE> 3N>$M0U6XO
MKV'4IYYT%K9S(TL"Q[9)$8R*N%&0"%.#D@MR>E &Q<:-I0T%=,F0IIUNJ%09
MW4QB,AD(?=N&TJ"#GC%4[7P]X:NX!<V\$%U;E[DY$[2Q,9B1.""Q4@D$$'@'
M/2N,UJ[\0ZAX>1;DW69K:!K^W%MM-M=K<Q92,@99"OG'^+Y8D;.&R_5^((VM
M[SPU+;FY6W75";DVZ$AE:";#2!1T,FSD\9;UP: -30+'2;#2(DT7RS8O\\;I
M.9@X/<.221@ #G@  <"K\]S!:P//<31PPH,M)(P55^I/%>6^'M1U[1] L+:*
M.\DA72K>1H#9[FMS]H"2;0%#,PC+-M)))48'8])JC75Y\*=;\R:YOII]/NTA
M=[-H)90RN(U\H\[N57H">N!F@#K+:^M+S?\ 9;J"?9C=Y4@;;GIG'2I\CUKS
MF\FU*#7HM1L(Y;R0:9'!--;6;*+>,7$7F8Z^;)Y;2,JY)4QG"G>06:WK7B>R
MTR^^QO?3R(;R33[B.RW^>D:QL@DPAYWM(BC:H=4W;L@;P#TC(J*UN[>^MUN+
M6>*>%B0)(G#J2"0>1QP01]17!_VIKT=Q>7KWFI/8+K)MVC2R4F"TV*_F*HCW
MM\_R$\X5F)&5W#;\ 02VOA**WGCN$D2ZN\_:(3&[ W$A#%<#J"#P .>* .GH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)U+Q%IVFV#7C
MW4+HMQ':G;(I E=E55)SQRX)]!S5Z_M?MVG75IYTL/GQ/%YL1PZ;@1N4]B,Y
M%<=)X/U)HQ*K62W(&FQ%$=DB=+2?SM_W20S?="\[0/O-0!O3^()+1-+%QITR
MS:C<-;1I')&P5PCN"6W<JRQL0>O(R <@-L_$T-[.]LD#17D%RMO=6T\B))#N
M4LK<$APP (VDYR>A4@+KNFWVH7VB3VJ6^VPO3=2"64KN'DR1@#"GO)GG'3WX
MP7\%ZA/KBZY<26DE]+J,-S-$"PCCABBDC2-#M)9OWK$L0N<] ,4 =<NK:<Z!
MTO[5E,BQ!EF4@NP!5>OWB""!U.1ZU%J.O:5I-M<SWU_;P):Q^;,&D&Y5XQ\O
M7DD >I( ZUQ\/@._@T#1--5K!T@L38:A [2"*93L!E&W:6;Y/NMP<]1C)LW_
M (0U:^TK6].DFTUTG6[-A<M$PF3SW\QHW/.U0>,K]X*N0-N" =B+VU:985N8
MC*T?FA XW%./FQZ<CGIS44>K:=,4$5_:R%VVJ$F4[C@' YY.&7_OH>M<Z_A:
M\FO_ #9Y(7B.H'4^9"7WF#RC!DKRG7YO[GR[>]5=.\%7MC::#''+:V\UA;6D
M%S)#DBX$1&\,C+M?(4;6^5D;)!/0@';.ZQHSNP55&22< "J$6MZ7=:BNG0WT
M$MT\'V@1QR DQYP&X[$YQ]#5*Z@U36?"C136]C#J$A#&*3,D/RR CEER"5 P
M2N5)!P<8.;X<\+:CHNNM=RRVTENZ7*'$CEQYEU).IY')_>8.3_#GG/ !K"72
M_#&C3VUFN4L+9YULTE#2;%RQQN;/XDXY%&B^(XM9O+BV2VFB,%M;7)9RI#"9
M68 8)Z;2#G'/;')P-0\'ZK>:[>7ZR:>$ECNXDVAHR5FBC52P (+*8@"Q))!!
MX"A*T_#F@7VD:E<W%RUNR2V-G;*(W).Z%6#'E1P2W'TH V6UC3$W[M0M!Y>W
M?F9?EW,47//&6!4>I&.M3F[MQ<?9S/&)]GF>5O&[;G&['7&2.:\]_P"%?:@-
M%>Q1=-1FTS5+,%68!7NI5="/DZ*!@_7BM&]\(:K>WM\S7=NB2[YK6X+R/+;2
ML@0H!D*4X/S#!*G;@=: .E;7]+^U6]K'?VTMQ<I(\$:2@^8$.&(/3@\?7Z&G
M6VKVLD%JT]Q;PS7"1E83.K'<X)"@@_-G:V".NTD5S$/A+4!=VM[)#IJRF&\C
MO($DD9',RQ -N8$O_J0#D#AN^W#4HO FI0:?# #IYEBLM(MC)O8;FLYC(Y^Y
MT88 ^@S0!W+ZG81S2PO>VZRPKNE1I5#(,9RPSP,9//:IUN(7A\Y94:+!.\,"
MN!U.:\QATJ[U/5Y[3^S69/M5UY<CRW$ M8Y+@3,P_=*0S-$A#"5R'(91L&!U
MTGAZ_F\)#2I;]7O%D$HN#& KE9A*JN%"A@<!7("[LL<#.* )M6\1:=;#3EB:
MWN[B]G:.S7S5"M(J.Q^?G'W"N1GYB!QDX9J?B^QTNWD$B.]]%%%-+8JR>;$L
MCA!N^;;P3S@GH<9XS23PS?)K5IJ"BT0#5I-1GA61MJ;K4V^U/E^8G/F$D#DG
MUS47BCPGJ&LZAJ$MJ]H8;RQM[8K.[+M:*=I.@4@A@Y'MCH<\ '4#4[ VRW(O
M;<P.^Q91*NQFR1@'."<@C'J*K:OK*Z3)IZ-;33F^N1;1^7M^5RK,"V2.,*>F
M:Y6Y\&:N]W>RQ2V#6]Y=W336<SRB.6&98@2VS;\X\K[IR"'89'6MWQ#H=SJB
M:+'!';2Q6-XMQ*ERQ =5C=0,!6!.6S^% %NR\0V5S%>/.WV,V5R;6=;ET7;(
M%5A\P)4@JZD<]\$ @@7Y+VUBE\J2XB2789-C. VT=6P>P]:Y*V\)7]I>R7D?
MV%HGDN0-*=F-K'',D88*=O4O$6/RX_>R#&3N.=??#_4I+2"SAN+*:*WA6%9)
MMT;RC[%):L9 %.YLN&#$GCY?EQE@#J=:\5:;H^COJ(GBNE5MBQPS(6<[PK 9
M/.TL,]QZ9XK6N+NWM$#W,\<*$A0TC!02>@R>]<-J7@C4Y[(VMD^FQQSZ;;6<
MRR*V(7A<N'3 ^8-G!!"GY5.>,5O:[H=UJ=[%<PM;R+]BN;*6VN0?+=9MAW<9
MY!C P1R&/([@$H\1QS>(9='LX#<RV^PW;+*@\D.&(.TG+ ;1G'3>N,\XJR^,
MX+>WU&ZGTZ^6TTV[-M=S*$<1 !6,A4-N* ."2 2!G(X-+X=\/7>B:E>/).+B
MWDMK6"*1Y"TK>2A7<^0!ELYZU0E\+ZO<Z=X@TUY+.&WUJ[D>69)&=XX'C2-E
M52@!<JIY)P"V><8(!TG]KVT3W)NIK>WAA<*LLEPF''EAR>OR\$\'L,]*L_;K
M4O,GVF+?  TR[QF,'."P[#@]?0UR \&3CQ#]K,-B]B-46\$;L6;RQ9?9BN"N
M"<X;KSC\:B'@[6%BN=MW9-=PR(]C>2B21Y%6X6<)*"<*,H%.SKG=P>" =5'K
MVE3:C'817]O)<R0&X5$D#9C!QNX[9S^1]#4K:MIR6RW+7]J+=B564S*$8C((
M!S@D8.?H:Y6_\'ZCJ$Q?SK*T,]A+!/\ 9E8*DKS";(7'SJQR'R5+98_Q<.;P
M=<3^([;5YTLSNU![RY@+%U13:?9]J$I\Q/#L2%Z <XS0!U\-U!<-(L,T<AC8
MJX1P=I!((..AR#^5(]U;QSQP23QK-+GRXV8!GP,G ZG@$\>E<QHFC:MX=\N.
M,V]Q#*\,1@WN1;QJ'WF-RI;9DC;&Y(4 @-R%":WX;U/4O$EMJ$3V/V:"6VE5
M6#)(?+,NY6(!W B7*YX!!  W%J .C34["59FCO;=Q"@>4K*I\M2,@MSP" 3D
M]JIZ/X@MM8M[ZXC'EP6ES);M([J5;9C+@@D;3G/7IUQTKC;7X>ZI:Z=9013:
M=%+:Z=!;@@,R/)%<B<!@ /D;;@\Y&X\'OOV7AN\CT'7;*\6S>35+B:?RD9Q&
M@D !4L-K'G/S#:>_!H T)?$]A%K=MI[2((KBU>X2[\U/*.V5(]F<_>+2*/TY
M/2;6=>M-&TS4+N1A-)8VLEW);1NOF%$&2<$_K7(W_@;5KNSG@-S:3,^DW]A&
M\S'<&N'5E9BJ?,5"G+8!8GGG))KG@G6=7O-2G$FFI]KMKVW7;N3 G@CC!8!?
MF96CP6.2P(^Z%"T ==IVLIJ.H:G9I!(CV#QHS,1A]\8<8Y]& YQS4>A>([+7
M=(BOXF6$M$)9())%WPJ<XWX/&0"?3BH=%TF]T_5]9O)_(*WS0O&L<A)4I$J$
M'*CNO!]#VKF;'P)JME9VD:_V6TD&FBU8."RNXN!+GE.,@'#8)5CG!QR =P-6
MTXXQ?VO,7GC]\O,?]_K]WWZ5+#>VMQ*8H;F&215#E$<$A3T.!V/8]ZY.V\'7
MD5I9(UU$DUO?7CR.I=_.M+F1W>(D\@DM&<\\Q@YYJ[HWA^_L=?N;N]FMKF 2
M7#VDVZ0S(LTGF-&025500!E>H5>!CD WC?V8NOLINH1<8SY/F#?CC^'KW'YB
MHWU?38X&G?4+185+!I&F4*"OWLG/;OZ5Y[)IEQJ'B?4K9+6Z19KJX\J=6EC>
MU:2#RFG4-"%;@9'[[;A@0NX #1C\&:E+>V>H7<.DF]C\\W#1M(?-+0>4IRX8
M\X&1T4  ;L9H [=KRW2=(&GC69U++&6 9@.I ZD5"FK:=(JM'?VK!W$:E9E(
M9R 0HYZD$<>XKCM'\%ZII_V""[DL+ZTM[>#"2O)F*:.W$)"#[I1@,Y*Y&]Q@
MYX@F\!ZD= T;3H?[+#V-C!#*^UD9Y8I(&SO"Y*L(<$$#!P2'P  #L-)UJ/55
MOG$+PK9W<MJWF$<E,9;@G@YX_7'2K']KZ;LW_;[7;Y9EW><N-@QENO09&3[B
ML6V\.W,>C>(;"<6LO]ISW,D:L6*%95P ^,'Z[3TZ&LB]\%:M/:LD=]!*SV=]
M99N6+.B7"1 ,9 H,K*T0Y8 E6Y)*Y8 [1=1LGN1;)=P-<$$B)9 7(&,G'7C<
MOYCUICZMIT<,DSW]JL4;%'<S*%5@-Q!.>"!SCTK@='\+7-Y?:G$Q%D+;5C.+
MJ%#')*WV%(24!'W=SN=V3RI&.21>MO!FH-/I<]_%I<LUK>I+<.K2-Y\:02Q
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M(=/%I'('EN;MS';P1XWRL$9R!N( PJL>2!QZD5F3^#=(DL;FT;S$MI+>>V5
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MF\>)!' ZR/&L,<G*O@[LN1V!&#TYJIIGC>*XU:2*\3[/:306,EJ1#(S![G>
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MD/)SQGJ*Y73_  AX@TO3XET^T@BG72-.@N$>90MS+ [>:I/S?>0A58@C  (
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MEEN0RW*-)#Y*M*9%"[BRA 21CG/N/6@#EO\ A&)WEO([C1TFL;G1+>P:WWH
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MB:=XLQE2<,!'DK\V&=5S_%5"'QMJ<EE"\EM81W5Y]J^QQF7"%K>1D9&=RO)
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MVVOY)E2_F7YLPXQAOEV[FVXQC/% $MYX&74+>5;G6]0>>YLI;"\G"Q SPOG
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM SR% P#R #0!D:%K,\RR37VI3+':W-\+B2>W1(!#!/)$"9-J@-@*Q()'#9
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M,GR^<Z>4>/38=H'OZ\T 5M2U&ZTKQ-&+BY?^R[JSE,2K&N4N(QO*YQDEH][
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M)V4KY&?+P1@\;FSZ[C[8OWNB6>HW23W&]WC:-U4N2JO&Q9&"G@,"QY&,]#D
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M.5<L01_>/MA8?!FD6\!MX%N8X/M$=PD7VAV2(QN)%6-6)"+O4-M4 ' !X %
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MDNIHK#4!:^8A80VSQ)P,.&,LI&,%@@ ;N8]#U&;3?%DMM;S0+:W_ (BNX)X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBK *0%.0>9%YXE>5MO\ ;<22SZ>X62W+.O\ I4BW*L0FT 1A"=N%QC:6!+,
M=GJMEH5JESJVK):HGV8VT]Q=$;3"QP8VSP5)/W>Y/K4G_".Z4KHXM=KQP?9U
M=9'#"+.=F0<[<]NG ]*\YUA?$-[X>U33+BVUJ>)K>[BL"D3EI'6YEVB4]2#
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M6C^3D!7)S\Y^7T1CZ9(O%I>YSJ$3VD*:K<V2O ZNA6&"1R9=PW $(S#8,@J
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M8E_=[M@W9)/'4D]>:?'X2T:.W2 P3RQ)_#/=RR[OF5AN+L2V"BXSG&,# )R
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M$C8+!M RQW/E6XP 01@Y[:WT:TM=.DL8C<F&3=O:2ZDDE;(P29&8N3C !SP
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MK%'-,9I40*\K*%+D#EB!P,]<#BI: ,"B@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'\HQ&&$DJO"G$BR8('<]CSF3Z?XEM_[8@M&NIEMIC/82R73%IXY2I>+EL;D
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MQ-]G"O;N3^\&" 5)/)Z9SGO7.:S::EJ'PKU&TN+2Y;49H9D6%)))&<[VV$'
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M3:"<R [0<<A@YW;2 >AT@:I'/XFC0W#C[2)-.-[O*D-!&3@GG;YOF?*/N]
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M1Y8U8J&QN )' .!D=\#TK*BU#3(-:F:ZU6&:Z%R+&%"@!A:15?RLC[Q.T-]
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MQNVI]XJ0"?NU6M_ 8LM6MKFTOHXK2UO(+B"V^SEBJ16K6XCW%^>&SNQQCH:
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M?XXM]0N;" 6DL+7FY5\\A SK*T;HA(PY4HS%>&VE3M^]MV9=!TV;3#ISV_\
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MELD2T<-<W@LVC:0"2WD*2/MD0C<K 1\@\?,"I8<U?D\'Z%(D0>TE)BC6,/\
M:9=[ 2"1=S;MS$.-P9B2"3@\G+;?PYX=O+.!K6%)8HC'Y,\-RY9/)+! L@;(
M"[G& <?,P/4T 9=M\08;B)9CIMQ' EC]ON93(F(8MTB\#.6.8^F!P?P-I_%M
MRE[:V/\ 85X;JXGEB0%EC0B-%<N"^UB"&P/E'S*P. ,F5-"\*Z/YT)BM;=&L
M'AEAFN#L-J&);*,V-@:0Y;'&[&>:M6/AC1K+[#):P29LR[6[M<R2$;U"G)9C
MN^4 #.<  # % #=7\21Z1J5I:RVTKQSRPQ>:K+P97,:_+UP&QDG  88+'BL>
M#XB6TD*RS:;=P+-;O-;JS(S2,LZP>6<'"L7>, Y(^8Y(Q6U?Z)H>I:PK7:*V
MH>7'(%6Y9'*Q2;T;:K#.UR<-CC<1G!(,7_"%>'C (&T_?$+>2V"232./+D<.
MXP6ZE@#GJ"!@C H HZ)KMQ;6OBV]UJ9Q!I=_*<?*_E0K;Q2$+M4;A\S$9&>>
M>:BUSQ/?Q126<%I]FO4O-/5UDE&&@N9Q'D,H.&.V1#W7!()^4G?L]%TO2;6[
M2*+$5P?,N6GE:7S#L"$NSDD_*H!)/..:JQ>&]!NM-@6&(RVK&":&2.ZD.1&0
MT6UPV=BGYE4';DD@<F@#)\0:MJ>A11:5;W#2M)I=[<B^F=3,C0JNWY=FUL&1
M>2.=O.3U=I?C+?;QV5S;RKJ.RW6,,=PG:2%I0?D#$'$<F1@XQWSQOZEH.G:O
M)%)>P.[Q1RQ*4F>/Y)  ZG:1D$ <'N >H%4I_!>@7$;I+8LV\0C=]HD#)Y((
MC*MNRC*"?F4@\G).: (-;UF^'A>RU"SMWMI;JZLXGAN?W<D2RSQQLIP#AL.5
M]NHS@5GV?B2;3KZ;25@U/4;MM1EM$:ZFA 5EM4G"AE ^0J0 2"W4MSQ72W.A
MZ?=Z?!831/\ 9H'CDC1)G3#1L&0Y4@G#*#R>HJ ^&-).H&_\B471N'N?,%S*
M/WC1B(MC=@?( OMCC% &;%XWM[B31?*L;GRM6BADA8LFX>;%)*@*@G'$3 DD
M#)XW8;;'IGCN#43:1_89();ZUMKFT661<2"<.5!(SM(\MR>O &.3MJ_!X*\/
MVK6S6]B\1MA"(BES*-OE*40_>Y(1BN3R5X.0 *@N/"'A:WM(8;FW$4(A@L83
M)>2+M"/F%58OD.&;Y2#NYP#0!'_PDKPZC/\ :;*]AFATS[5);/-"(QB1E/S%
M@,_+G<2%VX[YPS2]?GU;Q/IIC>6*UFL]026V<# FM[F&+<"5#?Q/UQP1P#FM
M.?PEHER&$UF6W6ZVQ_?2#Y%?>N,-PP?Y@X^;/.<U):>&]*L+Y;VV@D2=?.PQ
MN)& \YP\GREB/F90QXZB@#6HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME4MG;N(&#S@<\=N: ,G0[][G0;N\N;V6Z@9Y&BEN+)K9_+Q]TJ0"<'(!VKD
M<'&YN%LI-8L=#\,7&GVS7NH67AYX3#! RM:MY$9 E/.]MT841DKEN<';E?59
M;NVAD\N6XBC?:7VNX!VCJ<>@YYIBW]E(KLMW RI&LCD2 A48$ACZ @'![XH
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MM'NLLRH'>-%\]2$RQS&N00,C'/R\^CT4 16RNEK$DI4R*@#%>F<<X]JEHHH
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M0 4444 %%%&10 449I,B@!:*,T4 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,, EL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,D;MI&..HN]=U>?5-3M[6>:TDMX9O*B;3WGBD0Q@PSI(JG/S8X!8G++L) (
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MM&MFM[&<W!:5U8*&5U"JH VC^]G /!%-U;PU)J_BAY[AL:7+IC6<Z(X#2[I
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M^]0IW';V4 #&.F3DDD@$8\::4[)Y?FRI)-;Q))'M=&$[%8W!!Q@D<C[PX)4
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M"3VBO<%_("JRB-=P/R;79>?FP1SPN >"+!+=X([J_2-9A/:J)\BS<,6S$",
M9)X;<,?+C;Q0!GR^)M53X;:EKA,2:A;3W2#?#P!'<O& 4#'G:N.IY]>^M#XN
MLI+Z&S>UNX9WO&L9%E5!Y,PC\U0Q#$89/F4KD'IP>*D;PM8OX>O-$9YVM;MY
MI)6:3Y]TKF1B#C ^9B1QBJ^H>&H[F"2S^SI/#?W*7-_<RSLDN^/9L90J@$@1
MJ."N-H/.30!-J'B7[)8:5=1V%Q(-1N88%7<@,8D_B;YO3L,]LXK,\/>-$GL$
M76'$=TWVEQ,(_+AD6*Y,.%RQP06B&#UWC!/..@U71X-6AMXY7EB^SW$=Q$T1
M *NAR.H(QU'3OVK'_P"$#TMK=+>6:[DB2*XB ,BJ?W\JS.V54$,'12"",8H
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ME$8(*ED5QE3\RY5@<, <$5>*AAA@"/0TV61((9)6#;54LVU2Q( [ <D^PYH
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M.SAUB\TV82Q/:003/(R'8WFNZ(JG'S,2F !U) &2#@ R]&TC4=,\43,D<O\
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M)'%>0).BR##*&4'!_/Z>G%<QJ/C.ZL+37VS8&ZTR^CM8H'<J9E98FW=<Y_?
M< _</KP 8UCHGBVVTV -;:@TS:7:+>+)?JQFECN 9D!,AP[1;@&X'(RPQQUG
M@W3[K3K/4EN;%[,3:C//#$[HQ$;D%?NLP'<8SQCTQ6FFL67]HQ:8UPIO'5BJ
M[6 DV8W[2>"1D9 )(_ UHT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 0W<#7-G/ DS0M+&R"554E"1C< P()'7D$>HKE?^$"@C8"WO3!
M"(KJ);=(SY40G1%(C4M\BCRPP4<99L8! '3ZA<O9Z;=74<:R/#"\BH\@C#$
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M(E0 C<1MZ'( OIXRO%C@GN;:&.V_M"XTZ:15+%9$W")@,\!RH7;DD,P&3G(
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MTVV@NYT_CECED=,1CNP$9//!.%XSD0^&DN[[4M;OKJ[,D]OJ$]K!C>J*FU,
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M=4CFDFB">8_EJQ88^4CYNJY&01VH C3P_HT>W9I-@NR-8EQ;(,(N2JCCH,G
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M#;#C&0>QP2..QJ[1F@".*&*"%(88TCBC4*B(H"J!T  Z"G>6A<.47> 0&QR
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MI(]:F?P_</C<L:P9=47@M 9/,7:."IXP-A'5^$K@7D6IW<FF?V=>R7FV[@*
M$2K%&&^8#YP<95NZD'C.!T>*3'7WH \U\ W<-G>N;N?:DEM%';3LZJ7#2,%C
MN@/^7T,2K=<G..=U=;XC>&_A.@$N[WT3B6*&55E\C&&9=Q'=E7Z$XZ5NX^M!
M4&@#RV;66UK2M!NCJ.G'6+ 7,=W97\BFTN)(BD<ZLP)"2<[D;G"LW!4DU%JL
MUM':Z=<6]OYL*Z+:)-I%ZP6[2!RX1K9C_P MPPPR_P >U!D'&?5\>YJGINI6
MNJV\D]F[M''/) VY2I#QN488//#*10!YKJT5E-XH\116M_8V>H'4K)D:9%:"
M61;=G$=R 0=C;3WR'VD<C%2:Q'I,GPNN-4GTZVLY?,,8:5U=4S=DMY3G \MF
M+%< 97;V KTBUU"SO;J\MK><2364@BN$&<HQ57 ]^&'(XZCJ"!:(XZGB@#D-
M>L;6YL+K0-'5+>::)KQOLCHK0N3^ZEV[EP/,7?D=3&0<[C6<]];^+X= U;3+
MNPM=>-I+-:EW#[)E\OS(&Q@LG+JP'3[PY -=U:SK<1-(L<L8$CIME0J3M8KG
M!['&0>X(/>G0RQ7,0DAD#H21N4Y&0<']0: /.=;BTR^^'7BG6+O2(+"\%I>(
M4F10T,S0HKC/1B9(U 8?>PI'6NW31M%EL95BLK1K2ZE2[=44>7(Z["KX'!^X
MA_ 5?GFAM;:2>>18X8E+R2.<!5 R23V %0WVH6FFQ1O=2%?.E6*-54LTCGHJ
MJ 23P2<#@ D\ F@#RN[MM!?X3ZQJ BTYF6\O81-E-NUK]F52>F,!"/;&.M/U
M1K1/#'B:*[>RM;MM6MI?[.RIBMU\V()(F<;A(HWE@%!+,,!E;/J5C?6VI6_V
MFU=VCWO'ET9"&1RC## $892.G:K.WW- ')6E_865K/9V<VGMJ-U=E2-/*HKL
M1QMRV/,6!%)&>P/1AGFC<1R^'5\-_P!I0V6HZ-JJVUO'>,LL+JJ-+;I<@-RA
MCPN<Y\Q 1R,5ZA*\<4322N$C4%F9C@ #J2?2B-EDC5T;*L 01W% 'F^FFR;4
M?"FK3:?#96Z-J,;2.P>..5I,C9)@?(Q$A0\97&.HI_B>#3TOM&N(+/37:Z\0
M&6!9RL:7#?9)%)+;6.#(H^;:<G:><@UZ"TX6\CMO+F)DC>3S A*+M*C!;L3N
MX'<!O2IB,T >56S:6VD^#8&NK'[1%JMRKQ7<0'V0F"Y+P&,ME51BB ;L?*G)
M&*77&L'NO#2Z=8:/J5X(-05+5F413R[?WBQ[@<@OO ' [9 YKT^YF%K:37!2
M601(7*1*6=L#.%4=3Z#O5,:Q:-J7V",3R3*RK*8XRRPL4+J'(^[E1GGCE02"
MRY /,]0>S'A_2Y[75[?6DLM&:*:VOV\O[6A&&,39)CN!L*X;)&X \@FO2+[4
MUM-+M]I,-S=;(;:*4HLAD89Q@D L &.,_P )K5Q[G\Z",T >:H-*ET+4O"FK
M3+"=/U&%;?SKD">*&65&B96W$JR;VC!!)_=@]\57\0,Q\*>,X?$$%LVJV>BB
M!KYH51;I3YQBD7T+,!E/X74XXVD^I8]S5*ZU.TL=0T^PF:03W[ND 6-BI*H7
M.6 P.%/4\]N] '*Q&V_X619CP]Y/V;['-_;'V;_59^3R-V/E\S[^/XMO7C%)
MXLU?RV_MJU<R6_A^Z22X:*1-H&"MPKC=DD1.=H SN&.O3MV(1&8[B ,G )/X
M =:R=.\1Z9JL]G#:2RL]Y8C4(<Q,H,)( .2,9^8<=1WQD9 ..O+JV?QH;BWE
MMM4M+B^M(Y(PP^U6TFR)XY(#_P M+<J0SKQC,C GYA4.EO:1:])#<?9-0L;C
M[;/]L+*)[?D^9'=JW#1_,%5^VU5Q@Y/H6FZE:ZI%-+:.[)#/);ON0KAT8JPP
M>>H//>KF/K0!XM;R6L7A309;<VM[''X<M%O--<JLC1N'!>T;M<;PP9<?.0@R
M"!77:SI6A?\ "?Z)8S6EB1>VNH--%(JYG9S$22#R2?F_ ''2NPO-2M;"YLH+
MAW62^F,$ "DAGV,^"1P/E1CSZ5;*@T <%KNL16FI6'B..7_B6:?>?8)9UN$\
MGR9"(Y=WS9RLHC)R.!"<=35+5H;?3SXFU#3ECO=)N9&@U6Q@ E6-S"G^D!!Q
MD$XD7'*_-U7#>C++$\\D2R R1@;U!Y7/3-0:AJ%MI<$4UTSA)9XK=2J%OGD<
M(F<=!N8#)XYH Y#6=)T&+QSX>L7LK +=QWQDA=$_?$JG4'[W&1]!CH*E\:HL
M%WHQM[JR2>UCFECL]3(%I<QJ(U=68_<E"ME'YP-^0037:D9HQ0!Y85TJ77M%
M4QV%K&?#2^9#JX4ND/F1?+(200P7>,G/.?>M"TGT&[UC68O$;V_^F+&NF+=D
MIOL6A3 AW<[B_F;@OS9VY_AKM[/4K6^N[ZU@9S+8RB*<%"NUB@<8SU^5@<CU
MI+C4[2UU.RTZ5I!<WOF&%0C%3L&6RV,#@C@G)[=#0!Y;JPM!XMU;:]M%%%=:
M8][J9*BYLPH)\PC QN(",Q.%#DE2H-:\\VCCQWXAN)IM)^S)!8RS^:H9VXE.
M4(.=_P!PC@D\8[5Z.Q"(6.[ '8$G\A63I7B32]9E@BLII':>S2^CW1LH,+$A
M3DCKD'CJ.^.* .;DTG0?^%CKIC6=CM;1WD:#:NXL9U;?Z[LY.[KGG.:+G6H;
M?Q)I7B,S@:7?.^G&<SIY#1M\T+KACD^8C#.T<3')PHKKM.U.TU1;EK1W86]P
M]M)N0IAT.&&"!D9[]#VJ[M]S0!Y)HKV,'BF*96L+*RCU^_!O82NZ28@@6\A
M 16!W#).XQJ/E.W+(QHQUB((^E(__"7709I$1E ^QR;MPR.^WOUQ7KVWZT8H
M \QUJ6TCL=.GL9](GDM+>Z:6QF;R[.[.]?M'E.?N2!PP5L'&YATR1W6B7MK+
MI4$5OY@>W@B62WE*^="3&K!) #\K[2,CW]*U-OUJG9ZE:WMY?6L#.9K&58IP
MR$;6*!P!GK\K Y''- #X+N::0*^GW,(/\<C1D#_OER?TJU110 4444 %%%%
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M\V*$!(7?<TF[R\;0<AMK -TR,=>*GTSQ1I6KW,5O9SRM)+"\R![>2,,J.$<
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M95E9B48$,IQR><WM<\.PZ]9PVL]Y=PQ1A@PB93Y@9&3YMP()&[(/4$ ULT4
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ML D: 8],G))-.T?PS%HA)M+R9?,E$MPH5 L[!"I8J!A68D.S*%W,H[9!W:*
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M,PSCDPRJ0T<@]U<*WX5:L;=K6SBB<JT@&9&48#.>6/XDD_C0!8HHHH ****
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M'HHT>:#3(_L.I/'+<Q?)&TLD+ [25QEMQ /]TX&*S?$RI>:@D>CV8:!_#LT
MMQ:[I#;F6+*Q*2!O\H,R(W4@9 YP >E3:E8VTACGO+>)P,E9)54@?0FD.J6
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MCHSJ8]@V9,P;'IGJWKW]Z .IAU*RN9/*@O+>63&=D<JL<>N :FBGBG!,4B.
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MZ?=7Z7*7*VNI6TT!M\);$3P&-=P7G<@R&)(;JN,XH [R.>*9I%CD1S&VQPK
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M^T6]M96A0LWEW"P3!_,;*G8^!\G#;23R>H .W%S Q15FC)D * ,/F!!((]>
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MF&\(2>A .T?A56Y\'V\OB/3KZ*QLDMH;>Z$Y8;I3/*T3+*,J=S Q'YF(/(H
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M>F1ABPP"!AL8X4A[>#;7[)!%%?W\$]O<SW,5U#(JRJ9G9Y%^[M*DL>"O88Y
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MR%UR"O *@X8X!P0#D&K#:]IZF$/,R>;+Y*EXG4;MY0 DC"AF4JI. QP%SD9
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MT/BS1KD$P79E LS?9CB=@T()!*X7YB",%1\P/&*LMKFGI=M:-/MG"%PI1OG
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M#^*XBN$AU&2(W5L\,Y,0;>SSM.SCD8R[OQTY'IR^Y\">?J-QJ":FT-W+=R7
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M9DO(Y(DB50$N3&SA<=,-&,=>#CKS2V7@=K34['4'U62::V>!B&@4*WE0RPC
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MFZN(;BT21(O**X&_&[(93D\"@"F^IW=[XNN-%M76""ULH[F>?&YV:1V"*H/
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M4FB6-2,Y(VRX;G)(R"O2M&\\.07VE/I\]W=[7N1<^<K*)%<2"1<';QA@,<=
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M4RNC[0 R%V8X[9(!P2*Z.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#12;,#Y'&.2<?O$ .00WH=9MGK-E>)J+J[Q1Z?.]O.\PV!2JAB<G^'##G^E
M'":]K-WI=[K\>H:I8WRI9V$\-O<P*(-LEU*I*INR< 1_,6/S8)[ 0QW5LFK3
MWTLEA>W/_"5K:)+=QI(\*-&@Q&PQL;Y5'?[O3/->A6>L6E]JES80&4RV\$-P
MS%"%9)=^P@GK_JVS6AM% '"0>,VN[9+A=4MH&EFCM;BSDAS+8S&784=L@*2
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M\7WM[IL]W'JUK8Q075HES"C@3V)-VD4BS;EPBE">3@DJ2"5.!Z9CW-!&>YH
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MGD@EO0LJ ';Y;\YD6/ X^8AW52!D@L 0,BM.VN8[NW6>$ML;(&]&0Y!(((8
MCD=Z //[WP;?W6L#SK,7-D;BP:3S9_,$B112))NWG<V=X^]][G/OJ>,/#E_J
M<<5O8VMO<V/]GW5I]EEDV+%*ZH(I0""#M"LO8@.<9Y%:5MXQTVXL[BY87$2P
MSW$7EFW=Y&$#%)'"*"2H(ZXXW*#@G%:4^LZ?!9VUV;I'@NF5;=HLR>>6&X;
MN2V5!;C/ )Z F@#AI_"&L32W):%49UM-KI*DB;X[>2-LHX_>)N< J=AQE@0R
MC,U[X:UV[BU6&ZL+&>66WD^R7D5TZNA>V\KR=I'W0V3R<$$-C?S6T_C72%"W
MW]H#^SAI[7S 64Q?RPX4R9 X R05V[AU. #6A?\ B72],BNI;VY:%;4GSLPN
M< *'8@ ?, K*2PR!G&<T <Y%X7OK?4M+CBTVU.F+% [ 3"-[6X5F:5^%)?S
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MD!MNY0W49&=V,'M+/Q)-?>(GLH(8C:Q32VTQ>15E21!N!"[B2",\8'!4Y.<
M AM/!$-G=V]TFI7)FAO5O1^[C52XMOL[#:%  * ?0U/9^#[2UTW1+-KF9_[)
MD+Q2 *K2*592C\<J0PR!C)5?2F'7KR/Q+=Z/.;:(Q^7<PR,IPUH0WF,QW<,K
M*5ST&Y"1\W'.?\)5=ZWJ.CI\L2IJMHP>VF;9+'-:R2!3T+ '&"P&>#M6@#I(
M_""QI?6YU6ZEL;J1I!9S1Q/$F^7S)%(*9=&)(PQ.%8@$<$7='T>?1V2UBO)'
MTV*#RXH),,5;>S9#$;@H!"@$D850,8);E(?B/(L-C+=I:HMS:-(VQL>6_P!K
M2W!.Y@-OSY.2,;3SZ=#)X@N+3PNNIWD$*SBX6W;9*&C&Z<0B0D$@*,AV&3M&
M1DXS0 RW\(1V5TUU:ZE=1W GNI8G*H0BW+AY4QCD;PK GD%%ZC<&AU[0GB\/
M:5INDVUP]O82Q!([=X_-1(T*IM,I )!V<[E.,\GH<O4=0O\ 5];TO2+LI'"-
M6N+*Z6,.$N5%H\JL#N!'##CG:ZY!.T5#XSO=0M[3Q1IT=VZ6EGHMM/;A'=90
M[22J<R[MQ_U7.>H//?(!N:1X88/;W.HB'Y+&6P^R+"H0P-)N 8#(W;0H8#Y<
M[L9&*>?!L<=II4=IJ^H6USIL30I=@QR22QMLWB3>I5B?+0YQD%1]#F7'C>[M
M[^^TMH+3^T8)[A8=THCBF6.*"7:2[#:2MP 3\V-C-M(X&OX@\0S:-+8E84^S
M31R23SOEO)"[.65?F"?-S( 0F!NP&W  MZIH*:C<:9<+=302Z>[O&1AP^Z-D
M(;=DGANN<^]8R^ 8([.""/5+J"2VL[.UM[B)5#Q_9BYC?D%6)$CA@1@@]!46
MF>(]5FCALY)+9[^[O]0@@F>(I"HMY9%52 V2Q"9 !SA7/.TYAB\82>(=&=K4
M0V;-:123V\\[1SA9H=X:)EP>,X!P,E6^[@&@#H;_ ,/?VCH,.G2:E=K/#)'-
M'?+L\U948,&QMV=1@KMVX)&!5>X\(PW4<ZW&H7<QN[,6-\TA7-S#N9L' &T_
MO) "N,*Y&,A2M;P%JYU/PO9-),-UO;P6\B2 B42>4ARY)YW!E9<=00<G.!#X
MC\2WN@^(&)*2Z?#H]Q>/ L>&9TDB4$OGA1NY..!N)SQ@ ?<^'[VSET..R+3+
M!J]U?S3%5 B$T=QG*E@6'F3X './IDRQ>!--@A^SQ33BUE@@@NHF(/GB)RZL
M3CAB68,1U!Q@8!&CI6IW5W>:M8W$*>=83+&LR K',&17'7)5ANP1D]C_ !8'
M'6OC:]M=!L)+73[9;>/1K*_9))Y&;;*^PQ@G)R ,AB3SU'/ !T-SX+AO-)_L
MV74KE(3<W5Q((0H#_:#(S A@P^5I25/; ZD9ID?@E(K=X1J=PX>^M;YM\:?Z
MR!8E'0#@^2F?QQUS6%=>+)(]>L]8G)2RBLM6S:(Y!)MYHDR^3C=@,W0%02.<
M9J]=>,-8A98([73VE:*\E68S;E*PI&Z':A;&[S,$;CC&><XH N7'@"RFTLZ<
MMW.D$=M):6O )MX9)$=E'][_ %:*">0JCJ<DZD.@""+6U%]/&VK3-,\L/R/"
MQB2+*'G! 12#ZY/M7.1^.=3DGBA%A:!IY-/9#YK82.Z#\'CYF4QGG@$'H,<Y
MM]XLU"\T;5;J.&*TOX-!U"47,4KMMD@F:,[4.  2FX$Y(SCG'(!V.D^&(M*M
M=1MQ>33+?E6ERB)M80I$2H50!D1J?K52V\$VEJ;&87DYO;".WBMK@A?E2%9$
M4%<8.Y9I W3.[C:0N(+>]N]&UH:.%MU.H1QW%D^'*NX*K.-K.=NU=KX&-VYC
MR0Q.5\0]3U**/6K&*[\JU30)KM1%NCE$H< 'S V<>V.F0<YX -:X\ 6LT5W&
ME]-&MU;>1*=H)+&=IWD^K.[\8P,\ 8I\O@UHK@W5GJ][')%-<W-K$!%LBEG#
M>8<LC$C<[, <X)[CBJ]SXPO;>ZO=-,%J-0CO);>W8OMADVP13@$LRX;;+C@G
M[C-C^&M6_P!?:V@TJ,-;V]SJ61').VZ*-A&7VDC&XG&!R,C)[8(!9U+17U2+
M31-=[9;*YCN=ZQ\2.@(Z9X!R>/UJCH/A&+09[.2.\DF%K8"P4.@&Y ^X,<=^
MWI5.#Q=?7$MOML86#WPTYXHY&8K*8!,) V!F/G^Z"4(?_9K+'CC71I-G?-9:
M8JW.AR:TN97^5(UA8QGC@GS&&[.!P<'&& -N;P/:2FZD6\GBGGGAN3)$B+F6
M*7S5=E VLV?E+$9*A022-U$'@J.TO([JUUG4H)/,G,^PQ_OTEE:8H?DXP[MA
MEPP#,,],5+WQK=P)+<0:=NBCNGLC;S9299!;^>';KA>,$8SM._/\-0S^,]2L
M],TRYGATYY[M(+B2"*5]R12RPQC@CL96^8GDJ,+RVP U['PG'8ZG:W@O7=K>
M:\E"%  3<R>8XZ]FZ>W7/6H]0\$V6I3:E+-<3))?P/!+)$J*Q!*E=QQ\^S:
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ML!OP 5WX^5=NX@YP6JQ-:Z[;:AK%W::=>26\]Y:R2QPND<TT M@C>66( 99
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M(9F*1A&SO;9YF!CJ2GSCU7D9'-4_#&D_V3HXA!EV[V\A)1\T, 8^5$.^%4@
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M\]M%=0733RM8V:P1S(Z&-XRA+'#+C)+$Y4$$8  !T-M>6UXI:WE60 *20.S
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M8HHH ,"BBB@ Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M* -N'P;86]E<6<-Q<I!-?P7^T%/D:$Q%$7Y?N#R4ZY/7GFDD\&V\D5TAU/4
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MJEM8V.H%3<W4EC+_ &@A,?\ J&CP&E_B99<$\KEA@!\BQ=6E_I\5Q=W4=_\
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MPNM'GU#RK*W031(\2RI;$*%C?8Z"3&/E?@KG\.#5K^R=-"*HT^TVJ&"CR5P
MWWL<=\G/K7"_V-K-MI26T6DW:6LUYJ)N8;&XMXKA1+.TD$R,S;?E4D8W!E+
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M'"!BC%P?N@,"IW8P00>>*Y33?!-SJOAVU%_<265Y;><+5?(!\HM=+/N<,2)
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MT'B#2[F>*&&ZWRRK*R*(VSB)ML@/'!5B 0>02!WKG(O U]!;PI!KGDS16UY
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M#XET@3K ;U/->9(%3:V2[@E.W1@"0W0X.#Q5E]4LTM6N6FQ$LIASM.2X?9M
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MV-8;M1YO/W"_O^<G?QSSS]>>M %#P==7EQ'K?VZ1FDCU:>-093($4;<*I('
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M2-+%$L*A49@02![@D?3B@#G=+^(-SJ(@G?1$CLWGL[>21;O>Z-<PQR*0FP9
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M$I29 ^YP H;)R20H"@]0 !TH IZQJ[Q:5H]T]I*INKVTC>);K8T1D<#EDR'
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M--R+"X'D-LWR#Y)-^,<2"./&>LCYZ"MW3](TS25VZ=8VUHNQ8]L$80;5+$#
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M0PPSY;<D,ID4#)QABJD\8)XX.1SU,](JA5 &<#U.:6@ HHHH **** "BBB@
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MPO\ RS)(Y!(XSPH#T36Y=2TZ[^P7:ZG#I>II%YDDKPF8S1-"&<A<*P0X#@'
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MB' !?:4Y&1@COJ^+-/U#4;S0UL4N$$-U+)+=PF/-N&MIH@X#GDAI5. #P#[
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M"1\D@R,X+<X!)K MO#.N6\1M5TZ8VLMM91R(;M<"58)4E?;O*M@F$'<"#MW
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M)[?(=DG0,F0<@D'C@\U3MK;1+G4+PVT%F]Y!.C7++&-ZRB,;"Q_O!&&/0'%
M$;:U(GAV/5,VD@F\MHBDIV.LC@(0<$L2&!"@$L3M7.1G-?QA.O@:;7TTY&N(
M9I(6MGF*@LEP82=VTXY4G&/;/>MS^P]+_LQM-.G6AL&.YK4P+Y1.[=DKC&=W
MS?7GK2_V'I7]GR6']FV?V.1S));^0OENQ.XDKC!.><^O- &$_BZZMI[M;C3D
M>/369-2:WG5O)/D><I0-M9P057& <D]=IJ0>)KU[RTLHH+%YM0B-Q92BX)C=
M!'N^8A<@YX&,Y7<P^Z5K;.D::=474VL+5M01/+6Z,*F4+_=#XSCD\9[U!#X;
MT.WL?L4&CZ?%:^89?)CMD5-Y&"VT#&<<9].* .53XB7$]M+?)I,*6"6EE<AI
M;HK(?M61&"-A  <*&.3\I+#.-M6]'U>;2K/QKJ&IR2S1:9J$TNQ9&DVQ+;0R
M;4WGY0<D[<X!8@''-;GV;0I=3O-/,%D][<6JFZA,2EI8.44.,<K]X 'CK3K6
MWT/1[E-+M+>RLYKM&D6W@B5/-5 JDD <X!4<^PH YBRUK4H/%.KK,T,DEPM@
MMO!]K=XU+I*6,:XY.$.0H (7<2HSM;HWCFZOTGOKB&-()TTX6EN@Y1[F-6PS
MD@,<OC^'.   3STT?ACP[;((HM$TN)"R$(MI&H+)DH<8ZKEB/3)IR^&-!6"6
M!=$TT12Q+#)&+1-KQJ<JA&.5!Y Z4 6-)O+F^TR*>\M5M;DLR20K*L@5E8J<
M,O!Z9]1G! ((KEY?&]S%>K92V<*SBZN+*5=Y^28*7MQ])DP0>Q^7DG-=!IFF
MZ0)8=2TZVACVVPM(C' (PD2L3M P#C/8\#' &3F\UC:NSLUO"6=UD8F,$LZX
MVL?4C P>V!0!Q.CZ]J%KK-UI[Q_:HKO5[VWAEFNWW1LD7F*H!5L)\K#@\9&!
MBKNC>)7U32M.BL[91NL+">>.>\?>L=SE1ME/S,RA2<GECQD&MA+#P^=6>T2T
ML?M\6;MD6%=ZF7*&3.."P!!/4@5./#^CB6TE_LJQ\RS3R[5_LZ;H$Z;4.,J/
M84 <[X!U^]O]-TS3K^/?*-#L;T71F,CR^8K*=^1][*$YR<Y_-T/C#4YHPBZ7
M:_:[B>ZM[*%;O/FR6\DB."650,[%(QDX+''RX/266E:992K)9V5K#)'"+<-%
M$JE8P<A!CHHSD+T&:I:EIWAN*PM]/U.QTTVD]T!#;SP(R/.Y)X4C&XY8Y]R?
M6@#.?QF5M+R_6T5K2PW?:X_.7SEQ:BX^0 E9."%P#SRP) J*^\8ZA9WBV":=
M:37<LMH(V%T1%Y=QY@5MVPDE6A<$8P1M8$$[1NQP:&WB.62.WLCK4<"F240K
MYXB8D+EL9VG:>,]J>F@Z3'%'#'IMFD44JSQHL"@)(H 5@,<,   >PH Y9-;O
M-4\5>'I%_P!'MOME]:311W+$.\*,K;EP%8;T8J3R %. 6(5_B'7+B76+2"W<
MV]O8:Y;VMPXG9#)N@\TY X*;9%&&[@G^$9W9[+P[8ZO;WL]IIT6I7,X2*<P)
MYTDI0]&QG.P,,^@JU<:%I-W?"]N-+LIKL%2)Y+=&<%?N_,1GC)QZ9H Y&+QK
MJ.H7FG6T5O;V_G:A;0RL"9 T<MLT_P A..A4KN(Y'( SQO\ AWQ%+KZ)<I9B
M/3[FV2YM+CSD8R!LY4H"2"ORY/3+$<$<LFTSPGIUS#:2:9I<,S*LT42V:[B(
MN%8 +_!NZ_P[NV:OZ38Z-'$]]HUO8)'?$3/<6<: 7!.2&++][J>?<T <=<>*
M;[5;S0E@C-I=KJB1S6IG=-RO;W# /@8>/* JZ[E;:2.00+L'CV6>UTBX.GQ!
M;TVRS1K.6:(S2M%G[OW0RY!."PS@?*<=.NA:5&( FFV:B!E>$+ H\ME!"E>.
M" 2!CH"?6J%SH_A:P:QCN=,TJ)I'6VM%:U3.X$R*B<=F#-CL<F@# \.7-TWB
M/2X7O+N2(C6T9);AW#"*_1(\[B<E5)4$\@'%=]5&'1].MI8IH;&VCDB+F-TB
M4%-YR^".FX\GU/)I4U?3Y-2.GI<H;H!CY8S_  [=PSTR-ZY'4;A0!=HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJ7F?V5>>29%E\A]AB
M&6!VG&WW]*X+2U\3PI"LG]I20M:Z;)>^<7,F_$@N?+)Z,,0EE7MNVC<:]'HH
M X/P[I^K6_B_[5J$=])$]C)%;S2.Q C6XD,8?)X?RC']X;CWRP8U6B?5[GQ%
MJIMKO4G^RZQ+'( [&..U-FC8"_=+>8R;0 6!_P!G=GT6H+>RM+1YGMK:&%IY
M#+*8T"F1R "S8ZG ')]* //K*'Q)#8:%!/\ VP3=6MM+/.CL\L-V OFK(&<!
M8S@=59?O\9(JRMQXE&F3W?V#5/[0B,<5_ T@:*4"3+O;+N!^Z21@KE<+RX!'
M?T4 >7ZW9:]=Z*UE);ZU=QO90M99(#>:+AF=)L-U\KR<>83]ULMO)STNBOK,
MWB:^.H17T"Q-,@!4?9IHS)F%E.]OF"8!"JO);=GY:ZNB@#S!=$O!KRI+:ZHD
M(UF^GDF1I21$]LRHRN"2.6 &T@YX[<7M$F\47-SHB:M%J,4BV]M*TT:81SY(
M$Z3@M@'?O/W,G*[2,&O0:* .$\3V^L7>L/$UI>7%LEQIL]D+<GR\1W2-/Y@R
M!OP 1NXP!MY#5DW%MKU]'-]MM=9,/VC3KI8Y'8O&T=Z_GCY" 2(Q&<* I !4
M$C<?4:* .2\.R:W/KM\VJ0WL#1^9&R$#[-(/,S$\9+'G9G.T+UP^2%-<SXCE
M\365MJTL+:I$EK<:A/YXE.Q;<V3F(@DX($N,#DJ1VR,^IU%<VT%Y;26US#'/
M!*I22*10RNIX((/!!]* .%LH=<BF$BRZK<:++/;F=9G8W',,@E:/HX3S#;MA
M<?=DVC:<',N8?%T<$VZ?5WFM[*)[7R]WS.+I]N_:,,_DF/>#D'G(../3XHHX
M(DBB18XT 5448"@<  =A3Z .:\26.J7%YIUQILMUL?S+2ZCCG:,)'(IQ-C</
MF1@O3G#-BN>_LK6+@>&SJZ7YFBEG2[D@ED)14MGA$@93E=[?.,8;YQUP:]&H
MH \VTZZ\6QV;W%U!J=RPL=,:YBVE)-P#?:A%T&_[I(')Y"G.,$EGJD.JS7EO
M'K2L%TL1M+N:0HMW,94<KPX6"7&#NZC)+C->DT4 <'XTTN\N=6N9K>UNYUF\
M/7]JGE%V3SF\O8I4' ) ;MS@>@QGM_PD5E]JMXH=7GTQV@+E1(9HP\&&,7S(
M<"0+E5(VDY  W"O3** .5UJUU.XMO#=H;G4AON FHRV[;'*&WD!+-& %_>%.
M5P 3D8QD9%S_ ,)+<W&IKG5+.XBE*(\<)DMY(?M"F)@!+N)\H8<)L;!DSE@F
M?0:* .!*^*I413'=V]P(;4V)6<R1K()&$XF; W IM/S@?*1M <&LU[7Q!:G4
M&M+;4TCG?6%58=RYE=D>W?&1C(#X?L3C(S7J%% 'F<%KKMK<7DH@U6*XN-5T
MN9R"SAX?+A68$@D8!67<!Z#L5RNH1^+CHUP\<FHQZA_9\J7BPY*FZ$R>4T'4
M!2IE^[_"5#88<>ET4 <SHZW:1>(H+O[>UJEZ_P!D,ID+F%HHR=K??(\PRXP>
M.@XQ7/Z#::C8Z;H5G<1ZQ'9Q>&##=0PB0-'<CR@ N.1)@2 8/  Q@'GT:B@#
M@M/&N0WFEPWS:DUS;Z@T5]/$)3!<0"UD"2*",#Y_+W #_6;CR,&L>RE\366F
M6S7,NKF>?3;#[0LPD8M<"?$R+P2A,>0Q09VY<!B,GU6JU[I]EJ5L;:_M(+J!
MB"8IXPZ$@Y!P>.#S0!Q-];7&J_##7;&VFOKR_59T,3&9)58_.D7SX=L1LBY/
MWQR1EC5::TUF'Q+>WVFQZA$9=5MC&'63RGA-HJ,9!CY@&4 DY*[<C!.3Z%:V
MEM8VR6UI;Q6\$8PD42!%4>P' J:@#EO"3ZG-:7EQJB:E;R.$#P7 R(Y0N)#%
M\S$@\<@[3C*@9.<"*+Q%;^&=!1QK<LMY:_\ $PF1F>XM[S9$$(5G4*F5ESP4
MS@L""37I%% '".?$TPU,Q6^IQZG;M.JEI4^S7$+3 Q^4"<>8(1M4X4!MV_.0
M:9#::W<>*;>(W&K#1#-<R0;GD0A=D#()6X?'FB? 8_=X^Z0*[ZB@#@?"%MJ[
M>(X[_5+/4([AM'CAO9;E@4^U+*QD"?,1M.<C9\F,=#Q5":#Q$VL"^FT_5)=0
MMK?58W>"10GS,AMO)+DH,HJ@84G(^<$YKTVB@#R_['XE?58;E(+Z2:VN+]+)
M[@N(U$D*-"7!8G9N+#+9(^[Q@*.L\*M?2VUW<7B:C")9 5@O5YB(4!@GS,2N
M1U+$$YP ,9Z2B@#SSP^OB9;K1I+LZC*GE!+F*XWQX/F39DW9PQVE-R,HXV%&
MR"IO:T^O_P#"86;V,>HBUBFA$AR# Z-',"<#L',>[=D]"-H!)[6B@#RW3[?Q
M.MT=0^PZD+UM.L8M1>9AEI$N6-TL7S8R49BNSY<'Y<'%%\->&J2V"WVK'SK#
M4)=,A25UDW++ (#(>.0SN,N<;"H?^+/J50-8VC7JWK6T)NT0QK.4&\(3DJ&Z
MX) ..E 'GDMOKVFW&ME+*_DAN]562Z>U,C.8FM(U#P_.IP)5((5MR@+Q@8J2
M^L]>N=6L8KRVU.YDMM1L9HI05$1@6-1*SA"$WB4R$\9P5VY X]&HH X+Q-I.
MK3^)[VZTS[;#<R:=;)83P.5C\^.:5B)<<% '4E6X()P"P&-?3+.^M_$=[92S
MW4ME%+]OMY7N68_O0R>2P)Y5661@#P 4QRI-=-4-M9VUFLBVMO# ))&E<1(%
M#.QRS''4D\D]30!Y]?Z->-XGN1]FU#R9?$,%T9D+D" V7EEE;G;\^Y3C!7CI
MA32Z3+XH?^Q;:^BU8((H]MRJ_,)$E<.L^6'RF(1?,RMGYB#OQGT:B@#D]>AG
M/C;1;E/ML<$%C>++/;6YDVL[0;1]QASL;MV]^>>L;#Q-::"]G%!>VTPA9],D
M1^MS]IE8O<@$C]XK0NP.5&9 -IP*]-HH \RUM_%1U&X^R#68X)'D1B@+%=MY
M"4*E> # 92,*.#AB[#BS>Z=JW_"1V=NUKJEQ#8ZO;R6LIF+Q?8Q 59F9F^9Q
M*7R6^<Y&,BO1** .0U]/$$NJW261N$'E6S:;)$2(A*)&\X3 =5*[,[AC&=N&
MJ?P;9R6BZUYL%U%YVISRH)]_S(3\K#=Z\]/QKJ** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,B@ H
MHS29% "T49HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,, EL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=]V[@1@-&" #M;?'P6W!N #<C\'Z!:)8.EK)&-.B\J!_M4N5B!#>6QW?/&"
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MFA:R\U26"#&)_P!V&&!SAMQYH ZAO#.DO=_:C!*)_M:WN\7,H_?"+R@W#?\
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M18U)R1P&=<XR?:N33PCJ-MXDM[BWM=-^PVNJK=P2"0QO';_96@,"H$( 4D$
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MILDP2%W +[0<*N,D^@SQG/%<!'X%N+?47FL+:ST\#5)YX)[95#V]N]D;=0H
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ML8W*1D'GV-2T %%%&: "BBB@ HJO->PP,BN6)>41#8A?#$9 . <<=S@58S0
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MBB@ HHHH **** "BBB@ HHJA_;>E>5+)_:-KLA8+(?-7Y"5W 'GCY>?ISTH
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M&#/M 1LE05YP2>N,TS3-:T/7].LM7F>P^U0Q12LID21[-Y4!"[NJD@X[$^E
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MXV%MJ,[HN1Q_$$P#ND>TU"357U*TL]8M?W>D!$D>4OA+B4W"2')\S;%(<Y+
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M9IHK>Y:".0NT=O,2$<D+MR-K[@2,!#@MQD M6^A7B>'=1LGGT^"^O5DS/:6
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M&7RA+@Y4 KM(&<[LLORX.13NO%PM=4N++[ 7,.H6]D667[WG(&#8QVR!C]:
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M0R>=!'+@#>H; (/4>HX-/H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(!$ ?O(O((.1C(/IQ0!J:=X>\.#39/[-M+4V=ZRW(:!\HQSO5HR#\H#?,NW
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MF=P.3\K,#D\@G.:H?\(;X?-H;5M.5[<VB6?EO([ 0HVY%&3QM/(/4=B*W:*
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MACAAC2.*-0B(BX55 P  .@%/HHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF2YE%[9VVH0BYC;RW9[=I8UERN-K$QAL#@$XZ5U1T^#>\Z;$O7A$+7BQIYI
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M98W:.X,+,.I .TL!SC.,GK4$?B^_@U(PWJ6"VT6I7&GRS;FC'R6S7*R$DD*
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MW;3-/8P%K*V)MW,D),2_NF/5EXX)SU%-.DZ83DZ?:'%Q]JYA7_7?\].GW_\
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M25%@F,F\Q![>>7#(K')4PCDE=V2,*1FLI_&&I:AH.I:C<PVLEL="L[Y;(EE
M>5Y@_P X.3Q'GH.PXY)]#72-+1MRZ=9AO.:?(@7/F$8+]/O$<$]:H7<'ANSD
MM+.>QL0;E_L,,8M0PR09?+.%(4?*7P<#(SUQ0!R]YJ6HW&N&.XN]T=KXIBMX
M4A4Q_NOLBR;6^8[N7[]^>. +5CX[DU"VL+B$6GD:G/;1VLIE4^5YJR,5E56)
MR/+V@Y7<SA=JX)/7'2]-:<W!L+0S%TD,AA7=N485LXSD#@'M0VDZ8UO<V[:?
M:&"Z<R7$1A7;,QQEG&,,3@<GT% '!V&J:C8_"9KVUO4-['>S1&:3=-UO60X)
M;.<'@DGMUK=MO%%S/J]M$MO&UK+J,VF2(,B6-TC:02'DC8P0D#KM=&R<XKH1
M:6%QIYMA;VTME,IS%L5HW5N3QT(.<^^:KWT^E:,%U*YBBA),=J)UARWSNJ(F
M5!."Q4>@XH PM7\57FEZUJD<D5N-.TZ"UGE<[BY69I4SU"J%9 3G^')SFHHO
M%UY+.U@\FE0WR*9E,LQ$=Q'YFW"E2VU\=1E]I9.#GCH99=*AUI;22&)=0OX7
M;_4',T<>T-N;&"!O7@GOQ4R:5ID,5LL>GVBI:$M;JD*XA)ZE !\IZ]* .)U;
MQA-=:'K<\=G:SV=O;S'R99]DJO%+Y;*ZJQ;D<_P8(QSG(UKKQ->V%[K-O<11
MLVF*;TI%$Q::R\IF5E^;&_S%:/\ X#G&#5N2_P##$GARX\0R06SZ9=Q)-<3F
MS),R#A2Z[=S8]QQ6\L42/O6- VT+N  .!T'TY- &3X=U>;5XKF60VKPJZFWF
MMY5<21L@8$A68 \G^(Y&#QG%;506EG:6$)AL[:&WB+%RD,80%CR3@=S4] !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!3U7/]CWV
M&=3]GDPR,58?*>01R#[CFO/]!L];;1;&\A&HW5I=V>F&5);YF=I "TTHW2?=
M*F,%0R@X;@XPWI,J1RPO'*BO&RE75AD,#U!![5E+KV@V4*PK?6D"(QA2$$(0
M53?M"=?N888'(((X(H Y7P_I^M1OI$-_+<--<6$,6JQSWF^2&:W*D.NUB")
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M:V ;RS(^%Q,"2N5QU7W["/7])FM;>ZBU"WDM[A@D4R2!D9BVT#<.!EB%&>Y
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MHK*;Q-HB&W#ZI:JUP2L2M* SD.$(QUR'.TCL<@XP:U: "BBB@ HHHH ****
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M4"RHC2&:-+Q)?M  R,>65R2, HP]J .C/AGPQ'?6\*V%I%=8,\*)\C820/D
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M "@C(Q110!6L+"UTRSCL[.(16\>=B D@9.3U]S5FBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *BNK6WO;66UNH(Y[>52DD4BAE=3U!!X(J6B@"I8
MZ99Z9&4LX%B#'+')+,?<GD_C5NBB@ HHHH **** "BBB@ HHHH **** "J]S
M8VUW-;33Q[I+63S83N(V-@KD8/7!8?1B.YJQ10 4444 %%%% !1110 4444
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MK#-)+%;Q)+(<NZH S_4]Z .$T^_O;+7M2M=.:U!O?$4MGOG1I!$!8"9< ,.
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M0HW  C$O?#^KW2Z\(])N//N]:CNK1IKB/[/L180'EC#G<N8VXVENG0X([?\
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M[1@N$R">&&\A3C."0#C-5K[Q9IMOHUS?V\Z3-$)@L1W*3)$"61AM+)C')*\
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M#\2.[:G%M1))"P#$;8V*2$8'.PCYL?=&"< @UMHZR(KHP96&00<@B@!U%%%
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M(+>Q>"T2*1K)44K$I):,[>@Y0D?3-9V@PZK-X?U&VU 7/GAFCAF\Z1#,OE*
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M@Y^E<;J/@F^U#7+F]DGT]H)A<QF,PNFZ.:.)?FV,"7!BQNSN((Y&T"M0Z!J
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M/[Q'!7@X/(XX(/Y5R-YX1U"^U/4'N+BRN+&Z)FCBG$I>WD:$1,JLK ;<;B'
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M*3 H X+2O$FH1ZS;-J&I-+8R#4Q*ODKA!#=!8&&U=V6C8^H8*"!U)[ZBCI0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&:*X3QE?7UCJ5Q
M<"YN6TJ*P_TL64Q2?3MQDQ=[!CS5^3!4\KY9(!RP(!W>11FN(+7#>-=;CDGN
MA8P?9)7?^T'C6V79(S,%)V[244$=,$^].T.2;7=-O]1N]2N+6^CU*6-HTN&"
M6HAF(2)D!"D,@4MD982=0-N #M<CUHR/6N,M].8>-I],.H:H;>#3+6X7-]*2
M9//ERQYP=VP C&".,8K)\.W=[/XEMM'N+N]%@S:K.)'NI"\SQ7K0I'O)W;4C
MP=H(SP3WH ])R/6BO.XWUN[>Z&F:A*\^EZU);V3RS-Y5U$(=[0R\D-ABT?F$
M%E* G)#9Z#PUJUOJ5AJ>JVRWK*TYW6TS,TD+I&@>+820C!PP*C SR,YS0!TE
M&:X[P=K-Q?RV_P#:(=KV_P!-BU(2QS%H-CG[BIT3;D#H2PY+$YI/&5UJ%I>Q
MW%L;FYLK>TE>\L[*?R;E5)&+B/M(4"N-A/\ $#R<"@#LLCUHK@-UQ?\ B6ZB
MM[J]GM)='L)?,2^EM_+$DDR/,JDX#;%#8/\ =]:T/$^NS6,]GJ%M-+]AL)HI
M+SRXV9)(I 5<LP& (U99>3S@>G(!U^1ZT5S&G2.OQ \0++<3F"*QLY%C>=S&
MA8S;F"D[5SL7.!V]S6_/>106+WFV26)8S)B&,R,PQGY57)8^@&<T 6*,UGCR
MM=TN&13?6\4C+( 1);2_*V<$'# ''(XR#Z&O/[9K[^S/#VH1W]^]U)KUS:,D
MM]+Y<D8FN H=<D$ (HZ=OI@ ]0HKBM-\<7.I1VJ0:=&;ORHIKN'SU55C:9X6
M9&8@G:8V;&.?E'!(-;-_KLD6L/IEH+8W,%O'=R+<R>6'B:0H=IYP5VDG(QDJ
M.-V0 ;E%<'J'Q N[33Q?6^EI<131W+0JTQ0QF&98F$GRG&=V>!PPVGKNJRWB
MW6+?5+BUNM+L5BM+VSM9I(;MF9OM#!595,8Z%TR">F[F@#LZ*X2Y\?W,&CQ:
ME%IT,R7E@;ZTC,Y0@++'&Z2G:<,/.0\ \AE.-H9K=[XIU2TOXK!K:Q\^21[9
MI(I&E2*46\DZEAA?X4'R9!PP.0-NX ["BN(T'Q;J%]8Z0GV>.YG:ULY=0D+I
M%M^T+D.H+<X/8#YOF P1@Z&L>+#HVKFWN;9OLBPM()0&8R%8Y)&12 0' 1<*
MVW<&)!.T@@'3T5QMWXPOK;39+C[)9EGS):'[4K"XB\AY05"DGJA7)(&#O[;*
MF\-:A+J'BK6)B\PAFL+"X2!Y698RZRYV@\#H,X SC- '645YZ/$E_K5UH#PH
MMK?C46AFM&FD5<-93R 2 ##J&4;77<K;-RD9(%NT\>27B:#,EG"(]22T:6,3
M%GA-PLA&> ,#8,=V#'A=O(!V^:*\[\&W-T^KZ*DMW=RJ]EJH=9;AW#&.]C5"
M0Q.2%8C/7!QFI)?$]SX;U779IXI;K31J[1,/.9Y8A]@BG_=JV1MRKDJ",;B1
MP.0#T"BL?2-6N;V&ZEN;>-(D"R020S)()HF4,& 4G'.0.?F !&,X&&WB66]B
MT*Y:WAEM=0GM)+=X;QXV02I(WSH/O;=@')VMN/ *8(!VE%<5IOC'4M1@ME>S
MT^UN[V.ZDM(WNF9'\A]K(S;%P3E2" >-QQ\N"Z+Q;/?7T&GR6\:K<WMY8EHY
MB& BB+AU(YSQCCU!!'2@#LZ*\^\.>+;M=(\*V12.\DN[.TAEF>=C)YSVCS9<
MX./]4,\DD2;CC W[-GKE]J/@&77KJR@C$^G_ &R&WANG!*-"'VLX4%&R2,J#
MC@]: .HHKAK'QG=&XM;9=-B6U%U:6;.URS2?OH%D#<KS@L <DYZYS2>*M3GL
MO$5S)<2S-IVGZ.^H?9X&:-V=) <[U;_9 .01M+ C!- '=45Q]WXKU6#6!HT6
MFVTEZUVMLDSSLD)#V\DRMPI.1Y3*1_NG/S8%*7QUJL<3M_95GN$&I2@?:F(!
MLYO+8$[!PV1@XX_2@#O:*Y[6?$;Z?H=I?6\<)FNHV=(IGP3B%Y<  ?,?DP>@
M );M@XZ>/+N6YB*Z9&MH;BTA=C.3)BXB#@A=F,J2!C/(_*@#N:,UQ7AC6+O6
M/%37<KE+>[T*SO8K=969(_,>4]#QNP%!( S@51U+Q)>ZB]C&D;VEU#JMINA$
MKQET=Y5&X@;9(F" AE+ G((!6@#T.BN(M_'%Q-96,K6=MYCW"07,23EF0M>"
MTW#Y>%W;F!;D[2H'#,M#0[R\?Q+I<;WEV\9U+6(BKSNP9$EP@()P=H&!GIVQ
M0!Z-17/7'B1DOM0C@2*2+3)A%>1EL3$&$2AHU_B^\JA>,G=S\N#DGQQ?"YL;
M=-/MY6OELY8I4N"(UCN!)@$[3EE,9] P.>,8H [>BO/;+QOJ5Q<?:9DLH8$T
MV25K<LP#3K<&''F8)P2OR@)GYL88XI;[QM+;VRZB^F[Y[2+520+IXU8VC;3E
M "#OVY&<[>@SDF@#T&BL'1]9N]5N=6LIK>&WN+-HPCJQD4B2-74D84Y&<$=\
M=1GCBE\5:M:6VG>(I=MTY\*_VC<V_G/%$Q#QNQ5?F ?:2 <?7CB@#U.BN?TO
MQ!/JFK2Q16J_85>XA\\RH&66&7RV4IDD@\D' Q@9SN!KH* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BJNI>8=*O!$9!)Y#[#%G<#M.
M-N.<^E<!IZ>(H+>.&9-:E\^UTOSF,K;DGRXN#ECG&!%N5".I(Q\QH ])HKRO
M3(?%1MK>2^;6UNXAI*,"[[2P<K=G"G:PV$DDYR<$?-BKP7Q&EK;67E:N;8W%
MS'%<Q2$SPE;EC 9#(PW(8MGS-O'!# YH ]&K$OCX>EUF*&^@LY=0?;$C26X=
MA]YU4M@X^ZS $CD$BJ7BF/5I;I([7[9]B>QN%#63[9$NLIY)//3 <<_+D_-Q
MC$'A>PO+?Q%KEQJ"3">=+8-*/,$4KK$!(4SQC=G'MTXH T[BS\--JZPW%EIS
MZA?[I/FMT9YO*QDDXYVY'7I5U]%TN34QJ3Z;9M?@ "Z:!#* .GSXS^M><)H&
MI1V]G;BUU2$P/K1,D4D@<&24O"5<'=\PP00>3UZG.[X>E\1W.M6O]K6^HPF.
M)6,H*B"9&A7<'&[AQ+NX"!N,AMI((!UPTRQ74&U 6=N+UH_*:Y$2^:4_NEL9
MQ[9J&/0=(BMA;1:79);K*9A$MN@02'J^,8W<GGKS7.WB^(9M;U.&"&^BN(M\
MFF70E46;(;?:J2KG)(F+,1MSPI!V\5G75IKL[PB%M:AL9KFQ\Z(SOYL;#>+D
M;P21'M\H95MNX,5/.2 =R-+T]7MG%E;!K4L;<B)?W.1@[./ESGG'6ITABC:5
MHXU1I6W.5 !9L 9/J< #/H!7FMC#X@FN;_\ L?4+][NVOK^ ->SL]N(A$PB4
MAL@L)O*.0-V ^3@X-J:SUJZU:Q1'UR#2I[B#[3$UQ()8F\B=9AO4DA-QMAD-
MC<&93U:@#LSH^D0HS'3[)%$BSL?(0#>I+!SQU!)(/4'FDFL](UBXF%S8V]U+
M;$P.;BV#;<JK%06'(PPZ<=1U!KSW6['Q)J']IQ-9ZN]I(K.L+3;OFCO R[2K
M#K$<@*!D8!+LI:MS;K0U&\RNHMIC:P&E7<XE%J;-1^[((.T3@DA#G@D9!Y .
MHN=!TB\FFFNM+LIY9T\N5Y;=&:1>FUB1DCD\'UI\FEZ9]DNX);&T-M<L9+E&
MA79*3U9QC#'CDGTKS^TM?%$,NZ\GU:66%M,,9#N5(%PXG#!?E8_9RF_@@MDC
MD#'1^)UD\2_#W7H+*VNO/EM;F"*%LQNSJ&4#KR"1ZX(//<4 7;;2/#%[)?0P
M:7IDC1,MI=*+1.R B-OEY 1QQT .*V+>V@M49+>&.)6=I&"*%!9B69CCN222
M>Y-<"+358O$<E[8QZC$DNM(Q63S!&UN=/2,M(O\ $/-102<D;<C ))V?!QU6
MXM+F75X-1M;ATC66"Z<%5F"D2-$0S':?EY!"\955.[(!U1 (((R#6=%H&CP0
M001:58QPV\WGPQI;H%CEY^=1C ;D\CGFN62'7K#2+Z*#[7?3:9.+>$_:B\EU
M;O(DCGYG&9%A(0$D'<K8(#"JLH\1)+ICVL6MF*.6VD;SI 3Y37#B1&4-U6)E
M!WER5VGAE=B =BGAS1(S:%-'T]39LS6I6U0>02<DIQ\I)Y.,<TNJ6VD;K:_U
M.UM9)+5Q]GFFA#O$[,%&PX)#%MH&.2<5B>&;'5X?!T[M<79UN9)MIU&5W"N&
M?RB5/W5P4SM R!SDU@ZAI^KW@M?-AU1K47.FS/#(\CR13I(3<D%3]T((_NDJ
M6!*<DD@'7"#PWJ4$<GV&SN(M5."6M PG(!?$F5ZC9_'C!&.O%.LO#]K%KU]K
M1\J:2[,;1$Q#,.U"GRM[@GICJ:H>+[;4;NXTF&P^UF)VN4N5@=E4JUM(%WD8
M_P"6ACQD]>>V1E>&+76K6XT.-X+Y;)+2**:&X=D^SE8.6&&*NI<[=I <-@@E
M!@ '7R:%I$T=S'+I=DZ71#7"M;H1,0Q8%QCYOF)//<DTLFAZ3+??;I-,LWN]
MRMY[6Z&3*@A3NQG(!('H":YO6AK4VJZC"(-4553S;"ZL9@L000D,DBYR7WEL
M#:2<H01M)&?:VVOVZZ/;.-9>.6WMI7N5G+O'= YF6;>_$; +QM8#Y]H!*Y .
MPCT#1+22UGBTJPA>S4I;2+;(I@4YR$./E!R>F.IJ2"'3KF]FN8[>(W4$GE/,
MT&UPP7H&(R1ANHXY(]:\ZOK/Q'?R7AN;/6#:M+:7"0O-N*M%?EI-NU@/]5M(
M"@ @+C<RYK9C37#>W0N1J+:6VK3>:%>19EMS H0QE2&V"3=PG.<$<9- '31>
M&=!AM1:Q:+IR6XE,XB6UC""0KM+[<8W8XSUQQ5FRTG3=.=GL;"UMG:-(F:"%
M4)1!A%.!T4< =NU>?6T'BV*XBFOIM4DNHKG3=VQF\HJ>+G*K\C?+G=P1NY7!
MQ6[XG.MG6[5M-AU PQ/:.6A<>6Z_: )U*Y'(BZ[MP(/R@%2: .ACT/28EA6/
M3+)%@;=$%MT C.W;E>.#M)'';BJ%II?AB[DD2UTS37;39%MB%M$_<,F)%0?+
MQM\P,,="WKFN.AA\616(-JVJ27DEI?+)]ID?DBZ4P;=_RJYA,NT\?P[N@K=T
MG3KE]/\ %:+9WT,>H7'FVOVF8B1PUI"GWBQ8$.C#DC'3Z &QIT'AV/4WMM-M
M;".\LH@2+>!5:*.8EA@@<!BK,0.N,FKZZ98)>27BV5NMU*<O.(E#L<;>6QD\
M #Z#%>;:9INJV@MKB.TU2WEAM-$B 'F GRYI!<JP!^8"*1N#D<C'S 8Z?PS_
M &U+JMW)JL-[#*B&*5&<-:R,')5XLL3RI[!< @,"1P =#IVE:?I%NUOIMC;6
M4#,7,=M"L:ECU.% &>!S[5!%X<T2  0Z181@7 NALMD&)A_RTX'W_P#:ZUR4
MVD>*(M0\JWGO'M(;Z:$2/>/NEMKE<[\;_O0.V!GDJIP14E[;^(_-G*-?I<1R
MW@<Q2,8I;1HG\C8.0) _DCL^5D/W6RP!T&IZ;X9TW0P=2T_38M+LW\Y4DMD,
M<3D_>5<8#$MU SD^]7'T+29+M[M]+LFN9&W/,;="[';LR6QDG:2OT..E>>:M
MI.NS>'#8-;ZS>_:=)B9/])8G[9NS,LNYQ@$!-H/R##@8R >L\,QZM'J>J'4/
MM,D#OO@DG8J5!DD/E[-S+D!E^=" 1M!52I% #Q%X-*R2?9]&"Z>B[W:&,"W6
M-Y(UY(^4*R2J/0AL5H60T:[LI-+M(K8VT,8BDLO)"K&C X5HR!M!&>".1[&L
M3Q1X:S#9WND6*M+:ZC#>W-O$%5[I$DDD* D@;@\K2#) +=QG(L7\MY>P17VG
MV%S &N(5O"Z>5<26REB0HSN&TL3ZD;PH)(R :B>'=%C9632+!2KQR K;(,/&
M-J-TZJ. >PX%66TVQ>^-\UG;F[,?E?:#$OF;/[N[&<>W2O-KZVU^"QUJXN[W
M5XH;/1KJ:QD%Q(@5EDF,1<@C<XB,>=V2>^6&1J65OKD4JSI+JD^C2S6S3I-*
MQN#^YD$K1G(<)YAMVVJ1]R3:"#A@#L(]$TJ)85BTRS18)/-A"P(!&^-NY>.#
MCC(YQQ4;:!HG"MI5AR)5 -LG(DYD'3^+^+U[YKB[>R\2"6X:[DUB9K;27:S2
M*Y,9DF\R;RPS8V&7RFB!W!EW<D-BJ]I8^)3XE%V8+UC"M_%8RW+MY:&2.W>+
M>"['9N$V=Q.,;>RJ #T.?2=-N;6"VGL+66WMR#!$\*LL1 *@J",# )''8D5D
MZ;:>$KJ58M.L])9U\NX00V\8R(_ECD7 Y"]%<<#! /!IGA4Z@]K>W%[!J,#R
M%3]FOG#>6X7#;#N8E20.<X)R0!WYK3-.\1:18RPZ3:W,MG#9HUO:7Q FLR9$
M,EK%+D>8NP,%8G"E4^8]@#N[+1-)TVX>XL=,LK69P5>2"W1&8$[B"0 3R2?J
M:JV-GX>U&'S+.SL)H[>Y(RENN$FB8C(X^\IW8(Z9.*Y&<>(A'9-:0Z\8UFCN
M!YTBY$9NH_,C90V<B/=@.S_*<#D';N>%99=/DN;"YM+J.2[U._GC<Q$*$\TL
MI)[;E8$=N,<'B@"TNF>%)WN+-=+TQWL5S);BS0M$K-Y@PFW.&9=PP.67/)%7
M+#3M$E%OJ-C868R7N(9TMU4YD'S.IQD%QC)[\=:QM7TRXN-:GUC2X9%UC3U4
M0%E*)=Q$9>W9R,%6(&#_  , WJ#5M(-<.KV%I<P:A!:QQPM#+;2 1^6(0LD<
MWS<-NW$$*2<IAA@D '6-I.G/J:ZFUC;&_1/+6Z,*^:J\_*'QD#D\9[U2N['P
M]I=M%+=6-A!"+J-HR;=<"<L%1A@??RV >O-<]!9:[9:1+%<#4YY[2YCLX)8[
MLL\UOYX;SVRQW'RRJMT<[7 *[@1@FS\5WFDV]KJ=CJEQ+$UBUN!*,;H;S,WF
M?/AFV!""Y(( (.=Q(!Z)_P (UH7E+%_8VG>6L;Q*GV6/ 1SEU QT8\D=^]9N
MK0^"M$\K^U[?0[,7#2*GVF*) Y< 2=1W&T,>AR,]JR;'4-9TSQ!?WU_::LVF
M-%*/+8B;:XN6"E0#C&QP1M ^7 .\J36GXUF<Z>VGQZ3?7J:C&UO=26D(=HX"
M"'')'S,"57G@G<<XP0#4@&B6&I/;VR6=O>SA%=8HU1I-JG8"0.2$5L#KM4XX
M!K.6U\%+871CM-$-I:[K&<)!$53D,T) ']X@[/7MFLE=&U(ZHT?V:6(2ZY%J
M0GXVQP+;HI4D'KE#%@<X(.-N<7]-::SO/$LLMK?*MUJJO#+%;EF5#;0Q^8H(
M.0&1QT/KC!H O6UUX6MKQ+^U?3([G48T9;F%4#W*%TC4[@,L-SQJ.>K"M^N8
M\.>'$@T#3H-5M89;JSW)'(R#?L$PDC9L<;SY<3M_M@FNAM;@W, E,,L/S,NR
M5=K<,1G'H<9'L10!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #9'$<3N02%4DA1DGZ#O6!HGBJUUK3X=2$20Z=/;+<QW33(4 )QL<C[LB
M_P 0Y )P"><;ES')+:S1Q2&.1T95<?PDC@_A7(CP5=))J%U;WEI:W=ZD/GB&
MV/DW$J2!WF=-WRNX&W*G<N2VYCC: ;\>M64]^D,%WI\L#6SW!D6[4OA6"Y"
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MKE<^H!XZBJ-MXDT^:\M+-KBU-U>/<>0MO-YJND3[2VX  '[N5Z@DCG:37/\
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M<M%*[2 R&3S2WS$_Q_-CIFEFT#2YXWC>T4(]VEZXC9DW3J5(<[2,G*J?J,T
M8UMXU@NX?W=N5NGF^SI:R,1(LNQW,<B!2R,$C)^Z0<C:6'S5T=C=?;;"WNC!
M-;F:-7,,ZA9(R1G:P!.&'0\]:RI_!N@7-D+273U:-1&(V$KAXQ'N\L(X.Y-N
MY\;2,;F]36I;:?;6;LUNA3<B)M#DJ%484!2<#@]L9[T 6:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_K0K!2&*\Y5<D;6X^5L-;QGHL=V;:6:YBE5XHV$MC.@0R.R1EF* *K,K ,2
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M+LO[OY@N]<XSCGT.)I_%>F2(!:Z@BN+RVMV,EK*P;S6&S;C'#@X63E,^N,4
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M@= LB21N"!C<K11D9!!P<@YQ5R7PA'+J"Z@;QQ=&6::5M@VR/)"L/3/ 5$4
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MXQSCMQ69:^%[:WU'2(H;6>*#1H"D5R\BD7*L!E&4<DAT20D@895VYR<=110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V6*.:)XI45XW
M4JR,,A@>H([BJC:1IK?9-VGVI^QG-KF%?W!QCY./EX],5=HH JC3+!89(18V
MPBD_UD8B7:_U&,&FG2=-)R;"U_U'V;_4K_JO^>?3[G^STJY10!131=*C\K9I
MEFODL&BVP*-A"! 5XX.P!>.PQTIT>DZ;"END>GVJ);9\A5A4"+)R=O'R\@'C
MTJY10!2BTC38)DFAT^TCE1W='2%0RL_WR"!P6[GOWJ673[.:X-Q+:0/,4\LR
M-&"VSGY<XSCD\>YJQ10!633K&/3SI\=G;I9%#&;98E$>T\%=N,8/I4,>B:3$
MRM'I=DA2195*VZ JZKM5AQP0O /8<5?HH K6NGV5@LJV=I!;K-(991#&$WN>
MK' Y)P.3SQ4-MHFDV<D<EKIEE \>[8T4"H4W=<$#C/>K]% %-M(TUX9H6T^U
M:*=]\T9A4K(V<Y88Y.><GO26^D:9:O*]OIUI"\P*R-'"JEP26(8@<C+,>>Y/
MK5VB@"K9:;8Z;%Y5C96]K&<92")8QP !P .@ 'X4Q]&TN2!X'TVS:%Y/-:,P
M*59_[Q&,%O?K5VB@"M=Z=8WZQ+>6=O<+$V^,31*X1O49'!]Z9_9&F_9X[?\
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M,5)C7;-\Q)P"%&?[VU<>'=*_T1GFG@N8W=8;E+EHY6,C%W7<#\P8\[3D9 (
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MS*MT_EN?+$1<IG;YFQ0N[&>*1O!NC>8C.;C?_H^PB=E(, (CP1@\ MGUR?;
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M(-2@ @8Z=N: /.?[;UFW\3?->2WT$5OJ L8U5(UU%D6W>,<#YGR\R97&?*)
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MGC.<XP1TJ >!M.$%E"+J\\NP$26@+(3!'',DRQ@[<E=T40);)Q&.<EB>GHH
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M>74=Q<M$9Y%$8,P0DX8;,$D-M+XWX ^88S6Y10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<_JOBA-.U=]+BM&N+M;-KQ8O,5&F4%ALB!^^_RD
MD<8!7GFN@KE_$_A27Q(98Y;F!83'']F8Q'SK*=68^?%(&!#X*C''W <D9! +
M/_"0W#:[?:9'8Q,;1H!N:ZVF02 GY05Y("L<9[4L/B-[R.XNK'3Y+BP@N3;&
M97PSE7V2NB8^9$.[G()V-M!^4M5E\-W9\0ZGJT4ED)KH0K;RR0EGM=BLNX9Z
MDAVXX'8YJ32?#^I:))/:66HVXTF2>2>*.2W)F@\QB[JK[MI&YF()7(S@[L4
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M"Q_/U)0D@[B*==>$FN-)\31FXC_M#7XWCFFV$)&IB\I %SD[5YZ_,Q)^4$
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M^TFW!0ORY'S(1SZKZUH^'="30-.D@$QN+BXN)+NZG*[?-FD;<[!>=HSP!DX
M')/)R-/\"PZ=<:7+'>,QL9)5P5QOMR08H?I&8X,'OY9Z!B* -K4]<ATF73X[
MB-R;NX6 LG(C+$*&/MO:-/7+CWJG>^(+RWU/5+&VTL74MC81WJ*L^&FWLX"
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M'OM-O-5N[Z[MYY=1FCG98(&C5&6%(CC+-D'RP1Z<]: -NBBB@ HHHH ****
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MF8*&#.K!F4A$&TDC"*,8   ,Z?QW;VK7C7&G7<-I:7C64EY,T2PAPH;+-O\
MD4@@!FP,D E2:MR>+K:*X$;6UQL%W'8RR *?+N'C5U0C/?>BYZ!F&>,D6QX;
MTN,3;8I5\ZY:[DQ<2?-*R%"?O=-IQM^[[4RU\/:&I2:S@4)&4VK%*WE[HU\M
M3M!VEE "YQD;%_NC !FZ=XZM=2ABDBL+N/S[6VNX?.,:AHYGV*2=QV[3U[XZ
M!CQ3=$\1R:WXDM);>29-.N]&6\6VE104<R8R2!G..",D<<5=C\$Z!$MJL=I,
MHM88H(,7<H,:1,70 [L\$GGK@X.1Q4VE>'-$TJZ0Z=&R36MO]E"FZDD\N(MO
M"D,Q[\C/..!Q0!F3_$"QLY[@7=C>06UO-=0/<,$9=T$1E;@,6(*!B#CM@X)Q
M3[KQA)#K-KI*6!2\>]BMYDF?&R.2.219%*Y#9\IUQD$,IZC!-]_"&ARRL\MF
M9=T\URRR3.R,\J>7(2I.""A(VD8&3@"GMX5TE_)+PSM)#-'.DS74ID#HI1?G
MW;B K,,$X.YB023D S=.\5K/IP>WM[Z\N<W4K6\GE"<)%.T; ;<(2#PHSR!R
M2>NG8^(([_5'M(+:Y:%?- NQ$?*WQ2>6Z%L8#;LXZYVMZ53F\+^&[46BRJT&
MR600DWLD9=II-[H3O!D5WP2C9!/:K&EZ=H-OJMW<:;,ANI7=YHX[MG578@NP
MCW%4)."2 "2>>M &:_C*ULM0O;>9+PL-0:T7S_*1!((HG6-&! ^<2 JKG<3O
M] M7M?\ %46@2F.2QNKEA93WN8=@'EPE-_WF'.) 1Z^M.F\-Z!+=744T9:;4
M/-EGA:Y?]^&$:2$INY7"1+TP..F>;>I>']-U>0R7T+R,;::T.)73]U+M\Q?E
M(Z[5YZC P10!GOXOLQ.$CBD>(W<=B9^BI/)&KHK=\'>BY ."PXQDB*S\7;O
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M?:@"A+XBN+OQ7HD%F94T^6YO+:9BJ;9GA4@]?F&UU8 C&=K9XVD[>N:PNB6
MNFMY)QEAA"HQA&?DD]]NT8SEF4=R11/A+1+B5M0M5E2:4RS1217DPC5Y4*M(
MJJX +!B25P23NSGFK%]HFESZ9:1:HTLD6GC<D\MRZ,,1M&6=PP)RK,#DX.3F
M@#,B\=V<UW%%'8WIADFMH?/(0*#<('C.-V<<@'C()Z8YINE>(KC6/%]GY#2K
MI-UI#7<"NJ8D_>J%D'\0RK9P3C#+QG(%^#P9H5NJ"*VF 22WE7==2G#0#;$>
M6[ #CH<<YIUAX<T'0;Z*XM8S;S"-X85>[D*(C,I*(C,55<A<   =L4 4=1\=
MV>F7TUI<6-X9(^0$V$L/.CAS@L,<S1L,\E3G'3,L/C*"2XMXYK.:V22[GLI)
M963;%-$I?:<$YW*K$$>F#@X!)?!GAF]N9"T,KRB1Y65+Z8;&DE69OE#X4&1%
M?& ,C/K3KG0+!YSIT:6QM;FY.H7<,TC/(\JR1NKJ"2 NY<$=.F.^0#>M97GM
M(9I86@DD0,T3$$H2,[3CC(Z5-2#IUIJ31R.Z)(K,APX!R5. <'TX(/XT /HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJ<SV^E7DT4BQR
M1P.ZNPR%(4D$BN"TSQ-KC)"L]PTZRVNFW%S-Y2!K3SA()R%"_=4I&3N!V>86
M)V@ >B2RI#"\LC!412S$]@.M84'C#2Y+!+^X\VSLI+9+J*YNMJI)&YPI4@GY
MCD?+][YAQDXH XV;5];236)[F[F9X]#NS9!X5,5P8YI527;MP6=%B8XX.X8
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MW5MI(;:<X/H: //;_P 4ZI:7NIV(O7\D7DD=OJ(@$@B)A@DC1E2-MREI)E'
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ML;;7.X84^A]#3DEC=F".K,O# ')' //X$'\10 ^BBB@ HHHH **** "BBB@
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MBUD9-C2M/*\:');&UMJXSM(SSVKHIM7MH+2UGD653=%4@A9"LCNPW!-IP0V
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M+AQPQ)(4*!GIW.*L7'C?2K5I8I8[T74(F,MLMN6=/*5&?../NR(PYY##&>E
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M0 4444 %%%% !1110 4444 %%%% $5S;PWEK-;7$:RP3(8Y(V&0RD8(/L16
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MY1I6EV2 +C =WP5VL Q&<$U?O_#UO?:U!JBW5Y;7,<7D2?9Y JSQ;MP1P0>
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M-/LE0>?&)&E4-\F 59W(*@'YB#D5MZKH%IK4ELUV\Q2W=9$C!&W>K!E;D9#
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M<(K,QP=V1!(,C.5QM'\<7C^'] 26_P!-?4;RRBN3+>L8TNG+@21)MS^\ (X
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M<W9MYY99FERGF*[RF4D?+MX<D@$'TYHUC6;FVNM.LX3;VKWL<S"ZND9HHW1
MP0C*')!9NH^6-_PQ=$D?Q)XG^W:A;+$!I&FWT-K(&+VDKM<$@-D8/RX8X&X
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M R^4I50W< $G^9JQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM7Y#SRK8'(ET_P (7\/AWPXP@\O58$6+4UN)O,\Q9(1%,<Y8$C"./79CC<:
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M!(-ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6P#@XZ'!!Q[B@"Q1110 45%#<P7#2K#-'(T+^7*$8$HV =IQT."#@]B/6I:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HILDB1
M1M)(ZHB LS,<  =234*ZA9.6"W<#%0A;$@.-_P!W//?MZT 6**QM;\2V&BZ&
MVJLZW,6T-$D,B9E!(&5R0"!D$X[=,G .FUY;*\J-<1!X5#2*7&44]"WH..]
M$U<EXNTN66^L+ZVM/M)F2;2[M/*#CR)UX9AW59%CSZ*SFMVZUS3+.*VEGO[=
M4NIE@@/F#$CDXVKZGK],&H="U^UU[3A=HI@;+[[>5E,D861TRP4D#)1N<D<=
M30!Q$]K?GP2BWT4JWMC>V.G+(XW&1+>\CS./9U&\^R<\"IO^$AUN.'[)-=WJ
MM]LO((K]=-\]F9)5$*.J)M 96/.$W!>&4\UZ MW:O;?:DN(FM]I;S0X*8'4Y
MZ8XIC:C8K$96O+<1AVC+F5<!ESN7.>HP<CM@T >?W'B#Q':7ES+#+<7@%]?P
MQ6?V9,,D<)>+!"AB=X"@[L'=CDD&M)-2U<Z?::M97E_J%JFH^7+ =.\B66"0
M!!\K(&_=R,&W +\JL#NQN/7RZC8PF42WEO'Y.WS0TJC9N^[NYXSVSUIDFH1_
M:X8(?+FWRF*4K*N8CL+C(SDG@<#GG/0$T <F^H:S#K0TRXO[N%K90?.&GAX[
MV+R!OD,@79&RR%NI ^11M;<,S66H:G;_  V@U6[N[VXU*:SAFE(M49X9&5 X
M$:(.%;<3D,5^;J %KI?[1BDFM1;&*>&=F'FQRKA<*6'&?FSCMGUZ5*+ZS*NX
MNH"L;^6Y\P85^NT^AYZ4 >;W>N^)3IUT8KZ]ANH+'59%4V:!GEAN%^RC#1<[
MXR1@#YAD@ C(ZFQEU9O$=Q92W<\UH72_@N!''L,#J5^SDA1R'&X'J5Q\Q(.=
M];VT<0[;J$B==T6)!^\7CE?4<CIZBH8(+'3KE@L@2>\D+8EF+,[<DA=Q/ R3
MM7@9)QR: .0U#5]:M_%-TD5Y-]CBU*R@2#R$*-%(O[W+;=V!R<@C!')QQ69J
M^H>)+WPY.6>]CE;3S)?P10;6L[A9D&Q"%W,C*TW7=E8T.<-E^UT_Q+:ZE=7:
MVRJUG:-)%-=^:@5'3&X$$Y Y.&Z'8V<#:698^+=*U'4([:WF4Q2VL5S#<EU$
M<HD9E55YSNRAXP* .?N-?U"VO[Y))-0_L]M2\E;NUL?-F@C:TB9/D6,D@REU
MW%6P5VGVNZ;JNJ3>)H]/NYKN)H@-T1TXB.YC,"DR^9C:C"0D8WG&"NTY##K%
MN('G>!9HVFC +QA@64'ID=1FL>;Q-;I_:36UE=WD.FDI<RVX0JKJH9D 9@69
M5()P".< D@@ &-X@N_$FGZM>"R-W/:HL%_$(H$8&*-B+BW'R$EF7:RC.XEC@
MX7!SKM]3T_Q+=7:7<L=SY>CI<8CC*RAKF83(?EZ)')G*X( 4DXSGT#[7;!Y4
M:XA#P@-*N\90'H6],X[UG#Q'IUQ-/;Z=<V][/;O"LL<,Z?()'"Y))QP,G'4\
M <D9 ."U?6M?N_[1A$NJ1VF^&1"MB8V14O\ 9(,A.1Y1&1ELJH/1F%;L5]KN
ML7VI6=OJ%UIETB7$<<<FFYCC^?$$XD9=K94 E<L3N(PNTD;%EXIBU*^$5A;?
M:+47,EK)<K/&!&Z9!RA.XY((7:#G#'@8)UCJ%BJ3,UW;JL!Q,3(N(S_M>GXT
M <5=ZYK?]D6E],FIZ;'J 97*V/VB73I!&  8U0DAG$AW$$?<' ;%:OA275;V
M_P!8EU+4)Y%M[LP16_D1Q1[?+B;<, MPYD4?.1U!W$9K:36M,>_O+);VW-Q9
MHLEP@<?NE;.-WIP,_0CU%7!-$T(F61#$R[@X.5*XSG/IB@#@+36=?>ZMQYTL
ML U.YAF2.!5D:/[7B-A\FUAY0RP!5MC%P6QQK:Q<ZT?%LMOI]U,((-+-U':K
M''LN)P[ (SLI(!&,@$'H01SG1U+Q/9V<UI;6QCO;N]5VMH8ID'FA!DX8G;DG
M"CGECV&2)KC78;;78-)FMID>:TDN_/8H(D2,JK;CNR""Z]L<]>#@ Y6RU_5I
MI[.1KC46TZYG99)'TIHIK601#$)4KR"V3NVG#?+N.0!0TWQ%XBFT^PN)9[V5
MKJST6Y4Q6097$D@%W@K'TVG)[KD8QFO1)KVQ:UF>2\A6%2T4DGG!0C#@J6!X
M(^N13+""PTFVMM(M62-(( L-N9"S+$ORC&220.!F@#C+'4==N=0BACOIF*_V
MH_E"*%!,T5T@MU9BG >(L,C&Y<L#D;J;:>(=6GM[2X:XU$65S>1Q7+/I+1S6
M/[ERR8*G</-6-2Q0A=[#<>-G<'5=.V%C?VNT$ GSEQSMQW_VT_[Z7U%3&YMU
MN! 9HQ,4+B,L-VT<$XZX]Z //K&*\MOA'H83[?:S07%GYP2!EE$8ND$F4*YQ
MMW$\8('=>NOIVHZY<:_:I(9 GVJ[BO+5[?:D4"EO(E5L DL!'W(.]^ 4(7IE
MU"Q=$=;RW97D\M6$BX9_[HYY/M5.SUZSU)+:73I(KNWFN)(#-%*N$9 V>IRW
M*8XSP<].: .5QJ]GXPU-]/DG!GUF%GLVA7RKBW-G$KR[RNY=K(P#!@-R[2"3
MBM?P;JE[J]O<7%Y+=9*1;[>YL&MS;2[3YD8) W@''8XY^9@0%Z!;VS9'9;F
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MX.5=E.W.:LCPA.MV%#PM:KJ$=^A&4="L A\D+@@(0N,Y^ZQ7!ZGL:* /+_\
MA#VMUT'1/L&FF\7PY=6%S<;"8]Y^S('SM!8D"0@'!(##(Y-;%WX*N98IK47"
MW$!NOM:37#GS2PMO(\MOE(*G'+=U8KM[GM\"EH \]O?!&IR>'])TZT72T-I8
M1PRMM9"9D:!LAPN2K"'!&!CY20VT 2R^#-3N4LH9)[:$6^H:E/\ :H)&$RQW
M0GP4RO# S XSC]V#DYX[VB@#@IO!-[<S6ES*NG"6&73P\4881%;9G)D4%20[
M!]H7G 4#<:OVWA>\3P7<:,9;>"X-Y-=1F(LT6&NFG6-AA25((1@.H)Q7744
M<=;^&-0B\36VK 6D<7VV:[F@21B$,D"183Y!NR4+DD+RYZ]2WQ3X6U'6;_4)
M;5K0Q7FGP6I$\C*5:.<R= K9!#$>V.ASQV=% 'G]SX-U<W5]) =/>UO+RY:6
MQEEE2.2":.)26* ?.#$?EP00[#(/-;VN:1J5Q+ILNGM9S+;I)!/:WP/E31NH
M4MP#AACCCD,RY&<UT5% '#R>"[EAY&^U>"*YGNH7*E782P-%Y#C! C&\8()^
M5$7:<;JPY?!IDOK?0?L=BLTGAC[!/=B/Y4;<B;U.WYF &X [?NCD=1ZI28H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***,B@ HHS29% "T49HH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKA\D$XW%2?NUNZ/92V>HZY+)$L<=Y?">+!'*^1%&2<="6C8_0C\,J5M6:]O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,, EL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,J".#D<'/.  =O17*IXVBDLP\6F7<UVCSK+:0KYCJ(93$Y7:"&^8'&<9 ['
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MP1M+:.F>(4U34&@ALKG[/L=DNBA\LLC[&0G& V>1@G(!Z8Q0!LT444 %%%%
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M  )_B^4Y^[6?I?BCQ"FGV]S=RSW;3:5:7$R+:#= YF$<S*J+N)"$N5(;!7@
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M'91C#-DC"\\#&M10!@KX,T 64%FUBTEM!:264<4MQ)(H@<J63#,<CY$QGIM
M&,"G2>$-$ECM$DMI7-HS&.1KJ4R'=C<'?=ND4[5!5R00H!& *W** *EA8BQA
MEC\V63S)6E/F2,^TL<X&XD@>V<#M@8 J0^&=&MH4BM]/BA1+:2T0190K"Y#,
M@(.<$@'V[8S6M10!S[^"?#\D)B>R<KY5O$I^TR[D6 DQ%&W91ER<,I!Y//-2
M2>#]$EW[[67YU@5\74HW>2^^,G#<L&YW'D]R:W** ,%O!NA-<K<&SD$PGDGW
M"YE!9I&#.K8;YD8J"4.4..E:6GZ7::7!+#:1LD<LTD[AI&?+R,6<_,3C+$G
MXYJY10!AKX/T)=,.G"Q/V?RXHAF:0NB1$F,*^[<NPDE<$8)XJ1?"^CK*LC6A
MD(M6LR)IGD5XF.65U9B'W'DE@23R2:V** ,A?#&DK);2>1*TEM.MQ%(]Q(S!
MU0Q@EBV6 5F&#D<GCFI;#0=-TR^NKRS@:.:Y9GD_>NR!F.YBJ$E4W'D[0-QY
M.:TJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<L;BR2PFF\W#O A)"DXQGYB-V,D=ZMS^'HY[N[N3?WJ2W=O';3-&R*6C3?@
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MO7\P91,<1K$<+D8&07^9VZ-O&S_:[NU2RL?.LC&;AWU-$C$<A8(ZL5Y'"Y!
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MI*!)'*LR$QR>:'0 $QAO(;)!"LS<@+A>U.M:.+F.V.J6/GR%%2+[0FYBP)4
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MP%8'DGJ3S5"SUG79/[(?4M0OK)A:V$EU*]A*J(Y4_:$D_=F,%CM^9F79D$8
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MZ*WKG/;'-\^,[81W:+I^HO>6LDT;V,42R3,(U1F*A6((Q+'CGJX'!S0!C0>
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MC(ZG/R[J -CP[I#:?H LY9YW)#(DCG;(L0^6(9Z[A&%R>N[)XS6$O@:[CM;
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MI_=R8) !\MN>5W8HU?65^%%SXF;4'^VR:0NH1J88\1.(0Y48'*$]CDC)YZ8
M-*W\*SP^$4T9M0C^T170NX[@0$('6Y^T*"F[)7< #\PR,]*HW7@B[FO)+^WO
M+>"XN9+I[B,QEHU\Z&./Y,$'(\I"2?O%F/&0*3Q)XDN?"^H-;7=S=7-G=:==
MW*2P11?:+9H%5F(SA&&UL@,."O.X' U7\601ZE?V1L;W%E,EO)/A"AE=8V15
M 8N=PD'\/&#G'% &1#X$NH5>-K^*1"+8K)$)()HY(K<PEHW5CL/0\A@060@@
MYJ6+P=JD,\S#5+202W5O<NS6A4L4MA P&UALR5#C:1W7H3G5M_$ZW6Q8M,U
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ME10)#\P8@CL0>#GBM>WUN*\LKB]M4:>VBA65)(V4B8-&) $R1_"5Y.!R.>N
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MSW!)DFB">603R2!#&<=]G.><Y_B.#2['4?"$'E6=O!%J4FV/:J*B?9;C.!T
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MK'<21A=D#%"XWY(;IMY (RP'KC+\4>'KO6;AFB\B:WET^>S:&=BOE.Y4K*I
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A -+10 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=?10 #I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKF>*"(,J[Y7"KN8A5&3W)( ]210!+1110 4444 %%%% !12,RHI9B%4#)).
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MQM;"DLYW%<910>#@Z&L^(HM+N[6QCB^T:A=K(T%MYJQEP@R0"W&22  >I/4
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ME '$PZGX@*SVUQ=7Z01RZA$M\EF&EWHR&WRH3:05,F"%PQ51G)PT-KJ_BO\
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MU"\L[9/)%I)I<BRIM=I5N+LQ.A5A@?*I []\B@"K8^";Z+4[.XNDT^2&._\
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M@C-B]K%9Q6EY:R&0193;B1 N QXQM88.%Y&VMV+Q-9S:%I>JHDNS5!#]EB8
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M& 2& X9>N:RY_'^G6]I%<M9WKQ7-M%=VA1%)N(7D2/<N6&"#+&2&P<., G<
M 7I+.:V\:1ZCAWM[NQ%H6 )$3HY=<X[,'?DX * 9RPK*FT74+/PAK^G-''+<
MZI/=_9UA9F4&X+8WG:-H7=R>> ?I6[/K9MH=/$UE/'>WSF.&S9D+[@C.06#%
M1A4/.2.GK6*/B)ISP^='8:@\*I;/(WEH/+$TKP@$%\Y62-E8#TR,B@!?%?A2
M]UO1ET^TFM1_Q+Y[,S3@AP750K!@"=N4^9> <@G.W:;VM:+=ZEJ6E7T:VDC6
M:SK)!<9V.)(]IYP<X],#()Y%4SXMAN+VR @U.%S=75M);QI$X9X8V8JV"S'(
M&5V'K@'T+X?'>G3P6,T<;F.^D,=N_F1[7<;/D#;L;\N1L.&)CDP#MY ,JU\
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M<DC ".&+=,<9+$*=; QBN$E\-W6_5GCT]3+<:W8WT4H9 6BA-OO).[.3Y,A
M)YWC/).*5KX2UJU0&PAAL[LV^HQF9W4AO-NUF@1R"25"!U/7:9#C.30!W^HW
ML.F:9=:A.)##:PO-((P68JH).!W/%5WUFUC;25*R_P#$T?9 0O /E-+\WI\J
M-^-</?>$]6N]+\I-+M1!<VU\DFGR7F]()Y@FR9?EV<%7R%"X\TD9);/0ZGH4
MUYIGAN*YL[>\2PF5[RV)#K(OV:6$A=X ;YI ><9 /?B@#J,"J3ZG;QZW!I++
M+]HGMY+E&V_)M1D5AGUS(O%<3HWA>*PU&RT])[*YE6TCBUF -O95C;S+;DC)
MQS&-V"Z '^# W/$FF:A?:H)[*WCD"Z1?6@,LQC4RS&$H"5(<#]TV2N",C![@
M Z?:/\FC _R:\YMO ]^\KR3PVR(U[/&Z.X;=8W$2^8@ 0*&$@# 8QD-USD])
MX>T.\T[PR]E/<QKJ+1F$W<* \(OEQ/@]]BJQ'3<6QQ0!T6*KW=Y;V8A$S'=-
M((HD4$M(YR< #KP"3V !)P 2//IO!E_</IXN+& P1O9"^MEE!CG>(2"68YQN
M#*RK\PW,!AA@"NFU.U^R>(?#]XH"Z=;K/:M&!\L;NJB-SV &QDSZR@=S0!?N
M?$.EV=[<VDUP1+:0+<7&%8B*-B0&8CH."3Z#DX'-:F!_DUQ$6B7F@:Y>ZM?7
MK:A8G3! RF%/-N)3)(Q7:!R6+\ =2V,=*FG\/:G)X+T'29([>ZN+:**&\:24
MX.+=HRPR"'^<C(93QD@;@I !U=Q=6]IY?GRK'YL@BCW-C>YZ*/4__7J8 =:X
MN70-2N?#/A.&YMX;C4-+FM9+D2R[B=D91R'(.3D@^^#U-8S^![[_ (0V+3(-
M-LTO)WNOM4LDV&^99A$Q(R'QY@'S9VC[HR 0 >FX%&!7G%MX6U9;P7LFG+]J
M;49+AG%T WE/8>0R^8#N&Z8*YQ_=#=0!45]X.UV3P[/IL$-HX9+E8)FD$<J,
M846)W55\LL&5AN500!&1M)>@#T:ZN;>RM);JZE2*WB4O)*[85%'))/841SE[
MJ6 P2J(PI$C8VOG/"\YXQSP.HK@==\*:OK5CKEO<Z?83SS13M97KW!#CS$P(
M&7&,*0.<E?E5L;LD6[C0-4?Q%=:A%:QI9R/9.]HTB[;A(XY%>/T&#(C+D $Q
M@$@'- '<X'^36?JFK6^E+;J\4L\]P[)!;P %Y65&<@9('W4;J1Z=2*\^OO V
MJ/:7$45NDCKILL-EF8?Z-(;DRPJI)X\I"JAATV\>E=;KNER:AK_AV]2Q6:.Q
MN))9RVS*JT+H ,GD[F4\>F>N* .BB=9H4D4.%=0P#J5.#Z@\@^QK,OO#]KJ-
MS++/-=-#/&(Y[;SCY,R#.%93VY.0,;NC9%<;IW@N[L_#VF6LFG6TI%A-;7]J
M90OF3L$$<^\9W%0A7.=RJ_'3:61^"M1&I)/=Q"]D34K65KN1U#2PK:+#,2,\
M;V4EE_B!&<]* /2^M4-9U6VT'1KO5;M93;VD1ED$2EFVCK@5S=KX6N;GX:-X
M?NU2"Z59/LQ8AU@82,\!&,C"_)QV"XZ5FZAX,U271O$<06U>?4[5Y(8D( BN
MYD"2@$X 0;%(;[QWOGW .^FF,,D"B"67S9-A:/!$?RD[FR>G&.,\D57U'5;;
M3);&*X$I:]N1;1;%)&\JS<GL,*:Y)_#>H#5_-M+06L UTW\94IB.-K+R6;:#
M@GSB7([Y)ZG%58?"VISV^D_;](LDGAN[?[<8+HR+<K''*C2,' R6,@X(+$<,
M3@"@#O[FX@LX?.N)5BC#!=SM@9)  ^I)  [D@57TO5;;5H[F2V$@%O<R6S^8
MNWYT.&Q[9Z&N2;PS?R?#.TT22TB>\M;B&189'4KLCN5DV@\@?NQM';MP*I-X
M2UO[?+=6:)97LMSJ)%XLBDHDR'RN^2H?:VWU7.,T >D8'3^M9?\ ;=N=8NM,
MBMKJ2YMA TNU/E"REPK9)&0-C9QT]S65I>C:BOA[5HDABT?4+T2>7Y,_G+%*
M8]HD&%51R <!1G&3RQQST/A#5%U&*[72[2T7SM,9XH+@-@V[2^8V<#(*LN,\
MGC('8 ]*P.*KWQM(K"XEO72.UC1I)G=]JJ@Y8L?3 Y]J\^3P=J%OHR)%I=I*
MTT]VM]:R2K&T\4DSO"WF[6YC5R,=M[8.0,V-0\(:IJ.FZW87-I97$TEK=1V>
MHR7#F1Q*A"1.I'1"%^8D_<5L%B2 #N+FR@O4A\U/GAD$L3 X:-QD9!'3@D'L
M02#D$BEOK*'4+.2TN 6AE&V1=Q&Y>ZG'8]#Z@FN4NO#^H7.H_:#!&H-U:7-J
MZN ]DD>T2P#&.'4.O!(/G.#@ %GZ%X8N].^&ITBV6.PUJ73S"]PC<BX\O8LA
M=>3C"X/4 #IC% '16FJ6UWJE_I\2R">Q\L2EEPIWKN&T]^*LW4QMK9YE@FG*
M\^7%@LWTR0/UKSF3PKK:S7MS;:+IL5E=/ )]*%RH$BB%HVPWEE1ABI&1\PSG
M:0*?>^"KN:R\1'[#'+>W*VT=G.\^]]JQQ*_SL=PRT>23RW!.3T /2,#CVILC
M"*-G(9@H)PH))^@[UR,WA6Z^V:V]A+;VT=VK7=DY3+VU\\31,XP.%P%;CDLS
MU2A\.ZF3:7$NDV:0_:WDO-+-UYD<FZ,1B4'8$&.3LVC()8DOQ0!U%DUKK]GI
MFM0O<"WFMUGAB9RJLKA74NG0L,#'IDUK5Q\.A:E%X#\/:,]M:S36B6L-VAF.
MW;&H5F7C#<@':P(Z]2!GG-.\&:U;16DEQ9QM>6S:2%G6X#$"W^6=E)((W("O
M^T&P>,T >I!0.E&/K^=*.E% "8'^32]*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** &NXC1G()"@D[02?P Y-<Q9^-]+^QV?G7%Q<22
M6]G(\\5C(J-]IR(GV\X#,,8!."0#T..H890@,5XZCJ*Y6W\!V%O:QV\>H:AM
MBAL(%),>0MG(9(OX.NX\^OM0!._CG1TB5L7K.4N':)+21F00.$FW8&!M)'?G
MC&<C,J>,='FN)8H99I5C=(S,D#>4SR",QJKXVDL)4(P<8.>E93^#7BUV+[/<
MWOV&6+4?M$H>(.KW,D4A5?EX7Y'YQD97GKC2C\'Z9#!>0QO.D=Q<07,87:/L
MTD*1I&8_EX $2<-N!P0<@D$ ;+XYT6%<$W;RJD[R11VKNT7DLJRAL# *[A]0
M01G<N7W7C?0;02.]Z'B2WDN?-A'FJR1@,^-N3D Y]^<9VMBA<>$B^N6Y@DN4
MM9+2]CO+E&C$DDD[PGGCCB(C*@$?+COBR_@>Q-GJ5A#?ZA;Z;?PR1-8Q2)Y4
M.]-C-'E202,\$E<L3MSS0!H77B2QLM-BOKJ.\ABEN5MD5K23>79]B_*!D G&
M#CG([D"JI\;:&ME'=/<LBF1HI(V7$D++)Y;;U/(P_!QGN?N@FG>*=+N]2TFR
MMK3?)+%J%I.[Y4$+%,CLW/&<*<#'4CM4<?@^TAN8;JUOM0M9U,GVAX9%!NP\
MGF.),J>K$X*;2H8A2!0 H\:Z2\A1%O6/G20*?LKCS)(R_F*F0-[+Y;?*,D]@
M34U[XNTC3VE^T32+%$95:98F9#)&A=XP0.6"AC@?W6 Y4@5IO!6G76D3Z7<7
M-U-:3W$]Q(DGEG+2N9&_@XPQ)4_>7L:+WP1IE[%=0O-=I;W#RS>2CKMBEEC:
M-Y%RI.XJ[\$E<L3C/- $\?B_3)8[EHUNR\#(&C-NP8AT,BMR  I4$Y) &"#@
MT:/KQU?6[F.WDBETUM-L[^TD6-E9EF,PYS[1*1P",G-0#P7:"X:<:CJ D9[=
MSAH\'R8R@!&S!!#$G/1@"NT@8L:'X6M= :,V]W=RB.PM]/43%"/+A+[#\JCY
MOWC ]CQQ0!1TCQE;NC0ZQ(L%S]HO(DD$31Q2B"X>+"DDY;:%.,\Y..AQ-)X[
MT2*W>5GN3Y<4\TBI SE$A95E)(R/EWJ>"<@@C.1E)_ ^F74$L,\]XZ-+<30_
MO IMY)I#(SQE0"&#$E222,TMWX-AOX2E[JVIW$C65S8R3.T09XY]F\X$84$>
M6F-H XY!))( [5_&>FZ8DZ1DW%RD,DD<:$8=TB,I0G^$[!NR1C&<9/%91\8W
M6FV-S>7Y^U2+8P7:V,-MY3QB1MF3*9"K*7S@#D*!G<>NF_@ZW(OHUU74D@OH
M3'/ CQ[&<QB,RXV<,5'3[N>=N>:;<^"+&[BECEOK[$NGQ:>2#&"$C<NKCY/O
M9/T]J .D+[83(RL,+N*XR?I@9R?I6!X=\2_VQ.MJ(WE"Z;:7HO0@C2X$V_!6
M/<63_5G@\CD>A.I8VMW ERMS?2W!DE+1,X3,:X "C:BCJ">0>O4UGZ)X4M=!
ME@>VO+QUAT^#3PDI0AHX2YC8X4'</,8<$ ^F>: ,_2?&L+2W,&L.MNZ7=Y%%
M,(62%D@9LC<21N"*6//(#8Z$"R?%UA-?VL,%TZDSS12PBU>4L4A\W ="5'RE
M6&-V[H!D'"R>"M)N$NH;IKBXMKB6YE\AW 6-IU99"I4!N0[@9)QO..V'IX37
M=I\EQK.J74UBTC1S3M$6;?&8_FQ&!PI., 9/)S0 EKXVT:\A22%[@F5+:2!'
MA9&F6XSY17.,Y*N.V-I)P.:+OQ?9Q^%FU^S@GNX XB$87RW#^9Y1!#XQA^#]
M#C-95]X(:STVW@TN:[G$=O9V;I))"&\FV+M&5W1,I?<V3N !'3! K4A\.S7O
MA)]&U6X90S?(\"QJ\2JX9!P@0L,#H@7M@]2 0VOBV.#6-3L=6=85BOVM[>80
MLL846L=QM=LD!@ID.<@83MQG7T[7+'5!=_9G9FM'VRKMR1E0P(QG=D$=,]P<
M$$#-NO!5A>S3/=75Y,L]X;R6-B@5V-M]E93A =IC)'&#GG-:6D:2^E61MVU.
M_OFP%6:\=7D50, 9"@''J022>2: ,>W\<:5#IEG+<W4UP\EG;W4D\5E(J&.4
M[5D(YV@MVR2!UJ6'QI8C1Y-1OXI+/9-=1F%V1G*P2-&[ *3G&WH,G)P,Y&:H
M^'FG#3EL1J&HB)=.@TX'=%N\J)]Z'[GWN<'MCMGFK)\&6X:.6WU74[:>*YN;
MB*:%XPR+</YDL6"A#(6P?F!8$### H )O'6D(95B6\F:,SHNVW91(\*;W16?
M:N=N2"2 <'!I;#Q7;W#++<2&$R6EG*+0PG<KSLX3#YP^XC& !MVDD\\-;P/I
M[S>8]Y?,/M5Q=%"Z8+31F-AG;G 4G'.<GDFEC\$62!-]]?2O';VL$<C&,,GV
M=V>)QA -P+L#V(."",T +-X[T."%Y'>Y_=0SS3*MLY,*P.J3;L# *%@2/3!&
M05SKWNJVUB(0V^6:?=Y,,0R\F%+' ]@#U]AU(!QKKP-IUW%.CW5XGVBTN[69
MD,8,@N2IE<_)][Y%QV &,5IWNAPWIL93<3Q75B28;F+:'&5VL""I4@CJ",9
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M/0=S5"+PA"EG96LNK:I<K9W,5Q"T\B,P$?W(R=G*\G)/SGNQP* *D/C[2(+
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M"U@ENXK02!XD*JVY&*L"2<8!'4$Y'(W9&:^G>*Q_;>H:=JG[HIJ#6MK(L)5
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MT>1 JQ"T9U90=H'E;<D CIMXQ5P:3IBSB<:?9B82F82"%=PD(P7SC[Q'&>M
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M,HS9&2<'C/(S0!D>&M>O-8\0WJ27-M)9C3;*XA2*)EP\IFW\MACS'T*@C &
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M#TWD# Y[].:9#9>);C1A(8=8M=0+Q^=%=W2/$T@AD5ROE.'6-F* %6!#!7V
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M5<?+P*AO]%UL75U>6%MJT4HT^V%ONN]T@=;N1VC=@WS;8W'!++CC+8S7IM%
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MSJ'EF'!83K,KQE@P_P">[X88Z+QP28SX(S!:J;_=+:K9PPRO#SY-O,LRJP#
M%F**&;@<<*.:Z^B@#FF\*>9X2UG09;PE=2>[;SEBP8_M#NYXR<X+GN,@5#)X
M/FN;[[5<7\;EM2749$6W*AB+46S(/G) *\@]0?6NKHH P?#/AYO#ED\#W?VH
M!5CC<6Z1MY: [0VW[[\G+<9]!SGG?#W@F>7P[H$NJ.]OJ>FV4$,"!!_H[(ZN
MP;#$2!BB@\C@<;2<CT"B@#F?^$,LF^RO*[--'>3W5PRJ MQYP821LIS^[.5^
M7G[BY)/-5'\!JEEI,%IJ,B/IT<D DN8([CS87V95@P^\!'&%;MMY!!(KL:*
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MLV<\',@)/WE;9SQNN7WA.XGU.:ZL;Z.UC>TM+9$:(R%5@F:3KN!^8.5R"""
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M4[<$,"#PWWE%:NN>&WU6Z-Q#<I$9+&>PECEC\Q&CEVDD#(PP*_0@X/8CH**
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44A(! )Y/2@L%QDX
MSTH 6BDR* 0: %HHI RDX!Y]* %HI"0*"ZJ"2< =2: %HI 0P!!R#T(I: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1CM4G!./
M2@#F_$E]<VT4]U:-$LEF(D7S6"JSRR*I )!"OLX4L-H,@W<9J?0KM]96WOI
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4449% !11FDR* %HHS10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "-]PY&X8Z>M<1:>&;R*TT/Y&BE
ML+"*"=%F R8T=0D1'W-Q;YFR,J%&,_=[2X_X]I?GD3Y#\T:Y9>.H&#D_@:XR
MRCO%_LB5)-:,$1N6N4G$X<0,)"BG=GS&5@BC(,A^5@V,[P!]IX82SN-+0:3'
M)%9PSJLZM'%($?S-L)"@ C:_/8MM8DE<F.R\-30/I)@TBWL)[7SW6X21'%LT
MGF?NU4 9C_>,0HP.(\_=-3:7'JL$^GQ7<E^(EL;U)909),GSH_(;YLG>8PY
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>bivi-20210930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6Ips7xRiXgen8uHZH0sSayJSbPtzpN22ekhtWp6fZlqfycsyAY5aC62bRWmkc4J -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:bivi="http://nanoantibiotics.com/20210930" elementFormDefault="qualified" targetNamespace="http://nanoantibiotics.com/20210930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://nanoantibiotics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/BalanceSheet" id="BalanceSheet">
	  <link:definition>00000002 - Statement - Condensed Balance Sheet (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/BalanceSheetParenthetical" id="BalanceSheetParenthetical">
	  <link:definition>00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit" id="StatementsOfChangesInStockholdersEquityDeficit">
	  <link:definition>00000006 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical" id="StatementsOfChangesInStockholdersEquityDeficitParenthetical">
	  <link:definition>00000007 - Statement - Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/BackgroundInformation" id="BackgroundInformation">
	  <link:definition>00000008 - Disclosure - Background Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/Liquidity" id="Liquidity">
	  <link:definition>00000009 - Disclosure - Liquidity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000010 - Disclosure - Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000011 - Disclosure - Intangible Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000012 - Disclosure - Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/OtherLiabilities" id="OtherLiabilities">
	  <link:definition>00000013 - Disclosure - Other Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactions" id="EquityTransactions">
	  <link:definition>00000014 - Disclosure - Equity Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000015 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
	  <link:definition>00000016 - Disclosure - Employee Benefit Plan</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000017 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000018 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
	  <link:definition>00000019 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000020 - Disclosure - Intangible Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactionsTables" id="EquityTransactionsTables">
	  <link:definition>00000021 - Disclosure - Equity Transactions (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" id="LiquidityDetailsNarrative">
	  <link:definition>00000022 - Disclosure - Liquidity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" id="SignificantAccountingPoliciesDetails">
	  <link:definition>00000023 - Disclosure - Significant Accounting Policies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
	  <link:definition>00000024 - Disclosure - Intangible Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" id="IntangibleAssetsDetails2">
	  <link:definition>00000025 - Disclosure - Intangible Assets (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000026 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/OtherLiabilitiesDetailsNarrative" id="OtherLiabilitiesDetailsNarrative">
	  <link:definition>00000027 - Disclosure - Other Liabilities (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails" id="EquityTransactionsDetails">
	  <link:definition>00000028 - Disclosure - Equity Transactions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails2" id="EquityTransactionsDetails2">
	  <link:definition>00000029 - Disclosure - Equity Transactions (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails3" id="EquityTransactionsDetails3">
	  <link:definition>00000030 - Disclosure - Equity Transactions (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails4" id="EquityTransactionsDetails4">
	  <link:definition>00000031 - Disclosure - Equity Transactions (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" id="EquityTransactionsDetailsNarrative">
	  <link:definition>00000032 - Disclosure - Equity Transactions (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EmployeeBenefitPlanDetailsNarrative" id="EmployeeBenefitPlanDetailsNarrative">
	  <link:definition>00000033 - Disclosure - Employee Benefit Plan (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="bivi_AcuitasGroupHoldingsLLCMember" name="AcuitasGroupHoldingsLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption1Member" name="StockOption1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption2Member" name="StockOption2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption3Member" name="StockOption3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption4Member" name="StockOption4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption5Member" name="StockOption5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption6Member" name="StockOption6Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption7Member" name="StockOption7Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption8Member" name="StockOption8Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption9Member" name="StockOption9Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption10Member" name="StockOption10Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption11Member" name="StockOption11Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption12Member" name="StockOption12Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption13Member" name="StockOption13Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption14Member" name="StockOption14Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption15Member" name="StockOption15Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOption16Member" name="StockOption16Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_TotalOtherExpenseIncome" name="TotalOtherExpenseIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DeemedDividend" name="DeemedDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_InterestExpenseFromConvertibleDebenture" name="InterestExpenseFromConvertibleDebenture" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_PaymentOfConvertibleDebentureRelatedParty" name="PaymentOfConvertibleDebentureRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ProceedsFromConvertibleDebentureRelatedParty" name="ProceedsFromConvertibleDebentureRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedParty" name="RedemptionOfWarrantsAndPurchaseOptionRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares" name="RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DeemedDividendForCommitmentShares" name="DeemedDividendForCommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DeemedDividendForPurchaseOptionRelatedPartyInShares" name="DeemedDividendForPurchaseOptionRelatedPartyInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ProceedsFromIssuanceOfCommonStockNetOfCost" name="ProceedsFromIssuanceOfCommonStockNetOfCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureLiquidityAbstract" name="DisclosureLiquidityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_LiquidityTextBlock" name="LiquidityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureEmployeeBenefitPlanAbstract" name="DisclosureEmployeeBenefitPlanAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_EmployeeBenefitPlanTextBlock" name="EmployeeBenefitPlanTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract" name="DisclosureSignificantAccountingPoliciesDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIntangibleAssetsDetailsAbstract" name="DisclosureIntangibleAssetsDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIntangibleAssetsDetails2Abstract" name="DisclosureIntangibleAssetsDetails2Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureEquityTransactionsDetailsAbstract" name="DisclosureEquityTransactionsDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock" name="FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureEquityTransactionsDetails2Abstract" name="DisclosureEquityTransactionsDetails2Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureEquityTransactionsDetails3Abstract" name="DisclosureEquityTransactionsDetails3Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureEquityTransactionsDetails4Abstract" name="DisclosureEquityTransactionsDetails4Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock" name="LoanPursuantToPaycheckProtectionProgramPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>24
<FILENAME>bivi-20210930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Cover" xlink:href="bivi-20210930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheet" xlink:href="bivi-20210930.xsd#BalanceSheet" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheetParenthetical" xlink:href="bivi-20210930.xsd#BalanceSheetParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfOperations" xlink:href="bivi-20210930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfCashFlows" xlink:href="bivi-20210930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="bivi-20210930.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical" xlink:href="bivi-20210930.xsd#StatementsOfChangesInStockholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BackgroundInformation" xlink:href="bivi-20210930.xsd#BackgroundInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Liquidity" xlink:href="bivi-20210930.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:href="bivi-20210930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssets" xlink:href="bivi-20210930.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:href="bivi-20210930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/OtherLiabilities" xlink:href="bivi-20210930.xsd#OtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactions" xlink:href="bivi-20210930.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:href="bivi-20210930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EmployeeBenefitPlan" xlink:href="bivi-20210930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SubsequentEvents" xlink:href="bivi-20210930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:href="bivi-20210930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:href="bivi-20210930.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:href="bivi-20210930.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsTables" xlink:href="bivi-20210930.xsd#EquityTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" xlink:href="bivi-20210930.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:href="bivi-20210930.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:href="bivi-20210930.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:href="bivi-20210930.xsd#IntangibleAssetsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="bivi-20210930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/OtherLiabilitiesDetailsNarrative" xlink:href="bivi-20210930.xsd#OtherLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails" xlink:href="bivi-20210930.xsd#EquityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails2" xlink:href="bivi-20210930.xsd#EquityTransactionsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:href="bivi-20210930.xsd#EquityTransactionsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails4" xlink:href="bivi-20210930.xsd#EquityTransactionsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" xlink:href="bivi-20210930.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="bivi-20210930.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheet" xlink:title="00000002 - Statement - Condensed Balance Sheet (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheetParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_TotalOtherExpenseIncome" xlink:label="loc_biviTotalOtherExpenseIncome" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaapGainLossOnSaleOfDerivatives" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biviTotalOtherExpenseIncome" xlink:to="loc_us-gaapGainLossOnSaleOfDerivatives" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biviTotalOtherExpenseIncome" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biviTotalOtherExpenseIncome" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_biviTotalOtherExpenseIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="loc_us-gaapIncomeLossAttributableToParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossAttributableToParent" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DeemedDividend" xlink:label="loc_biviDeemedDividend" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossAttributableToParent" xlink:to="loc_biviDeemedDividend" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_PaymentOfConvertibleDebentureRelatedParty" xlink:label="loc_biviPaymentOfConvertibleDebentureRelatedParty" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_biviPaymentOfConvertibleDebentureRelatedParty" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_ProceedsFromConvertibleDebentureRelatedParty" xlink:label="loc_biviProceedsFromConvertibleDebentureRelatedParty" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_biviProceedsFromConvertibleDebentureRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000006 - Statement - Statements of Changes in Stockholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical" xlink:title="00000007 - Statement - Statements of Changes in Stockholders&apos; Equity (Deficit) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BackgroundInformation" xlink:title="00000008 - Disclosure - Background Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Liquidity" xlink:title="00000009 - Disclosure - Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssets" xlink:title="00000011 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/OtherLiabilities" xlink:title="00000013 - Disclosure - Other Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactions" xlink:title="00000014 - Disclosure - Equity Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EmployeeBenefitPlan" xlink:title="00000016 - Disclosure - Employee Benefit Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:title="00000020 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsTables" xlink:title="00000021 - Disclosure - Equity Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" xlink:title="00000022 - Disclosure - Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:title="00000024 - Disclosure - Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:title="00000025 - Disclosure - Intangible Assets (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000026 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/OtherLiabilitiesDetailsNarrative" xlink:title="00000027 - Disclosure - Other Liabilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails" xlink:title="00000028 - Disclosure - Equity Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails2" xlink:title="00000029 - Disclosure - Equity Transactions (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:title="00000030 - Disclosure - Equity Transactions (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails4" xlink:title="00000031 - Disclosure - Equity Transactions (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000032 - Disclosure - Equity Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000033 - Disclosure - Employee Benefit Plan (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>bivi-20210930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Cover" xlink:href="bivi-20210930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheet" xlink:href="bivi-20210930.xsd#BalanceSheet" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheetParenthetical" xlink:href="bivi-20210930.xsd#BalanceSheetParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfOperations" xlink:href="bivi-20210930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfCashFlows" xlink:href="bivi-20210930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="bivi-20210930.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical" xlink:href="bivi-20210930.xsd#StatementsOfChangesInStockholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BackgroundInformation" xlink:href="bivi-20210930.xsd#BackgroundInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Liquidity" xlink:href="bivi-20210930.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:href="bivi-20210930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssets" xlink:href="bivi-20210930.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:href="bivi-20210930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/OtherLiabilities" xlink:href="bivi-20210930.xsd#OtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactions" xlink:href="bivi-20210930.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:href="bivi-20210930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EmployeeBenefitPlan" xlink:href="bivi-20210930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SubsequentEvents" xlink:href="bivi-20210930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:href="bivi-20210930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:href="bivi-20210930.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:href="bivi-20210930.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsTables" xlink:href="bivi-20210930.xsd#EquityTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" xlink:href="bivi-20210930.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:href="bivi-20210930.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:href="bivi-20210930.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:href="bivi-20210930.xsd#IntangibleAssetsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="bivi-20210930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/OtherLiabilitiesDetailsNarrative" xlink:href="bivi-20210930.xsd#OtherLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails" xlink:href="bivi-20210930.xsd#EquityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails2" xlink:href="bivi-20210930.xsd#EquityTransactionsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:href="bivi-20210930.xsd#EquityTransactionsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails4" xlink:href="bivi-20210930.xsd#EquityTransactionsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" xlink:href="bivi-20210930.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="bivi-20210930.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheet" xlink:title="00000002 - Statement - Condensed Balance Sheet (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheetParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000006 - Statement - Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedParty" xlink:label="loc_biviRedemptionOfWarrantsAndPurchaseOptionRelatedParty_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviRedemptionOfWarrantsAndPurchaseOptionRelatedParty_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares" xlink:label="loc_biviRedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviRedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DeemedDividendForCommitmentShares" xlink:label="loc_biviDeemedDividendForCommitmentShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviDeemedDividendForCommitmentShares_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DeemedDividendForPurchaseOptionRelatedPartyInShares" xlink:label="loc_biviDeemedDividendForPurchaseOptionRelatedPartyInShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviDeemedDividendForPurchaseOptionRelatedPartyInShares_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_50" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical" xlink:title="00000007 - Statement - Statements of Changes in Stockholders&apos; Equity (Deficit) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BackgroundInformation" xlink:title="00000008 - Disclosure - Background Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Liquidity" xlink:title="00000009 - Disclosure - Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssets" xlink:title="00000011 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/OtherLiabilities" xlink:title="00000013 - Disclosure - Other Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactions" xlink:title="00000014 - Disclosure - Equity Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EmployeeBenefitPlan" xlink:title="00000016 - Disclosure - Employee Benefit Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:title="00000020 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsTables" xlink:title="00000021 - Disclosure - Equity Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" xlink:title="00000022 - Disclosure - Liquidity (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:title="00000024 - Disclosure - Intangible Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:title="00000025 - Disclosure - Intangible Assets (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000026 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_AcuitasGroupHoldingsLLCMember" xlink:label="loc_biviAcuitasGroupHoldingsLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_biviAcuitasGroupHoldingsLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/OtherLiabilitiesDetailsNarrative" xlink:title="00000027 - Disclosure - Other Liabilities (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails" xlink:title="00000028 - Disclosure - Equity Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails2" xlink:title="00000029 - Disclosure - Equity Transactions (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:title="00000030 - Disclosure - Equity Transactions (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption1Member" xlink:label="loc_biviStockOption1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption2Member" xlink:label="loc_biviStockOption2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption3Member" xlink:label="loc_biviStockOption3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption3Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption4Member" xlink:label="loc_biviStockOption4Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption4Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption5Member" xlink:label="loc_biviStockOption5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption5Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption6Member" xlink:label="loc_biviStockOption6Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption6Member_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption7Member" xlink:label="loc_biviStockOption7Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption7Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption8Member" xlink:label="loc_biviStockOption8Member_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption8Member_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption9Member" xlink:label="loc_biviStockOption9Member_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption9Member_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption10Member" xlink:label="loc_biviStockOption10Member_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption10Member_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption11Member" xlink:label="loc_biviStockOption11Member_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption11Member_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption12Member" xlink:label="loc_biviStockOption12Member_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption12Member_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption13Member" xlink:label="loc_biviStockOption13Member_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption13Member_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption14Member" xlink:label="loc_biviStockOption14Member_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption14Member_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption15Member" xlink:label="loc_biviStockOption15Member_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption15Member_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption16Member" xlink:label="loc_biviStockOption16Member_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption16Member_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_340" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_340" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_340" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_340" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails4" xlink:title="00000031 - Disclosure - Equity Transactions (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2_40" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000032 - Disclosure - Equity Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000033 - Disclosure - Employee Benefit Plan (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>bivi-20210930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_AcuitasGroupHoldingsLLCMember" xlink:label="bivi_AcuitasGroupHoldingsLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AcuitasGroupHoldingsLLCMember" xlink:to="bivi_AcuitasGroupHoldingsLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_AcuitasGroupHoldingsLLCMember_lbl" xml:lang="en-US">Acuitas Group Holdings L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption1Member" xlink:label="bivi_StockOption1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption1Member" xlink:to="bivi_StockOption1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption1Member_lbl" xml:lang="en-US">Stock Option 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption2Member" xlink:label="bivi_StockOption2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption2Member" xlink:to="bivi_StockOption2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption2Member_lbl" xml:lang="en-US">Stock Option 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption3Member" xlink:label="bivi_StockOption3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption3Member" xlink:to="bivi_StockOption3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption3Member_lbl" xml:lang="en-US">Stock Option 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption4Member" xlink:label="bivi_StockOption4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption4Member" xlink:to="bivi_StockOption4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption4Member_lbl" xml:lang="en-US">Stock Option 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption5Member" xlink:label="bivi_StockOption5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption5Member" xlink:to="bivi_StockOption5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption5Member_lbl" xml:lang="en-US">Stock Option 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption6Member" xlink:label="bivi_StockOption6Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption6Member" xlink:to="bivi_StockOption6Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption6Member_lbl" xml:lang="en-US">Stock Option 6 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption7Member" xlink:label="bivi_StockOption7Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption7Member" xlink:to="bivi_StockOption7Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption7Member_lbl" xml:lang="en-US">Stock Option 7 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption8Member" xlink:label="bivi_StockOption8Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption8Member" xlink:to="bivi_StockOption8Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption8Member_lbl" xml:lang="en-US">Stock Option 8 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption9Member" xlink:label="bivi_StockOption9Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption9Member" xlink:to="bivi_StockOption9Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption9Member_lbl" xml:lang="en-US">Stock Option 9 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption10Member" xlink:label="bivi_StockOption10Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption10Member" xlink:to="bivi_StockOption10Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption10Member_lbl" xml:lang="en-US">Stock Option 10 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption11Member" xlink:label="bivi_StockOption11Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption11Member" xlink:to="bivi_StockOption11Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption11Member_lbl" xml:lang="en-US">Stock Option 11 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption12Member" xlink:label="bivi_StockOption12Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption12Member" xlink:to="bivi_StockOption12Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption12Member_lbl" xml:lang="en-US">Stock Option 12 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption13Member" xlink:label="bivi_StockOption13Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption13Member" xlink:to="bivi_StockOption13Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption13Member_lbl" xml:lang="en-US">Stock Option 13 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption14Member" xlink:label="bivi_StockOption14Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption14Member" xlink:to="bivi_StockOption14Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption14Member_lbl" xml:lang="en-US">Stock Option 14 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption15Member" xlink:label="bivi_StockOption15Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption15Member" xlink:to="bivi_StockOption15Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption15Member_lbl" xml:lang="en-US">Stock Option 15 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption16Member" xlink:label="bivi_StockOption16Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOption16Member" xlink:to="bivi_StockOption16Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOption16Member_lbl" xml:lang="en-US">Stock Option 16 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">OTHER&#160;&#160;ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#146; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Current portion of other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#146; EQUITY :</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 800,000,000 shares authorized at September 30, 2021 and June 30, 2021, respectively; 24,962,373 and 22,333,324 shares issued and outstanding at September 30, 2021 and June 30, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#146; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#146; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">TOTAL OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">OTHER EXPENSE (INCOME) EXPENSE:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_TotalOtherExpenseIncome" xlink:label="bivi_TotalOtherExpenseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_TotalOtherExpenseIncome" xlink:to="bivi_TotalOtherExpenseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="bivi_TotalOtherExpenseIncome_lbl" xml:lang="en-US">TOTAL OTHER INCOME, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET (LOSS)/INCOME</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DeemedDividend" xlink:label="bivi_DeemedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividend" xlink:to="bivi_DeemedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DeemedDividend_lbl" xml:lang="en-US">Deemed dividends - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="us-gaap_IncomeLossAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">- Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">- Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">- Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">- Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net (loss)/income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash used in operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Stock based compensation - restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock option based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_InterestExpenseFromConvertibleDebenture" xlink:label="bivi_InterestExpenseFromConvertibleDebenture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_InterestExpenseFromConvertibleDebenture" xlink:to="bivi_InterestExpenseFromConvertibleDebenture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_InterestExpenseFromConvertibleDebenture_lbl" xml:lang="en-US">Interest expense from convertible debenture</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_PaymentOfConvertibleDebentureRelatedParty" xlink:label="bivi_PaymentOfConvertibleDebentureRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_PaymentOfConvertibleDebentureRelatedParty" xlink:to="bivi_PaymentOfConvertibleDebentureRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bivi_PaymentOfConvertibleDebentureRelatedParty_lbl" xml:lang="en-US">Payment of convertible debenture - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_ProceedsFromConvertibleDebentureRelatedParty" xlink:label="bivi_ProceedsFromConvertibleDebentureRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ProceedsFromConvertibleDebentureRelatedParty" xlink:to="bivi_ProceedsFromConvertibleDebentureRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ProceedsFromConvertibleDebentureRelatedParty_lbl" xml:lang="en-US">Proceeds from convertible debenture - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net cost of&#160;&#160;$2,224,992</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedParty" xlink:label="bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedParty" xlink:to="bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedParty_lbl" xml:lang="en-US">Redemption of warrants&#160;&#160;- related party</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares" xlink:label="bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares" xlink:to="bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares_lbl" xml:lang="en-US">[custom:RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DeemedDividendForCommitmentShares" xlink:label="bivi_DeemedDividendForCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividendForCommitmentShares" xlink:to="bivi_DeemedDividendForCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DeemedDividendForCommitmentShares_lbl" xml:lang="en-US">Deemed dividend for purchase option - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DeemedDividendForPurchaseOptionRelatedPartyInShares" xlink:label="bivi_DeemedDividendForPurchaseOptionRelatedPartyInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividendForPurchaseOptionRelatedPartyInShares" xlink:to="bivi_DeemedDividendForPurchaseOptionRelatedPartyInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DeemedDividendForPurchaseOptionRelatedPartyInShares_lbl" xml:lang="en-US">[custom:DeemedDividendForPurchaseOptionRelatedPartyInShares]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Cashless exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Shares, Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock based compensation - restricted stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock option based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetOfCost" xlink:label="bivi_ProceedsFromIssuanceOfCommonStockNetOfCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ProceedsFromIssuanceOfCommonStockNetOfCost" xlink:to="bivi_ProceedsFromIssuanceOfCommonStockNetOfCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ProceedsFromIssuanceOfCommonStockNetOfCost_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock, Net of Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Background Information</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureLiquidityAbstract" xlink:label="bivi_DisclosureLiquidityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureLiquidityAbstract" xlink:to="bivi_DisclosureLiquidityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureLiquidityAbstract_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_LiquidityTextBlock" xlink:label="bivi_LiquidityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LiquidityTextBlock" xlink:to="bivi_LiquidityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_LiquidityTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Other Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureEmployeeBenefitPlanAbstract" xlink:label="bivi_DisclosureEmployeeBenefitPlanAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureEmployeeBenefitPlanAbstract" xlink:to="bivi_DisclosureEmployeeBenefitPlanAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureEmployeeBenefitPlanAbstract_lbl" xml:lang="en-US">Employee Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_EmployeeBenefitPlanTextBlock" xlink:label="bivi_EmployeeBenefitPlanTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_EmployeeBenefitPlanTextBlock" xlink:to="bivi_EmployeeBenefitPlanTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_EmployeeBenefitPlanTextBlock_lbl" xml:lang="en-US">Employee Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation &#8211; Interim Financial Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Dilutive securities were excluded from the computation of diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract" xlink:label="bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract" xlink:to="bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">summary of the intangible assets as of September 30, 2021 and June 30, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureIntangibleAssetsDetailsAbstract" xlink:label="bivi_DisclosureIntangibleAssetsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIntangibleAssetsDetailsAbstract" xlink:to="bivi_DisclosureIntangibleAssetsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureIntangibleAssetsDetailsAbstract_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Future expected Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureIntangibleAssetsDetails2Abstract" xlink:label="bivi_DisclosureIntangibleAssetsDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIntangibleAssetsDetails2Abstract" xlink:to="bivi_DisclosureIntangibleAssetsDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureIntangibleAssetsDetails2Abstract_lbl" xml:lang="en-US">Intangible Assets (Details 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">activity relating to the Company&#8217;s stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureEquityTransactionsDetailsAbstract" xlink:label="bivi_DisclosureEquityTransactionsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureEquityTransactionsDetailsAbstract" xlink:to="bivi_DisclosureEquityTransactionsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureEquityTransactionsDetailsAbstract_lbl" xml:lang="en-US">Equity Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock" xlink:label="bivi_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock" xlink:to="bivi_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock_lbl" xml:lang="en-US">weighted-average assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureEquityTransactionsDetails2Abstract" xlink:label="bivi_DisclosureEquityTransactionsDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureEquityTransactionsDetails2Abstract" xlink:to="bivi_DisclosureEquityTransactionsDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureEquityTransactionsDetails2Abstract_lbl" xml:lang="en-US">Equity Transactions (Details 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xml:lang="en-US">summary of stock options outstanding and exercisable by exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureEquityTransactionsDetails3Abstract" xlink:label="bivi_DisclosureEquityTransactionsDetails3Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureEquityTransactionsDetails3Abstract" xlink:to="bivi_DisclosureEquityTransactionsDetails3Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureEquityTransactionsDetails3Abstract_lbl" xml:lang="en-US">Equity Transactions (Details 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xml:lang="en-US">summarizes warrant activity</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureEquityTransactionsDetails4Abstract" xlink:label="bivi_DisclosureEquityTransactionsDetails4Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureEquityTransactionsDetails4Abstract" xlink:to="bivi_DisclosureEquityTransactionsDetails4Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureEquityTransactionsDetails4Abstract_lbl" xml:lang="en-US">Equity Transactions (Details 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_WorkingCapital" xlink:label="bivi_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_WorkingCapital" xlink:to="bivi_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_WorkingCapital_lbl" xml:lang="en-US">[custom:WorkingCapital-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Intellectual Property</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intellectual Property, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xml:lang="en-US">Year ending June 30, 2022 (Remaining nine months)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Retention Bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_lbl" xml:lang="en-US">Weighted Average Contractual Term, Granted (in Years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_lbl" xml:lang="en-US">[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend Yield</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl" xml:lang="en-US">Weighted Average Remaining Life, at the end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US">Comtribuiton made by Company</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock" xlink:label="bivi_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock" xlink:to="bivi_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock_doc" xml:lang="en-US">Loan Pursuant to Paycheck Protection Program [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_2_lbl" xml:lang="en-US">Gain (Loss) on Sale of Derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_2_lbl" xml:lang="en-US">Interest Income, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_TotalOtherExpenseIncome" xlink:to="bivi_TotalOtherExpenseIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_TotalOtherExpenseIncome_2_lbl" xml:lang="en-US">TotalOtherExpenseIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossAttributableToParent_2_lbl" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_PaymentOfConvertibleDebentureRelatedParty" xlink:to="bivi_PaymentOfConvertibleDebentureRelatedParty_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_PaymentOfConvertibleDebentureRelatedParty_2_lbl" xml:lang="en-US">PaymentOfConvertibleDebentureRelatedParty</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LiquidityTextBlock" xlink:to="bivi_LiquidityTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_LiquidityTextBlock_2_lbl" xml:lang="en-US">LiquidityTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_EmployeeBenefitPlanTextBlock" xlink:to="bivi_EmployeeBenefitPlanTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_EmployeeBenefitPlanTextBlock_2_lbl" xml:lang="en-US">EmployeeBenefitPlanTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract" xlink:to="bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract_2_lbl" xml:lang="en-US">DisclosureSignificantAccountingPoliciesDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIntangibleAssetsDetailsAbstract" xlink:to="bivi_DisclosureIntangibleAssetsDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureIntangibleAssetsDetailsAbstract_2_lbl" xml:lang="en-US">DisclosureIntangibleAssetsDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureEquityTransactionsDetailsAbstract" xlink:to="bivi_DisclosureEquityTransactionsDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureEquityTransactionsDetailsAbstract_2_lbl" xml:lang="en-US">DisclosureEquityTransactionsDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>27
<FILENAME>bivi-20210930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Cover" xlink:href="bivi-20210930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheet" xlink:href="bivi-20210930.xsd#BalanceSheet" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheetParenthetical" xlink:href="bivi-20210930.xsd#BalanceSheetParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfOperations" xlink:href="bivi-20210930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfCashFlows" xlink:href="bivi-20210930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="bivi-20210930.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical" xlink:href="bivi-20210930.xsd#StatementsOfChangesInStockholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BackgroundInformation" xlink:href="bivi-20210930.xsd#BackgroundInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Liquidity" xlink:href="bivi-20210930.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:href="bivi-20210930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssets" xlink:href="bivi-20210930.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:href="bivi-20210930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/OtherLiabilities" xlink:href="bivi-20210930.xsd#OtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactions" xlink:href="bivi-20210930.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:href="bivi-20210930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EmployeeBenefitPlan" xlink:href="bivi-20210930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SubsequentEvents" xlink:href="bivi-20210930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:href="bivi-20210930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:href="bivi-20210930.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:href="bivi-20210930.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsTables" xlink:href="bivi-20210930.xsd#EquityTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" xlink:href="bivi-20210930.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:href="bivi-20210930.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:href="bivi-20210930.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:href="bivi-20210930.xsd#IntangibleAssetsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="bivi-20210930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/OtherLiabilitiesDetailsNarrative" xlink:href="bivi-20210930.xsd#OtherLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails" xlink:href="bivi-20210930.xsd#EquityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails2" xlink:href="bivi-20210930.xsd#EquityTransactionsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:href="bivi-20210930.xsd#EquityTransactionsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails4" xlink:href="bivi-20210930.xsd#EquityTransactionsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" xlink:href="bivi-20210930.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="bivi-20210930.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheet" xlink:title="00000002 - Statement - Condensed Balance Sheet (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheetParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaapOtherExpensesAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaapGainLossOnSaleOfDerivatives" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_TotalOtherExpenseIncome" xlink:label="loc_biviTotalOtherExpenseIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_biviTotalOtherExpenseIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DeemedDividend" xlink:label="loc_biviDeemedDividend" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_biviDeemedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="loc_us-gaapIncomeLossAttributableToParent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_InterestExpenseFromConvertibleDebenture" xlink:label="loc_biviInterestExpenseFromConvertibleDebenture" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_biviInterestExpenseFromConvertibleDebenture" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaapGainLossOnSaleOfDerivatives" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_PaymentOfConvertibleDebentureRelatedParty" xlink:label="loc_biviPaymentOfConvertibleDebentureRelatedParty" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_biviPaymentOfConvertibleDebentureRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_ProceedsFromConvertibleDebentureRelatedParty" xlink:label="loc_biviProceedsFromConvertibleDebentureRelatedParty" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_biviProceedsFromConvertibleDebentureRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DeemedDividend" xlink:label="loc_biviDeemedDividend" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_biviDeemedDividend" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000006 - Statement - Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedParty" xlink:label="loc_biviRedemptionOfWarrantsAndPurchaseOptionRelatedParty" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviRedemptionOfWarrantsAndPurchaseOptionRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares" xlink:label="loc_biviRedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviRedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DeemedDividendForCommitmentShares" xlink:label="loc_biviDeemedDividendForCommitmentShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviDeemedDividendForCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DeemedDividendForPurchaseOptionRelatedPartyInShares" xlink:label="loc_biviDeemedDividendForPurchaseOptionRelatedPartyInShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviDeemedDividendForPurchaseOptionRelatedPartyInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical" xlink:title="00000007 - Statement - Statements of Changes in Stockholders&apos; Equity (Deficit) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetOfCost" xlink:label="loc_biviProceedsFromIssuanceOfCommonStockNetOfCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_biviProceedsFromIssuanceOfCommonStockNetOfCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BackgroundInformation" xlink:title="00000008 - Disclosure - Background Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Liquidity" xlink:title="00000009 - Disclosure - Liquidity">
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureLiquidityAbstract" xlink:label="loc_biviDisclosureLiquidityAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_LiquidityTextBlock" xlink:label="loc_biviLiquidityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLiquidityAbstract" xlink:to="loc_biviLiquidityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssets" xlink:title="00000011 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/OtherLiabilities" xlink:title="00000013 - Disclosure - Other Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactions" xlink:title="00000014 - Disclosure - Equity Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EmployeeBenefitPlan" xlink:title="00000016 - Disclosure - Employee Benefit Plan">
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureEmployeeBenefitPlanAbstract" xlink:label="loc_biviDisclosureEmployeeBenefitPlanAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_EmployeeBenefitPlanTextBlock" xlink:label="loc_biviEmployeeBenefitPlanTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureEmployeeBenefitPlanAbstract" xlink:to="loc_biviEmployeeBenefitPlanTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract" xlink:label="loc_biviDisclosureSignificantAccountingPoliciesDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_biviDisclosureSignificantAccountingPoliciesDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:title="00000020 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureIntangibleAssetsDetailsAbstract" xlink:label="loc_biviDisclosureIntangibleAssetsDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_biviDisclosureIntangibleAssetsDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureIntangibleAssetsDetails2Abstract" xlink:label="loc_biviDisclosureIntangibleAssetsDetails2Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsTables" xlink:title="00000021 - Disclosure - Equity Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureEquityTransactionsDetailsAbstract" xlink:label="loc_biviDisclosureEquityTransactionsDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_biviDisclosureEquityTransactionsDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock" xlink:label="loc_biviFairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_biviFairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureEquityTransactionsDetails2Abstract" xlink:label="loc_biviDisclosureEquityTransactionsDetails2Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_biviDisclosureEquityTransactionsDetails2Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureEquityTransactionsDetails3Abstract" xlink:label="loc_biviDisclosureEquityTransactionsDetails3Abstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_biviDisclosureEquityTransactionsDetails3Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureEquityTransactionsDetails4Abstract" xlink:label="loc_biviDisclosureEquityTransactionsDetails4Abstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_biviDisclosureEquityTransactionsDetails4Abstract" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/LiquidityDetailsNarrative" xlink:title="00000022 - Disclosure - Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureLiquidityAbstract" xlink:label="loc_biviDisclosureLiquidityAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_WorkingCapital" xlink:label="loc_biviWorkingCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLiquidityAbstract" xlink:to="loc_biviWorkingCapital" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:title="00000024 - Disclosure - Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:title="00000025 - Disclosure - Intangible Assets (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000026 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_AcuitasGroupHoldingsLLCMember" xlink:label="loc_biviAcuitasGroupHoldingsLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_biviAcuitasGroupHoldingsLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/OtherLiabilitiesDetailsNarrative" xlink:title="00000027 - Disclosure - Other Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails" xlink:title="00000028 - Disclosure - Equity Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails2" xlink:title="00000029 - Disclosure - Equity Transactions (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:title="00000030 - Disclosure - Equity Transactions (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption1Member" xlink:label="loc_biviStockOption1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption2Member" xlink:label="loc_biviStockOption2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption3Member" xlink:label="loc_biviStockOption3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption4Member" xlink:label="loc_biviStockOption4Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption5Member" xlink:label="loc_biviStockOption5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption6Member" xlink:label="loc_biviStockOption6Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption7Member" xlink:label="loc_biviStockOption7Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption7Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption8Member" xlink:label="loc_biviStockOption8Member" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption8Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption9Member" xlink:label="loc_biviStockOption9Member" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption9Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption10Member" xlink:label="loc_biviStockOption10Member" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption10Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption11Member" xlink:label="loc_biviStockOption11Member" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption11Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption12Member" xlink:label="loc_biviStockOption12Member" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption12Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption13Member" xlink:label="loc_biviStockOption13Member" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption13Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption14Member" xlink:label="loc_biviStockOption14Member" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption14Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption15Member" xlink:label="loc_biviStockOption15Member" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption15Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_StockOption16Member" xlink:label="loc_biviStockOption16Member" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOption16Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails4" xlink:title="00000031 - Disclosure - Equity Transactions (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000032 - Disclosure - Equity Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000033 - Disclosure - Employee Benefit Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bivi-20210930.xsd#bivi_DisclosureEmployeeBenefitPlanAbstract" xlink:label="loc_biviDisclosureEmployeeBenefitPlanAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaapDefinedBenefitPlanContributionsByEmployer" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureEmployeeBenefitPlanAbstract" xlink:to="loc_us-gaapDefinedBenefitPlanContributionsByEmployer" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>bivi-20210930_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bivi="http://nanoantibiotics.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bivi-20210930.xsd" xlink:type="simple"/>
    <context id="From2021-07-01to2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2020-07-012020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-22_custom_AcuitasGroupHoldingsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bivi:AcuitasGroupHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-22</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2020-07-012021-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_StockOptionMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2020-07-012021-06-30_us-gaap_StockOptionMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption8Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption8Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption9Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption9Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption10Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption10Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption11Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption11Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption11Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption11Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption12Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption12Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption12Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption12Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption13Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption13Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption13Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption13Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption14Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption14Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption14Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption14Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption15Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption15Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOption16Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption16Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOption16Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOption16Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_WarrantMember217574359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-07-01to2021-09-30">0001580149</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-07-01to2021-09-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2021-07-01to2021-09-30">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-07-01to2021-09-30">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-07-01to2021-09-30">--06-30</dei:CurrentFiscalYearEndDate>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0084"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-09-30"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0096"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="From2021-07-01to2021-09-30"
      id="xdx2ixbrl0152"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:DeemedDividend
      contextRef="From2021-07-01to2021-09-30"
      id="xdx2ixbrl0167"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RestrictedStockExpense
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0201"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:InterestExpenseFromConvertibleDebenture
      contextRef="From2021-07-01to2021-09-30"
      id="xdx2ixbrl0203"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="From2021-07-01to2021-09-30"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:PaymentOfConvertibleDebentureRelatedParty
      contextRef="From2021-07-01to2021-09-30"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:ProceedsFromConvertibleDebentureRelatedParty
      contextRef="From2021-07-01to2021-09-30"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-07-01to2021-09-30"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:DeemedDividend
      contextRef="From2021-07-01to2021-09-30"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedParty
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:DeemedDividendForCommitmentShares
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0321"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember">P4Y8M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1 contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember">P5Y</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4 contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember">P4Y7M6D</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember">P4Y8M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-07-012021-06-30_us-gaap_StockOptionMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2020-07-012021-06-30_us-gaap_StockOptionMember_srt_DirectorMember">P4Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2021-07-012021-09-30_us-gaap_WarrantMember217574359">P3Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2021-07-012021-09-30_us-gaap_WarrantMember217574359"
      id="xdx2ixbrl0524"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease
      contextRef="From2021-07-012021-09-30_us-gaap_WarrantMember217574359"
      id="xdx2ixbrl0525"
      unitRef="Shares"
      xsi:nil="true"/>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2 contextRef="From2021-07-012021-09-30_us-gaap_WarrantMember217574359">P2Y9M18D</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2>
    <dei:DocumentType contextRef="From2021-07-01to2021-09-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2021-07-01to2021-09-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-07-01to2021-09-30">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2021-07-01to2021-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-07-01to2021-09-30">001-39015</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-07-01to2021-09-30">BIOVIE INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-07-01to2021-09-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-07-01to2021-09-30">46-2510769</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-07-01to2021-09-30">9120 Double Diamond Parkway Suite 1400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-07-01to2021-09-30">Reno</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-07-01to2021-09-30">NV</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-07-01to2021-09-30">89521</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-07-01to2021-09-30">(775)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-07-01to2021-09-30">888-3162</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-07-01to2021-09-30">Class A Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-07-01to2021-09-30">BIVI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-07-01to2021-09-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2021-07-01to2021-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-07-01to2021-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-07-01to2021-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-07-01to2021-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-07-01to2021-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2021-07-01to2021-09-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-11-04" decimals="INF" unitRef="Shares">24962373</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">20488025</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">4511642</us-gaap:Cash>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">105923</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">93487</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">20593948</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">4605129</us-gaap:AssetsCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1038505</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1095849</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">345711</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">345711</us-gaap:Goodwill>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1384216</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1441560</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">21978164</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">6046689</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">679393</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">996374</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">580625</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1260018</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">996374</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">483854</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1743872</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">996374</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">24962373</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">24962373</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">22333324</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">22333324</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2494</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">2232</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">250657973</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">229933505</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-230426175</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-224885422</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">20234292</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">5050315</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">21978164</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">6046689</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">57344</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">57344</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">2845594</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">100914</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">2644346</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">228497</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">5547284</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">386755</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">-5547284</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-386755</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">8279919</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:InterestExpense
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">1114</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">559312</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeOther
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">7645</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">64</us-gaap:InterestIncomeOther>
    <bivi:TotalOtherExpenseIncome
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">-6531</bivi:TotalOtherExpenseIncome>
    <bivi:TotalOtherExpenseIncome
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-7720671</bivi:TotalOtherExpenseIncome>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">-5540753</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">7333916</us-gaap:NetIncomeLoss>
    <bivi:DeemedDividend
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">53598320</bivi:DeemedDividend>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">-5540753</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-46264404</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-07-01to2021-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">-7.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-07-01to2021-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">-7.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-07-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">23719927</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="Shares">5971622</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-07-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">23719927</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="Shares">5971622</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">-5540753</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">7333916</us-gaap:NetIncomeLoss>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">57344</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">57344</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:RestrictedStockExpense
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">286759</us-gaap:RestrictedStockExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">1926962</us-gaap:ShareBasedCompensation>
    <bivi:InterestExpenseFromConvertibleDebenture
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">537275</bivi:InterestExpenseFromConvertibleDebenture>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">8279919</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">-12436</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">323591</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">-316981</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-1056032</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">1064479</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">-2534626</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-1083825</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">18511009</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">15628010</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <bivi:PaymentOfConvertibleDebentureRelatedParty
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">1821818</bivi:PaymentOfConvertibleDebentureRelatedParty>
    <bivi:ProceedsFromConvertibleDebentureRelatedParty
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">436000</bivi:ProceedsFromConvertibleDebentureRelatedParty>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">18511009</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">14242192</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">15976383</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">13158367</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:Cash contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">4511642</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">37195</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">20488025</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">13195562</us-gaap:Cash>
    <us-gaap:InterestPaidNet
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">1114</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">70444</us-gaap:InterestPaidNet>
    <bivi:DeemedDividend
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">53598320</bivi:DeemedDividend>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5204392.00</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">520</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">19538742</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-41037898</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">-21498636</us-gaap:StockholdersEquity>
    <bivi:ProceedsFromIssuanceOfCommonStockNetOfCost
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">2371790</bivi:ProceedsFromIssuanceOfCommonStockNetOfCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1799980</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">180</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">15627830</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">15628010</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1549750</bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares>
    <bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedParty
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">155</bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedParty>
    <bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedParty
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">13132230</bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedParty>
    <bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedParty
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">13132385</bivi:RedemptionOfWarrantsAndPurchaseOptionRelatedParty>
    <bivi:DeemedDividendForPurchaseOptionRelatedPartyInShares
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5359832</bivi:DeemedDividendForPurchaseOptionRelatedPartyInShares>
    <bivi:DeemedDividendForCommitmentShares
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">536</bivi:DeemedDividendForCommitmentShares>
    <bivi:DeemedDividendForCommitmentShares
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">53597784</bivi:DeemedDividendForCommitmentShares>
    <bivi:DeemedDividendForCommitmentShares
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-53598320</bivi:DeemedDividendForCommitmentShares>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2210</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">7333916</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">7333916</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13916164</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1391</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">101896586</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-87302302</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">14595675</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">22333324</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2232</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">229933505</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-224885422</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">5050315</us-gaap:StockholdersEquity>
    <bivi:ProceedsFromIssuanceOfCommonStockNetOfCost
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">2224992</bivi:ProceedsFromIssuanceOfCommonStockNetOfCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2592000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">259</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18510750</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">18511009</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="INF"
      unitRef="Shares">286756</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2021-07-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">286759</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1926962</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">1926962</us-gaap:ShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5540753</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">-5540753</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">24962373</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2494</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">250657973</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-230426175</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">20234292</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zNrpROp71wV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.3in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span id="xdx_824_zfeb1p92e3gf"&gt;Background
Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;BioVie
Inc. (the &#x93;Company&#x94; or &#x93;we&#x94; or &#x93;our&#x94;) is a clinical-stage company developing innovative drug therapies
to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
liver disease, our Orphan Drug candidate BIV201 (continuous infusion terlipressin) is being developed as a future treatment option for
patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by NASH, hepatitis, and alcoholism.
The initial target for BIV201 therapy is refractory ascites. These patients suffer from frequent life-threatening complications, generate
more than $5 billion in annual treatment costs, and have an estimated 50% mortality rate within 6 to 12 months. The US Food and Drug
Administration (FDA) has not approved any drug to treat refractory ascites. A Phase 2a clinical trial of BIV201 was completed in 2019,
and a multi-center, randomized 30-patient Phase 2b trial is currently underway. As of October 31, 2021, the nine planned US study centers
have been activated and are actively screening patients, and multiple patients have been enrolled in the study. The FDA has communicated
to us that pending positive Phase 2 study results, a sufficiently large and well-controlled Phase 3 trial, with supportive trend data
from the Phase 2b (statistical significance not required), could potentially yield the clinical data needed to apply for BIV201 marketing
approval. The Phase 2b clinical trial protocol is summarized on www.clinicaltrials.gov, trial identifier NCT04112199.at nine US study
centers. (NCT04112199). Top-line results from this trial are expected in mid-2022, to be followed by a proposed single pivotal Phase
3 clinical trial beginning in late 2022. In June 2021, BioVie received written feedback from the FDA in response to a Type B meeting
request to conduct a pivotal US Phase 3 clinical trial in HRS-AKI, which is a life-threatening complication of advanced ascites. Based
on the guidance received in subsequent communications with the FDA, we are revising certain elements of our proposed study and are planning
to initiate this study in early 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The BIV201 development program was initiated by LAT Pharma LLC. On April
11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development
and marketing rights to its drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor
entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous
infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In neurodegenerative disease, BioVie acquired the biopharmaceutical assets
of NeurMedix, Inc. (&#x201c;NeurMedix&#x201d;), a privately held clinical-stage pharmaceutical company, in June 2021 (See Note 5 Related
Party Transactions&lt;i&gt;).&lt;/i&gt; The acquired assets included NE3107, a potentially selective inhibitor of inflammatory ERK signaling that,
based on animal studies, is believed to reduce neuroinflammation. NE3107 is a novel orally administered small molecule that is thought
to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There
is emerging scientific consensus that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer&#x2019;s
and Parkinson&#x2019;s Disease, and NE3107 could, if approved represent an entirely new medical approach to treating these devastating
conditions affecting an estimated 6 million Americans suffering from Alzheimer&#x2019;s and 1 million from Parkinson&#x2019;s. The FDA has
authorized a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate NE3107
in subjects who have mild to moderate Alzheimer&#x2019;s disease (NCT04669028). In August 2021, the study was initiated and the Company
is anticipating top line results in late calendar year 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In September 2021, the FDA authorized the Company to initiate a Phase 2
study assessing NE3107&#x2019;s potential pro-motoric impact in Parkinson&#x2019;s disease patients, and to assess its safety and tolerability.
The NM201 study (NCT05083260) is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinson&#x2019;s
Disease (PD) participants treated with carbidopa/levodopa and NE3107. Forty patients with a defined L-dopa &#x201c;off state&#x201d; will
be randomized 1:1 placebo: active 20 mg twice daily for 28 days. Safety assessments will look at standard measures of patient health and
potential for drug-drug interactions affecting L-dopa PK and activity. Efficacy assessments will use the Motor Disease Society Unified
Parkinson&#x2019;s Disease Rating (MDS-UPDRS) parts 1-4, Hauser ON/OFF Diary, and Non-Motor Symptom Scale. This study is planned to start
in early 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Inflammation-driven insulin resistance is believed to be implicated in
a broad range of serious diseases, including multiple myeloma and prostate cancer, and we plan to begin exploring these opportunities
in the coming months using NE3107 or related compounds acquired in the NeurMedix asset purchase. NE3107 is patented in the United States,
Australia, Canada, Europe and South Korea.&lt;/p&gt;



</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <bivi:LiquidityTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_801_ecustom--LiquidityTextBlock_z991OxaD6U2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.3in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span id="xdx_82B_zbJRFTLwN668"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x92;s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors
include, but are not limited to: the results of clinical testing and trial activities of the Company&#x92;s products, the Company&#x92;s
ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other
companies; the price of, and demand for, Company products; the Company&#x92;s ability to negotiate favorable licensing or other manufacturing
and marketing agreements for its products; and the Company&#x92;s ability to raise capital. The Company&#x92;s financial statements
have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction
of liabilities in the normal course of business. As of September 30, 2021, the Company had working capital of approximately $&lt;span id="xdx_904_ecustom--WorkingCapital_iI_pp0p0_dm_c20210930_za0hGIVuyKTl"&gt;19.3 million&lt;/span&gt;,
cash of approximately $20.5 million, stockholders&#x92; equity of approximately $20.2 million, and an accumulated deficit of approximately
$230.4 million. In addition, the Company has not generated any revenues to date and no revenues are expected in the foreseeable future.
The Company&#x92;s future operations are dependent on the success of the Company&#x92;s ongoing development and commercialization efforts,
as well as its ability to secure additional financing as needed. Although our cash balance could possibly sustain operations over the
next 12 months if measures are taken to delay planned expenditures in our research protocols and slow the progress in the Company&#x92;s
clinical programs, the Company&#x92;s current planned operations to meet certain goals and objectives, project cash flows to be depleted
within that period of time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management
expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
emergence of widespread health emergencies or pandemics such as the coronavirus (&#x93;COVID-19&#x94;) pandemic (and its related variants),
may lead to continued regional quarantines, business shutdowns, labor shortages, disruptions to supply chains, and overall economic instability.
&lt;span style="background-color: white"&gt;Although some jurisdictions have relaxed these measures, others have not or have reinstated them
as COVID-19 cases surge and variants emerge. &lt;/span&gt;The duration and spread of the COVID-19 pandemic and the long-term impact of COVID-19
and its variants on the financial markets and the overall economy are highly uncertain and cannot be predicted at this time. If the financial
markets and/or the overall economy are impacted for an extended period, the Company&#x92;s ability to raise funds may be materially
adversely affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Although
management continues to pursue the Company&#x92;s strategic plans, there is no assurance that the Company will be successful in obtaining
sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial
doubt on the Company&#x92;s ability to continue as a going concern. The financial statements do not include any adjustments that might
result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

</bivi:LiquidityTextBlock>
    <bivi:WorkingCapital contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">19300000</bivi:WorkingCapital>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_808_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKVLHe8KPZtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.3in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span id="xdx_82F_zn1En0B21Igg"&gt;Significant
Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zVt5wK2ghfz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86B_zXIe4pq7YEI2"&gt;Basis
of Presentation &#x2013; Interim Financial Information&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally
accepted in the United State of America (&#x93;U.S. GAAP&#x94;) for interim financial information and with the instructions to Form
10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the &#x93;SEC&#x94;) for Interim Reporting. Accordingly,
they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim
condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of
management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily
indicative of the results for the full year. The condensed balance sheet at June 30, 2021 was derived from audited annual financial statements
but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements
and information included under the heading &#x93;Management&#x92;s Discussion and Analysis of Financial Condition and Results of Operations&#x94;
should be read in conjunction with the Company&#x92;s audited financial statements for the fiscal years ended June 30, 2021 and 2020
in our Annual Report on Form 10-K filed with the SEC on August 30, 2021. For a summary of significant accounting policies, see the Company&#x92;s
Annual Report on Form 10-K for the fiscal year ended June 30, 2021, filed with the SEC on August 30, 2021.&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zofzqztTEL9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_864_zX1qceKp9L2f"&gt;Net
loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of
shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable
to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common
stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants,
and convertible debentures. For the three months ended September 30, 2021 and 2020, such amounts were excluded from the diluted loss
since their effect was considered anti-dilutive due to the net loss for the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMbKKVIrooBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
table below shows the number of outstanding stock options and warrants as of September 30, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B2_z0tX7T0yqcz4" style="display: none"&gt;Schedule of Dilutive securities were excluded from the computation of diluted loss per share&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureSignificantAccountingPoliciesDetailsAbstract_zgt12QaPmEk9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20210701__20210930_zANOx7Ka9fB8" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20200701__20200930_zuPppPHBr576" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgntrTihfehd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;2,047,910&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;57,200&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zQJkEJ2hQtqf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;158,761&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;214,665&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zSQKHWPtcXL7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,206,671&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;271,865&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zGydOHp7dvJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znuIQdnZzy2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_868_zetsEdpzxnWl"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company considers the applicability and impact of all Accounting Standards Updates (&#x93;ASU&#x92;s&#x94;). There were no recent
ASUs that are expected to have a material impact on the Company&#x92;s balance sheets or statements of operations.&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zVt5wK2ghfz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86B_zXIe4pq7YEI2"&gt;Basis
of Presentation &#x2013; Interim Financial Information&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally
accepted in the United State of America (&#x93;U.S. GAAP&#x94;) for interim financial information and with the instructions to Form
10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the &#x93;SEC&#x94;) for Interim Reporting. Accordingly,
they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim
condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of
management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily
indicative of the results for the full year. The condensed balance sheet at June 30, 2021 was derived from audited annual financial statements
but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements
and information included under the heading &#x93;Management&#x92;s Discussion and Analysis of Financial Condition and Results of Operations&#x94;
should be read in conjunction with the Company&#x92;s audited financial statements for the fiscal years ended June 30, 2021 and 2020
in our Annual Report on Form 10-K filed with the SEC on August 30, 2021. For a summary of significant accounting policies, see the Company&#x92;s
Annual Report on Form 10-K for the fiscal year ended June 30, 2021, filed with the SEC on August 30, 2021.&lt;/span&gt;&lt;/p&gt;




</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zofzqztTEL9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_864_zX1qceKp9L2f"&gt;Net
loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of
shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable
to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common
stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants,
and convertible debentures. For the three months ended September 30, 2021 and 2020, such amounts were excluded from the diluted loss
since their effect was considered anti-dilutive due to the net loss for the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMbKKVIrooBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
table below shows the number of outstanding stock options and warrants as of September 30, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B2_z0tX7T0yqcz4" style="display: none"&gt;Schedule of Dilutive securities were excluded from the computation of diluted loss per share&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureSignificantAccountingPoliciesDetailsAbstract_zgt12QaPmEk9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20210701__20210930_zANOx7Ka9fB8" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20200701__20200930_zuPppPHBr576" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgntrTihfehd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;2,047,910&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;57,200&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zQJkEJ2hQtqf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;158,761&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;214,665&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zSQKHWPtcXL7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,206,671&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;271,865&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zGydOHp7dvJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMbKKVIrooBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
table below shows the number of outstanding stock options and warrants as of September 30, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B2_z0tX7T0yqcz4" style="display: none"&gt;Schedule of Dilutive securities were excluded from the computation of diluted loss per share&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <bivi:DisclosureSignificantAccountingPoliciesDetailsAbstract contextRef="From2021-07-01to2021-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureSignificantAccountingPoliciesDetailsAbstract_zgt12QaPmEk9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20210701__20210930_zANOx7Ka9fB8" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20200701__20200930_zuPppPHBr576" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgntrTihfehd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;2,047,910&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;57,200&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zQJkEJ2hQtqf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;158,761&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;214,665&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zSQKHWPtcXL7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,206,671&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;271,865&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</bivi:DisclosureSignificantAccountingPoliciesDetailsAbstract>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">2047910</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-07-012020-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">57200</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-07-012021-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">158761</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-07-012020-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">214665</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-07-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">2206671</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="Shares">271865</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znuIQdnZzy2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_868_zetsEdpzxnWl"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company considers the applicability and impact of all Accounting Standards Updates (&#x93;ASU&#x92;s&#x94;). There were no recent
ASUs that are expected to have a material impact on the Company&#x92;s balance sheets or statements of operations.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_zGtlPgtmNg23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.3in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span id="xdx_820_zAyUUkDNcuBc"&gt;Intangible
Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x92;s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated
useful lives.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zhDBduEhQHwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The following is a &lt;span id="xdx_8B2_zXdi33piIYW3"&gt;summary of the intangible assets as of September 30, 2021 and June 30, 2021&lt;/span&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureIntangibleAssetsDetailsAbstract_zdhkg5UeB2ja" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210930_zEV02dG0L4e4" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20210630_z0RuQ3iaOTMc" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maCzIr2_zHjf2GhR7Qu7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Intellectual Property&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;2,293,770&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;2,293,770&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzIr2_zqwGU197JWEc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,255,265&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,197,921&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzIr2_zQyuieteyjx4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Intellectual Property, Net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,038,505&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,095,849&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zDpD6RehzK82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization
expense was $57,344 in each of the three-month periods ended September 30, 2021 and 2020. The Company amortizes intellectual property
over the expected original useful lives of 10 years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zBeeBe3sD9c9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated
future amortization expense is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8B6_zyPIF4pR1JY7" style="display: none"&gt;Schedule of Future expected Amortization of intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIntangibleAssetsDetails2Abstract_zCW8JWPDF8o2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td/&gt;
    &lt;td style="text-align: left"/&gt;&lt;td id="xdx_49D_20210930_zTbrrOgzxROd" style="text-align: right"/&gt;&lt;td style="white-space: nowrap; text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_maFLIANzEri_zgO6p3tEYCzd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: center"&gt;Year ending June 30, 2022 (Remaining nine months)&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 40%; text-align: right"&gt;172,033&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_maFLIANzEri_zFjNRrlOHuvk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_maFLIANzEri_zmKyI8W5u2J9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_maFLIANzEri_zcqdEgWzFoqe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_maFLIANzEri_z12jBGdCK2L3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;178,341&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzEri_zocxriG53r7i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; text-align: center; padding-bottom: 4pt"&gt;Intellectual Property, Net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,038,505&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zPrO3xzOO9jh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;


</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zhDBduEhQHwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The following is a &lt;span id="xdx_8B2_zXdi33piIYW3"&gt;summary of the intangible assets as of September 30, 2021 and June 30, 2021&lt;/span&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <bivi:DisclosureIntangibleAssetsDetailsAbstract contextRef="From2021-07-01to2021-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureIntangibleAssetsDetailsAbstract_zdhkg5UeB2ja" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210930_zEV02dG0L4e4" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20210630_z0RuQ3iaOTMc" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maCzIr2_zHjf2GhR7Qu7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Intellectual Property&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;2,293,770&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;2,293,770&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzIr2_zqwGU197JWEc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,255,265&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,197,921&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzIr2_zQyuieteyjx4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Intellectual Property, Net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,038,505&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,095,849&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</bivi:DisclosureIntangibleAssetsDetailsAbstract>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2293770</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">2293770</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1255265</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1197921</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1038505</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1095849</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zBeeBe3sD9c9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated
future amortization expense is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8B6_zyPIF4pR1JY7" style="display: none"&gt;Schedule of Future expected Amortization of intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <bivi:DisclosureIntangibleAssetsDetails2Abstract contextRef="From2021-07-01to2021-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIntangibleAssetsDetails2Abstract_zCW8JWPDF8o2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td/&gt;
    &lt;td style="text-align: left"/&gt;&lt;td id="xdx_49D_20210930_zTbrrOgzxROd" style="text-align: right"/&gt;&lt;td style="white-space: nowrap; text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_maFLIANzEri_zgO6p3tEYCzd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: center"&gt;Year ending June 30, 2022 (Remaining nine months)&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 40%; text-align: right"&gt;172,033&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_maFLIANzEri_zFjNRrlOHuvk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_maFLIANzEri_zmKyI8W5u2J9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_maFLIANzEri_zcqdEgWzFoqe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_maFLIANzEri_z12jBGdCK2L3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;178,341&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzEri_zocxriG53r7i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; text-align: center; padding-bottom: 4pt"&gt;Intellectual Property, Net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,038,505&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</bivi:DisclosureIntangibleAssetsDetails2Abstract>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">172033</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">178341</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1038505</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zLAQgIxIgor" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.3in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span id="xdx_82D_z6w4wutwLP8l"&gt;Related
Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Asset
Acquisition with NeurMedix&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 27, 2021, the Company entered into an Asset Purchase Agreement (&#x93;APA&#x94;) with NeurMedix and Acuitas Group Holdings, LLC
(&#x93;Acuitas&#x94;), which are related party affiliates, pursuant to which the Company acquired certain assets from NeurMedix and
assumed certain liabilities of NeurMedix, in exchange for consideration of cash and shares of common stock. The acquired assets include,
among others, those related to certain drug candidates being developed by NeurMedix, including NE3107, a small molecule orally administered
inhibitor of insulin resistance and the pathological inflammatory cascade, with a novel mechanism of action that has potential applications
for treatment against Alzheimer&#x92;s Disease and Parkinson&#x92;s Disease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Subject
to the terms and conditions of the APA, following the closing, the Company was potentially obligated to deliver contingent stock consideration
to NeurMedix (or its successor). Previously, the Company was obligated to deliver contingent stock consideration to NeurMedix (or its
successor) consisting of shares of the Company&#x92;s common stock having an aggregate value of up to $3.0 billion, subject to the Company&#x92;s
achievement of certain clinical, regulatory and commercial milestones related to the drug candidates to be acquired from NeurMedix, and
subject to a cap limiting each issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates
exceeding 89.9999% of the Company&#x92;s issued and outstanding common stock. Pursuant to Amendment No. 1 to the APA, dated May 9, 2021,
the Company is now obligated to deliver to NeurMedix (or its successor) 4.5 million shares upon the achievement of each of the four milestones
set forth in the APA, for an aggregate of up to 18 million shares, subject to a cap limiting the issuance of shares if such issuance
would result in the beneficial ownership of NeurMedix and its affiliates exceeding 87.5% of the Company&#x92;s issued and outstanding
common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 10, 2021, and pursuant to the APA, the Company issued to Acuitas (as NeurMedix&#x92;s assignee) 8,361,308 shares of the Company&#x92;s
common stock and made a cash payment of approximately $2.3 million, representing NeurMedix&#x92;s direct and documented cash expenditures
to advance certain programs from March 1, 2021 through the closing date and cash payments to other third parties for expenses totaling
approximately $4.0 million for due diligence, legal fees, transaction fees and the fairness opinion. Since the transaction was between
entities under common control, there were no fair value adjustments of the purchased assets, and the historical cost basis of the purchased
assets was zero. The total consideration paid was expensed as research and development expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Equity
Transactions with Acuitas&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
September 22, 2020, concurrent with the closing of the Company&#x92;s Offering, approximately $1.8 million was paid to Acuitas satisfying
all amounts owed on the Debenture due September 24, 2020 held by the Company&#x92;s controlling stockholder, Acuitas.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Additionally,
in connection with the close of the public offering on September 22, 2020, the Company issued an aggregate of &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20200922__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AcuitasGroupHoldingsLLCMember_zvgPmNM7sVxi"&gt;6,909,582&lt;/span&gt; shares of Common
Stock to Acuitas, representing (i) 5.4 million shares issuable pursuant to Acuitas&#x92; rights under the Purchase Agreement dated July
3, 2018, as amended on June 24, 2019 and October 9, 2019; and the various extension letters; which resulted in a deemed dividend at the
close of the public offering at price of $10 per share, consistent with the Company&#x92;s accounting policy; and (ii) the automatic
exercise of 1.5 million warrants issued to Acuitas in connection with the Debenture financing at the par value of the Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended June 30, 2021, the Company received additional draws under the Debenture totaling $436,000. The total draws as of September
22, 2020 were $1.7 million and the related total number of warrants issuable at $4.00 per share of common stock was 424,750 of which
328,250 warrants had been issued. In accordance with the Debenture agreements, at September 22, 2020 upon the Company&#x92;s close of
its public offering, all the warrants issued related to the debenture totaling 1,453,250 were mandatorily redeemed along with the additional
96,500 shares common stock issued to Acuitas.&lt;/span&gt;&lt;/p&gt;



</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2020-09-22_custom_AcuitasGroupHoldingsLLCMember"
      decimals="INF"
      unitRef="Shares">6909582</us-gaap:CommonStockSharesIssued>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_800_eus-gaap--OtherLiabilitiesDisclosureTextBlock_z27grdkoDrFg" style="margin-top: 0; margin-bottom: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.3in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span id="xdx_829_zGDg4XdRTQD2"&gt;Other
Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
liabilities represent retention bonus arrangements with certain employees. Retention bonuses of $&lt;span id="xdx_904_eus-gaap--AccruedBonusesCurrent_iI_c20210930_zNOMLZiWpNrf" title="Retention Bonus"&gt;1,161,000&lt;/span&gt; were expensed in the accompanying
statements of operations for three months ended September 30, 2021, and will be paid in equal monthly installments, which began in August
2021, over a 24-month period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1161000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLic4YiI8IQg" style="margin-top: 0; margin-bottom: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.3in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span id="xdx_829_zQxFcBSeMoLb"&gt;Equity
Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zkjsdSwEZukf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the &lt;span id="xdx_8B2_zMhGPBJKM8rg"&gt;activity relating to the Company&#x92;s stock options&lt;/span&gt; for the three months ended September 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureEquityTransactionsDetailsAbstract_zUDksJz3P2nd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Remaining&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%"&gt;Outstanding at June 30, 2021&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zc3sQt12uA11" style="width: 8%; text-align: right"&gt;755,200&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMxtvcFHYt3d" style="width: 8%; text-align: right"&gt;4.34&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgWpdyzBbep1" style="width: 8%; text-align: right" title="::XDX::P4Y8M24D"&gt;4.4&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zItGo8gYfZ73" style="width: 8%; text-align: right"&gt;2,569,232&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3ULBQYYxxkl" style="text-align: right"&gt;1,365,835&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zurnkyE7C562" style="text-align: right"&gt;7.74&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zREAmJUKkSM3" style="text-align: right" title="::XDX::P5Y"&gt;5.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6feaz93nisc" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0416"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBL8tIOO6VKf" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(73,125&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9GTkYzO0rOa" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13.91&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuRonGsbCsVb" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0419"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding at September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zcGmFG5ACdGh" style="border-bottom: Black 4pt double; text-align: right"&gt;2,047,910&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMJZkkwl6G4" style="border-bottom: Black 4pt double; text-align: right"&gt;9.79&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLPY99ECMA2" style="border-bottom: Black 4pt double; text-align: right" title="::XDX::P4Y7M6D"&gt;4.6&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zl0mN8nW0oKk" style="border-bottom: Black 4pt double; text-align: right"&gt;42,824&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable at&#160;&#160;September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zG06cFgtjtl7" style="border-bottom: Black 4pt double; text-align: right"&gt;509,667&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYEKm8VMNp02" style="border-bottom: Black 4pt double; text-align: right"&gt;9.36&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoaXe3SIlpMk" style="border-bottom: Black 4pt double; text-align: right" title="::XDX::P4Y8M24D"&gt;4.4&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zD5o5odkHXR8" style="border-bottom: Black 4pt double; text-align: right"&gt;42,824&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zYKHA4IpbzN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock_z0Sf7wfJ4g61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflects the following
&lt;span id="xdx_8BE_zZReCL1jqSnk"&gt;weighted-average assumptions&lt;/span&gt; for the three months ended September 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureEquityTransactionsDetails2Abstract_ztDB9NrRcIC" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210701__20210930_zJZX4vp7yhA1" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20200701__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0UE2NTouSrh" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Expected life of options (In years)&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvnvxxV9xDm1" style="width: 8%; text-align: right" title="::XDX::P5Y"&gt;5&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20200701__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUcs8CRqY0Ka" style="width: 8%; text-align: right" title="::XDX::P5Y"&gt;5&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zxvi4Duh82Qg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;74.96&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77.29&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_zjGkd7w4ZJDj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.80&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.39&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_znPMQ03DqbCk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zOqXzsw6BJd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
volatility is based on the historical volatilities of the daily closing price of the common stock of three comparable companies and the
expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures
as they are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recorded stock option-based compensation expense of $1,926,962 and $0 for three-month periods ended September 30, 2021 and 2020,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2021, there was approximately $&lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_dm_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zwW4jAOxrI34"&gt;6.8 million&lt;/span&gt; of unrecognized compensation cost related to non-vested stock options granted
to Directors and Officers, which is expected to be recognized over a weighted-average period of approximately &lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxH_c20200701__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zdn0w0PZUJad" title="::XDX::P4Y8M12D"&gt;4.7 years&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_895_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zZkgcsyrksQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following is a &lt;span id="xdx_8B5_z30SSZRKMv1f"&gt;summary of stock options outstanding and exercisable by exercise price&lt;/span&gt; as of September 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureEquityTransactionsDetails3Abstract_zuGgkXD8B0lj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_482_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_zzse3RhQHwkd" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_z6AVEBugc5fg" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted Average&lt;br/&gt; Contract Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_znLpV2PdUlF2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_zlzWDlwQARrg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 0%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;7,200&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_z2BhotaHlggb" style="width: 21%; text-align: right"&gt;3.3&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;7,200&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zK6SEnRVxODh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.75&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zkIWEQcIHs36" style="text-align: right"&gt;2.3&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zNjkQSVc90mf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.25&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zcAKX7Nj6Qtg" style="text-align: right"&gt;2.1&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zXswctEcCdO7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zHv847TXCduf" style="text-align: right"&gt;4.4&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_zbtwRNK63AS9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.74&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,365,835&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_zMvqH2XqrVIi" style="text-align: right"&gt;4.9&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;273,167&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_ztSnC8kSrty5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.75&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_zE0hM2NgIRhk" style="text-align: right"&gt;2.5&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_zYe19PNHete6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9.54&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_zdCFSzIXDAJd" style="text-align: right"&gt;4.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_411_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_zTmyxofmFDxf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9.90&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_zkUeEtm3VuT3" style="text-align: right"&gt;4.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_412_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_z4SlBLPnFzG9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12.50&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_zOxlQhdvwmtb" style="text-align: right"&gt;1.3&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zFM8eGshjUQb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13.91&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;618,475&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zTlZXajx5WQa" style="text-align: right"&gt;4.2&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;172,900&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_zlDTv2rgQolb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25.00&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_z9Qn1iDR2Xj3" style="text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zEhx08uKnpE4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;26.25&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,400&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zBGQOEMkbi6" style="text-align: right"&gt;0.6&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,400&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zqCnXaFC2qwc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;27.50&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zBGR9jsY5Y6f" style="text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_zCySkBFogFaj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;28.75&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_ziYGtqREeKo2" style="text-align: right"&gt;0.8&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_z2jLPQp4wguh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;31.25&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_zjm1Q8zchuIf" style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption16Member_zVuBtCZMvXAd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;42.09&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,800&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption16Member_zj4aoKSv3kR6" style="padding-bottom: 1.5pt; text-align: right"&gt;4.3&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,800&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20210930_z4xEfT2Ho4y8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,047,910&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;509,667&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zp9zzJdhA1w7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Stock
Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zrw56hMAvk93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table &lt;span id="xdx_8B7_z0QQjTnsMeX4"&gt;summarizes warrant activity&lt;/span&gt; during the three months ended September 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureEquityTransactionsDetails4Abstract_zkBDdZCjc6Zi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; text-align: left"&gt;Outstanding and exercisable at June 30, 2021&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zs7KfeRTh9Xh" style="width: 8%; text-align: right"&gt;158,761&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zE5cSaAK3pKd" style="width: 8%; text-align: right"&gt;10.37&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dxH_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmmEkRQSS2O6" style="width: 8%; text-align: right" title="::XDX::P3Y1M6D"&gt;3.1&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlt4gJQyWyR8" style="width: 8%; text-align: right"&gt;1,765,437&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNMcf371zRSg" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0524"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuhbLfWasxQ6" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0525"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"/&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Outstanding and exercisable at September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zajLGq3UdVYj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;158,761&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoPZj7imp9Te" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10.37&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2_dxH_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdh4kevjau9a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Remaining Life, at the end of period::XDX::P2Y9M18D"&gt;2.8&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z720uyEvkK52" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;486,666&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z1xMCc7fxPMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Of
the above warrants, 9,391 expire in the fiscal year ending June 30, 2022, 4,815 expire in the fiscal year ending June 30, 2023, 2,714
expire in the fiscal year ending June 30, 2025, and 141,841 expire in the fiscal year ending June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Issuance
of common stock for cash&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
August 11, 2021, the Company closed a registered public offering issuing 2,500,000 of its Class A common stock at $8.00&#160;per share,
resulting in net proceeds to the Company of approximately $17.8 million, net of issuance costs of approximately $2.2 million&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
September 24, 2021, the Company issued 92,000 of its Class A common stock at $8.00&#160;per share in connection with the underwriters&#x92;
exercise of its over-allotment option in for the August 2021 registered public offering, resulting in net proceeds to the Company of
approximately $707,000, net of issuance cost of approximately $29,000.&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Issuance
of Shares for Services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
August 20, 2021, the Company awarded 58,759 restricted stock units (&#x93;RSUs&#x94;) to the President and CEO under the Company&#x92;s
2019 Omnibus Incentive Equity Plan (the &#x93;2019 Omnibus Plan&#x94;) as his salary for the period from April 27, 2021, the date of
his appointment, through December 31, 2021. The number of RSUs awarded was based on a prorated annual base salary of $600,000 at a 10%
discount to the grant date fair value of $7.74 per share of the Company&#x92;s common stock. Each RSU awarded the to the CEO entitles
him to receive one share of common stock upon vesting. A total of 15,339 RSUs (representing the pro rata portion of the RSU award for
the period from April 27, 2021 to June 30, 2021) vested at the grant date, 21,710 RSUs vested at September 30, 2021, and 21,710 will
vest at December 31, 2021. Accordingly, during the three months ended September 30, 2021, 37,049 RSUs vested and 37,049 shares of common
were issued to the CEO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recorded stock-based compensation expense related to these RSUs of $286,759 and $0 for three- month periods ended September 30,
2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Issuance
of Stock Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
August 20, 2021, the Company granted, under the 2019 Omnibus Plan, stock options to purchase 1,365,835 shares of common stock to the
executive management team. Twenty percent (20%) of the shares underlying the options awarded vested on the grant date, and the remaining
80% vest equally over a 5-year period, on the first, second, third, fourth and fifth anniversary of the grant date. The option price
per share is $7.74 per share, the grant date fair value, and the options terminate on the tenth anniversary of the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Forfeiture
of Stock Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
August 27, 2021, the Chief Executive Officer forfeited unvested stock options to purchase up to 73,125 shares of common stock that were
previously granted to him as compensation as an independent director of the board.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zkjsdSwEZukf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the &lt;span id="xdx_8B2_zMhGPBJKM8rg"&gt;activity relating to the Company&#x92;s stock options&lt;/span&gt; for the three months ended September 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <bivi:DisclosureEquityTransactionsDetailsAbstract contextRef="From2021-07-01to2021-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureEquityTransactionsDetailsAbstract_zUDksJz3P2nd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Remaining&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%"&gt;Outstanding at June 30, 2021&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zc3sQt12uA11" style="width: 8%; text-align: right"&gt;755,200&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMxtvcFHYt3d" style="width: 8%; text-align: right"&gt;4.34&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgWpdyzBbep1" style="width: 8%; text-align: right" title="::XDX::P4Y8M24D"&gt;4.4&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zItGo8gYfZ73" style="width: 8%; text-align: right"&gt;2,569,232&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3ULBQYYxxkl" style="text-align: right"&gt;1,365,835&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zurnkyE7C562" style="text-align: right"&gt;7.74&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zREAmJUKkSM3" style="text-align: right" title="::XDX::P5Y"&gt;5.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6feaz93nisc" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0416"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBL8tIOO6VKf" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(73,125&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9GTkYzO0rOa" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13.91&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuRonGsbCsVb" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0419"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding at September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zcGmFG5ACdGh" style="border-bottom: Black 4pt double; text-align: right"&gt;2,047,910&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMJZkkwl6G4" style="border-bottom: Black 4pt double; text-align: right"&gt;9.79&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLPY99ECMA2" style="border-bottom: Black 4pt double; text-align: right" title="::XDX::P4Y7M6D"&gt;4.6&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zl0mN8nW0oKk" style="border-bottom: Black 4pt double; text-align: right"&gt;42,824&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable at&#160;&#160;September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zG06cFgtjtl7" style="border-bottom: Black 4pt double; text-align: right"&gt;509,667&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYEKm8VMNp02" style="border-bottom: Black 4pt double; text-align: right"&gt;9.36&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoaXe3SIlpMk" style="border-bottom: Black 4pt double; text-align: right" title="::XDX::P4Y8M24D"&gt;4.4&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zD5o5odkHXR8" style="border-bottom: Black 4pt double; text-align: right"&gt;42,824&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</bivi:DisclosureEquityTransactionsDetailsAbstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">755200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">2569232</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1365835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">7.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">73125</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">13.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">2047910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">9.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">42824</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">509667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">9.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">42824</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <bivi:FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_894_ecustom--FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock_z0Sf7wfJ4g61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflects the following
&lt;span id="xdx_8BE_zZReCL1jqSnk"&gt;weighted-average assumptions&lt;/span&gt; for the three months ended September 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</bivi:FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock>
    <bivi:DisclosureEquityTransactionsDetails2Abstract contextRef="From2021-07-01to2021-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureEquityTransactionsDetails2Abstract_ztDB9NrRcIC" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210701__20210930_zJZX4vp7yhA1" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20200701__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0UE2NTouSrh" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Expected life of options (In years)&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvnvxxV9xDm1" style="width: 8%; text-align: right" title="::XDX::P5Y"&gt;5&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20200701__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUcs8CRqY0Ka" style="width: 8%; text-align: right" title="::XDX::P5Y"&gt;5&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zxvi4Duh82Qg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;74.96&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77.29&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_zjGkd7w4ZJDj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.80&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.39&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_znPMQ03DqbCk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</bivi:DisclosureEquityTransactionsDetails2Abstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-07-01to2021-09-30"
      decimals="INF"
      unitRef="Pure">0.7496</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-07-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Pure">0.7729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-07-01to2021-09-30"
      decimals="INF"
      unitRef="Pure">0.0080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-07-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-07-01to2021-09-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-07-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">6800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_895_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zZkgcsyrksQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following is a &lt;span id="xdx_8B5_z30SSZRKMv1f"&gt;summary of stock options outstanding and exercisable by exercise price&lt;/span&gt; as of September 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <bivi:DisclosureEquityTransactionsDetails3Abstract contextRef="From2021-07-01to2021-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureEquityTransactionsDetails3Abstract_zuGgkXD8B0lj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_482_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_zzse3RhQHwkd" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_z6AVEBugc5fg" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted Average&lt;br/&gt; Contract Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_znLpV2PdUlF2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_zlzWDlwQARrg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 0%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;7,200&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_z2BhotaHlggb" style="width: 21%; text-align: right"&gt;3.3&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;7,200&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zK6SEnRVxODh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.75&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zkIWEQcIHs36" style="text-align: right"&gt;2.3&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zNjkQSVc90mf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.25&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zcAKX7Nj6Qtg" style="text-align: right"&gt;2.1&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zXswctEcCdO7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zHv847TXCduf" style="text-align: right"&gt;4.4&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_zbtwRNK63AS9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.74&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,365,835&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_zMvqH2XqrVIi" style="text-align: right"&gt;4.9&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;273,167&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_ztSnC8kSrty5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.75&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_zE0hM2NgIRhk" style="text-align: right"&gt;2.5&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_zYe19PNHete6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9.54&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_zdCFSzIXDAJd" style="text-align: right"&gt;4.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_411_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_zTmyxofmFDxf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9.90&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_zkUeEtm3VuT3" style="text-align: right"&gt;4.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_412_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_z4SlBLPnFzG9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12.50&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_zOxlQhdvwmtb" style="text-align: right"&gt;1.3&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zFM8eGshjUQb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13.91&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;618,475&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zTlZXajx5WQa" style="text-align: right"&gt;4.2&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;172,900&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_zlDTv2rgQolb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25.00&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_z9Qn1iDR2Xj3" style="text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zEhx08uKnpE4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;26.25&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,400&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zBGQOEMkbi6" style="text-align: right"&gt;0.6&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,400&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zqCnXaFC2qwc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;27.50&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zBGR9jsY5Y6f" style="text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_zCySkBFogFaj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;28.75&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_ziYGtqREeKo2" style="text-align: right"&gt;0.8&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_z2jLPQp4wguh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;31.25&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_zjm1Q8zchuIf" style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption16Member_zVuBtCZMvXAd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;42.09&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,800&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption16Member_zj4aoKSv3kR6" style="padding-bottom: 1.5pt; text-align: right"&gt;4.3&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,800&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20210930_z4xEfT2Ho4y8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,047,910&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;509,667&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</bivi:DisclosureEquityTransactionsDetails3Abstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption1Member"
      decimals="INF"
      unitRef="USDPShares">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption1Member"
      decimals="INF"
      unitRef="Shares">7200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption1Member">P3Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption1Member"
      decimals="INF"
      unitRef="Shares">7200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption2Member"
      decimals="INF"
      unitRef="USDPShares">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption2Member"
      decimals="INF"
      unitRef="Shares">4800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption2Member">P2Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption2Member"
      decimals="INF"
      unitRef="Shares">4800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption3Member"
      decimals="INF"
      unitRef="USDPShares">6.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption3Member"
      decimals="INF"
      unitRef="Shares">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption3Member">P2Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption3Member"
      decimals="INF"
      unitRef="Shares">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption4Member"
      decimals="INF"
      unitRef="USDPShares">7.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption4Member"
      decimals="INF"
      unitRef="Shares">25600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption4Member">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption4Member"
      decimals="INF"
      unitRef="Shares">25600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption5Member"
      decimals="INF"
      unitRef="USDPShares">7.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption5Member"
      decimals="INF"
      unitRef="Shares">1365835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption5Member">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption5Member"
      decimals="INF"
      unitRef="Shares">273167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption6Member"
      decimals="INF"
      unitRef="USDPShares">8.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption6Member"
      decimals="INF"
      unitRef="Shares">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption6Member">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption6Member"
      decimals="INF"
      unitRef="Shares">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption7Member"
      decimals="INF"
      unitRef="USDPShares">9.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption7Member"
      decimals="INF"
      unitRef="Shares">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption7Member">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption7Member"
      decimals="INF"
      unitRef="Shares">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption8Member"
      decimals="INF"
      unitRef="USDPShares">9.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption8Member"
      decimals="INF"
      unitRef="Shares">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption8Member">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption8Member"
      decimals="INF"
      unitRef="Shares">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption9Member"
      decimals="INF"
      unitRef="USDPShares">12.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption9Member"
      decimals="INF"
      unitRef="Shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption9Member">P1Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption9Member"
      decimals="INF"
      unitRef="Shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption10Member"
      decimals="INF"
      unitRef="USDPShares">13.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption10Member"
      decimals="INF"
      unitRef="Shares">618475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption10Member">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption10Member"
      decimals="INF"
      unitRef="Shares">172900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption11Member"
      decimals="INF"
      unitRef="USDPShares">25.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption11Member"
      decimals="INF"
      unitRef="Shares">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption11Member">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption11Member"
      decimals="INF"
      unitRef="Shares">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption12Member"
      decimals="INF"
      unitRef="USDPShares">26.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption12Member"
      decimals="INF"
      unitRef="Shares">4400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption12Member">P0Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption12Member"
      decimals="INF"
      unitRef="Shares">4400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption13Member"
      decimals="INF"
      unitRef="USDPShares">27.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption13Member"
      decimals="INF"
      unitRef="Shares">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption13Member">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption13Member"
      decimals="INF"
      unitRef="Shares">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption14Member"
      decimals="INF"
      unitRef="USDPShares">28.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption14Member"
      decimals="INF"
      unitRef="Shares">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption14Member">P0Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption14Member"
      decimals="INF"
      unitRef="Shares">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption15Member"
      decimals="INF"
      unitRef="USDPShares">31.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption15Member"
      decimals="INF"
      unitRef="Shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption15Member">P0Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption15Member"
      decimals="INF"
      unitRef="Shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOption16Member"
      decimals="INF"
      unitRef="USDPShares">42.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOption16Member"
      decimals="INF"
      unitRef="Shares">4800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-07-012021-09-30_custom_StockOption16Member">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-09-30_custom_StockOption16Member"
      decimals="INF"
      unitRef="Shares">4800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">2047910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">509667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_89A_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zrw56hMAvk93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table &lt;span id="xdx_8B7_z0QQjTnsMeX4"&gt;summarizes warrant activity&lt;/span&gt; during the three months ended September 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <bivi:DisclosureEquityTransactionsDetails4Abstract contextRef="From2021-07-01to2021-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureEquityTransactionsDetails4Abstract_zkBDdZCjc6Zi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; text-align: left"&gt;Outstanding and exercisable at June 30, 2021&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zs7KfeRTh9Xh" style="width: 8%; text-align: right"&gt;158,761&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zE5cSaAK3pKd" style="width: 8%; text-align: right"&gt;10.37&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dxH_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmmEkRQSS2O6" style="width: 8%; text-align: right" title="::XDX::P3Y1M6D"&gt;3.1&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlt4gJQyWyR8" style="width: 8%; text-align: right"&gt;1,765,437&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNMcf371zRSg" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0524"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuhbLfWasxQ6" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0525"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"/&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Outstanding and exercisable at September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zajLGq3UdVYj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;158,761&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoPZj7imp9Te" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10.37&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2_dxH_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdh4kevjau9a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Remaining Life, at the end of period::XDX::P2Y9M18D"&gt;2.8&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z720uyEvkK52" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;486,666&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</bivi:DisclosureEquityTransactionsDetails4Abstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">158761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">10.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">1765437</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">158761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="AsOf2021-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">10.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2021-09-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">486666</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zAQoMn1NrdT3" style="margin-top: 0; margin-bottom: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.3in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span id="xdx_82D_z1IN49lgSPDd"&gt;Commitments
and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Office
Lease&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;From
July 1, 2019 to October 31, 2021, the Company paid monthly rent of $1,000 to Acuitas for its headquarter office at 2120 Colorado Avenue
Suite 230, Santa Monica, CA 90404. Effective November 1, 2021, the Company relocated its headquarters to Nevada at 9120 Double Diamond
Parkway, Suite 1400, Reno Nevada 89521.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 1, 2021, the Company assumed a NeurMedix office lease that was extended to February 2022 at 6165 Greenwich Dr Suite 150, San Diego,
CA 92122. The lease agreement requires monthly payments of $8,782.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Challenge
to US Patent &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent and Trademark Office (&#x93;USPTO&#x94;) to institute
an Inter Partes Review (&#x93;IPR&#x94;) of our U.S. Patent No. 9,655,945 titled &#x93;Treatment of Ascites&#x94; (the &#x93;&#x92;945
patent&#x94;). On November 13, 2019, the Patent Trial and Appeal Board of USPTO issued a written decision in the IPR from which no appeal
was taken. The decision revoked all of the claims of the patent as lacking novelty or as obvious.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;This
ruling is unrelated to the Company&#x92;s Company&#x2019;s Orphan drug designations for ascites and hepatorenal syndrome
(&#x201c;HRS&#x201d;), which remain unchanged. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in
the United States for the designated use(s). In addition, the ruling does not affect the Company&#x2019;s rights in its pending patent
application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2 and Phase 3 trials, subject to
FDA review and authorization, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks
patent protection, such as the United States, if a patent issues from a patent application according to the patent laws of each issuing
count.&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Royalty
Agreements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant
to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor entities, LAT Pharma LLC and NanoAntibiotics,
Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among
LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company and PharmaIN Corporation, LAT Pharma&#x92;s former partner focused on the development of new modified drug candidates in the same
therapeutic field but not including BIV201 and on December 24, 2018, the Company returned its partial ownership rights to the PharmaIN
modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights
to our program remain unchanged and the Company remains obligated to pay royalties equal to less than 1% of future net sales of each
company&#x92;s ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company&#x92;s net license
revenues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant
to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated
to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign
issuances capped at a maximum of $200,000 per year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <bivi:EmployeeBenefitPlanTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_809_ecustom--EmployeeBenefitPlanTextBlock_zHPD37oeQPDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.3in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span id="xdx_82D_zFo2qBuLu881"&gt;Employee
Benefit Plan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
August 1, 2021, the Company began sponsoring an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code
(the &#x93;401K Plan&#x94;) pursuant to which, all employees meeting eligibility requirements are able to participate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Subject
to certain limitations in the Internal Revenue Code, eligible employees are permitted to make contributions to the 401K Plan on a pre-tax
salary reduction basis and the Company will match 5% of the first 5% of an employee&#x92;s contributions to the 401K Plan. For the three
months ended September 30, 2021, the Company made contributions of approximately $&lt;span id="xdx_905_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20210701__20210930_zd7Vg0Zg6ZU3" title="Comtribuiton made by Company"&gt;23,600&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

</bivi:EmployeeBenefitPlanTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      unitRef="USD">23600</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-07-01to2021-09-30">&lt;p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zuHULBLJJ0sg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.3in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span id="xdx_825_zVYGpY83f0xg"&gt;Subsequent
Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Effective
November 1, 2021, the Company relocated its headquarters to Nevada at 9120 Double Diamond Parkway, Suite 1400, Reno Nevada 89521.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297864872472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOVIE INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001580149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-2510769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9120 Double Diamond Parkway Suite 1400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Reno<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">89521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">888-3162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIVI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,962,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297867699544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheet (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 20,488,025<span></span>
</td>
<td class="nump">$ 4,511,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">105,923<span></span>
</td>
<td class="nump">93,487<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">20,593,948<span></span>
</td>
<td class="nump">4,605,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>OTHER&#160;&#160;ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,038,505<span></span>
</td>
<td class="nump">1,095,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">345,711<span></span>
</td>
<td class="nump">345,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">1,384,216<span></span>
</td>
<td class="nump">1,441,560<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">21,978,164<span></span>
</td>
<td class="nump">6,046,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">679,393<span></span>
</td>
<td class="nump">996,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Current portion of other liabilities</a></td>
<td class="nump">580,625<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,260,018<span></span>
</td>
<td class="nump">996,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">483,854<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">1,743,872<span></span>
</td>
<td class="nump">996,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#146; EQUITY :</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 800,000,000 shares authorized at September 30, 2021 and June 30, 2021, respectively; 24,962,373 and 22,333,324 shares issued and outstanding at September 30, 2021 and June 30, 2021, respectively</a></td>
<td class="nump">2,494<span></span>
</td>
<td class="nump">2,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">250,657,973<span></span>
</td>
<td class="nump">229,933,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(230,426,175)<span></span>
</td>
<td class="num">(224,885,422)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#146; equity</a></td>
<td class="nump">20,234,292<span></span>
</td>
<td class="nump">5,050,315<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#146; EQUITY</a></td>
<td class="nump">$ 21,978,164<span></span>
</td>
<td class="nump">$ 6,046,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297870692072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheet (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par Value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">24,962,373<span></span>
</td>
<td class="nump">22,333,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">24,962,373<span></span>
</td>
<td class="nump">22,333,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297864753704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">$ 57,344<span></span>
</td>
<td class="nump">$ 57,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">2,845,594<span></span>
</td>
<td class="nump">100,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">2,644,346<span></span>
</td>
<td class="nump">228,497<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">5,547,284<span></span>
</td>
<td class="nump">386,755<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(5,547,284)<span></span>
</td>
<td class="num">(386,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>OTHER EXPENSE (INCOME) EXPENSE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Change in fair value of derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(8,279,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">559,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="num">(7,645)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_TotalOtherExpenseIncome', window );">TOTAL OTHER INCOME, NET</a></td>
<td class="num">(6,531)<span></span>
</td>
<td class="num">(7,720,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET (LOSS)/INCOME</a></td>
<td class="num">(5,540,753)<span></span>
</td>
<td class="nump">7,333,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividend', window );">Deemed dividends - related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">53,598,320<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">$ (5,540,753)<span></span>
</td>
<td class="num">$ (46,264,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">- Basic</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (7.75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">- Diluted</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (7.75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- Basic</a></td>
<td class="nump">23,719,927<span></span>
</td>
<td class="nump">5,971,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- Diluted</a></td>
<td class="nump">23,719,927<span></span>
</td>
<td class="nump">5,971,622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_TotalOtherExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_TotalOtherExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297864898408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss)/income</a></td>
<td class="num">$ (5,540,753)<span></span>
</td>
<td class="nump">$ 7,333,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">57,344<span></span>
</td>
<td class="nump">57,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Stock based compensation - restricted stock</a></td>
<td class="nump">286,759<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option based compensation expense</a></td>
<td class="nump">1,926,962<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_InterestExpenseFromConvertibleDebenture', window );">Interest expense from convertible debenture</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">537,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Change in fair value of derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(8,279,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="num">(12,436)<span></span>
</td>
<td class="nump">323,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(316,981)<span></span>
</td>
<td class="num">(1,056,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">1,064,479<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,534,626)<span></span>
</td>
<td class="num">(1,083,825)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">18,511,009<span></span>
</td>
<td class="nump">15,628,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_PaymentOfConvertibleDebentureRelatedParty', window );">Payment of convertible debenture - related party</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,821,818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ProceedsFromConvertibleDebentureRelatedParty', window );">Proceeds from convertible debenture - related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">436,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">18,511,009<span></span>
</td>
<td class="nump">14,242,192<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash</a></td>
<td class="nump">15,976,383<span></span>
</td>
<td class="nump">13,158,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, beginning of period</a></td>
<td class="nump">4,511,642<span></span>
</td>
<td class="nump">37,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, end of period</a></td>
<td class="nump">20,488,025<span></span>
</td>
<td class="nump">13,195,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">70,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividend', window );">Deemed dividends - related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 53,598,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_InterestExpenseFromConvertibleDebenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_InterestExpenseFromConvertibleDebenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_PaymentOfConvertibleDebentureRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_PaymentOfConvertibleDebentureRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ProceedsFromConvertibleDebentureRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ProceedsFromConvertibleDebentureRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297861821064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 520<span></span>
</td>
<td class="nump">$ 19,538,742<span></span>
</td>
<td class="num">$ (41,037,898)<span></span>
</td>
<td class="num">$ (21,498,636)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Beginning Balance at Jun. 30, 2020</a></td>
<td class="nump">5,204,392.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of common stock, net cost of&#160;&#160;$2,224,992</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">15,627,830<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,628,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">1,799,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedParty', window );">Redemption of warrants&#160;&#160;- related party</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">13,132,230<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,132,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares', window );">[custom:RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares]</a></td>
<td class="nump">1,549,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividendForCommitmentShares', window );">Deemed dividend for purchase option - related party</a></td>
<td class="nump">$ 536<span></span>
</td>
<td class="nump">53,597,784<span></span>
</td>
<td class="num">(53,598,320)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividendForPurchaseOptionRelatedPartyInShares', window );">[custom:DeemedDividendForPurchaseOptionRelatedPartyInShares]</a></td>
<td class="nump">5,359,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Cashless exercise of options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">2,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,333,916<span></span>
</td>
<td class="nump">7,333,916<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 1,391<span></span>
</td>
<td class="nump">101,896,586<span></span>
</td>
<td class="num">(87,302,302)<span></span>
</td>
<td class="nump">14,595,675<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">13,916,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 2,232<span></span>
</td>
<td class="nump">229,933,505<span></span>
</td>
<td class="num">(224,885,422)<span></span>
</td>
<td class="nump">5,050,315<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Beginning Balance at Jun. 30, 2021</a></td>
<td class="nump">22,333,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of common stock, net cost of&#160;&#160;$2,224,992</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">18,510,750<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,511,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">2,592,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,540,753)<span></span>
</td>
<td class="num">(5,540,753)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 2,494<span></span>
</td>
<td class="nump">$ 250,657,973<span></span>
</td>
<td class="num">$ (230,426,175)<span></span>
</td>
<td class="nump">$ 20,234,292<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Ending Balance at Sep. 30, 2021</a></td>
<td class="nump">24,962,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock based compensation - restricted stock</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">286,756<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">286,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,926,962<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,926,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividendForCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividendForCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividendForPurchaseOptionRelatedPartyInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividendForPurchaseOptionRelatedPartyInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297866631320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ProceedsFromIssuanceOfCommonStockNetOfCost', window );">Proceeds from Issuance of Common Stock, Net of Cost</a></td>
<td class="nump">$ 2,224,992<span></span>
</td>
<td class="nump">$ 2,371,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ProceedsFromIssuanceOfCommonStockNetOfCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ProceedsFromIssuanceOfCommonStockNetOfCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297870134488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Background Information</a></td>
<td class="text"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zNrpROp71wV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>1.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_824_zfeb1p92e3gf">Background
Information</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">BioVie
Inc. (the &#147;Company&#148; or &#147;we&#148; or &#147;our&#148;) is a clinical-stage company developing innovative drug therapies
to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">In
liver disease, our Orphan Drug candidate BIV201 (continuous infusion terlipressin) is being developed as a future treatment option for
patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by NASH, hepatitis, and alcoholism.
The initial target for BIV201 therapy is refractory ascites. These patients suffer from frequent life-threatening complications, generate
more than $5 billion in annual treatment costs, and have an estimated 50% mortality rate within 6 to 12 months. The US Food and Drug
Administration (FDA) has not approved any drug to treat refractory ascites. A Phase 2a clinical trial of BIV201 was completed in 2019,
and a multi-center, randomized 30-patient Phase 2b trial is currently underway. As of October 31, 2021, the nine planned US study centers
have been activated and are actively screening patients, and multiple patients have been enrolled in the study. The FDA has communicated
to us that pending positive Phase 2 study results, a sufficiently large and well-controlled Phase 3 trial, with supportive trend data
from the Phase 2b (statistical significance not required), could potentially yield the clinical data needed to apply for BIV201 marketing
approval. The Phase 2b clinical trial protocol is summarized on www.clinicaltrials.gov, trial identifier NCT04112199.at nine US study
centers. (NCT04112199). Top-line results from this trial are expected in mid-2022, to be followed by a proposed single pivotal Phase
3 clinical trial beginning in late 2022. In June 2021, BioVie received written feedback from the FDA in response to a Type B meeting
request to conduct a pivotal US Phase 3 clinical trial in HRS-AKI, which is a life-threatening complication of advanced ascites. Based
on the guidance received in subsequent communications with the FDA, we are revising certain elements of our proposed study and are planning
to initiate this study in early 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The BIV201 development program was initiated by LAT Pharma LLC. On April
11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development
and marketing rights to its drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor
entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous
infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In neurodegenerative disease, BioVie acquired the biopharmaceutical assets
of NeurMedix, Inc. (&#8220;NeurMedix&#8221;), a privately held clinical-stage pharmaceutical company, in June 2021 (See Note 5 Related
Party Transactions<i>).</i> The acquired assets included NE3107, a potentially selective inhibitor of inflammatory ERK signaling that,
based on animal studies, is believed to reduce neuroinflammation. NE3107 is a novel orally administered small molecule that is thought
to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There
is emerging scientific consensus that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer&#8217;s
and Parkinson&#8217;s Disease, and NE3107 could, if approved represent an entirely new medical approach to treating these devastating
conditions affecting an estimated 6 million Americans suffering from Alzheimer&#8217;s and 1 million from Parkinson&#8217;s. The FDA has
authorized a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate NE3107
in subjects who have mild to moderate Alzheimer&#8217;s disease (NCT04669028). In August 2021, the study was initiated and the Company
is anticipating top line results in late calendar year 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In September 2021, the FDA authorized the Company to initiate a Phase 2
study assessing NE3107&#8217;s potential pro-motoric impact in Parkinson&#8217;s disease patients, and to assess its safety and tolerability.
The NM201 study (NCT05083260) is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinson&#8217;s
Disease (PD) participants treated with carbidopa/levodopa and NE3107. Forty patients with a defined L-dopa &#8220;off state&#8221; will
be randomized 1:1 placebo: active 20 mg twice daily for 28 days. Safety assessments will look at standard measures of patient health and
potential for drug-drug interactions affecting L-dopa PK and activity. Efficacy assessments will use the Motor Disease Society Unified
Parkinson&#8217;s Disease Rating (MDS-UPDRS) parts 1-4, Hauser ON/OFF Diary, and Non-Motor Symptom Scale. This study is planned to start
in early 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inflammation-driven insulin resistance is believed to be implicated in
a broad range of serious diseases, including multiple myeloma and prostate cancer, and we plan to begin exploring these opportunities
in the coming months using NE3107 or related compounds acquired in the NeurMedix asset purchase. NE3107 is patented in the United States,
Australia, Canada, Europe and South Korea.</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297956515624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureLiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_LiquidityTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_801_ecustom--LiquidityTextBlock_z991OxaD6U2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>2.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_82B_zbJRFTLwN668">Liquidity</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#146;s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors
include, but are not limited to: the results of clinical testing and trial activities of the Company&#146;s products, the Company&#146;s
ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other
companies; the price of, and demand for, Company products; the Company&#146;s ability to negotiate favorable licensing or other manufacturing
and marketing agreements for its products; and the Company&#146;s ability to raise capital. The Company&#146;s financial statements
have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction
of liabilities in the normal course of business. As of September 30, 2021, the Company had working capital of approximately $<span id="xdx_904_ecustom--WorkingCapital_iI_pp0p0_dm_c20210930_za0hGIVuyKTl">19.3 million</span>,
cash of approximately $20.5 million, stockholders&#146; equity of approximately $20.2 million, and an accumulated deficit of approximately
$230.4 million. In addition, the Company has not generated any revenues to date and no revenues are expected in the foreseeable future.
The Company&#146;s future operations are dependent on the success of the Company&#146;s ongoing development and commercialization efforts,
as well as its ability to secure additional financing as needed. Although our cash balance could possibly sustain operations over the
next 12 months if measures are taken to delay planned expenditures in our research protocols and slow the progress in the Company&#146;s
clinical programs, the Company&#146;s current planned operations to meet certain goals and objectives, project cash flows to be depleted
within that period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management
expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
emergence of widespread health emergencies or pandemics such as the coronavirus (&#147;COVID-19&#148;) pandemic (and its related variants),
may lead to continued regional quarantines, business shutdowns, labor shortages, disruptions to supply chains, and overall economic instability.
<span style="background-color: white">Although some jurisdictions have relaxed these measures, others have not or have reinstated them
as COVID-19 cases surge and variants emerge. </span>The duration and spread of the COVID-19 pandemic and the long-term impact of COVID-19
and its variants on the financial markets and the overall economy are highly uncertain and cannot be predicted at this time. If the financial
markets and/or the overall economy are impacted for an extended period, the Company&#146;s ability to raise funds may be materially
adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Although
management continues to pursue the Company&#146;s strategic plans, there is no assurance that the Company will be successful in obtaining
sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial
doubt on the Company&#146;s ability to continue as a going concern. The financial statements do not include any adjustments that might
result from the outcome of this uncertainty.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_LiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_LiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297866506872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_808_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKVLHe8KPZtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>3.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_82F_zn1En0B21Igg">Significant
Accounting Policies</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zVt5wK2ghfz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86B_zXIe4pq7YEI2">Basis
of Presentation &#8211; Interim Financial Information</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">These
unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally
accepted in the United State of America (&#147;U.S. GAAP&#148;) for interim financial information and with the instructions to Form
10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the &#147;SEC&#148;) for Interim Reporting. Accordingly,
they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim
condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of
management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily
indicative of the results for the full year. The condensed balance sheet at June 30, 2021 was derived from audited annual financial statements
but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements
and information included under the heading &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
should be read in conjunction with the Company&#146;s audited financial statements for the fiscal years ended June 30, 2021 and 2020
in our Annual Report on Form 10-K filed with the SEC on August 30, 2021. For a summary of significant accounting policies, see the Company&#146;s
Annual Report on Form 10-K for the fiscal year ended June 30, 2021, filed with the SEC on August 30, 2021.</span></p>




<p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zofzqztTEL9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_zX1qceKp9L2f">Net
loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Basic
net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of
shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable
to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common
stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants,
and convertible debentures. For the three months ended September 30, 2021 and 2020, such amounts were excluded from the diluted loss
since their effect was considered anti-dilutive due to the net loss for the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMbKKVIrooBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
table below shows the number of outstanding stock options and warrants as of September 30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B2_z0tX7T0yqcz4" style="display: none">Schedule of Dilutive securities were excluded from the computation of diluted loss per share</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureSignificantAccountingPoliciesDetailsAbstract_zgt12QaPmEk9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20210701__20210930_zANOx7Ka9fB8" style="white-space: nowrap; font-weight: bold; text-align: center">September 30,<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20200701__20200930_zuPppPHBr576" style="white-space: nowrap; font-weight: bold; text-align: center">September 30,<br/> 2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgntrTihfehd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Stock Options</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">2,047,910</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">57,200</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zQJkEJ2hQtqf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">158,761</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">214,665</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zSQKHWPtcXL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,206,671</td><td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">271,865</td><td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zGydOHp7dvJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znuIQdnZzy2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_868_zetsEdpzxnWl">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers the applicability and impact of all Accounting Standards Updates (&#147;ASU&#146;s&#148;). There were no recent
ASUs that are expected to have a material impact on the Company&#146;s balance sheets or statements of operations.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297870534296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_zGtlPgtmNg23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>4.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_820_zAyUUkDNcuBc">Intangible
Assets</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#146;s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated
useful lives.</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zhDBduEhQHwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The following is a <span id="xdx_8B2_zXdi33piIYW3">summary of the intangible assets as of September 30, 2021 and June 30, 2021</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureIntangibleAssetsDetailsAbstract_zdhkg5UeB2ja" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210930_zEV02dG0L4e4" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20210630_z0RuQ3iaOTMc" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maCzIr2_zHjf2GhR7Qu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Intellectual Property</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,293,770</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,293,770</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzIr2_zqwGU197JWEc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Accumulated Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,255,265</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,197,921</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzIr2_zQyuieteyjx4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Intellectual Property, Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,038,505</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,095,849</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zDpD6RehzK82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
expense was $57,344 in each of the three-month periods ended September 30, 2021 and 2020. The Company amortizes intellectual property
over the expected original useful lives of 10 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zBeeBe3sD9c9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Estimated
future amortization expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B6_zyPIF4pR1JY7" style="display: none">Schedule of Future expected Amortization of intangible assets</span></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIntangibleAssetsDetails2Abstract_zCW8JWPDF8o2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details 2)">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"/><td/>
    <td style="text-align: left"/><td id="xdx_49D_20210930_zTbrrOgzxROd" style="text-align: right"/><td style="white-space: nowrap; text-align: left"/></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_maFLIANzEri_zgO6p3tEYCzd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: center">Year ending June 30, 2022 (Remaining nine months)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 40%; text-align: right">172,033</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_maFLIANzEri_zFjNRrlOHuvk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_maFLIANzEri_zmKyI8W5u2J9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_maFLIANzEri_zcqdEgWzFoqe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_maFLIANzEri_z12jBGdCK2L3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">178,341</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzEri_zocxriG53r7i" style="vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: center; padding-bottom: 4pt">Intellectual Property, Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,038,505</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zPrO3xzOO9jh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297869787672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zLAQgIxIgor" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>5.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_82D_z6w4wutwLP8l">Related
Party Transactions</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Asset
Acquisition with NeurMedix</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
April 27, 2021, the Company entered into an Asset Purchase Agreement (&#147;APA&#148;) with NeurMedix and Acuitas Group Holdings, LLC
(&#147;Acuitas&#148;), which are related party affiliates, pursuant to which the Company acquired certain assets from NeurMedix and
assumed certain liabilities of NeurMedix, in exchange for consideration of cash and shares of common stock. The acquired assets include,
among others, those related to certain drug candidates being developed by NeurMedix, including NE3107, a small molecule orally administered
inhibitor of insulin resistance and the pathological inflammatory cascade, with a novel mechanism of action that has potential applications
for treatment against Alzheimer&#146;s Disease and Parkinson&#146;s Disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Subject
to the terms and conditions of the APA, following the closing, the Company was potentially obligated to deliver contingent stock consideration
to NeurMedix (or its successor). Previously, the Company was obligated to deliver contingent stock consideration to NeurMedix (or its
successor) consisting of shares of the Company&#146;s common stock having an aggregate value of up to $3.0 billion, subject to the Company&#146;s
achievement of certain clinical, regulatory and commercial milestones related to the drug candidates to be acquired from NeurMedix, and
subject to a cap limiting each issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates
exceeding 89.9999% of the Company&#146;s issued and outstanding common stock. Pursuant to Amendment No. 1 to the APA, dated May 9, 2021,
the Company is now obligated to deliver to NeurMedix (or its successor) 4.5 million shares upon the achievement of each of the four milestones
set forth in the APA, for an aggregate of up to 18 million shares, subject to a cap limiting the issuance of shares if such issuance
would result in the beneficial ownership of NeurMedix and its affiliates exceeding 87.5% of the Company&#146;s issued and outstanding
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
June 10, 2021, and pursuant to the APA, the Company issued to Acuitas (as NeurMedix&#146;s assignee) 8,361,308 shares of the Company&#146;s
common stock and made a cash payment of approximately $2.3 million, representing NeurMedix&#146;s direct and documented cash expenditures
to advance certain programs from March 1, 2021 through the closing date and cash payments to other third parties for expenses totaling
approximately $4.0 million for due diligence, legal fees, transaction fees and the fairness opinion. Since the transaction was between
entities under common control, there were no fair value adjustments of the purchased assets, and the historical cost basis of the purchased
assets was zero. The total consideration paid was expensed as research and development expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Equity
Transactions with Acuitas&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
September 22, 2020, concurrent with the closing of the Company&#146;s Offering, approximately $1.8 million was paid to Acuitas satisfying
all amounts owed on the Debenture due September 24, 2020 held by the Company&#146;s controlling stockholder, Acuitas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Additionally,
in connection with the close of the public offering on September 22, 2020, the Company issued an aggregate of <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20200922__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AcuitasGroupHoldingsLLCMember_zvgPmNM7sVxi">6,909,582</span> shares of Common
Stock to Acuitas, representing (i) 5.4 million shares issuable pursuant to Acuitas&#146; rights under the Purchase Agreement dated July
3, 2018, as amended on June 24, 2019 and October 9, 2019; and the various extension letters; which resulted in a deemed dividend at the
close of the public offering at price of $10 per share, consistent with the Company&#146;s accounting policy; and (ii) the automatic
exercise of 1.5 million warrants issued to Acuitas in connection with the Debenture financing at the par value of the Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended June 30, 2021, the Company received additional draws under the Debenture totaling $436,000. The total draws as of September
22, 2020 were $1.7 million and the related total number of warrants issuable at $4.00 per share of common stock was 424,750 of which
328,250 warrants had been issued. In accordance with the Debenture agreements, at September 22, 2020 upon the Company&#146;s close of
its public offering, all the warrants issued related to the debenture totaling 1,453,250 were mandatorily redeemed along with the additional
96,500 shares common stock issued to Acuitas.</span></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297866726216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Liabilities</a></td>
<td class="text"><p id="xdx_800_eus-gaap--OtherLiabilitiesDisclosureTextBlock_z27grdkoDrFg" style="margin-top: 0; margin-bottom: 0"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>6.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_829_zGDg4XdRTQD2">Other
Liabilities</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Other
liabilities represent retention bonus arrangements with certain employees. Retention bonuses of $<span id="xdx_904_eus-gaap--AccruedBonusesCurrent_iI_c20210930_zNOMLZiWpNrf" title="Retention Bonus">1,161,000</span> were expensed in the accompanying
statements of operations for three months ended September 30, 2021, and will be paid in equal monthly installments, which began in August
2021, over a 24-month period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297866625704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity Transactions</a></td>
<td class="text"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLic4YiI8IQg" style="margin-top: 0; margin-bottom: 0"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>7.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_829_zQxFcBSeMoLb">Equity
Transactions</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zkjsdSwEZukf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the <span id="xdx_8B2_zMhGPBJKM8rg">activity relating to the Company&#146;s stock options</span> for the three months ended September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureEquityTransactionsDetailsAbstract_zUDksJz3P2nd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Remaining<br/> Average<br/> Contractual<br/> Term</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%">Outstanding at June 30, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zc3sQt12uA11" style="width: 8%; text-align: right">755,200</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMxtvcFHYt3d" style="width: 8%; text-align: right">4.34</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgWpdyzBbep1" style="width: 8%; text-align: right" title="::XDX::P4Y8M24D">4.4</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zItGo8gYfZ73" style="width: 8%; text-align: right">2,569,232</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3ULBQYYxxkl" style="text-align: right">1,365,835</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zurnkyE7C562" style="text-align: right">7.74</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zREAmJUKkSM3" style="text-align: right" title="::XDX::P5Y">5.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6feaz93nisc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBL8tIOO6VKf" style="border-bottom: Black 1.5pt solid; text-align: right">(73,125</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9GTkYzO0rOa" style="border-bottom: Black 1.5pt solid; text-align: right">(13.91</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuRonGsbCsVb" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding at September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zcGmFG5ACdGh" style="border-bottom: Black 4pt double; text-align: right">2,047,910</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMJZkkwl6G4" style="border-bottom: Black 4pt double; text-align: right">9.79</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLPY99ECMA2" style="border-bottom: Black 4pt double; text-align: right" title="::XDX::P4Y7M6D">4.6</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zl0mN8nW0oKk" style="border-bottom: Black 4pt double; text-align: right">42,824</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable at&#160;&#160;September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zG06cFgtjtl7" style="border-bottom: Black 4pt double; text-align: right">509,667</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYEKm8VMNp02" style="border-bottom: Black 4pt double; text-align: right">9.36</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoaXe3SIlpMk" style="border-bottom: Black 4pt double; text-align: right" title="::XDX::P4Y8M24D">4.4</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zD5o5odkHXR8" style="border-bottom: Black 4pt double; text-align: right">42,824</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zYKHA4IpbzN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_894_ecustom--FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock_z0Sf7wfJ4g61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflects the following
<span id="xdx_8BE_zZReCL1jqSnk">weighted-average assumptions</span> for the three months ended September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureEquityTransactionsDetails2Abstract_ztDB9NrRcIC" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210701__20210930_zJZX4vp7yhA1" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30,<br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20200701__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0UE2NTouSrh" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Expected life of options (In years)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvnvxxV9xDm1" style="width: 8%; text-align: right" title="::XDX::P5Y">5</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20200701__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUcs8CRqY0Ka" style="width: 8%; text-align: right" title="::XDX::P5Y">5</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zxvi4Duh82Qg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74.96</td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77.29</td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_zjGkd7w4ZJDj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.80</td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.39</td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_znPMQ03DqbCk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="white-space: nowrap; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A5_zOqXzsw6BJd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Expected
volatility is based on the historical volatilities of the daily closing price of the common stock of three comparable companies and the
expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures
as they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded stock option-based compensation expense of $1,926,962 and $0 for three-month periods ended September 30, 2021 and 2020,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2021, there was approximately $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_dm_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zwW4jAOxrI34">6.8 million</span> of unrecognized compensation cost related to non-vested stock options granted
to Directors and Officers, which is expected to be recognized over a weighted-average period of approximately <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxH_c20200701__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zdn0w0PZUJad" title="::XDX::P4Y8M12D">4.7 years</span>.</span></p>




<p id="xdx_895_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zZkgcsyrksQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following is a <span id="xdx_8B5_z30SSZRKMv1f">summary of stock options outstanding and exercisable by exercise price</span> as of September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureEquityTransactionsDetails3Abstract_zuGgkXD8B0lj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" id="xdx_482_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_zzse3RhQHwkd" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_z6AVEBugc5fg" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted Average<br/> Contract Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_znLpV2PdUlF2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_41F_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_zlzWDlwQARrg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 0%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">2.80</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right">7,200</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_z2BhotaHlggb" style="width: 21%; text-align: right">3.3</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right">7,200</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zK6SEnRVxODh" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.75</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,800</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zkIWEQcIHs36" style="text-align: right">2.3</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,800</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zNjkQSVc90mf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.25</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zcAKX7Nj6Qtg" style="text-align: right">2.1</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41C_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zXswctEcCdO7" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,600</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zHv847TXCduf" style="text-align: right">4.4</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,600</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_zbtwRNK63AS9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.74</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,365,835</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_zMvqH2XqrVIi" style="text-align: right">4.9</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">273,167</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_ztSnC8kSrty5" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.75</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_zE0hM2NgIRhk" style="text-align: right">2.5</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41E_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_zYe19PNHete6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.54</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_zdCFSzIXDAJd" style="text-align: right">4.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_zTmyxofmFDxf" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.90</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_zkUeEtm3VuT3" style="text-align: right">4.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_412_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_z4SlBLPnFzG9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12.50</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_zOxlQhdvwmtb" style="text-align: right">1.3</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zFM8eGshjUQb" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13.91</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">618,475</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zTlZXajx5WQa" style="text-align: right">4.2</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172,900</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_zlDTv2rgQolb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25.00</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_z9Qn1iDR2Xj3" style="text-align: right">1.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zEhx08uKnpE4" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">26.25</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,400</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zBGQOEMkbi6" style="text-align: right">0.6</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,400</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zqCnXaFC2qwc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">27.50</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zBGR9jsY5Y6f" style="text-align: right">0.5</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_zCySkBFogFaj" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">28.75</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_ziYGtqREeKo2" style="text-align: right">0.8</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_z2jLPQp4wguh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">31.25</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_zjm1Q8zchuIf" style="text-align: right">0.1</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption16Member_zVuBtCZMvXAd" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">42.09</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,800</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption16Member_zj4aoKSv3kR6" style="padding-bottom: 1.5pt; text-align: right">4.3</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,800</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20210930_z4xEfT2Ho4y8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,047,910</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">509,667</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zp9zzJdhA1w7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zrw56hMAvk93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following table <span id="xdx_8B7_z0QQjTnsMeX4">summarizes warrant activity</span> during the three months ended September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureEquityTransactionsDetails4Abstract_zkBDdZCjc6Zi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 4)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: left">Outstanding and exercisable at June 30, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zs7KfeRTh9Xh" style="width: 8%; text-align: right">158,761</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zE5cSaAK3pKd" style="width: 8%; text-align: right">10.37</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dxH_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmmEkRQSS2O6" style="width: 8%; text-align: right" title="::XDX::P3Y1M6D">3.1</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlt4gJQyWyR8" style="width: 8%; text-align: right">1,765,437</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNMcf371zRSg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0524">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuhbLfWasxQ6" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"/><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and exercisable at September 30, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zajLGq3UdVYj" style="border-bottom: Black 1.5pt solid; text-align: right">158,761</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoPZj7imp9Te" style="border-bottom: Black 1.5pt solid; text-align: right">10.37</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2_dxH_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdh4kevjau9a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Remaining Life, at the end of period::XDX::P2Y9M18D">2.8</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z720uyEvkK52" style="border-bottom: Black 1.5pt solid; text-align: right">486,666</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_z1xMCc7fxPMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Of
the above warrants, 9,391 expire in the fiscal year ending June 30, 2022, 4,815 expire in the fiscal year ending June 30, 2023, 2,714
expire in the fiscal year ending June 30, 2025, and 141,841 expire in the fiscal year ending June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuance
of common stock for cash</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
August 11, 2021, the Company closed a registered public offering issuing 2,500,000 of its Class A common stock at $8.00&#160;per share,
resulting in net proceeds to the Company of approximately $17.8 million, net of issuance costs of approximately $2.2 million</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
September 24, 2021, the Company issued 92,000 of its Class A common stock at $8.00&#160;per share in connection with the underwriters&#146;
exercise of its over-allotment option in for the August 2021 registered public offering, resulting in net proceeds to the Company of
approximately $707,000, net of issuance cost of approximately $29,000.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuance
of Shares for Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
August 20, 2021, the Company awarded 58,759 restricted stock units (&#147;RSUs&#148;) to the President and CEO under the Company&#146;s
2019 Omnibus Incentive Equity Plan (the &#147;2019 Omnibus Plan&#148;) as his salary for the period from April 27, 2021, the date of
his appointment, through December 31, 2021. The number of RSUs awarded was based on a prorated annual base salary of $600,000 at a 10%
discount to the grant date fair value of $7.74 per share of the Company&#146;s common stock. Each RSU awarded the to the CEO entitles
him to receive one share of common stock upon vesting. A total of 15,339 RSUs (representing the pro rata portion of the RSU award for
the period from April 27, 2021 to June 30, 2021) vested at the grant date, 21,710 RSUs vested at September 30, 2021, and 21,710 will
vest at December 31, 2021. Accordingly, during the three months ended September 30, 2021, 37,049 RSUs vested and 37,049 shares of common
were issued to the CEO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded stock-based compensation expense related to these RSUs of $286,759 and $0 for three- month periods ended September 30,
2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuance
of Stock Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
August 20, 2021, the Company granted, under the 2019 Omnibus Plan, stock options to purchase 1,365,835 shares of common stock to the
executive management team. Twenty percent (20%) of the shares underlying the options awarded vested on the grant date, and the remaining
80% vest equally over a 5-year period, on the first, second, third, fourth and fifth anniversary of the grant date. The option price
per share is $7.74 per share, the grant date fair value, and the options terminate on the tenth anniversary of the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Forfeiture
of Stock Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
August 27, 2021, the Chief Executive Officer forfeited unvested stock options to purchase up to 73,125 shares of common stock that were
previously granted to him as compensation as an independent director of the board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297866594776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zAQoMn1NrdT3" style="margin-top: 0; margin-bottom: 0"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>8.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_82D_z1IN49lgSPDd">Commitments
and Contingencies</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Office
Lease&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">From
July 1, 2019 to October 31, 2021, the Company paid monthly rent of $1,000 to Acuitas for its headquarter office at 2120 Colorado Avenue
Suite 230, Santa Monica, CA 90404. Effective November 1, 2021, the Company relocated its headquarters to Nevada at 9120 Double Diamond
Parkway, Suite 1400, Reno Nevada 89521.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
June 1, 2021, the Company assumed a NeurMedix office lease that was extended to February 2022 at 6165 Greenwich Dr Suite 150, San Diego,
CA 92122. The lease agreement requires monthly payments of $8,782.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Challenge
to US Patent </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent and Trademark Office (&#147;USPTO&#148;) to institute
an Inter Partes Review (&#147;IPR&#148;) of our U.S. Patent No. 9,655,945 titled &#147;Treatment of Ascites&#148; (the &#147;&#146;945
patent&#148;). On November 13, 2019, the Patent Trial and Appeal Board of USPTO issued a written decision in the IPR from which no appeal
was taken. The decision revoked all of the claims of the patent as lacking novelty or as obvious.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">This
ruling is unrelated to the Company&#146;s Company&#8217;s Orphan drug designations for ascites and hepatorenal syndrome
(&#8220;HRS&#8221;), which remain unchanged. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in
the United States for the designated use(s). In addition, the ruling does not affect the Company&#8217;s rights in its pending patent
application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2 and Phase 3 trials, subject to
FDA review and authorization, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks
patent protection, such as the United States, if a patent issues from a patent application according to the patent laws of each issuing
count.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Royalty
Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor entities, LAT Pharma LLC and NanoAntibiotics,
Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among
LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company and PharmaIN Corporation, LAT Pharma&#146;s former partner focused on the development of new modified drug candidates in the same
therapeutic field but not including BIV201 and on December 24, 2018, the Company returned its partial ownership rights to the PharmaIN
modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights
to our program remain unchanged and the Company remains obligated to pay royalties equal to less than 1% of future net sales of each
company&#146;s ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company&#146;s net license
revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated
to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign
issuances capped at a maximum of $200,000 per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297870599992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureEmployeeBenefitPlanAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_EmployeeBenefitPlanTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p id="xdx_809_ecustom--EmployeeBenefitPlanTextBlock_zHPD37oeQPDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>9.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_82D_zFo2qBuLu881">Employee
Benefit Plan</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
August 1, 2021, the Company began sponsoring an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code
(the &#147;401K Plan&#148;) pursuant to which, all employees meeting eligibility requirements are able to participate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Subject
to certain limitations in the Internal Revenue Code, eligible employees are permitted to make contributions to the 401K Plan on a pre-tax
salary reduction basis and the Company will match 5% of the first 5% of an employee&#146;s contributions to the 401K Plan. For the three
months ended September 30, 2021, the Company made contributions of approximately $<span id="xdx_905_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20210701__20210930_zd7Vg0Zg6ZU3" title="Comtribuiton made by Company">23,600</span>.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureEmployeeBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureEmployeeBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_EmployeeBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_EmployeeBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297870093624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zuHULBLJJ0sg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>10.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_825_zVYGpY83f0xg">Subsequent
Events</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Effective
November 1, 2021, the Company relocated its headquarters to Nevada at 9120 Double Diamond Parkway, Suite 1400, Reno Nevada 89521.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297866427224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation &#8211; Interim Financial Information</a></td>
<td class="text"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zVt5wK2ghfz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86B_zXIe4pq7YEI2">Basis
of Presentation &#8211; Interim Financial Information</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">These
unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally
accepted in the United State of America (&#147;U.S. GAAP&#148;) for interim financial information and with the instructions to Form
10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the &#147;SEC&#148;) for Interim Reporting. Accordingly,
they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim
condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of
management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily
indicative of the results for the full year. The condensed balance sheet at June 30, 2021 was derived from audited annual financial statements
but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements
and information included under the heading &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
should be read in conjunction with the Company&#146;s audited financial statements for the fiscal years ended June 30, 2021 and 2020
in our Annual Report on Form 10-K filed with the SEC on August 30, 2021. For a summary of significant accounting policies, see the Company&#146;s
Annual Report on Form 10-K for the fiscal year ended June 30, 2021, filed with the SEC on August 30, 2021.</span></p>




<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per Common Share</a></td>
<td class="text"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zofzqztTEL9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_zX1qceKp9L2f">Net
loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Basic
net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of
shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable
to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common
stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants,
and convertible debentures. For the three months ended September 30, 2021 and 2020, such amounts were excluded from the diluted loss
since their effect was considered anti-dilutive due to the net loss for the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMbKKVIrooBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
table below shows the number of outstanding stock options and warrants as of September 30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B2_z0tX7T0yqcz4" style="display: none">Schedule of Dilutive securities were excluded from the computation of diluted loss per share</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureSignificantAccountingPoliciesDetailsAbstract_zgt12QaPmEk9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20210701__20210930_zANOx7Ka9fB8" style="white-space: nowrap; font-weight: bold; text-align: center">September 30,<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20200701__20200930_zuPppPHBr576" style="white-space: nowrap; font-weight: bold; text-align: center">September 30,<br/> 2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgntrTihfehd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Stock Options</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">2,047,910</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">57,200</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zQJkEJ2hQtqf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">158,761</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">214,665</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zSQKHWPtcXL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,206,671</td><td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">271,865</td><td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zGydOHp7dvJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znuIQdnZzy2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_868_zetsEdpzxnWl">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers the applicability and impact of all Accounting Standards Updates (&#147;ASU&#146;s&#148;). There were no recent
ASUs that are expected to have a material impact on the Company&#146;s balance sheets or statements of operations.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297951427288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive securities were excluded from the computation of diluted loss per share</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMbKKVIrooBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
table below shows the number of outstanding stock options and warrants as of September 30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B2_z0tX7T0yqcz4" style="display: none">Schedule of Dilutive securities were excluded from the computation of diluted loss per share</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract', window );">Significant Accounting Policies</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureSignificantAccountingPoliciesDetailsAbstract_zgt12QaPmEk9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20210701__20210930_zANOx7Ka9fB8" style="white-space: nowrap; font-weight: bold; text-align: center">September 30,<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20200701__20200930_zuPppPHBr576" style="white-space: nowrap; font-weight: bold; text-align: center">September 30,<br/> 2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgntrTihfehd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Stock Options</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">2,047,910</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">57,200</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zQJkEJ2hQtqf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">158,761</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">214,665</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zSQKHWPtcXL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,206,671</td><td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">271,865</td><td style="white-space: nowrap; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297951874616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">summary of the intangible assets as of September 30, 2021 and June 30, 2021</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zhDBduEhQHwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The following is a <span id="xdx_8B2_zXdi33piIYW3">summary of the intangible assets as of September 30, 2021 and June 30, 2021</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureIntangibleAssetsDetailsAbstract', window );">Intangible Assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureIntangibleAssetsDetailsAbstract_zdhkg5UeB2ja" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210930_zEV02dG0L4e4" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20210630_z0RuQ3iaOTMc" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maCzIr2_zHjf2GhR7Qu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Intellectual Property</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,293,770</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,293,770</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzIr2_zqwGU197JWEc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Accumulated Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,255,265</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,197,921</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzIr2_zQyuieteyjx4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Intellectual Property, Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,038,505</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,095,849</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future expected Amortization of intangible assets</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zBeeBe3sD9c9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Estimated
future amortization expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B6_zyPIF4pR1JY7" style="display: none">Schedule of Future expected Amortization of intangible assets</span></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureIntangibleAssetsDetails2Abstract', window );">Intangible Assets (Details 2)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIntangibleAssetsDetails2Abstract_zCW8JWPDF8o2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details 2)">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"/><td/>
    <td style="text-align: left"/><td id="xdx_49D_20210930_zTbrrOgzxROd" style="text-align: right"/><td style="white-space: nowrap; text-align: left"/></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_maFLIANzEri_zgO6p3tEYCzd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: center">Year ending June 30, 2022 (Remaining nine months)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 40%; text-align: right">172,033</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_maFLIANzEri_zFjNRrlOHuvk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_maFLIANzEri_zmKyI8W5u2J9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_maFLIANzEri_zcqdEgWzFoqe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_maFLIANzEri_z12jBGdCK2L3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">178,341</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzEri_zocxriG53r7i" style="vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: center; padding-bottom: 4pt">Intellectual Property, Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,038,505</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureIntangibleAssetsDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureIntangibleAssetsDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureIntangibleAssetsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureIntangibleAssetsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297951236072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">activity relating to the Company&#8217;s stock options</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zkjsdSwEZukf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the <span id="xdx_8B2_zMhGPBJKM8rg">activity relating to the Company&#146;s stock options</span> for the three months ended September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureEquityTransactionsDetailsAbstract', window );">Equity Transactions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureEquityTransactionsDetailsAbstract_zUDksJz3P2nd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Remaining<br/> Average<br/> Contractual<br/> Term</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%">Outstanding at June 30, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zc3sQt12uA11" style="width: 8%; text-align: right">755,200</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMxtvcFHYt3d" style="width: 8%; text-align: right">4.34</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgWpdyzBbep1" style="width: 8%; text-align: right" title="::XDX::P4Y8M24D">4.4</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zItGo8gYfZ73" style="width: 8%; text-align: right">2,569,232</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3ULBQYYxxkl" style="text-align: right">1,365,835</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zurnkyE7C562" style="text-align: right">7.74</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zREAmJUKkSM3" style="text-align: right" title="::XDX::P5Y">5.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6feaz93nisc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBL8tIOO6VKf" style="border-bottom: Black 1.5pt solid; text-align: right">(73,125</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9GTkYzO0rOa" style="border-bottom: Black 1.5pt solid; text-align: right">(13.91</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuRonGsbCsVb" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding at September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zcGmFG5ACdGh" style="border-bottom: Black 4pt double; text-align: right">2,047,910</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMJZkkwl6G4" style="border-bottom: Black 4pt double; text-align: right">9.79</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLPY99ECMA2" style="border-bottom: Black 4pt double; text-align: right" title="::XDX::P4Y7M6D">4.6</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zl0mN8nW0oKk" style="border-bottom: Black 4pt double; text-align: right">42,824</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable at&#160;&#160;September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zG06cFgtjtl7" style="border-bottom: Black 4pt double; text-align: right">509,667</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYEKm8VMNp02" style="border-bottom: Black 4pt double; text-align: right">9.36</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoaXe3SIlpMk" style="border-bottom: Black 4pt double; text-align: right" title="::XDX::P4Y8M24D">4.4</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zD5o5odkHXR8" style="border-bottom: Black 4pt double; text-align: right">42,824</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock', window );">weighted-average assumptions</a></td>
<td class="text"><p id="xdx_894_ecustom--FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock_z0Sf7wfJ4g61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflects the following
<span id="xdx_8BE_zZReCL1jqSnk">weighted-average assumptions</span> for the three months ended September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureEquityTransactionsDetails2Abstract', window );">Equity Transactions (Details 2)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureEquityTransactionsDetails2Abstract_ztDB9NrRcIC" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210701__20210930_zJZX4vp7yhA1" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30,<br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20200701__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0UE2NTouSrh" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Expected life of options (In years)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvnvxxV9xDm1" style="width: 8%; text-align: right" title="::XDX::P5Y">5</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20200701__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUcs8CRqY0Ka" style="width: 8%; text-align: right" title="::XDX::P5Y">5</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zxvi4Duh82Qg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74.96</td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77.29</td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_zjGkd7w4ZJDj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.80</td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.39</td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_znPMQ03DqbCk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="white-space: nowrap; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">summary of stock options outstanding and exercisable by exercise price</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zZkgcsyrksQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following is a <span id="xdx_8B5_z30SSZRKMv1f">summary of stock options outstanding and exercisable by exercise price</span> as of September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureEquityTransactionsDetails3Abstract', window );">Equity Transactions (Details 3)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureEquityTransactionsDetails3Abstract_zuGgkXD8B0lj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" id="xdx_482_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_zzse3RhQHwkd" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_z6AVEBugc5fg" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted Average<br/> Contract Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_znLpV2PdUlF2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_41F_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_zlzWDlwQARrg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 0%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">2.80</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right">7,200</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_z2BhotaHlggb" style="width: 21%; text-align: right">3.3</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right">7,200</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zK6SEnRVxODh" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.75</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,800</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zkIWEQcIHs36" style="text-align: right">2.3</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,800</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zNjkQSVc90mf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.25</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zcAKX7Nj6Qtg" style="text-align: right">2.1</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41C_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zXswctEcCdO7" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,600</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zHv847TXCduf" style="text-align: right">4.4</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,600</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_zbtwRNK63AS9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.74</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,365,835</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_zMvqH2XqrVIi" style="text-align: right">4.9</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">273,167</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_ztSnC8kSrty5" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.75</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_zE0hM2NgIRhk" style="text-align: right">2.5</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41E_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_zYe19PNHete6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.54</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_zdCFSzIXDAJd" style="text-align: right">4.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_zTmyxofmFDxf" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.90</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_zkUeEtm3VuT3" style="text-align: right">4.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_412_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_z4SlBLPnFzG9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12.50</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_zOxlQhdvwmtb" style="text-align: right">1.3</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zFM8eGshjUQb" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13.91</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">618,475</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zTlZXajx5WQa" style="text-align: right">4.2</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172,900</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_zlDTv2rgQolb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25.00</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_z9Qn1iDR2Xj3" style="text-align: right">1.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zEhx08uKnpE4" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">26.25</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,400</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zBGQOEMkbi6" style="text-align: right">0.6</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,400</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zqCnXaFC2qwc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">27.50</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zBGR9jsY5Y6f" style="text-align: right">0.5</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_zCySkBFogFaj" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">28.75</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_ziYGtqREeKo2" style="text-align: right">0.8</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_z2jLPQp4wguh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">31.25</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_zjm1Q8zchuIf" style="text-align: right">0.1</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption16Member_zVuBtCZMvXAd" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">42.09</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,800</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption16Member_zj4aoKSv3kR6" style="padding-bottom: 1.5pt; text-align: right">4.3</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,800</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20210930_z4xEfT2Ho4y8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,047,910</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">509,667</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">summarizes warrant activity</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zrw56hMAvk93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following table <span id="xdx_8B7_z0QQjTnsMeX4">summarizes warrant activity</span> during the three months ended September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureEquityTransactionsDetails4Abstract', window );">Equity Transactions (Details 4)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureEquityTransactionsDetails4Abstract_zkBDdZCjc6Zi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 4)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: left">Outstanding and exercisable at June 30, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zs7KfeRTh9Xh" style="width: 8%; text-align: right">158,761</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zE5cSaAK3pKd" style="width: 8%; text-align: right">10.37</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dxH_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmmEkRQSS2O6" style="width: 8%; text-align: right" title="::XDX::P3Y1M6D">3.1</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlt4gJQyWyR8" style="width: 8%; text-align: right">1,765,437</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNMcf371zRSg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0524">&#8212;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuhbLfWasxQ6" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">&#8212;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"/><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and exercisable at September 30, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zajLGq3UdVYj" style="border-bottom: Black 1.5pt solid; text-align: right">158,761</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoPZj7imp9Te" style="border-bottom: Black 1.5pt solid; text-align: right">10.37</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2_dxH_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdh4kevjau9a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Remaining Life, at the end of period::XDX::P2Y9M18D">2.8</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z720uyEvkK52" style="border-bottom: Black 1.5pt solid; text-align: right">486,666</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureEquityTransactionsDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureEquityTransactionsDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureEquityTransactionsDetails3Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureEquityTransactionsDetails3Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureEquityTransactionsDetails4Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureEquityTransactionsDetails4Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureEquityTransactionsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureEquityTransactionsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297866537096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liquidity (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureLiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_WorkingCapital', window );">[custom:WorkingCapital-0]</a></td>
<td class="nump">$ 19,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297866802904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,206,671<span></span>
</td>
<td class="nump">271,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,047,910<span></span>
</td>
<td class="nump">57,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">158,761<span></span>
</td>
<td class="nump">214,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297955586632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intellectual Property</a></td>
<td class="nump">$ 2,293,770<span></span>
</td>
<td class="nump">$ 2,293,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less Accumulated Amortization</a></td>
<td class="num">(1,255,265)<span></span>
</td>
<td class="num">(1,197,921)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intellectual Property, Net</a></td>
<td class="nump">$ 1,038,505<span></span>
</td>
<td class="nump">$ 1,095,849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297951580536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details 2) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">Year ending June 30, 2022 (Remaining nine months)</a></td>
<td class="nump">$ 172,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2023</a></td>
<td class="nump">229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2024</a></td>
<td class="nump">229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2025</a></td>
<td class="nump">229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive', window );">2026</a></td>
<td class="nump">178,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intellectual Property, Net</a></td>
<td class="nump">$ 1,038,505<span></span>
</td>
<td class="nump">$ 1,095,849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297970066152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 22, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">24,962,373<span></span>
</td>
<td class="nump">22,333,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bivi_AcuitasGroupHoldingsLLCMember', window );">Acuitas Group Holdings L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,909,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bivi_AcuitasGroupHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bivi_AcuitasGroupHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297866502744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Retention Bonus</a></td>
<td class="nump">$ 1,161,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297861873304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="nump">2,047,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">509,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance</a></td>
<td class="nump">755,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 4.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 8 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 2,569,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">1,365,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 7.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1', window );">Weighted Average Contractual Term, Granted (in Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="num">(73,125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares</a></td>
<td class="num">$ (13.91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="nump">2,047,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ / shares</a></td>
<td class="nump">$ 9.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4', window );">[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4]</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 42,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">509,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 9.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 8 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | $</a></td>
<td class="nump">$ 42,824<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297864871992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details 2)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">74.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.29%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.39%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297862770664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details 3)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">2,047,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">509,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption1Member', window );">Stock Option 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">7,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">7,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption2Member', window );">Stock Option 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption3Member', window );">Stock Option 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption4Member', window );">Stock Option 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">25,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">25,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption5Member', window );">Stock Option 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 7.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">1,365,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">273,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption6Member', window );">Stock Option 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 8.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption7Member', window );">Stock Option 7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 9.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption8Member', window );">Stock Option 8 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 9.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption9Member', window );">Stock Option 9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 12.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption10Member', window );">Stock Option 10 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 13.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">618,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">172,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption11Member', window );">Stock Option 11 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 25.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption12Member', window );">Stock Option 12 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 26.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption13Member', window );">Stock Option 13 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 27.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption14Member', window );">Stock Option 14 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 28.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption15Member', window );">Stock Option 15 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 31.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption16Member', window );">Stock Option 16 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 42.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption8Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption8Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption11Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption11Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption12Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption12Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption13Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption13Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption14Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption14Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption16Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOption16Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297951794520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details 4) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance</a></td>
<td class="nump">158,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 10.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 1,765,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance</a></td>
<td class="nump">158,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value, Ending Balance | $ / shares</a></td>
<td class="nump">$ 10.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2', window );">Weighted Average Remaining Life, at the end of period</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 486,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297866544200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details Narrative) - Equity Option [Member] - Director [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 6,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140297866504360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureEmployeeBenefitPlanAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Comtribuiton made by Company</a></td>
<td class="nump">$ 23,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureEmployeeBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureEmployeeBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MX^LN8)& 83]C\FW+=F2>!=!ZIVFC0[FH%0YN\>?T8WT&N7T1V[B4')=[YK'
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M5A\TM6F\=38BJY=QJ0K]K]!^:CJ76:P7A<?@@B4LBSA8-MWS_CYC52P4CS^
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M:"+Y2IN'_:J0@&+D'6$TV%&*7 ^:02*XHU=HAWFSFEVW?&.D3]AO<A3Z@6:
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M<PM<KL=>VWM=N&?+#.V"/QFMZ!)F@ ^K6)F97[ND+ >AF11$P6+LW;2OI^W
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M F4#S/V%E/@ZL6=M_6TU^0=02P,$%     @ H8%J4Z9H6BZ*!   LP\  !@
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M)WC%I0DD_O9X@I-$6A(<?Q^-&K5/J7CY?++^K9R\F,P[*O"$)G^2F&\'1L\
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MWJ-Y_PMKHY!T?5GXK*X]?ZYH4%_2;L$8%62E!*PTPTNWUIW=HE.(!7=!1V&
MYPH&]27L%CR09,>;-]4C6^]K; HQ#=NY:L'P?T<M;%\]G "&H1TTX=J27AA
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MC/1&*R@:INMT27F.MC39,%U-,<OYEFI91@FG"YX4==NJ%,8)/D%QYVB?XTE
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M! ,4LQ7=IO*ZV/W)Z@VY*EY4I*)\1;O:UAJ@:"MDD=7.D$&6Y-5_>E\#<>!
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M\^K7Y0O^>G[Z>#04CU@6S(0C%E E=A+C!S)]/"TX/<W!0=J@PXH'2:;T2Y2
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M717H/ U]9U*P?>2<;EX<$N.J6++<FFJ5-]Z6H7G[8$-K 6K7#YR"GD6\7I)
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M.X:FPW=7 ERW59U"MHF3O+7$>Q'%BA\B="& _3MKZ:2$!/W3EO\&4$L#!!0
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M8N&@1A @YEROV'WMW39+=.8LBO:@K(=N*C?P%@<0+U$,@'%SMFYF99$COA:
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M;*U8;7/;N!'^SE^!T?4ZSHQ.+[3EV(GM&=E.>N[$B<9VKA\Z_0"1*PDU"#
M*$7]]7T6(!7)E\O,=?I%(BGL[K-OSRYUL;'NV:^(@OA::>,O>ZL0ZC?#H2]6
M5$D_L#49_+*PKI(!MVXY]+4C64:A2@_ST>AT6$EE>E<7\=G,75W8)FAE:.:$
M;ZI*NNTU:;NY[(U[W8,'M5P%?C"\NJCEDAXI?*YG#G?#G992562\LD8X6ESV
MIN,WUR=\/A[X3='&[UT+]F1N[3/?W)67O1$#(DU%8 T27VNZ(:U9$6!\:77V
M=B99</^ZT_X^^@Y?YM+3C=7_4&587?;.>J*DA6QT>+";7ZGU9\+Z"JM]_!2;
M=':2]T31^&"K5A@(*F72M_S:QF%/X&ST!P)Y*Y!'W,E01'DK@[RZ<'8C')^&
M-KZ(KD9I@%.&D_(8''Y5D M7-[:J5$"4@Q?2E.+&FJ#,DDRAR%\, TSPP6'1
MJKM.ZO(_4'<L[J%@Y<4[4U)Y*#\$M!V^O,-WG?]0X2/5 W$\ZHM\E(]_H.]X
MY^]QU'?\O_@K;I4OM/6-(_'/Z=P'AZ+YUP^LGNRLGD2K)_^O*/]0'3?J&U_+
M@BY[Z$1/;DV]J[.!V#.3_=ZY3XN%*BC[0"AB\=[9*OM[H[=BS+$=GXM@Q:<B
MV#DY<3Q.\>Z+L"+66DNS%;54I:@XO9!R,"+L0OQEW!^-1BP\+1H5I!<@"J'@
MYPH4\:61+D"AC::%#"(?YR-HU-;)$C)K,@UECY DD7.:'Z4)DHM(%;(O;J;B
M?'0R.AF(=XL%Q086'^V:*D;Y79 .-%/(0.5+#)XQ?J2U+"7C.&<<M[:9:T+6
M)=PJLYETSQNY!8B(9WPR J ',CNYL_-)/AZ(3P:1,_1] -*#WV!>0JAQ]U2J
MKYW[.D8^K&!^@T#1UT#<)0SL/<T=<&Y98<[X3L>G$_$W1V0VJEB)6]>!FJ0@
M 30M;3_C""&F^4 \K3H+<@DYK@)$XTNC4"&[M-5RFZJ04W?6?WT&P9N5U)I0
M)AF ?'X4,X0/LO!R6CNEV^X;G_7%AJ"Q(&2A%,8&]BEZ<P\%RA3/SI9!K&0I
M:@J*29>= ZS/@\=!IY;K\@G)QVQQSVU-BJ.__C0^>?WV\^/LZ1-?GKU]Q5%1
MQD-/$PC5+.X,5]*,D^F1E34S?BMW-WOHI."7;=R!Q8]V(,[[IY-)__QD(J!0
M U82?,(<B_W"<E-?(,(^:1)'##R=XL_3MQ#.ZJBQM<6%L%>-QZF/4C6TII^<
MDCJZ/*UKPN6UE:YD8]%5H5 LL58V3@5(8)X4*LX[9:(>>"86:%6Q67$9H!1E
M5)1Q 07Y3"8E?B?G:&V?6:76;(9U%%JJRG=W=9L&+[0LGL$.4+HF';8"?8NG
M=KY6MO&L5OG,-9J/*"\:@]:*C87$[!5\"H[_=GN6CU_C_I.K5\A:Z9HET'FU
M-)(K(O&#3*&.D5D1(%GP"<+CMZ:$MY0=L9Y\]/;7A\=X-7[[JM_&P!'O&L!3
M0/^2RH&8F@-KL22!>*&<#[\$^PM7&M:;L*U!*CJ25RQB+UZ++4D78],>HJ^%
M;KQ:*P1$F2Q6KU'L]F.0#)GAAQCQY!-^:3P=>93#'9:,LHR%GZJ@C5YI(8=^
M$3*2V&'TVG YWAX\IYUY"RM7R9(I61ERK@$]KC$E^KEHTU [BPZEP,2A%5J]
M9'A5H]M0<\K):<5#PD,U8P?8G14M#;?H;,6LD<=LI.MC$;AR?1_+VOS?$;/-
MWM].N;RX[_BD;,+*.O4?F?Q-R2ELHTM!H/70Q% #XEJ5))J: 8-S=P%O"[%
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MXK*AWPW:$$#?MUK[@Q$*##^PU5=02P,$%     @ H8%J4QCK_=DZ @  X 0
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MQCNX\TIK.AC^@O&GMOP-4$L#!!0    ( *&!:E-A+BM)]P8  .$1   9
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MF=/-U>V\; 6K:C^CULK2Q//+'?UBH'8*=+Y1RCX*SD'WT[+\#U!+ P04
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MIKVUKK H"9.(0J$IO9-$BQ+M1= &BC=VEBZYTI/9+BM]>8(P"?I]P;G:!*9
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M "ZLJ*)NX'D3M\*$.7EFQQ8BSWBC*&&P$$@V587%RRU0WDX=W]D//)!MJ<R
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MZ@.?)1SU"4<G$[[*&ZJ)0I^D:&IT(UA!JXU"M^8W0?=WP%<@3QD3]SKQ_^U
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M0=_^N*S\>P,;$OSYP1@\!V$&QA=<_ %02P,$%     @ H8%J4\8&_TOO!
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M]=V!ZE"\>A=4$\D*<[6NF%07M1FFZBT%7!NH[PEC<C_1#IK7V?0W4$L#!!0
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MH\VD99N5)%QE$X7=ADD2!MGB7'LS':4[F-_OPC#9KJ0GV,T==_$O4$L#!!0
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M5*\)TXS5^PVY7J#F-XS)EXY64+\(9_\"4$L#!!0    ( *&!:E/75!I@?P(
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MW!B?04$[OEM75F&AZ;K7'Y"M0W.S069*9TQW87ID8YJ,!,M!CN;% NY&52&
MQJC2#C)."R5IHV'CT0XL[9P)<0O/S8_\"?<JWZEJ!#65W= *:H>.QDV ?Y?-
M<>_21B_B#2K^H,SGI=V.;.;0+.Q&LYROFODJ[P1@[#V<G5:56'\2O) E<YL_
M.N!D1#=^P4)I_FBC0:O,K8%I$CPP;?A\U_)+T^J.K<RFG58YKKG_!C7_W3P7
M3#)-Q:YHV_NO.<LO5AQ?_BO)S7^5?<%>C>UA^-I%#MZ"R.0MB'R=/1FVQ\[.
MV?;D9.NL ;Q!C,EW>%L1VZ#!;,F%X;*=+7B6,?GL@+/TAL[LZ^83?KL^8SE=
M"G/7@6.R'7]C&5^6:;?J!A+1KMJ.O\+V>DGW^F)C<9FQ%<NF[507LV88V(&-
MVE[@L(]<-Y<?P7P<YD< P^)@"C ?YX7%^9_V,T3WXS!,V]"+#%&?(>KCO'S(
MM/E@<?P^J;W\.TW3.$X2+*/3J5?!%,M;DL#7SX9I P\L#D3ZLUSCU<8[Y' ?
M8#4]U"'83O%.Q':*YQH0?][ (TW]U<;B@ =6!:QW(+X_#O24WR>.H:J8-NP)
MQI$TQ1#H17^/)@F2G00^_OI@3TD<IZD? <RO((XQ!)Y&',$4@ 8,B>/F'-P[
MC\+-.15N?X.9_ 902P,$%     @ H8%J4Y>*NQS     $P(   L   !?<F5L
M<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5Q
MD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC
M0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W
M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ
M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "A@6I3$N2+R#P#  !Z%@
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M0UYF>_CA(<%^\4MHRAQI8'-LR3);&2F)I($E\K<F8'N7X+B0EMUR4Y?/*^A
MDA\C@3U"[\B^CTE9)0ULE2T[\D],.Y&D[)(&MLOGB"SM0%)V20/;Y?/"IJ'U
M,2G/I($]\Z&ZZ;Y"/B9EG32P=;9FH6W[DG).&M@Y%.3&SJ2<DP9V#HF9^9@9
M)9YL%^)98_8[F)1[LL#N(3%ON8])V2<+;)^MQ>X[J(])'H8U]HG79YT%3J6@
MN,5'6&S/N<S'AM67]K.MOU]75].EE!?8=J=N-"_61Z?K8]_3WU!+ P04
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M(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M
M(:M (:M (:M (6N*0M84A:PI"EG3_R3KA];+O_[UUJY)+55S\&?=_\W9%U!+
M 0(4 Q0    ( *&!:E,'04UB@0   +$    0              "  0    !D
M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ H8%J4W-V1V#M    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MH8%J4YE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " "A@6I3W=O@93<%  !M%0  &
M    @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MH8%J4_XY7;$>!0  9Q(  !@              ("!>0T  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *&!:E/!& ^.V@(  &<)   8
M          " @<T2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " "A@6I3IFA:+HH$  "S#P  &               @('=%0  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ H8%J4\<(3U3G!0  -18
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M965T.2YX;6Q02P$"% ,4    " "A@6I3BG$>,\$&  "F$   &0
M    @(&T.0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M *&!:E-A?:=+DP,   $(   9              " @:Q   !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ H8%J4WL+2PC_!P  G!,  !D
M             ("!=D0  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " "A@6I3<7.;?#$"  #F!   &0              @(&L3   >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( *&!:E-\$HM2<0D
M /\7   9              " @11/  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ H8%J4Z4@2M$W"   ?1$  !D              ("!
MO%@  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "A@6I3
M5NL\3A(#  #,!@  &0              @($J80  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( *&!:E,8Z_W9.@(  . $   9
M      " @7-D  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ H8%J4V$N*TGW!@  X1$  !D              ("!Y&8  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "A@6I3_BCC!\4"  "L!@
M&0              @($2;@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( *&!:E.B$9M8/@,  , (   9              " @0YQ  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ H8%J4Z\T/V\L
M!0  7P\  !D              ("!@W0  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " "A@6I3J68Y_M4!  "R P  &0
M@('F>0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( *&!
M:E/X L,6F0(  )H'   9              " @?)[  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ H8%J4Q75-GU8 @  T 4  !D
M         ("!PGX  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " "A@6I3BQ*)?'\"  #+!@  &0              @(%1@0  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *&!:E,KMZST5@(  $8&
M   9              " @0>$  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ H8%J4Z7L7_'A 0  S0,  !D              ("!E(8
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "A@6I3Q@;_
M2^\$  #A&   &0              @(&LB   >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( *&!:E,,;_D7]@(  *D)   9
M  " @=*-  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MH8%J4_(84+F%!P  1TX  !D              ("!_Y   'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " "A@6I30206Y\4#   =#@  &0
M            @(&[F   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( *&!:E/75!I@?P(  + %   9              " @;><  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ H8%J4_I1I9@& @
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M2P$"% ,4    " "A@6I3X#T)5V@!  !*%   &@              @ $_J0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "A@6I3')H)
M78P!  #G%   $P              @ '?J@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     *0 I !8+  "<K      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>70</ContextCount>
  <ElementCount>230</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>24</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Balance Sheet (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/BalanceSheet</Role>
      <ShortName>Condensed Balance Sheet (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/BalanceSheetParenthetical</Role>
      <ShortName>Condensed Balance Sheet (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Background Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/BackgroundInformation</Role>
      <ShortName>Background Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/OtherLiabilities</Role>
      <ShortName>Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Equity Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactions</Role>
      <ShortName>Equity Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IntangibleAssets</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Equity Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactionsTables</Role>
      <ShortName>Equity Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/EquityTransactions</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/LiquidityDetailsNarrative</Role>
      <ShortName>Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/Liquidity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IntangibleAssetsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Intangible Assets (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IntangibleAssetsDetails2</Role>
      <ShortName>Intangible Assets (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IntangibleAssetsTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Other Liabilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/OtherLiabilitiesDetailsNarrative</Role>
      <ShortName>Other Liabilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/OtherLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Equity Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactionsDetails</Role>
      <ShortName>Equity Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/EquityTransactionsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Equity Transactions (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactionsDetails2</Role>
      <ShortName>Equity Transactions (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/EquityTransactionsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Equity Transactions (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactionsDetails3</Role>
      <ShortName>Equity Transactions (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/EquityTransactionsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Equity Transactions (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactionsDetails4</Role>
      <ShortName>Equity Transactions (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/EquityTransactionsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Equity Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative</Role>
      <ShortName>Equity Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/EquityTransactionsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bivi-20210930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Employee Benefit Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EmployeeBenefitPlanDetailsNarrative</Role>
      <ShortName>Employee Benefit Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="bivi-20210930_10q.htm">bivi-20210930_10q.htm</File>
    <File>bivi-20210930.xsd</File>
    <File>bivi-20210930_10qex10z14.htm</File>
    <File>bivi-20210930_10qex10z15.htm</File>
    <File>bivi-20210930_10qex10z16.htm</File>
    <File>bivi-20210930_10qex10z17.htm</File>
    <File>bivi-20210930_10qex10z18.htm</File>
    <File>bivi-20210930_10qex10z19.htm</File>
    <File>bivi-20210930_10qex31z1.htm</File>
    <File>bivi-20210930_10qex31z2.htm</File>
    <File>bivi-20210930_10qex32z1.htm</File>
    <File>bivi-20210930_10qex32z2.htm</File>
    <File>bivi-20210930_10qex3z5.htm</File>
    <File>bivi-20210930_cal.xml</File>
    <File>bivi-20210930_def.xml</File>
    <File>bivi-20210930_lab.xml</File>
    <File>bivi-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bivi-20210930_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 4,
   "contextCount": 70,
   "dts": {
    "calculationLink": {
     "local": [
      "bivi-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bivi-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bivi-20210930_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bivi-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bivi-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bivi-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 261,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 34,
    "http://nanoantibiotics.com/20210930": 10,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 49
   },
   "keyCustom": 24,
   "keyStandard": 206,
   "memberCustom": 17,
   "memberStandard": 6,
   "nsprefix": "bivi",
   "nsuri": "http://nanoantibiotics.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://nanoantibiotics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Significant Accounting Policies",
     "role": "http://nanoantibiotics.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Intangible Assets",
     "role": "http://nanoantibiotics.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Related Party Transactions",
     "role": "http://nanoantibiotics.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Other Liabilities",
     "role": "http://nanoantibiotics.com/role/OtherLiabilities",
     "shortName": "Other Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Equity Transactions",
     "role": "http://nanoantibiotics.com/role/EquityTransactions",
     "shortName": "Equity Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Commitments and Contingencies",
     "role": "http://nanoantibiotics.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bivi:EmployeeBenefitPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Employee Benefit Plan",
     "role": "http://nanoantibiotics.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bivi:EmployeeBenefitPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Subsequent Events",
     "role": "http://nanoantibiotics.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Balance Sheet (Unaudited)",
     "role": "http://nanoantibiotics.com/role/BalanceSheet",
     "shortName": "Condensed Balance Sheet (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Intangible Assets (Tables)",
     "role": "http://nanoantibiotics.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Equity Transactions (Tables)",
     "role": "http://nanoantibiotics.com/role/EquityTransactionsTables",
     "shortName": "Equity Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "bivi:LiquidityTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "bivi:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Liquidity (Details Narrative)",
     "role": "http://nanoantibiotics.com/role/LiquidityDetailsNarrative",
     "shortName": "Liquidity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "bivi:LiquidityTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "bivi:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureSignificantAccountingPoliciesDetailsAbstract",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Significant Accounting Policies (Details)",
     "role": "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails",
     "shortName": "Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureSignificantAccountingPoliciesDetailsAbstract",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureIntangibleAssetsDetailsAbstract",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Intangible Assets (Details)",
     "role": "http://nanoantibiotics.com/role/IntangibleAssetsDetails",
     "shortName": "Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureIntangibleAssetsDetailsAbstract",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureIntangibleAssetsDetails2Abstract",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Intangible Assets (Details 2)",
     "role": "http://nanoantibiotics.com/role/IntangibleAssetsDetails2",
     "shortName": "Intangible Assets (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureIntangibleAssetsDetails2Abstract",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Related Party Transactions (Details Narrative)",
     "role": "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "Related Party Transactions (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2020-09-22_custom_AcuitasGroupHoldingsLLCMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Other Liabilities (Details Narrative)",
     "role": "http://nanoantibiotics.com/role/OtherLiabilitiesDetailsNarrative",
     "shortName": "Other Liabilities (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureEquityTransactionsDetails3Abstract",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Equity Transactions (Details)",
     "role": "http://nanoantibiotics.com/role/EquityTransactionsDetails",
     "shortName": "Equity Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureEquityTransactionsDetailsAbstract",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-06-30_us-gaap_StockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureEquityTransactionsDetails2Abstract",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Equity Transactions (Details 2)",
     "role": "http://nanoantibiotics.com/role/EquityTransactionsDetails2",
     "shortName": "Equity Transactions (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureEquityTransactionsDetails2Abstract",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical)",
     "role": "http://nanoantibiotics.com/role/BalanceSheetParenthetical",
     "shortName": "Condensed Balance Sheet (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureEquityTransactionsDetails3Abstract",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Equity Transactions (Details 3)",
     "role": "http://nanoantibiotics.com/role/EquityTransactionsDetails3",
     "shortName": "Equity Transactions (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureEquityTransactionsDetails3Abstract",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-09-30_custom_StockOption1Member",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureEquityTransactionsDetails4Abstract",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-06-30_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Equity Transactions (Details 4)",
     "role": "http://nanoantibiotics.com/role/EquityTransactionsDetails4",
     "shortName": "Equity Transactions (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:DisclosureEquityTransactionsDetails4Abstract",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-06-30_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-06-30_us-gaap_StockOptionMember_srt_DirectorMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Equity Transactions (Details Narrative)",
     "role": "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative",
     "shortName": "Equity Transactions (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2021-06-30_us-gaap_StockOptionMember_srt_DirectorMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "bivi:EmployeeBenefitPlanTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Employee Benefit Plan (Details Narrative)",
     "role": "http://nanoantibiotics.com/role/EmployeeBenefitPlanDetailsNarrative",
     "shortName": "Employee Benefit Plan (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "bivi:EmployeeBenefitPlanTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)",
     "role": "http://nanoantibiotics.com/role/StatementsOfOperations",
     "shortName": "Condensed Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)",
     "role": "http://nanoantibiotics.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RestrictedStockExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2020-06-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Statements of Changes in Stockholders' Equity (Deficit)",
     "role": "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit",
     "shortName": "Statements of Changes in Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "AsOf2020-06-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "bivi:ProceedsFromIssuanceOfCommonStockNetOfCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "bivi:ProceedsFromIssuanceOfCommonStockNetOfCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Background Information",
     "role": "http://nanoantibiotics.com/role/BackgroundInformation",
     "shortName": "Background Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bivi:LiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Liquidity",
     "role": "http://nanoantibiotics.com/role/Liquidity",
     "shortName": "Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bivi-20210930_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bivi:LiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 24,
   "tag": {
    "bivi_AcuitasGroupHoldingsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acuitas Group Holdings L L C [Member]"
       }
      }
     },
     "localname": "AcuitasGroupHoldingsLLCMember",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_DeemedDividend": {
     "auth_ref": [],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividends - related party"
       }
      }
     },
     "localname": "DeemedDividend",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows",
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bivi_DeemedDividendForCommitmentShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend for purchase option - related party"
       }
      }
     },
     "localname": "DeemedDividendForCommitmentShares",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bivi_DeemedDividendForPurchaseOptionRelatedPartyInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:DeemedDividendForPurchaseOptionRelatedPartyInShares]"
       }
      }
     },
     "localname": "DeemedDividendForPurchaseOptionRelatedPartyInShares",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "bivi_DisclosureEmployeeBenefitPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plan"
       }
      }
     },
     "localname": "DisclosureEmployeeBenefitPlanAbstract",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bivi_DisclosureEquityTransactionsDetails2Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Transactions (Details 2)"
       }
      }
     },
     "localname": "DisclosureEquityTransactionsDetails2Abstract",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bivi_DisclosureEquityTransactionsDetails3Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Transactions (Details 3)"
       }
      }
     },
     "localname": "DisclosureEquityTransactionsDetails3Abstract",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bivi_DisclosureEquityTransactionsDetails4Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Transactions (Details 4)"
       }
      }
     },
     "localname": "DisclosureEquityTransactionsDetails4Abstract",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bivi_DisclosureEquityTransactionsDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureEquityTransactionsDetailsAbstract",
        "verboseLabel": "Equity Transactions"
       }
      }
     },
     "localname": "DisclosureEquityTransactionsDetailsAbstract",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bivi_DisclosureIntangibleAssetsDetails2Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details 2)"
       }
      }
     },
     "localname": "DisclosureIntangibleAssetsDetails2Abstract",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bivi_DisclosureIntangibleAssetsDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureIntangibleAssetsDetailsAbstract",
        "verboseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "DisclosureIntangibleAssetsDetailsAbstract",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bivi_DisclosureLiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity"
       }
      }
     },
     "localname": "DisclosureLiquidityAbstract",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureSignificantAccountingPoliciesDetailsAbstract",
        "verboseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "DisclosureSignificantAccountingPoliciesDetailsAbstract",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bivi_EmployeeBenefitPlanTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EmployeeBenefitPlanTextBlock",
        "verboseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "EmployeeBenefitPlanTextBlock",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bivi_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "weighted-average assumptions"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bivi_InterestExpenseFromConvertibleDebenture": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense from convertible debenture"
       }
      }
     },
     "localname": "InterestExpenseFromConvertibleDebenture",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bivi_LiquidityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LiquidityTextBlock",
        "verboseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityTextBlock",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/Liquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bivi_PaymentOfConvertibleDebentureRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PaymentOfConvertibleDebentureRelatedParty",
        "negatedLabel": "Payment of convertible debenture - related party"
       }
      }
     },
     "localname": "PaymentOfConvertibleDebentureRelatedParty",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bivi_ProceedsFromConvertibleDebentureRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from convertible debenture - related party"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebentureRelatedParty",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bivi_ProceedsFromIssuanceOfCommonStockNetOfCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock, Net of Cost"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfCost",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption of warrants\u00a0\u00a0- related party"
       }
      }
     },
     "localname": "RedemptionOfWarrantsAndPurchaseOptionRelatedParty",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares]"
       }
      }
     },
     "localname": "RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life, at the end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails4"
     ],
     "xbrltype": "durationItemType"
    },
    "bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Contractual Term, Granted (in Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bivi_StockOption10Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 10 [Member]"
       }
      }
     },
     "localname": "StockOption10Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption11Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 11 [Member]"
       }
      }
     },
     "localname": "StockOption11Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption12Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 12 [Member]"
       }
      }
     },
     "localname": "StockOption12Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption13Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 13 [Member]"
       }
      }
     },
     "localname": "StockOption13Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption14Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 14 [Member]"
       }
      }
     },
     "localname": "StockOption14Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption15Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 15 [Member]"
       }
      }
     },
     "localname": "StockOption15Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption16Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 16 [Member]"
       }
      }
     },
     "localname": "StockOption16Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 1 [Member]"
       }
      }
     },
     "localname": "StockOption1Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 2 [Member]"
       }
      }
     },
     "localname": "StockOption2Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 3 [Member]"
       }
      }
     },
     "localname": "StockOption3Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 4 [Member]"
       }
      }
     },
     "localname": "StockOption4Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 5 [Member]"
       }
      }
     },
     "localname": "StockOption5Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption6Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 6 [Member]"
       }
      }
     },
     "localname": "StockOption6Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption7Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 7 [Member]"
       }
      }
     },
     "localname": "StockOption7Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption8Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 8 [Member]"
       }
      }
     },
     "localname": "StockOption8Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_StockOption9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 9 [Member]"
       }
      }
     },
     "localname": "StockOption9Member",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "bivi_TotalOtherExpenseIncome": {
     "auth_ref": [],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "TotalOtherExpenseIncome",
        "totalLabel": "TOTAL OTHER INCOME, NET"
       }
      }
     },
     "localname": "TotalOtherExpenseIncome",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bivi_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:WorkingCapital-0]"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://nanoantibiotics.com/20210930",
     "presentation": [
      "http://nanoantibiotics.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r263",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r94",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r24",
      "r211"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r26"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Retention Bonus"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/OtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r39",
      "r40",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r166",
      "r167",
      "r168",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net (loss) income to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r54",
      "r101",
      "r106"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows",
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r58",
      "r86",
      "r88",
      "r92",
      "r96",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r175",
      "r179",
      "r191",
      "r209",
      "r211",
      "r231",
      "r239"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r33",
      "r58",
      "r96",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r175",
      "r179",
      "r191",
      "r209",
      "r211"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r58",
      "r96",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r175",
      "r179",
      "r191",
      "r209"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total other assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER\u00a0\u00a0ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation \u2013 Interim Financial Information"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r23",
      "r211",
      "r250",
      "r251"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet",
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase in cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r30",
      "r111",
      "r233",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r112",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r60",
      "r61",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheetParenthetical",
      "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17",
      "r211"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.0001 par value; 800,000,000 shares authorized at September 30, 2021 and June 30, 2021, respectively; 24,962,373 and 22,333,324 shares issued and outstanding at September 30, 2021 and June 30, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r144",
      "r145",
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Comtribuiton made by Company"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails2",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3",
      "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative",
      "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r36",
      "r184",
      "r185",
      "r186",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails2",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3",
      "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative",
      "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r44",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r73",
      "r75",
      "r77",
      "r78",
      "r79",
      "r82",
      "r83",
      "r189",
      "r190",
      "r235",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "- Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r44",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r75",
      "r77",
      "r78",
      "r79",
      "r82",
      "r83",
      "r189",
      "r190",
      "r235",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "- Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r39",
      "r40",
      "r41",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r84",
      "r97",
      "r137",
      "r138",
      "r166",
      "r167",
      "r168",
      "r172",
      "r173",
      "r188",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r245",
      "r246",
      "r247",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails4",
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Year ending June 30, 2022 (Remaining nine months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails2": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails2": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r105",
      "r217"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Intellectual Property"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r105",
      "r216"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intellectual Property, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails",
      "http://nanoantibiotics.com/role/IntangibleAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfDerivatives": {
     "auth_ref": [
      "r54",
      "r236"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "bivi_TotalOtherExpenseIncome",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.",
        "label": "Gain (Loss) on Sale of Derivatives",
        "negatedLabel": "Change in fair value of derivative liabilities"
       }
      }
     },
     "localname": "GainLossOnSaleOfDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows",
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r98",
      "r99",
      "r211",
      "r230"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r41",
      "r45"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r100",
      "r103"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r42",
      "r85",
      "r198",
      "r199",
      "r237"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "bivi_TotalOtherExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "bivi_TotalOtherExpenseIncome",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r48",
      "r51",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r25",
      "r58",
      "r89",
      "r96",
      "r113",
      "r114",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r176",
      "r179",
      "r180",
      "r191",
      "r209",
      "r210"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r58",
      "r96",
      "r191",
      "r211",
      "r232",
      "r241"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u0092 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u0092 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r58",
      "r96",
      "r113",
      "r114",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r176",
      "r179",
      "r180",
      "r191",
      "r209",
      "r210",
      "r211"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r50",
      "r52",
      "r55"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r37",
      "r38",
      "r41",
      "r43",
      "r55",
      "r58",
      "r63",
      "r65",
      "r66",
      "r67",
      "r68",
      "r71",
      "r72",
      "r76",
      "r86",
      "r87",
      "r90",
      "r91",
      "r93",
      "r96",
      "r113",
      "r114",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r190",
      "r191",
      "r234",
      "r243"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "NET (LOSS)/INCOME",
        "verboseLabel": "Net (loss)/income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows",
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF NON-CASH FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Offsetting Assets [Line Items]"
       }
      }
     },
     "localname": "OffsettingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails2",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3",
      "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative",
      "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsTable": {
     "auth_ref": [
      "r34",
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.",
        "label": "Offsetting Assets [Table]"
       }
      }
     },
     "localname": "OffsettingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails2",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3",
      "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative",
      "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "TOTAL OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r86",
      "r87",
      "r90",
      "r91",
      "r93"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "LOSS FROM OPERATIONS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Background Information"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BackgroundInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r32",
      "r211"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER EXPENSE (INCOME) EXPENSE:"
       }
      }
     },
     "localname": "OtherExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r26",
      "r211"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Current portion of other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/OtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par Value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16",
      "r211"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r37",
      "r38",
      "r41",
      "r49",
      "r58",
      "r63",
      "r71",
      "r72",
      "r86",
      "r87",
      "r90",
      "r91",
      "r93",
      "r96",
      "r113",
      "r114",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r174",
      "r177",
      "r178",
      "r181",
      "r182",
      "r190",
      "r191",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r143",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r143",
      "r202",
      "r206",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r200",
      "r201",
      "r203",
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r171",
      "r214",
      "r253"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockExpense": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.",
        "label": "Stock based compensation - restricted stock"
       }
      }
     },
     "localname": "RestrictedStockExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r138",
      "r169",
      "r211",
      "r240",
      "r248",
      "r249"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r97",
      "r166",
      "r167",
      "r168",
      "r172",
      "r173",
      "r188",
      "r245",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Dilutive securities were excluded from the computation of diluted loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in common stock outstanding.",
        "label": "summarizes warrant activity"
       }
      }
     },
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r102",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "summary of the intangible assets as of September 30, 2021 and June 30, 2021"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r204",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r148",
      "r155",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "activity relating to the Company\u2019s stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Future expected Amortization of intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock option based compensation expense",
        "verboseLabel": "Stock option based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows",
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails4"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend Yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r150",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "negatedLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.",
        "label": "summary of stock options outstanding and exercisable by exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r160",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails3"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Shares, Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r31",
      "r39",
      "r40",
      "r41",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r84",
      "r97",
      "r137",
      "r138",
      "r166",
      "r167",
      "r168",
      "r172",
      "r173",
      "r188",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r245",
      "r246",
      "r247",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails4",
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r84",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "verboseLabel": "Stock based compensation - restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r137",
      "r138",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails",
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r137",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Proceeds from issuance of common stock, net cost of\u00a0\u00a0$2,224,992"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r137",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Cashless exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails",
      "http://nanoantibiotics.com/role/EquityTransactionsDetails2",
      "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative",
      "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r20",
      "r21",
      "r58",
      "r95",
      "r96",
      "r191",
      "r211"
     ],
     "calculation": {
      "http://nanoantibiotics.com/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u0092 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet",
      "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u0092 EQUITY :"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r57",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Equity Transactions"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/EquityTransactionsDetails4",
      "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r74",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "- Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r73",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "- Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nanoantibiotics.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.13(h))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r254": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r255": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r256": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r257": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r258": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r259": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r261": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r262": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r263": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r264": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r265": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r266": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r267": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r268": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r269": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r271": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r272": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001520138-21-000706-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001520138-21-000706-xbrl.zip
M4$L#!!0    ( *&!:E/Y1C+0] D  +EE   1    8FEV:2TR,#(Q,#DS,"YX
M<V3M7$MSVS@2/N]6[7_ ZK+9@RQ1DIW88\^4'W&B*2=V64XR.Y<IB(0DE$E
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M;H8D!?2+CE^=MJ/07Q\%\&IE@:U&)74=OYY<SU7.(1?E$22&.3L> R,>2W&
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M!Q/ME5$Y=(:*K-+.K=*>L]!D[!>9L%V;L-</9R,+M,\6:,?\$!F0G1N05^:
MZ5*)R!+LWA*$NA$QA^Z1)=A?2[ +?H@LP3Y9@M?8FESG4,'[8(.=VX0]+R'9
M\GS'^V"BO3(JA\Y0D57:N57:<Q::K-B*3-BN3=CK%Z%%%FB?+=".^2$R(#LW
M(*_% 1N<VCIP-ABW.!L?*[A5S(=)+IA9=N1!K+?+&O'-'O#-_FVMKG>:Z'WP
MS,22(SVSGIZ)^"72+W.V; 6A*=FFI?>:!0D\/M&\,G2[_TU7\;2@>7U]\3:8
MQML_L(%W@;!SG>;YP/L-8R%Z&G,A-G:]DXLMT\,-=98<XC]P;C@0-^7U-^XB
M[W3OR!YZ6+M.\XZ( 0[#?9A2%V$EQM=OC1(QD#\#K0($H/-S R^YJK;+FHR-
MA6U193/C5Y.8?JNV*I@./1$;OE$V/!C523TM)_+R$(I_#PS*VMW,+/J-^UFS
MZ;R(_+LD_YXG]9:J"N$]\HH0J8J(_)&J6%-5)-\CKR0C51&1/U(5:ZJ*U'OD
ME52D*B+R1ZIB3561?H^\DHY4143^2%6LJ2HR[Y%7,I&JB,@?J8HU547V/?)*
M-E(5$?DC5;&FJLB]1U[)1:HB(G^D*M94%?GWR"OY2%5$Y(]4Q;HE6(GWR"SN
MJB-E$3% I"[641?OLV8OJMF,&"!2%QNHBW=9M\='=9L1 T3J8@-U\2YK]_BH
M=C-B@$A=;* NWF7]GKOJ2%U$#!"IBW74Q;NLX>.C&LZ( 2)UL8&Z>)=U?'Q4
MQQDQ0*0N%JB+B?XK;ZK7Y(KML'?:;')O+O>9P(+ 9]/95#*=CU@@TA3^_04C
M3?&&/ I;4QBQ[^K%&5KVB&C:!CE33#T%BN$S/.,.YGXU.06.-F?\>E<TB#EW
M"@=?]*&-YP#X:G/FH0VO?&0)WZV (V&(EN[346L-'$S#Z#>J9](BT?2>HBV;
M=CE>IN?U&]C]?@(+*R"T!M,L(5D??EV18%\_*2^?81VZ;4C$Q(_H)UTBRE1Z
MOGX"^. G_M_7_XG'N4N%J/)G[M962;PF=@@7CY]]A6<XTQJHH$!ZHM%1M+BE
M]S]SB2^<\V=+M\#_I9\\*[+5_<SQB<0_)Q-OMG0#YF1OGJNB],"E^A9GZJHB
M?^&<+]UQV/?\^/LV"%+<5(;D,WYZ<O;__I?/)+XPZ)U_/=!_F@"?K0[6UW=!
MP=$01!B_ ?K)Y"KDF;O5>Z(68Q_$N#J(<]M='RP,'H7%H3#'157IP$<2:!14
MQE_-OJAY1W;@S'GAQ&< T/[9:P("(Z>6C0ROM<[N*N5&J7A\5&\4&J7ZUT^M
MLWV'N%ZZN+LM-\JE^O%1H5+D2K\OOA4J5R7NHGIS4Z[7R]7*;I<AK+2,>]'L
M*EK'TK78\5'Q].*4\0O[5TBDT1SO<!6YY8O8-8.O "+@^5(W>@ 6?1^5[(O\
MTLPG4DTB$R4>+^H2C6L;@SYI2FCR$]D$WVS2W_+@A@TO?MW\T-JW_1N^!>.!
M M5TC1H;1>(<&W]+VM..OZ6/W8<33A/1 8,)/WOG.SGC$_&?5"F/QQQ3/"+^
M(N(O'?GD[,.-:#P<'U4U\G''T&Z,3TMLJ01&5E7X7 )U\>\)L!/^W1=EV?U[
M[55X#/7(_DJZJHI]$ZR7^QMS1;Y:QOH3/!'#4B11=7$#EM]U;+Y:\L8 "XG^
MRR325=*V-F:094KAIPU!(3'4P2WIZX;EKQ\*OQX?!L)]KY@3-M8/;=!1HO7O
MB?)B?6[INDH@RC!LXJ<XIF!"QLEG4YDO<]6(\\.2 \!_MO^R,;*G&'P[>+PL
M\-<V(5@=;,X%K;.?=X7;1NGV^@\#Z;94J]XVN-K=;?VN4&EPC2H'3D<#' N.
M3W+56XY/?Y _<M5+KO&MQ(W]D;$K4KAHX-=\/IF:4.2P:OC'</QS*MUG[],[
M78$P8+F/CZPNX1Y=GN=8I,T132;@ZT_+;V9*?FOTZ1++TOA+[Z^<F+A-Z>D+
M[2$0Z94QOP'O=65Q," 01FI^0CP!V,E9G?0MEC)))F(<#KU,FB,#%ADP'P/&
M3WNU>(</O8MTD07CC5HV^[=]TSA/!6G!VJ)J^IJP::@<&Y:*;-@V-JQQ6ZC4
MRVBD(B.VCT;,&G&]:\7:($]<T_,_2Y_XLWEXZGZO4(]W<2LF;D <'UTJ8(9
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M^J-<N3H^JC<*C=+-TM-L[QQSC:YBN@T2Z<%E4=%H!_!GT9#CJJX_."TXW%)
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MB'T-""#*MFSZF$,U%1%!A=U!PV":DL='7E*^]4XT6\1.$NE;@"S349/CGN7
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MLR0,0QWPB70L+_C=M; "P\ZAW:I(>[\4VT;)Y).@P+.O2#!_;<//<Q[1:6R
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M09/Q1^G15IY$%0_UUHBAZ/+TWK!CSL9F3*G=*219&GX7]^J4LIN[1'NE.&O
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MPG[4'I]>\HT?U>R&P<4&2]II6)&.)=/Y6"ZY8<'0'KH@2X5T5V%$>M.:E'>
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MX\K]6$(JIH\E\WQ$OE<F7SAE^0D^ELMG8NE<0+[KVR1H8 V27J-P)P?A2$+
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M-'=+5.9%U$0#Z-\ ;\ID&T3F5^7L(Z!?.:.4&2V' >Z$;?!WI93D$UD*FL>
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M71#,ZDID8&'L@JQQ$=F(#2 -OV5&\VIU%><*B:&,X:PQFLD7'QU$GR'(HOD
M+G.54]-@,YK#BF/$IOBBXLN*+4E7?95-<0#UV>.#FL4@!RD<2L;Z_'LLV"*F
M7/'I9FP:08N5.K-)MRJ%7N ;+H)"&D&YV$,"/G(Y%":+30Y#YZLN3IU.;XV=
MG!83<6)P!)M+ERHKA52YH! =_)6)QD,DQC1,CU/1=334<76%TX%Y;UB#Y9E-
M&ZH)1!X?R):< X=CBW&J87*"ZF/33VJ<X^#V]R !)JNU0\>^9RD\J,$\*CV,
M_WW#\?Q#Q[\R0'5H3MLVAVR:IM[E;MH9>?=N/-=?6SM%K]Y1:\>F@8J!:K'K
MZ&]5&HGMN,(=V+_(W5:.'MR=;.XIC3ZWG7A=HR]\GYODZSP_:8,K],)H^D8A
M71I3Z&)\GX@S W4%MANN/LG\-,DZ-L@.;K3&-B0A-SP63D<%!5\2;\&TQ5&K
M!=OKA@-?3#;06N-W;!I2[.%\[,M8?)S)E?'QZ:.D7GH/4F<%N9N.RS_"[T69
M:G/P<K^<#W0[T\_4K\]V57UB:INL8')/NLBB1IP4WC C4%[."%S[6?[0&8&5
MF^'I=7GG85-6FT/];<CY/6<$SF?.R$1F!\8EB6IS:>"QE+NH9N99(T?R3_I!
M7OF<F^'U75OS!NZ==UQ>E.DC(*[5L6DC8*5E,XW&]<G>P;T,U_#<%B2*I%IP
MXB7PH R,6 E-<Q"#_:QU/]-((S-HETE.STYRRKXAR:GPHB2G;)3D%&RU[RZK
MI?6,=?OZ+*?L(F4YO2!?IC03K^A+Z\MW;H9#S\B>=(ZW^W?Z.Z73?)HY&]'A
MC%6RSK:G!1Q#H7)>6P_:6K[5?J=CB*UC@<_@7;9",,F4J2;2OMGZ\^CT)06:
M0WN_=Z[4]3-K\[W.++:.V:?DA3LJ;[X\2RQLD!#97W)8+CZ\J%K]X\J)^YI$
MFN<G_F5FTR4^^6U%^81S'ZB>A1W)S?B)O+G$3WEUG/OU67S*#+/X%NR$GU'3
M/-NS#'M5?L0(FED>Y.(/\/"OWI1\^YA85=8[CJ]N6^UV<S154QG=O21)/VU5
MO9CTL#_=/WK@HDMLHC]A(<[CR\]L.CMF:GX>>G_1*2]RCX;/*\\F(Z;<3%A;
M$:R]5VC4[)/SAZ-J9P:Y.R],^AA#0K\)^E%FA'ZRZ>)"CL]8@--Z%>>_Y5S"
M262ITFLY_[W&#HQYOA="(\X#H81B[&[GHG:L[6Q[V<(SQIZ\$95,(J//@DJ4
M5Z*2WU.@S EA++2<F0PK"C/AQZS@Q\/;N^/&N5;.=%NS=<0L$49\H]^,, KI
MUTZ0^#T%PEL1QEO.)9J<5EATA+'YQR",4*)IE;W+XN%MX=AOSQ]A3"*CSX,P
MY"7"F#?"6&@Y,QEA;,R$'W."'R^]ON;7M W]J+AT7,P*5N1F-E0QOY :; %.
MZU7L_I9S"4-I^<7'%;/L5KC8N"*48]OWI5SQ]')##UKSQQ63Z.BSX IJT[G$
M%?/%%8LM:.;INL@+AFSZ_9/#O4*VTB@O71=SP!CYWWQP\P*<UJM8_RWG$ID4
MGV+H^TPZ:GT*F!%*M8/[7]O*Y2_W?,></\R81$J?!V:4ES!CWC!C%K)&P?G'
MKQV3\1J<L3X3CBP(CO0;]D;IKN'Z@_S2@3$K<%&8$;@H+3,O9@HNWG(NGR@N
M,C;(9B&4VCR 12C&:IG.@7+8WCGIW,T?6$PBH\\"+)1T?@DLY@TL%EK.3(85
MM9GP8S&<-V7(Y?KAMN$;A:7[8@X(HSBSX57YI?MBA@CC+><2HKY%QQ=_3F9G
M*,_TC<W&<.>R6MG5YX\O)A'19\$7N71FB2_FC2\66,I,1A?R3+BQ)+CQM#MX
M<%K=S>K#:_(ZETZ+B415FAFD*"^D_EJ TWH5L[_E7#X-I"C\,9 B%&)W9T;-
M[V;/@]/L_"'%)"):0HK/*$[F!"D66,I,AA3*3+BQ++@QU[#6]^OVYG!KF6\Q
M#W11GA&ZD)5E4N=,X<5;#B:J$LLL.L 8:YJT$,IM'@ C%&E'#]9Q1[_O=_WF
M_ '&)#+Z+ !#7E:CSA]@++2<F0PQRK/I7Y,1#+EY4#*VO,[MV7%SZ;:868^O
MS*R0139=EA=1B2W >;VNP\U;3B8L#99+J=QB9L%$X*+\QX"+2)B=6M>7ZNU#
M_N)8G3^ZF$A*GP5>Y-+*$E[,O9W6+(2-7%12Y?=$&+-IHR5'G4>KI_>*VSYV
MK-<@C*47XTDJFUE'T7QZ,2WF!3BOU_'_+/KI?8+<SO4_!VJ$4JU\;,MF]42Y
MO'V'2,E$0OHL4$->ADK> 6HLM*B9##2JLV')L--=K?.0*05[=J^66[HR9H8N
M9M6Q4UDVU)HQNIA-+[W<HJ.+/Z>C5B3*UK>.CVH'=TWS'7IV3J2CSP(N,NG"
M$ES,'5PLM*299TFJ'#:Y^[5A7ZJ;&\JOOK;T8LP#9\RJ;Z>R[+ U8YPQBXYZ
M"Y_L^>?4CT0R;7WKI'SK7>6O"N_08&LB&7T>F+&L4)T_S%A@03,99&1GPY!A
MQ[N-0>-N?=-I;ZJW2P_&S)#%K%IW*LO6%S-&%K/HJ?<)XB-_3B%)),K,JRW_
MUTG-V'.4=\ 6G[E[9R9=6F*+N6.+A18U<T478:,[Y7:_?MS+]=O!:P::+5T8
M3]+8K/IW9N5EJ&2V0&,67?4^04')'^3$"*7:;5<^+@VU3K#S'DZ,S]R_,[,<
M/_(.0&.A1<U<8R5AX[OS8-W?N#ZXOZSH\W9C]%0=F6"-W>X?24[G>_ZS1LL_
MX\K/C$5FU>XSIZ0SY=>1XK//9K)$F'CYXV.<FXZK&VYXQ;H%Q,6NDSS',O7G
M/_QE=_H<(&@6'0#?,'OQ_<GAM4_\(W-/0NE]FU.=O<9]]NXD2CYYL;!\*\[Z
MS.U,<Z\LW5W*RT\!\#ZC&'TR 7>8>ZBU3I5M)S<HO:-S:/1E<F\A^+&+.9E-
MOOI9F_O6];R"_> J27<"(,\W<M^T&RT>6'G;L(-4)E=,E>49L=-\3WQ)[[\I
MO<]"V;R)#?*9<JKPVID?KR"#4*/\\/'M?HXBGM65U97_]$)E4ZKD;H:]\G"X
MJW<J<C\:3-J"[0 EEH'#.S6[AB<=&GWIQ.FJ=HI]D)(:<,/6OU)7==LFK 6_
MFH'SA'>P7WJ7Z!WP:EAT3RST@Y;S'_,G88O5E0L5B<WW8"-_+LSR)N_6<R&^
M[\2)V_ TM8>>/C<PQN"[UC'TP#*.6L!^7<=F>"O2(2>.96TZ+C+<*9+;*3QP
MW8+OP)O%B*Q<B=MKK[WGS=#MYPN=@\K]73G[881ZVC%65UJP1J</BY6(RR1V
MK_!]UXLWP\SQ\>VI[1T8E[DO/[V@"T\WAW#C/J,G">7 O>D/^"%*8$#1_3H&
M_-\U# FVQN]XDF'KA@X/[_D$;Z5L)B7A\?VSX,0X:FG-CCB;L&__5$U/LQPO
M<(W:KP"V\10VU6.RU:L:OFI:7J[2],@$A#=CQZ09EL5EZG^_P-WQ=Q2YXO?P
M #$U1!CC+WG2S?!NO:I?;]QJA6N<6D;'/J";_B-%-Y+6)'8O*7XSZ2N_G93[
M]@KRYLH7D+^E]CS0(N*G?Z6^J?L=O$OF[R^AO?&H,?%E'"4\Z=;60/>")IV"
M#?!%UOIDK.-#+'V*R30%JL#+('W]]TN4MO*T;3MQR1,6,NDM&"Z0G-9_FJ[T
MXZ?$%/HSO=5CS_A==D5X6_BF<*<+_TTXQB7RC"^WZI&M"MU4_/=]LV5(7Z\,
MU?6^_>D;5VFW7:.M^F*O=FP?5*,'6N-<M8(9T57<\S)+MTHH+9G(S97^GH38
M8W!'@G\D([)')-67=@/;"!7]F*7 [IS]^W&C3LC\B<]_?LN(U]A>3+=%#F[O
M"%"->]I1;6Z5'3KV/1EF3,C>F(TGW.8-'\@!;\5NC>MQ;+PS\YN'W^-@7;C,
MO>)>RS@Y[90OH\PJOB^CYS)?:_2E.S+-'"V@[Y.OYB;QLF]+H,N74L7"*QO:
MO8309DC"?TV@WN+[4F\HF$@NS8V*:WFMH5;VLKT]_;-0<7)GWHF:$PT:,^GL
M*YTN'T3/4T7RV.CGN1S=RR-JWHW^L#T?BN]V:W<GQXV&<E3X(OFFCYOWSS^7
MU<M__JEGK^2#0O69C)!-CZO/!3KS23)L)OTAGSSN$&,E.35&!7,39Y:?:^\>
M#RX&)Z79B;,/VJ2Y2;9,4JYACGNQD$_EYB[4WH2+QU+$MO#%P02:<3[MV-#:
MN8A$6KRW8]<-UW3T^3##X8'6RA;EX4FC_6B6;-PSA_D6:^;#6L?4=0.^ WNB
MF ]-U\KDE1SN6DF1E<@?]_Z9I,_((0T7N<!YKG_6&N=M$$]Q.0B?D3[Z"A^3
M-A/)F,J[R!@F6W9LS37@VJK!_IV/K DZS?W6A>H]'!=>X,EYBS3*OTH:?8Y\
MJYED6KV$?3_'MLPP#6VY.1^Y.3,%@M,TW51/]!,.TO%PZ&*<Z",E7^_C2*W-
M1W6HM_M;O[)G^OG5[1M5QT=[IIZ16[I@_M7/(=HFN3+>F0=&W;%SX@6G?GU;
M-+N]\JGQR7GA>5[:&?/$C+RTGX,K'O-@A,4>B^335>;GU-4[N3OC_E8-RFKH
MU!7+$M'Q*"Y.$?$4ZGK,B#(  C@MJ4?6DO $*U?E [E4?1L3*MCEX[>AMTE2
MN+0P#N4Y">2BD@D&M?N[O?Q+,A1^"S_SFV7SF)\Y5RJD"H7"1]3 /#=CN70S
ME!\.-K1BZZ%^<+?,6&;+.6JMKJ"H5)O.O2&R3.'/Y52V+(/]U#-=0S)M$J<M
MTP,S3L*"/12M*&[C*2=*2LJE2G+^95=EX;^IHIQ;77G19?D4&7AR3DZ5<B]<
M:"&],-N_8-3P'_/GCN<%JJT9JRN@.35*M8;[." '03)(FNIU/D%*^\>QD[VZ
M4@G:@-$D668NAA21) I_U1Y(F,H+P$650'2;@*9=^*47-"U3 Z32,BB9VX0C
MP'^55#Z3P=X1"&),WY,V+-7SI$KR6 #K_%5*9S)L)P#K2![JD]3J"H#EP/+I
MCJ"5#%_JN8YF&+HG^4YB47![M0=_? #Q[AO60/I++J9+4M>T+!#B*;H6E\!)
M Y[OP6K&KU+2BKAH84YD 0DD<D,IN4DT@OL,9%%67GOV>-Z@^6V# 9*^Z7?H
M 8$-Z*;O@@IV/;@D5_@7I2[/ON7/ 37@@M:U'!]!A^00UL ;(OOC33AYX[(?
M(>*4] +J6UT9(:1BIHCO/IGR)A%>&;\^*M99;8OQH%F!#@#A_ZVM29NF8>G_
M2'4P&OZ%(_D5&#8B$5GYEV6)PH_2VII U;IY_R@R5")<R*ACS7=Z>#>$+_P3
M<44!@?MKZ&X\US7YM,S8HX ZU^)O*][S7^ETT(-7K+AJT]3^E0X!J+*].'3P
MK>5,_*H?XC+\TQKNZ7]^P(9,VAO74._6F@90"-RO1WL;7V%APG;@'B6J?10L
M6U8VW>'Z_K[<MYMO VAP:U7JN(A/_X?*@;!L"/8.L,V7G_0!4I'XZ#\_U%!.
MC+QF?$-PIW S"&H*LEHLA<U<),2K\(U[4S,^0P7:(JAK)3-)%*MHB8%T0T]L
MOHPR#4PM+ CE ABM($_ZBL*T^.])XXS$:NG?;T+&U>$*4T=!BFAUHW;$9'#\
M&4P0>ZLK2D8N2T==VVP&GK1C(Z^;@,EYR4_=@A?\BM>QAR6^C7\43U8]J6-Z
MDJ=:JCL(I3;S@4@MU^E*E9YK6I)2C+^P#I*4)#%>"]+5,6U2 /A7UPG:':EJ
M:#QVPH%-6CJ%"VU1\"+AZX<;UH=ED$DK@?904?:[*FZ;:ML!0'/\DU@B7/I7
M@0,=4&@JG-S?JRLZ8'@G@(WC.]FF\C=:9DLU7>D>Q35=6TP7<U*D^^"C\=U-
MJ,VT5%.U#JXW7"[5SW&U!(>$6^];AH?;T<4_N/#R>!@.6!'A8Q*J..C!C^@@
M!8V7!CWM.SZ\)WQ+SJ>RV3+;G:^NT0.*P-OSHCW8& EV!G;(<4G3\N6'B\,3
M9";:]"/$%2:2_[])S%4K'&'1YL'?93"W,FP]T;?&0V/,P.+?[@.J6UW!K^.7
M)Y!"1=- 0\);68/4BXL24U(6]'VNG%P4/)U_[#&I%F[YZDK?0)3#<%)T;DN[
M[K'J4R'3@)8=(GHBW#7&I5K,.876-/QLP#<M8EJVPY[!S@=Y3BD52"#B(?V5
MX5(&3GJ-'36GU8DGCH(.2):(*X-2%XX6B^R!O:S!\@2?J^A)Z'!/X%+%OT'%
MMUFR:2JFF<=T:XH+>68-D073"URM@UI,3F4+^50IFQ\34_PBQCUD:6D!J718
MILJ<OX#NU2XHTC[\/$"N0:TO?54R?W\3FH#?E59G#81<%2L1"HP+3<<>D_?(
M:/B9*V(DJRNES-]T@00('TR] 1E]H'CS:^0R8\R;$C=KF:X'., #L6'KN'>F
M"_^TG, %1L>[M\P6_63#N[D>5^G)93"LP(W)'M9YKJ[$S%5O5(NGINO\Z(W"
MTS#<KFD3@&$K1E#_U((6AD 7C%] T&PZ;LLP_<!=BII7BYH$N-[HF$8+ZYPY
M_Q^U6L !+JI-W&C@VX#'UA^1,T$/?RUF4[(R7=1T )TA-@+N<HU[TPD\*Y1P
M>#G"6=5+:GOX';M0@'SIH;I&!C$!(_B.*]BFZ8"066B.F6/?"!'(P[8C)ME$
M7L76T74 LM2P-=/PHA8-4SJ99.(Y+2^[T<VP<NP<V/*AJY]&[4N>= "%I_2\
M%A:O/,FI"T"/3Z)]Q"/Y@'"/I)?K%CC(; TP$7"\)"HSGD,K_I+.FO;$G-M7
M2L+FSQ(0??/GE"SDB4M^_;-&FL$HU9NAO'.8*UOM1KVJ?_D9(YO5%?(FQ"DG
M7&-RN<@9OOM3!$G?PK6/GC7_#/>;?T*[8Y(\B7\RH_U:,,D/2I/)]-65?<S$
M%\M;ZLIIRT$IO+JR&X!Z(A\" &Y03T>@=>)^A212[ZFFSNQ+"ZU8FR(!?\GD
M.(*+*UI@^BIS?J)7KF.H.N!;UR?W%)X.^BX46<G '2W'574'$XCL $ZM 9<"
M[D>'1 .4I2H=.#;(J)2T49'*F5PFEY9JK1:S4J5#@,MDS4Y<)1C-CD9F\\@B
M2)T?&O>JKN)"RKB0*G6XDZJF"N^EKZ[45?>NKPY@%;0@.8=!D!/##B\LE?.*
MO-"J^*,1&#G")IZ,"@9TEX*OAT;@'ABZ^2 (PT*NY? )2 @D%?-<P(EM&DTW
M0!L"4QSPX IR(2]MN89A]TVM(U5=<5AY1CUPFD;;2:VN(.T N2G,^&&/4-MP
M(5E^+AA?)H(X0=$]EOS#'"RE5+&D+,]YNKS=Z(#E:H#Z6UV!0SIK2'45S3YI
M*72?,%#(<\P\KW(I!=:"<&[KDNWXR S$!@>PO::MW;F.[DL=50?;W#?17N#>
M\K-T(RWV'-'(*<A3 Y9YQZT;$10Y:]1/CV)1$=,&S>\'OH$@!IOT@!RMHWST
M0,[=F[!T?N%._41<!@SA!&[BD8=.6BJG"OE\JIS+L[Q0G4=&3EU#Y<'KEE3Q
M-.!-'I:)QT]88  N!E.);LD?EI:.[)B$SS+EQ 0)?_:I:ZH6O72EUS/@QW6T
MC_!I]++"+ZU*&&J'*RAQSN-A=+P/O!ISX_<[*$% NJMTH]45%#Z^>F?83&:$
M%X(QY]SA/2U+&&6:I9I=3_S6XR?A21B91B^1#>]@^0,)M"%\ZC3)&EQ*E*D>
M<A-@M1M8+ $'#/*D\WLTGA3^6E+D(OQ^Y/8Z\%S=#=IP:AZ 7)69\"W:?R)"
M(IF. 4?E 'H!NO$&M@YD *SP%6^D9/[=/FG03_*_WU*<.IC?#A:D=3!E5$]+
M%3OQ.&)76#+YZ0"EKR$7&K[D#WIH9A%6(@;WI"+EQ!'1\"]1&-NCEI) G2S0
M=&:33X+R:KTP@BC>"KT5GO'5 T[9L26T*7U*$B(?(]L_W8'K0)A(*F&FY/[Q
M#:/D60\Y F%2CZ?I,3*F?! +%D_^">:-8"?1<QV07X:/^M@R08%2?*P;6'RW
MD1L,US(QRN;QI!58;?@82[51@-7)HZ+0@;"?LY*/7 T$X07-6UJTL[JR6:T@
MZZ%4PJ^J@=]Q7'.HLC=FYZ,Y@:5+!@!)GSE388WWIBX<-@#RPCWG3*HY/&T=
M5F6H[!:V[^(!\'O&48MG&'>>$%)X<Y^E]>!*X:LH,$;/+"69+0RZLDM(''E,
MX(0?QC=8%;$[0>O\.Y;:IV73&GE2VNH*+?8-J3;99:K-VD]9_M!4F_S-L'UP
M5&QL;VRXPS=V;_Z#4FU.G($**A5 E$#Q2W_X(\NI!RY&+'U"Z)0Z&!H_)'@Q
MHP5(X\!PVP8F:K-$0M.&;X-48D"59='*A934-/P^V%R$!$&\ S0"$>^X+%?#
MQ,?N5TY1FKM=5=K?WZ!G'*JV4X$O-$V$MAX893NVEDY)ZZ9S;E+@R6D"OPM%
M#R88B$C+Z4L>IC* TC/;)IAJ[-QQ59B0Z*D6\[VO[YS#VJ2O&GGB L!7L/I6
M0(@MKH8(^#9Y* _4"%A\($ACRV7%%_ *['?0JQN.V\.4&1+TA*]A_]95US5\
M7ZKI;2.%*4(SA7.C/KL%(L.9+2V1",&U/V[X87+#HZ,1> ]1!A!I#RP5FR(W
M6N!%\58=U+_E](318</CNXYNMDSX"F$T#0MR=,)3W ;P5,1]6-*C]HP B!/P
M&\@^J1GX!)W ]@*AATJ94QFN%AX7YMZPW&$TX9+>)S]P;>Y\PM6BJ>+T8<U>
MQ^P)U"6RT_C+KZZ$JTV@I_AK ?!HNVJ7EN&9@+A\U398?(G\<HD0L]14+<K7
MU0.#)8 )-*T;33\=/CA%VY[FRR(YP=B;/6L4^H:1W^AM\0L3F)AQ+$@%%N+&
MCX%G$2H!U<A_XR&U HQP)AD:D0XBG 34%^B=8_NQ+0'J0H]CB^$QL780+0"P
M,(V&%J6RN#D=R2 56TS^[Q!BC3P75\9O@;G\Y*F<K0$W7XY?*-5S:F@=V[&<
M-F^>W@(.BM31J.XAOS36&*'J"34/5QJ"",]8>@%:3G""=55W[E7IZXZO6H-O
M$S4,+>:%*@8-_@1/ GWI@>9[S(J -3<'Z/WBD-T.W2*%7)[9+, FG-01- *V
M75T1Z?1P$W0\Z"SMLJL^ %]W67X7S\?$A PT7Q;:;S#OH0&U;L]R!H:Q;MA&
MR_01MTR+\Y:C NW'KKH9;M>KV:)C'->KQGRBKZ^/R+$]7<:-WQ#++7]LW'C3
M47ZM!_M!J21_^2GH<'6%4R(![V6\^,,=\;Q,<%*DJFFT\;8]QP8+AS4SD@Q^
MCO!'=HSHS(IYJ^#>K-PKEY&_[H7I@^1A1V?C"4,0HBX$GJ6CXS'RB,-U>XE*
M@AY7HGAS\DNE2!V)A7A2US HD=V 0P(3RT)5R,-:+)*%R7TD1TCQ(?N:O67R
MW?3E--AI$E#00-PA^K7,KNES]Z:('XR>*9YEBA\#['9T0G@ /4R/]#DX[JIW
M!FE$UP1+0R29X4W#XQ<5&\::KSZLKO J#8 : :.OINJ9WA@4QPH!N+L/.)9!
MVC!UE/\>(^&H*..Q=:2E3>YZIM1R-%*>J"*(KZ>KZJ,O.EXWF)2=Y42:5A68
M# RIF/K>B-]M?< %JSNQ/<50+YZW,]?MPO59-NQ; FNC&Y@^;",M$, ;7_!3
M?22>O9POSP8\KVOUH&13A8G33HF'QEA[_HEYP#0>^4_]&CKAO6G8K!#O:#+M
MFIMAL'VVO[Z_NYOQVHO4)&()R-X"DN3,!R*R_,WP_&JK=U7*MC(/;9+RG/A6
M5QCYS1^-_6:*,DS&6EV96S:6],IDK%&)%Y-!,I!"Z?YHMS8H7#=_E=XN7Z)0
M"O>X/!9YRRTC;VL_9>4#(F\+&U_[T(!:7%*JF4SIYE[^(N3?#H"[U14E+1V$
MM5("-6*2?.!1D(5R<  (#Q"1PBYLFK9J:^CRAOU@B0GTG1/J14%?.0(XK/)2
MEIBT_6B!MF#RE:?#&%B53""-W.PM-E]US7(<2C'R1.<UCWJ,<.ND:Z@4 \#2
M(6Z2*G)-F 3P4>!2P$ZJ/3"_OE31*&PBE[,Y%NP*KRM6J 1IY,+H^UG,AAG$
M%\(72\Y<]+E[$G\+2I-!>PBC*[$+X$;P+1_L;.P9U0(X"WN()OCHZX(I%%Z5
MEBXZAHW)<P'EC1I2'V2GQRUI$WE1]U(\ZXQ]B*7A7<K.2'R,H4Q3\T<_=9";
M@9"3'_- 8WB/U17V.1CIW+0>O0_8":/KH)'6(Q\VP78$6W+D4Z^#N2VC2X@^
M$H^'_4I^"8U!_@$WX6SL5$<5]"U>2XQ5>Q[^V<$@& M^N,Q90/5\Y*RG_$0J
M$43'$. R)*Q'SV5S.HV:]KUCP1)<T[MC!FQ@<RN;!9!9\@V>OJ;BN6(LBG6Y
MY-ULX#L@/LAN0IV!J5U:!S>.EV6P,"^>,B83@86IF]@/!SWSE'[C=QRX+9P
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M+$R_1^RK2^PE-=-UP3PQ/6;\$)0[K#2V4ZLK5+,"-,.AEVII3L>Q3*_+JI2
MABG-T(?-!S+$=?)M8-2*'4T1XKND< =BL<*H&7DG]D(MEWG(Q]Z#I>>%+Y*2
MVH:-V@*;C+D&RZG[*R\U61M:Y +><B[:3VI?RUZEH]X;%)GDQKDNY3-_XYW
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M>"]A! ',1J S NG3Q<Q"#EXY6D^"*U%>3OU]IBV+)%)LJ$*8!(*'$-M_ZIK
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M95"% P9Z#61#/CHF7 L+)C8][!4Q"9FE1*]V :3A#RKQE$DYD)&JG)QN$[F
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ME;(S9IE[NNBK*%8W@0+9;D0DF(K7=^"!P<U82T+8KZ<I.(5F01?S"URI V]
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MWSSF_\*OC^7G-^\.]OY4QR=_?NC_X]$X38I7:GMK5JB3:&IRM6_.U5$ZU4G
M7P3JV&31^!&\"*\>VO<*\Z78T'%TFKQ2(Y,4)GNMKCK6:S75V6F4;!3I[)6"
MQ]T7P[0HTBE]]^CMF\'']^KX:/<?CX;CK:WM_W>VO?G7[/21ZGTX^<>CM7>#
M@]\'??7AX/W!.CS[^+"QP.LNAB956S#4KP?[)_XH&V,]C>+YJ\O&H6?SZ#^&
MIWWT]N_),)^]?O,8![RY%;Y6=/91$AI\?V-K\QF=UHTM^Y]E8KJ=[5\"M;.U
ML_V]EG\UH/R^1WRU->YEFVIWDD6Y.C(ZC)+3-^^.8)W/?GGR1.VF__F/27)U
M7&3&%/S#L4[47F1.TT#M]M3+G>V=G0<'0[=S+S>YPC?OWAZ95]W.W__[Y>N#
M\=AD*AVK_G06I_,I',J;Q^_>WN?E/U#:LF=TUNT0-@0/;O$/],P!TIE9!MW.
M8']W$T$[4!I&.-.A5J,TFZ69+J(T46O%Q*B___?VTQ>OX:TW@[>[Z72FD_F;
MQX.W^!K^],OK=06T;!8;G9M0%2D@#J+//"T5OCY+\X@& WR"0?I?S*@LHC.C
M?H]&1AUF)H]PI["8?5-F:3Z*3 (_')D<8&,T47_7T]EKM6?.3)S.+"HJ& \'
M'Z=QG)X##85#RZ;YYH.[C <*0W^F9;=S'L6Q&AH%5SA+DSP:QG@AF3)C^+?(
M$11T>*;Q-O&NPNH*$1;PJ_W^D^VM%THGH8!*5L"-1JDZCXJ)FNFLB$9EK&'(
MZ6RB<P SN/=1FH3EJ*!+GX!D<J:S*"US-8JC)!KI6!59I..<1IUE!D;!1V4J
M7-\HG4Y--H*'5*S+!& ,'TW/3)8;(\/BFV[ \S3[3&^F\$NF=)X;V%Z4U!>]
MV>W L2@Z%9@6OL83V"U3&'$OI3GH-QI-PQF4F7*\78WU*(JC8KZI#L:PPA+6
M$M#X@G)PP7,UFNCDU"!J90ZO A4"/N%ET0PP>+<3IR-&X'&63E4!=XE+H?_"
MJB-8?!CEH\S@,RN<N:-E?TJ**.YV_#L%2 2Z6< P>"?C,@DS'>4(@ED*'P*^
MZ2$05I5KP(.YLC@'E/1_MG>V@JVM+84$$>Y:X_\E)2AA_P$Z/$1T"51L<J#-
M>IX!H00,),0!7.UV&!R+R22-40:%1V<Z@M>BC7-C/L=S2V%EJ4CIG[_.59)F
M4\ (.V(^FL"8L=E4GV:$FK0?H?9$H*L]R6ZJ-78[_J:B!  2=PJ0BKO;>4J[
MP\VM0/3.R3I0/X-,6JO_>;;%8 ;D J;%NQVF"=#;8@)$S-Y:KH9S]3_;_.0,
MB.04QIX0T20B"1.F(0$%$J&A*0#*$@:(O  ZKT)=&,<(\*%NAWZE<0 <!52J
M^9"@P:,63GS8!^D%(/)D ORBN6C!'P!4@T"LD6>=3TP-UNMHV>U8&#85#1]6
M;R/?H+?S<IB;?Y?(WG:>\KKS374\2<LX)&DH1UZ$VV2J#*^,9,*A@8-B+LG+
MC) :Q+!M1,J ^9P]"9@X+0M5<5] :D1X1%FS,='QF-8);!)X9&E4B71'D!%>
MT5,@+84"=@IOP\9QAA6"W3F"@822XO69.#HER0G@&01>CXQ[/!HA'U!HC,07
MQ2D/ 2T8A 8EX"AA2&BAW+O] X=?[U*=A?(#J%_PH$EREAC@PS0J"D,(9"RT
M$#4'H*PAD3^G"$-Y"CNIUFVY@$4LG!^Y&8!TE)!\%R"?043O=OP-.HG0^ZXQ
M5EAF5E8#&<TD(8B)<SA!7K=]BI8*&"/JB-T"S(]8,@_PL)(4Y,""L%@GW<Y'
M4CNVGP'YLDS,:1DM,SF$3=*";A!.@U&.&"KN!":89>D&XGYH3[0B(_ 0+(:(
MG7'V!I 3Z&@U4B&DHK@9I'QP7#.@I9FE?[ WDJB1?J[0N+;LFCGZ)E>] Y(7
MHDT,>G*8JMZ9 3H+CY<1$/>=)UN@,K]\_N+E:Q3O"ZT^IJA&L/5NZ^G6T\9V
M8</_M;&A?HU,'+Y2A_K4P(O$2$8XH]K8$!O^F[W![W;]OL5\>Z?%9/X<OQNF
M66@R]]V[6(\^*W@:\30*X4B^XJ3;+/TU^_VB];ZZYT/8->RB94-# .[/&\P(
M7P%4XRGXPSYOV2-NW-^$!P1+I_2.^C&>-1_O/;/F[1%M$PFH(@HD03O*X7,.
M5I6C&4H7EA07&BD5$%R3F#'J%[-8)SE;9]A0DT>P/)VA=!45)5$GGLRP/.>1
M6Y""FJID@!+/7V9$:BZ.S388HGBG,&>F48#1LUD,T(_KM#1Y!L W HUU$Y3C
M+(-]Q?.ZJMMF3H+A33)!1@!Z0[6E+#W-]'13.<U[HDEJS4A1!OJ=SDCAP8%&
MDS3-1?I"DCHU(:KWH$##&H#?XL+/0%4A10:D.H".%F9"/ZE?MO[6[0A[ -Y@
M\@)^@'_P'%@3QZL:Z828CQ6#PX@.GUBXB,">&+B1ES,T&U1,PK)!/2I0(* 9
M9%(Z\#F*$[F)X1)XI2-_I21BP F=12&P?- '1^I#-#9B4>OMT7_WW%YQY)W_
M=2HG/,TR]Z;JL>08&N#KT<QC[+EQT-7MP*WI,PT A7==HCJ8(17+"^]V:$G_
M1CE]/%\"MT^WMM<^K\M!GD\BX,5378">F?/24*[-HF')UQH":];9!ASP!O_9
M[90S''F,V@N(#TBBU-JSOZWCDEG?D%WUOP"P%Q[$HX6ET)\)?(C3TDX\"0B!
M'Z#16J< :D&(GB&?+@HG=T69&&18QW;&,;3N.#,-O >( 5?#HI,UD[D1 !),
M!K"8@I#1R^'C:.(AOSU !JO,&+7V9%VAWH[HS2+%F6834+<#F(0H03(E(.0:
M3,N2B!SX.,H0>GW)!D>IR Y>1IF3!.(6;0%M@HQ$S_,ZHGBVJI$G7/*)..2]
MBG%*]<*0S%RX]@;] R&KB)E&T)8!9#\KV6UN 9^NQ2-"0!8+4*9B?8X7\1A.
M$(UEL0)."=(67,*-"U$/1EZZ/3'OF!D%"+6I@!"<>+N:0JH)PM]>E,$K:98O
M>B'HF88/(F@H&I:LY H81$+68@0>80>TDED)@CY9G!:7@39BH&!YD8[(6$N(
MH@$SX> ^FP+0*RX)S!;U+MZ!SBVE)LL&_$WK6-S, :VHL1M0$IM&"538K6$B
MK-D+65W2-52#E9?AO-+RQ6C.V.+6;'<SRX##1"-1-9#:\&KSS6Z'M$!WG*'B
M]3HL/$7NX>V^D@%PRHBI=%UULV<\2$:;:F=K^Z4ZF"9 T7/5_S>(T'/\ 9$;
M\/@0N=P:F3_\,\.OFSXHX;F9G+,^!;K(0I.SVIPAFR;V3=QA#09[AD.L,]&S
MQLR:8$-#[K(M)2T!<(Z1, .M7J/+'_O:+RYK76[>:#A$.LF59G:'R^XAVW4X
M8WE[@W%\F1F+"GJ(PA&R"/C-OI8!$(C_R(FJP(5U!=)U!LG#3TN KAST(GRS
MVR%<G;.L0#)<46@$, DJ,(@.R9A\G^B)&B1DZ*#!<>9!<L:&RQRFQE%)R^]9
MJ!;)"$CI!$0+( 9EHLMBDF9D "V!)@ B(Q^-T[S,C)-5&R@([\^RR!1L6G4K
M"%#J 8K)_JYT")H&?;]RL-[5L@>):'_.]^C=WA)P1@,4@'3]\HUBB[8':K6+
MCI)17(9D2<LTH$)N4/2"E:5D( .]#YXU5@M%:+!N4)!0T1H%,YY/0)##);'R
ME7@0@\/XDY.'\TCC ,N1DG:0Q'/K8G#+1;:(8 ^J1J5A?D[2<\:9,F<^Q"O+
M!?> 12:X/WP"9\DXP( DV$R+ DUG#>-8E2-R(@ .#U+FJ5-0X-(!TS,X&GL4
MY\B#8W-*R[%NX1+.8 3ZR12F#_#4W,#5.TY&Q?MB]_B"_9:U)V)G?![NU/"^
MAVPH /!)*_TZ,],H-RRQEPFM)$?*$Z:C$HE'CO,AZINL0.=##+A.$)#2*]]V
MXT1J%JX<]P!#F"%:,6&!.=(PMQT:Q0)L:$V;E3 W9ZT/A)3J<:2)^"R.@?H&
MC EZ(3^1H<8<G46LAJ'SQY!?I$X$5\3LCI:]3T[C;@=$/!"7\ARTQA+D>IV)
M,>;E*_3?;4XW\>:?X8<9? C0<!JB3C[)TO)THG[-4-5D5IP *I/Z3MI\Y%FN
MEI,5#KQP^F2W(\O(R5 1917J);H INDL!ORBX\(+7/!B"^[.:Y&9\U=X9L>&
M7/"OU>^H0L#//X2!US\ N_77ZF0^@QWV@,I&H]=J7T\-'\]^BIO>J1EC[5OX
MRP]M*+X+)V/6[53B:26#U@R90ZN'ZF(#O]AD38I(-9G"K .JZ9M:'$\71*3)
MAH-L5AQ6W8YXK,Z!2.>I0<TKCT@L)K=;$8WGUH>WHLEWN^P/T6>#,DA0CTBZ
M^.*]>PX8"E"N@?]B0,)(B^1IK9EXP2-#O+\Q"L$;F>(P;@_%!Y#VT*ROIFD8
MC2.QBJKS#"VK2:7,6ZX_9(<NF1/G)'^,QS!7MN+PWV?9&&N#@A]Z:DAT)HL;
M7A@Y M"@;AT?H .C20UN#BU5^5BCD0^%UC0=.XZ;1:>3PO%L$:D_)1%R\F.T
MX.8UL3@E[@SJMX95),:@2$V^D]29S APK0 L:G;1IA*+TP+?G1I3B)NC,F:M
M8.JN8"H%)I:@]8*N*=,S":<P<!GIE")S0>A/X](JFJ!!S$HT^3JE $3#G!0W
M>"5AP8OIUF4LC:V&$8J9[,@@19B>F);DC . 92T+@5U79D  _\I*8QUX2+8V
M7!":)5TU%NH@.1M&!86)H4G*;2DSL2Y(U[/:ZH6KY]"0#!6@Q:$)^$.@\8 R
M1L3>?_8^'J-%/"_1>@H/HU&IRG\!(:YZ]PCM8]T.^Q$/LW1D0K@EMIAYIE,:
M\A M:!1-NF2PC[",:3E%M"9_-5E/[:!PSK_J*$.E00+ZY/0=1V"?@CLS>"('
MI,4 ] DPD\Q(')V0$*! K&)^Y&&JFX)1>FZ4:JE'>.SP_)Z]AS66F?P=N$&L
M*X)9JN%,!P9-I_PWC(B7W>2*VGP'#@;\HD#[5)&>&C)\5"3C9HRW%OE;H2A@
MFUON0@.$?:'U:A2#"GTF7DR;2;$@I55&XB8TJ4'!OF7  3$024Z#?<?:AHBV
M=3M3M DRQ6%):YXF*/M-^&#2C%RG5E##Q$8DEI0<T5P6>88"F0]#[> ?M$^.
MY!50U8&(Y#&9<DQVY@Q!'*'HL6@OP-"27'MEHLE[LB-+E)(/48F/RV5&-2#+
M)QOG<A?LT 0/[YBCFANPH+C.*#D#'9HL>V5B$#Y&!HV-%/EX/L$X2?C)14'2
M)NP@LM:)%B.?AFE'175;W<["VM22I;E 2O<"3$D"3C6%+W;G*$K)%D!>"XD]
M>,MGN1P0*L%EC#"R(2]JH!8EA9?A8WE0E.3I6&?DF$]SSA4J<7C?-Q_K<Z'R
ML@]DX11G&@/0XTK.(HV9,A2X!$=)D2\9AM<AI$:Q6JO,V;-PK"1NLGJ, ("-
M.^R?P2?=TC]M'F^J,6 &0G7_>/!^7_5&M)6=K:VM  50Q$S5K\8[R722ZY'@
M.KJXJS2AVL;6*S-J@>\ ?M%U3 &14I9KW&V$>'D$2&3I) =N6,8</TM@!7]7
MA\)!%?P#TPF"%_B5A18<%3@[G+M92:]WM>Q#"F#K=JQ#D,, :K3*XJ832FZ.
MN0!U+#,2>:8 1H <Y./$3'ZU\XP3^27H&* _GY!P.!H9%PYEM7U?0F5TK7S\
M' XV1  <IF>&Z"9)MCP0.520* &W@',XIS2(./IL.!0[E;P/V-0_$;2W>577
M,ZT^65E1WSY965%O!8'_P"BQ-"7GZSE&]%B]:ZS/4O8;9F8F1!GQ!WDLY=>=
MB;26_)5*@A$:,5B! ZR=1+/O1H5_G"H:Q\#I@?O%\Q^E;L!)[]V'OMKM?_AP
M?-C;'>R__\>CK4?T^;"WMV<_7WMKYU%83/#1K;\Y0C?"2-E9#@NR?STB?'US
M<O0U=8"XO-#>1:6 6BGLMJ6PURD5!")/@:8?.P,/Z?;Y9.MO-UHKH59S:*=1
M<P@EQ-[)IZ/^^L*EGNPM'LS7;Q)(LMOALQO=X*TNNW$WSV][Z?#/T0T"\K=N
M_"8W2V4$>(5[Z>U!V0,#K;L"I\=$G-]^"W-9*O5Y@E9LQH5\4V-!U3>R^[_*
M''VG]UC-NN_;/?EM<-SM[,)P1[W=$X5_] ;[QZJGW@WVD=NJWM&[ ?QX,CC8
M5X='![\/CO&O/WX;[/ZF/O;^5._ZJK__Z\'1;G]/O?M3G?S65X>]HY-!__CF
MI+O[?HH_&=!\0@TX+](TY$R6'FFZ)GSUTYS #RZZWK:86AV@SPU;O[P_2[IG
M4M5MB?I4A(Y7:^LR7B2Z>-+X1==W7W>[IPMSE?T]:6SP1F4BER!7&8_N7<9=
M/Y$4BOQ:ELFG*\ODVZ<_M67RUJI/8/W&*/T],MT.9M#=1F72V]["PRS[ 0</
M>L*O@[W^_LF@]P&K9X+\_Y%5A-[^GAKL_XX_X:=CM U]A$^J]_ZHW\>_5A?5
MONI;$%,Q>XI\T^C*M:$VT_E"H,WBC%A,4N.F\JF.XXT12)@>QJD&P@44)86%
MOZ(PPC0$*J.')2TPSW\\CN((8Q6#;B<O05?(<TQGYOQ_=-QA:K,-,;F\RFKE
M,*PE^E+J.P4KJB0]9U<CET9:W+"+I B:\6<VM$+[ 5&V=@0,3<>E:0\V.&RI
MD]+/C,7DHG-8^L!F_Q"(=CM10K$=T07#U'R=[:[.A61J]U-;=C#'P>E<ZCGE
M-Z>VW15<WR$Z-I7+*+FYC<C8% >!]_U*E3,LU:%1FX.+W-[DC5[E7Y^JOKM)
M=< #2V2T%5P>9FG!H:252-@R\]74H]OR!-[=9=XK*]#VB\TG2\T@+<!SD[+!
M]N;VU<'VR(S2TR1R"9,-,GR$\>\YB-08*VJ3N*D4*E#2DLU01-+P_T=5BBH'
M/B\R.E?9$H1KC&+5-7<T<$?BEP3PMOI>ANGL]#*6L)&0WF9-P:NS &$XL#R_
MH 4YS1&;)+8,PY'S@N)G,Q-A^9>"PI<*N@[A:[3I,<6'S6M9^ ,I 97&H<1\
M^SMR.;,VT33 A&$LD3NB@##,5*!$74F811O?7"W>S;)-!QB?B9$O.I?"#^[F
M IN4S5G!?$82W.9R#UNBU*=S#)R1!'#'NBFDD K[UH,87=4#%TCI2@(LK&C3
M'E8ZQ.#UYAY=XHT4:\'<'"I1*F>#UT"50H98^P@_C1N[XV0BN"0\I349+Z"
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MP\KJO&0WG<TY1B[@G]"3CNX.%^Z@[,_8 \SZKIBY1/X"''67D#L7-^=:*V
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MKKIE<_ONYHZK1T$36!B+A0SDJ'H$MY*;+X&"FP0@#E LB4[)$, / QASI_
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MGH$P7UNVI"7/OI;!C!P3302G;+T!E#M+H["6%HL9-2Q=(X,B.\'Y)(T)<="
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MZ(#@21P%!MPO4WCA(.7O+]/LH])P%&6F0')0)#@H6$$41\5\6QV-8=PRRTU
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MB%<(^S'HQV&*5DL@GO!X&0'%WGNRHWX< OE\C2)]H=6'%%4'-@?N/-UYVJ1
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MEQG:;9/*"F#%@2&[C,E8.2?!9#R&N;(UZ[\?R\=H'Y00T2]$,C:9[O "R>V
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M-3_WW&*C%[",$%?+30U8#[Z- <ISH"RHDFNP?2!@^^(6<L0EIOQ/HAD9D/Y
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MXA'^Y,K^Y&JCTA[T;&9TQN%,%+H.9 WMU)OXR:YWJC'4RU:<G9.A'PG06.A
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MTL3H\-\EH"RF/L6I35;VJDGQI!3F2H,$*M9#@XC(Y0=ZJ!K26_L38$ZJ3\E
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MYP#?JD*P5P-Q3PU-G%X&'-]*47F4.IQ+,R2*<\77;)5P.Z/7_>K5@SOL.PB
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MQV#%3_&3MT 7P$E'< Z"0B4JGSNJ!<+_7WM[+\*=G9T 21TV4N'_3RL8S7^
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MD,=MGW)GEV4Q.P7H'X_-/,3%2K, Y!HZUJ@[?U!Y- EV7X X)%W6TEA'3^X
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M.$^$H;VS H9F_WI"A^?-V<GGX*DP3,N!.^==[&W7LC=>F9N-'>2%$@TI=E>
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MK(/67.7U;3D4V*!&?V[S+*2 IY@"C:<148X4N6&IQ2FQH.RY)[QENPI4O(-
MJ?O"[CVH,OA+;5]JE :Q=H#O+72#789^K[T. R;&9K-D66F9J:A2#EL(J4I4
M++7D/&@$!TS1O<T>VT8(3$]=X)N*95,X?469Z!%6NLE%*2"T/MQHMPUVI;TN
M:= RP@4;VUI;?C#']?55//[[Y7??O[QA&8^K(WY>K%R<SZ)O916J='Q=)IIG
M-S?1G$U,#D+A1Y53.8>6A<9W"(5<;"F6DL +_A8G-0I:'5WWK$8V2H1* 4[H
MU@'P..'5LQ:)J=XW(UQMU*$J$6(..'Q+\PHZIG4H1@$N)^%!Q"DL/47H<.VJ
MM3A,DK+0"*J,K3O6 ,;&"X)XM&F9]ZTP5S(N*QIK(YU3,_:J</@WP4%=1Y$,
M8^V;DS-:R!1"7JJF7VK)G&_BKQ+$\"S5P88'@N6 R*V$CNA0I&D2/@MNR.*L
M.YQ-O,%M=Q/!#I&?3+Q;G6ZJA=="?Z)-]TCMONIP5'5 :[FB>2FYI6#MUQ?K
MBO"XY[?@<7"4R.3;<'F#S,@X\VPP7/!_"X.[PG.W]+P5<$2H-#$9+ZB8@5?'
M 6LPSDE#\2NM62W%N;P8ZPU6=SHC)+O:#HT\"LZ%5YLA[2X8L7@T/41TFBHP
ME 826!V\U5"]T'^8U\NU46PBTC3V6I= H*IRA,46(UN2B"AHK0$K*F(M<;C+
MC,OY8"4'RM8;ER*#$_Y44V?0:5PTW)]="Y/K1%^(%]%JE#!L'?NC?QVPN=@N
M?0C<\Q+W"R\'4+.0%F20!.&))I5(USP35XP*,#:L^9XN85&\NT;8B2NWYCFK
MP7->W)SG'&5P,TW9'Q_\PE[9QDV%P+)HO1$<-;$+'I-2S-SH8%FH91->U_.(
M&^D0R+/%"NH8G';A&%*6FP5C;#EF+AS3547$<_,T*XD<WJQR3,B"C._,I[EF
MJ:VD;"N?-&RY5Q1!$5#,FQ="\0$K/VL.5M+ 8&#D$23JU8($5YQ095??W.'Z
MV#^B4,/KXD;W'D'<:!VG3'"O@>_O7 >+?@,WT-YMPD /T']N:NFVWQL4+(LN
M&,3#6N/T=>BK?/1-1=J&8V!86?,NV<]F<XZ1"_DG]*2CN\.%.P3V9ZQ::7U7
M?+D8?P".NTO(G8N;<\5], #)7EI_P.59Q"SP45@8^M!SW+?NH!,993-P $9)
M\V)+L@VRH_I@M=< /77H10-Y'L:'O(.<]K,$:US#'UQPFT7A*<;<@0!H+LBM
MYX5D\%(T@C,HTE6!\ C#53G>F5,80"1!CF@Z 5*,Z,7-SUT-*^TOK,@'$ESK
MO5Y<%-QLW+(<?1DA[=5Y3G_ZP:DHK\2YNL11HR/:2*WX6H*PEN];;ROYNF4F
MB_"N5UE5O[NZ//+>5V%T_79JB7Q=+/X6\77#/RFV+$8CF,-9=FI$0SY A6)@
M"YFB_9#J^B"['_Y)A4B# 3%RPRRG*#&*) +61:$-<-3UG\ANX,.A%[-F-06*
M;0-A%\1Z#)J]%!S[J<619P]T+5C;:'PV1L*?' U:AT[;UWT/MRW//#8YO'F5
M3M3O8;R75U PH7C?A1P#%Z9 '=,M0^$S4YA<B="[?GWJV(6*>44>:Q!K#/_A
M .Y<BST&(]LE[)JU ZO);/B<UFYBL#1\C2Q!:<;F'-H;W"793%0 ZT*,=2X:
M5]R$'3%86)H*BMD-@*8Z.MT.?J0X>[9%+_K[F[%VBQ36$9Y9_XQA6DTJR/(Z
M9-ZCB-"KQXUU.Y'_6#]XVR_?,(1W6*V]0^$%%.*NN*R1SG4X;.2]M)=TC&9"
MJ<;:\;K5+=L+9%TB101B# 6>M#),\*1@VQ(P>E7[76V+ HSA/%Y(5R.RC'N8
M.@F*W^KW;MH+994D6&<]8]DLQV@Q.GZAW<^&/=#9&N%F"$6* IV*?IW7$2I2
MGU9&U75@K'>^28]B/C! )3$FP\)Q+3*IT==EV@]^88W=#Q2QADHW;J94T>&Y
MW 2YJ:(*A90;+I67E,I%SNNYA"XK)#)Y5$W1V(Q!5QMUV1*< L8#G:.(: >;
M4@' 1DU+-<HN-.;N4L23$U!)#IUI9&<AUW. ;>+R'E2 :(O2>BGU))NKI)QO
M8=01C"O/]47&5DGBRUF>Q)<F1GQRCE250H6R425RI)'\Y&IY3JND-#,T;"*'
M+-@O9I^B:+2&R+Q,(O9%YU"R?S#9P8G8''_)7UMYVYX#*H2!! ET44WKBC#H
MKN+()PQE0=FU+M;+0PF9(>%M)"E<&.L;HF4MPU(H%"#)*1>%PA7E_!LA:C\<
MW7)D>%*\H.[4A;S_7;34=7EO!V>+P2QT8II>5!IYXVAS/U<09_/BN%0Y$ZN+
MEJD[H&"?1D]2ZX,M>37M",5KFSA.]=*LKB2' 85Z(1N*+!)27AO$'ME42!Z]
M13!!;:#R,RP6Y%"?WCN8O:0[-8@/KV_*AVI$I3:RQJSC;&_[.Y+!J"IF+I[J
MCG)X11<N0H=$8VO,GM:A G57SVT"'KJOD2MT'>I"E\0R2G3&+8K<76<^O#+O
M$-B+O<6!GYK2,B(G5AL7>^"S)%\<V[A)(D8K@IS5ADWACE&6<L '!BLC,X\Y
M91!C]2-)>0-QV:D"+LU-)1AF(-5N)3H;$QWJV =V""Z)&VR4PVIR1K_:L^=B
M<]8=,B74SDDI;7J>4@*;%Z^"=S$ST,B^2@WYA(OE_$@1&9L_;8U=N,K/*3Z4
M+QZ<@,0AP#N;.)EZ*#ZCCODNC2:^(@?Z6CKWBE,'G2<J^"L;B?]ET<IE*6&6
M8?,48]N^-:B]Z'11^ ]8U_ 2Y4>FV[C0M.!F2&J@PK^= 0C$#[0 &;LC9/#!
M.QVVH-$OJ:C>R:E2%X1*0<_MB^I2H<3!58W(<6V7>6%*(8?.4YI9HHP-<46E
MBDU3D742X1 _&5(9E $MTN=JN50N6E1$78)!N)"T06/)9>4/@4)S=EI=H:*D
M<M"F)  (-@S<$EN./Z1T.-&,B8$Y*%)20!*.L[&B\MU2LDLI_N:V=+>^YQ_9
M5.B>OT5 S2^I/=AD@SW*Y'.+2=J@FE:&>U<POO"+NKB<JY78X'\-(N36#FL1
M'FOTE@:K[M@(&<R4, (QA!$95=&JW6X/(/8FQAQ)]\+4-!69Q$@.3=.M0=%H
M2[ :8!BU/,!E)+V#0X.6 [IA-CWC5!=DDC-*^7:H.E%MJ44*DQ8V##5?@$+&
M09?D-= VQ$X"5=CQ(&J5L[O9G/*Z[F0S]K.Q@W$&U-:(C&GL4[_'AA],A<!"
MCH74P1US>*< WO 0O>UNKHB7R$]N!*R:23R]ON8Y28&"F/P8_;RB<I:@.G)*
MT(RK #=L<*?2I+]1[]5EVPYW*R?#]VM_PK=:.^Y1^1-N$;1T[.)=2&GZE]8S
M[^YG!M&(3;I"6'?F.:S7.RM%_.*3[T<=+]KI%G05=HFBHN'I'"1/+:@=RU2-
M/S*0?5#DJS./" "(?)]X0Z"HCFEN"^@Z,@L57Y!QL&.X[7NIL!?32,,]<F'+
M?C/[6V![=>)1,]N($KFZV=+K1O24$H,-3</"ZBU?6'TA<>!P!\ =0NGY9,A#
M0V1IN/"G*GGPXVW7#/7U"2FB$4[.0W%W.!K&QS8<R^*1Y(T-;QJM[,T\G=M
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M4\": E:? M;7R8W,%NOK9,U,ULQD30%K"EA?)W_U.GFVOD[6S&3-3-84L*:
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M6XN8'6;C!<;>9+DY36*4Y"->F"2E$)(1N]OB@+AGA@>P*1$#[72ZD;)(0 L
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MEB8I(%B9:8PANW.>P?=@@ E>(UW78<O6&RHVQ]-VRV*)6(%-U32$!UVMW[&
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MD#B>!D@=_8EN)B06A)!*TEAIQ1KW/YJ6A=2Z! G'S%T$]$D*8\1'(S06Y'!
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M(B9R ;()0EOXC3>9$0U"&I'%+_3$7T5"XYU8? E/U\82#;"NAA>8.1"-@3I
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MH%MN!D6J<XPN5$)81=C/@[$GO;+2%<F#LU$\<@O-K!@FD6,JDTD!(41_*OW
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MABV4J6]>E&"[9FYYQRWC+L ZG1(+;;=T#W%,(,_#+4QD3T/+W['S\DIOVT]
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M)J4@7&></!"<2\TY1#N[!._0_(3228K^>?81V[0H6UC"/N2QDC'&9:IA?X6
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MLW#_T)<=\I<?0^"? J/_7W$,Q 5T?#Y#!GRIKKN1-5\TBZ:-T^M-$5SOG*!
MIAJ:L"T0-B3ONZ-E#NZ)XA/Q/!H8?UP;KGNB9\D$!<Y%]%GBY26DYK &A20N
MFS#DI[TJ]KE8L"09(JTT#2Z<\G"%61,S7$+EDDK9? @#8^>Q1LS^![9LU#@8
M&MB?BB&09N=^06)1T$G%*>\Z[%SBEO&!0F<Q3@W"CF@E8G0P$"DNKD DIG26
M.4-/6^2%VD->E_X;' !;Y$]D,]97;(T!*RA'AF)DPT'1^=3"7'A]22VVP0Q\
M1Z/]B6_P NV.E#<>?1[BB4U(UNNP<PZX#**V(J)M[B8 0DRG/%<3[@RGPEA.
MF!^MK$I4[6'A@G<&"_=@E ZY-4N5X@+2A,V6A4V@M&!?X^)8Q)/WJI_EAIL>
M6*'&?PR.K:M-X-_EKI/57.6UM.Q:-"S_?>[P+ "$9Y@2C:<#IAS3V<=TO;!&
M+!E[[@EOVY;!P2\)D/'K"WOV9,K@D]J_U&B'8OT /UF@#;L-[=;L/AA0BN:P
M[%F9<5-Q>R#Q$'(KK,@TUO* +!R,R.)C]M@VL$@]<T$DE>BF=/N*,M%]M/?)
MC5' ,(HX:'<,=J>]5_*DS0SG?&PK:_F;!:YOLQ?)51D_SU?]2!9DTGQ?#I5G
MUW>HG(YB]/@X4CFWSICQI_CAFU#Z046FN>I<=,3I>.P>-JV<Q.@SO6'Y<]-E
M":]UX$9.U?1\.\:Q[AO]E[M@@K6W8IZ3\=Y[Q^L*%BRK9TQX+'#=!RI4:([%
M&(6S[4 Q3=:)X+)4L6V-UL /!SMGCAK/...MZE4*O"U<JP.=\S"6L3MLH6"_
M[OG(;JQ9.2=]&]AQP3&E9A1IR9JO$UTRP.I9JH,U#V#,X;5;?1K(6VP7,C .
M#F1^U0M"0W+ L\$AAG3BJ):)12T,*LU]+?07V@QFU,&F!6&E!;!EKJ]?RD$D
MVON5&'PD/.[Y#7@<725VT#8"U&A3SFC\XMZ;BU8;!G=)G&WI?0/\,/"WQ=7
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MK@5SB6$&;*R T0T_EQSI^+\WBC-M;ZT"31QH^FD5:'H=)'IXJZTBP?X]J;J
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M_?**-[#LWX^S6)4Z[O<.QV.=!]DX&$QG23:? G5__?3MFT>W\4=Z7_M: <,
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MN8%Z67N'J&H<_//)\R_0*^Z^E.OI;\,37NSANW>#X^#]X/04_K/[Z_%@\&$
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MVQLD1N>V(@I_:I5YQ4/AZMLP"H!8U "QH(:P"(A*-K6CU0?IOO?5-+](C'T
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M<2\MQ3>L#8VUV%G!IOX?7NL3EKI0BO9;U5E)VOEEN(8BG.YT1M4C:V,ITBC
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M3>\VK)+VQ=9.&PE&+?5JRS9ZD]#5 _*\U%8FQ_(LP=;@\ ?W*6=1>(J!82
MFG-R/05UV  ?12. @%SU"H1'6*[*D6=.80&11.*AZ01 ,:(7U[_T-*RTOW B
M'TAPK>]Z\5#PLO'*<K2WLZ_X+*<__0A*E%?B7%W@JM%;BM)',YK!6F=O?*UD
M1)>=M,G7Y3;0%RL;Z#=N ]VY22S5X#/%$<5H2W(EG)TTWF"S*)?OVI:Y:(:C
MEE!(-0>?J>5ML$OTT##F%J6MGDQ>;, 8_=EPF^BA%Y]D!6X*8P*9$6NG:^S[
MR4@P%0>B.!MK^=1&7K--#VN33\7;*&&R]G7?F6F;BX]-#F]>IEKT>QC;XW6R
M3"BV<R&>W'FD:6(BUA0J,:7*]J#E^OW78Q<5Y+47K>MC8Z@'!^OF6LP:&,4L
M(;8L9%N%8,TG6/82@Z6A2F1023.IGH]W@[<DEXEZ5-T"M,X[XE:O)75>'6GN
M="<7 $-U3+H9O*.8:C;I+KIVFW%5BQ#6$8I7_TS>VP849'D='NU!1.AUD\>&
ML4CWK,=SP0/KVY,[C+\>4GC!8W@K+D.@\QR&C1R']I&.T=HF?8 [7K<J6ON
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M@UIF] 6VV\,.7%HJCZ?%U)3<M;V.9?2:05[6!BJ\I*V[Y^.RYH1&0)ERN]B
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MC,NWO<MNI#W=??L>!+K!^_='N_O[(*7]\\G6$_I\<K2[9S];.&( C0!-U*R
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M]1'OBLH(8,/K7$4P64E=4JE7=@DRP#A751P&4U/D>@:(#H,I)D6YU[\WT6?
MR^%/.--0J,*(NC]-35DR+Y:V4B-D_MQ>B?I-NLAAH%#N+G ]V$N5>R_]:_?#
M"75H!<W3M8@/)?09?Y3]PORIW]$QKQ+-M!$H2:1C[,M##16]@ZGIU9HZ5R:A
M%ZL9+ $;#V/[>:*M29$%405B18K=8NLGX38 GB9E.7OY].G%Q<7F7VI:J#C?
MA.M[2O-OU)-M>#M\BN"VOAG\F548XBTS*&S"2=N%@==VME^L!SO/?]SXY?DO
MS[$5V!P>IF84EJH7&.]=<;<H__AHOT6Q&0R9\-*0M>SO@WUPS*=$+<NQ\QC&
M@:>EM//"EY=T40XO^U%@@+E8&&A7N8+@Y<(47F-GN.%$7:P(^L,GZ,\>*D'?
MR[B1ZAZ)0W=.R1N0CNJ7T^0B7 CWKCO+#>A-(- 4X8+ 1C0]4E6A"7>X-6VP
MYNLQ8:VN1+(KIZV@!@5ZF33!96J-/>>"),-6U5%6Y=3C5IWI-)H+H?0(X[(7
ML?-TV)84+9]B(EMXQ-.C$0OZ&=(%(/BT+T1YG8VQ!;9M_"MRJ^.!V$.8*)LZ
M4]AHN#DH;86_1QZ0C<<F@F,&1L8MNS/XF[L(@KQ('^ J8?/XEY8I^,SQ1,I"
M&C$:O(.9BBCGIN#6B+8!,)(H;A;.$KJWFO9:^SV[#1:.96^1P"0U#VSV6:1C
MT-*..>=FY8F9&N:43JI'5H7F2.[NS(V'F4US^\!SG2J\A37]&5DS-0TWL!2C
MXW5FY [<O!$O\BP]&U=)XXK6J/-S7G%[,CPH2OM97^A:/JM& $7!+(-_YW;<
M?F\L;1ISXX:$;R8J5T5!>ZZ;/O.VVUOV'ET<BL44Y,DJ@F,K].<P@(N,L84[
M2#;F#$T2_1X_#7#,#:]#O&T$A=R4\"6)- @:.C:,)2G;M<-@5LRC"="4L_8/
MN)[F-[ R-3*8YD30 4NI>$(K&*W#0KS3;AP>7F$3]\*ZXS3S2ID1,-$3PNI.
M\/Q\#N>(E,7#J(53Q0RSD B1U1$%K9D:4 7?X/?AT.IF>^;<),$Q9W?M1L+>
M=\_(.N5?!D"$+TFX)Z= ,4&2*8(_D"CLVW.BUJ#TE*P#YEN$E%S#K@U_Y 4>
MZ30MY@E04*/X.*@_*@EC<)G86UP19?"$.:1?.+[_;DAX#>HH*^4-3B!\Y+]V
M7N#_GKSQW[L>[V%.]5L%]"9PX>WN4!HBPI<._@<0#[BK49)=H&[_7EW<WMA'
MC,V.#+>V8(GYT00..];);&)4O_=. >$\0C($5+@(#BTT-EDNPQ[VL\4^K-+D
MG(FNI 8BI4%R1401(;,&\R*T&@T(0\1DD0KS10H82=?Y"P7#\.! "302BE=N
MW1.Z%R]C<8Q+]P!FYG9!H+-F]2+&O,SU:9T"6.(3Z]1<EAK;6LY)?_#HQ$0)
MXJF/+&4].I&=C!EX#@5R*9Q2=FA;_ZX1H:\/;)VYB;37M:WE?,L^GB*UO:5>
M=IX662,]XQ).\QXTA1PFB_4BAEQ!FSUREI%P.-5 Y*ITIDP,%W"&O!7W+\^9
M]#Q+SO%"IQK5.KH:8-WD62L:VN%?+C\5&:2GE-1V'L\FWI;R[LYZN](=;EUW
M>/Y@=0>&V@, >@&P.]8?9$+.ZEXF(Y);PQ/:LOP3B+-BZ/ [1Z,=Q*-HC:;2
M(YWJ,4C,@)XQ<%O@(XA>Z 'B]M4\=I4264R(0-04<03G!3<=L"N<:,B!%;"8
MF-3<XFVF\CBL4\QEBVLQ3)^RA>D(!+RS7,TFP0NI:;8>-HU(LETD82$W0J^[
MAB?"]9SE6=+BA>IY*M@FWN2$:E^FW4:)D4;]"08&H5EL4T"H4J:=3EV@&X G
M9$?C/)MBXT]27JQIKJAMU0UQI2T/ (F?&FI@CM3P*38'%S$P&/P;Y4=/H#J<
MS4!PKU)42IKO77'\"T3PLMB+9ZO8BX[8BV^=!K]XJ#3X#Y3B"-&!<A0D?5J@
M/_;,SB!&R2_W8NCYPE6Y0KUC4FP:#PJ-8]E0:%@MQ;8--?T>T#V:CU]03(=S
MILCZLT^;6J1.I*86119Y*5ST2%HI5$P)(%"2^Q+42-?(C CDRV!-K>,VX#Q4
M?1ZM;<HOGMD=EXXK'\U]D9T)LAP"# F0JX&/I,CQT L**YO#"N! YJ%U=S3L
MW%5>5"KU9$A[ *^"M=%Z0"(UC43,@B9H+G[QBN0'JS5;&P\>$O,I7(>W!M]B
MQ*K'6K2^_(!YRUD*)\SN$5&*LHL4M^@"(YPP[4_&M^$V5&C]";?N=N#\SBAP
M%];DP,N>@?R0I:!4+"I6BZXCZV]B61ZE@0P9':!, A<"?! NL,WM/15@0;1O
M.@TL$W?<>V3&51ZA1D5048)N-\Y8;P'P<?:3EINCWR, TZBY%+13,N&UUK52
M#AX^8_KQX3.FTQQ]E.B-K/+Y/?B*+8YX_>G)@E&UE'U8$86"L<2[@' -V9BP
M;TZT^,R0AE[-K"$<[;^FK&R@+QE-*(2*+-U!:;?_5X4N7EI.QS!\\=;D@O1G
M-D,C0%WOB2-:<%/D8X G@EA'%.91NPG[O;;YS]I/6&7YJXI-A O*];F!D\5A
MVNY/)@O->!5@%?#>3)77.[R0R/Y<(G(4>PV<5L6++V8P$QLF$[3! P,%_0L9
MB:6A7OR.8X@KHO3PB=)/#Y4H";\]LL!TQ]3(M\LYXYT!!=50_# %2[!$P5ZH
MBQQC/E*44$Q$UD9M6 +!"D&,D.J,W*/P.GT93*NB1&*B%]]&F4>B8JS)-/.'
M^V-A.I4N."WY=;?ZJ2()!M _PNL?&W0OH21XAM$/:)'!)]#Q4E8YAH)$VLQ
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ML%*]&\^Q=XK"YVP_"<1W^INL:45A[B<][F[RX^XK#^Y#)HW!Z]PWA/K:6N#
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M61FHBRH_-Z)3^%F#EV:';@;#DE+;*=:-\.(\^\2.UFD6L],5\V2 & #Z@=8
M-\%80\%FUD3"J3]^JHM+N;$E5B@$#@=W8R_&T[,N6<_1X03M]SJ\MRB)U JH
MME[<%2H_ E2^FWCGF]AAD=^*6'S'6#P4GFYKYG349&A@-C)BU-W/V*P"^'F>
MF;@1S8J9)2R/(]\+.:DM2YQE1>42SXEO@M2?-U_PUN)Y%SGAA<(\2?CV[0=U
M.+"B8F4\.-QK;+C3('/BJ3*D5BSLD+LJNDR0QP7LWR>*WDWDYPU0]/<LJ=(2
MK57WQ6_?SBT;H7#(Y>'1?E@W1VE+X8$15NG#:"DVW&=>RA 6VJ$048Z,Y#I"
M:"V5^-%4GV44 L,1[4O*MS2C)KT0U,M*OI"A$SXD'.YS+@=KD&/#M:\*>-UU
MG<#7;]\,#_J]/X:G!X.3D^"/WP;'@\-W& S6A"N"(09!)/ZM6RQ<B)@M&!GL
MD]$8.\O>1YW$ZXQRA]?Q)>U;L?[X'A"W46["X#<-VA_2NQ #]XH-F>?Z_5LO
M+V;MM8ZXIZKM>X=X% ?_?++C6Z(? ,#;.L1!Q_]A\=)N&&ELSFV\+LO^H(__
M/F;\.V=BGQ)H?T'%V>_EF)H3/[O5>=_.?>GBTOFOZD]@FWC>[@*O?S [SW]X
M\MT"_8&:PM][50:2UWYVZ\#_J,^&*@*]#(XX,@8D@7^HZ>P5,+[#:Y^37_E_
MT6/I^RN_N%'Z5^*T#Y<'#CX<O3_\<S!H<#E:]2VLDCS+C5N_'P;T^&>Y,=^\
M?RZ_FN6F5[G(5#N;S5C9YU8Y_ F,3SDS+V]#_'AVNXN[@?CQM03"K[7A.S_I
MR\"3S%P;Q4QA5%2:7>1JMJ0=X>VM\"@W(#R0I/4W('5%!!_6+!TBWA4Q>"\>
M3 S>51V7GKX]W/^3-O?;Z8?W;_X_4$L#!!0    ( *&!:E.AX&DL%0@  %$O
M   ;    8FEV:2TR,#(Q,#DS,%\Q,'%E>#,Q>C$N:'1M[5I;;QHY%'ZOU/_@
MC=0JD2! TE2[@2)QRP8IFV0)J;:/9L: E9DQM6<@[*_?[]@S9$A(2[9D0U;-
M V1\.3X^\WWG8EP[[?]Q5G_[IG;::;3QS>BOUN_VSSKU6LE]H[>4=M>:%^TO
M[*K_Y:SS:6>HHOB85<J3F/5E* P[%S/64R&/"JZAP*Z$EL,=3,34RVQ>R/5(
M1L>LO(,E+N]UKBNTRA9BJBP6MW&1!W*$1RU'XQB2F_7.[5@.9,P.*_N56JGY
M'(MY(HJ%MJN]CP9F4GW^=5J=7K][TFTU^MV+<W9YW;NZ;ISW6?^"775:MNVP
M?, N3MZ^Z9]VV%6CUVR<=Z[8Q5]GG2^LT>JCBQV4RP?/KVGCO,UZUV<=9YG*
M8;%1^4"KDUZ=OUJGC?/?.Z31VS=HK/QV^&%C*NTLWL9S[J]VO?PR:J7K^J:M
M*B-?T-SR_I&,LFT]]KE8N-]HGG58JW-V=G79:'7/?_^T4]ZQSY>-=CM[7E:N
M N5:V.1 RP([%<%4Q-+C4(Q'IIAJ-Y-^/*:-E-]5V8![-R.MDL@O>BI0^IC-
MQC(6Z%#:%YH: SXQ C9+_R-'4.OW4C=3Z[=9ZX(T//^T<[A0)Y"1*(X%L9A6
M^O@.MCZY ,)SZA:'/)3!_/A[UK1CC?Q;..-7V0KAW0)K)2H:L<^LK0IXOSJ6
MPSF+QSP^KI5H97*$;?KH/= _U2FSR[N5*V0OI]]^AIF__?K=J=_2?$K;]7B0
MP3M6DY7BGO455/;SAEZ!CH.70P<;\ZE@6DREF D?L)"&?4VXAA,(YFB?*!TS
M%;$3I4/,*?[)U) UI?HL!>M&WGYU70P]\?6O.?Q5X>!@>W'0Y 9O'^\YG+.;
M2,T"X8]$P<$A!8&OL$BD8KB[*.8R8CR:LR2*=2*8B7DL0GAR0@>'EP=\) _8
MD'MHTDR%R%-BY<8]&! )3QC#]9R&A/Q&8-V<3(,V'\I@R8!TIC5H@">UEX08
M%F$Z-(%3)A?MC9E)Z.-N_DQHD0JA#832!(+[$DYQ)N,Q-F@FPK,*DMP)5%,^
MM@G0P"B#>=X,+XSW]89O/1,.7R$3!!O*"%@CV-YAJP :8#BZ=:Y?1D/X2QY+
MR)&1%R0^9 *_.2 5@'U)/G8"^!%SB%%!<$>-%)7FWM)@GR])<(%&) $&@ \*
MH+7+&:N/Q\V8#0,U,QE9M!A)$VN.A3@U.KVA92&'>9,I\T#;G[#?!+8^;"_L
M^TL8>:_-UT1530KL-&DDAZF&0XG'7;-G =1E7 L+54!/#@)!D&("_!@$THQI
M!@T+$2\H9M"S+XT7*)-@'D42K0*'V8E6GO#1;-@N(.H+8-[AL'/KC7DT$JP!
M)]U+ HRH'/)BY6A7."TJ1[Y[<H^22IC(<87D,_+D.0HY2),N:RW$WD<^^%3%
M,KO#Q8++K7MVW_>)AI&47JV=9Z_+AAQ>UL7_$XFV%73A>ZOI\D(4:0L#6P I
M-KWX/HP+E/EX/#'K3Z$49"  R70EE]2H1$, 7/14&NOX,4I$5@Z5<7<A(Q]V
MM BXQ7B:U=SALI"&).J4"!_0Q:A ^CRVB@Z,]"77DC8@7>YE V%$DA)#^9#U
M"L8F3S9,*".@4(RP1),FG+"3!)RB&[9EE;C+JS##96GYY!+_#00-1 #"?.&_
M^H#S&@DWV&;"K>W5'_!N_7BP-OU V:GTB57<J(A3X.,&C*1:A*C&M9_!'D24
M?" #&<\I&5NU+#D!RQ +?L??I:&Y6L;&U]MT0Y-$3T ^8Y-'SU/:MPK8JF8D
M(N2$ 3B('C$A<M,05&R.9W "<H(0]Y-I+\ T;[N8UIGR(+'^GV HAD,4'G(*
M )D5!<0B.5PCGKG'U36%)18F(A895[D,5!(_KL$Z$9<O1@LJRX;?+^C9("OX
MK*\0SA+0ITK"?W+CO^>&OUW<:#O8/80OG7^E]8+M6<F1)\0>2N64YR6:0)K+
MFU9(#96)T4X_UD"6P1O+#FW9[B-3AF ;HL*]T:GB'CB0L85'4;)0;,^I->9F
MD6520+'T%+Z-M-8@:12<PX W(D@/\NZ-+_RPC?X7E-P*CAT]<A*Q,6-LYV&%
M_;'#SPA=N//]%(KRI+H+ T2+)Z2>#ZJMA78<%5>LM%ED>[8!(L-0QK$0WPBT
M X5\DOI]"?VLD%TP#W'-4-S$-]5]F;\07Q,)]:UO2"+/G@KN;?P,XF<D>W4'
M&(T E02L(<$*.I^BDR]/"F XS=06!PDSP6\H]7*5A4V^;$UD?\O)CIJ?Q(RT
MYG>GA2NB!?<QT8A%L'B416DEA2F@ @J>@LO_#$QADC#D&C:PFTFC],I#^?]%
M('F-C-BR$X8&4KBAAB,N )_"A@\@W/Y&F%*AX!(@&4U5,!64!45\E/[4J=.(
M(\))H.8"O;.Q<C&&+Q$-Q-A(CKB_"K(E>QNF_HSW<39T9ZD-DQXS=H[=A0-L
ML%(NL(/R0>6'KO6LH<+RK9[U+^\\PIN!BF,5;H9KKU&&V_^&Q+S@TAL3DT+*
M/:(YX-X-H^MF]E1]IUXRI=P5K"?7!]DR*8P/*O_FG?_[>UBO2]P]8VU>XN'!
MC\W_^!KV^(B2SQJ*:TWB0HXG[GDLQ9!U;H67T'$@NW 5'7.]M6Y]]](=9"-,
M/AB%7*-;_W;(_*589"=2!/XQNT1<KT+CKPDR8M*TRBXFMG@Z9F<<I6&QF%FR
MW?V\?-E[0?Z/M+M[#J'I',+^T9U+R(6Z?&B['_KN7:)$ *.IO7KN53Z\N[L4
M\!XFD]GF:R7L(MM0S@PELH/;JPW*);H2[^[(TU7Z?P!02P,$%     @ H8%J
M4W5+L\(V"   U"\  !L   !B:79I+3(P,C$P.3,P7S$P<65X,S%Z,BYH=&WM
M6FUSVCH6_MZ9_@=M9MI)9B"\I.GL#30SO.6&W6R2)>3N[4=A"]#$EJAD0]E?
MO\^1;7" W));NB5WD@\$V](Y1\?/<UZ$ZI?]?UV=OWU3O^PTVOC/Z*_>[_:O
M.N?U4O(?3TOIXWKSIOV9W?4_7W4^'0RUBLY8I3R)6%^&PK)K,6,]'7)52&X4
MV)TP<GB B9AZF\T+N1E)=<;*!U!QN_)P6Z$UMA!38Y'X&A5Y($>X-'(TCB"Y
M>=[Y.I8#&;&3RG&U7FK^6&7OU<!.:KM14XSTQ*E*+P<ZBG2XIMP3*A+&:6]U
M>OWN1;?5Z'=OKMGM?>_NOG'=9_T;=M=IN7LGY2J[N6#]R\[;-W>-7K-QW;EC
M-[]?=3ZS1JM/CZKE\H[<]'S[&]=MUKN_ZB1>K)P4&Y4/J;FL\WOKLG']:X?L
M?/L&-RN_G'S8V?L\6+RYG8,CM[[Z_>-75"_=G^\:DE+Y@N:6CT^ERI;UU.="
M<;_1O.JP5N?JZNZVT>I>__KIH'S@KF\;[79V_=BX"HQK89$#(POL4@13$4F/
MPS"N;#&U;B;]:$P+*;^KL0'W'D9&Q\HO>CK0YHS-QC(2>*"-+PS=#/C$"O@L
M_48QH][OI1&IWF^SU@U9>/WIX&1A3B"5*(X%<9 T?7P'7U_< /<Y<XM#'LI@
M?O8M;[JQ5OY7),ZOL0W"NP7V#\V5$NP_0OES]D\9%O"6322'<Q:->716+Y%^
MBIQM^NBMK2*U+//.NXUZLE?4;_^ F;_\_9M3_\CR*2W7XT$&<E!]H[@?^B(J
MQWE';\!(]>=AA(WY5# CIE+,A ]82,N^Q-P@% 1SW)]H$S&MV(4V(>84_\WT
MD#6E_DT*UE7><6U;##WS]>]T^-XCI+J_"&ER"UP  >&</2@]"X0_$H4$*"D\
M? TE2D<(ARKB4C&NYBQ6D8D%LQ&/1(A(3[CAR ( EN0!&W(/MPS3(4J>2"?C
MU@8HX0EKN9G3D) _".C-R;2XY\,8J S(9M)! SQIO#C$,(7IL 1!FT*X-V8V
MIH_E_)DP(A5""PBE#03WI1HA(T1C+-!.A.<,)+D3F*9]+!.@@5,&\[P;7IFP
M"[B=O$ F"#:4"E@CV"ZQ50 -,!R/3>ZY5$-$4AY)R)'*"V(?,H'?') *P+ZD
MZ#L!_(@YQ*@@6%(C1:5=40WV^9($%VA$'&  ^* !6J?..GL\;L=L&.B9S<AB
MQ$C:R' HXG0SL1M6%G*8MYDQ:]:^PGX7V/JPO[#O/\+(>V._Q+IF4V"GY20%
M3#T<2EP>VB,'H"[C1CBH GIR$ B"%!/@QR"0=DPS:%B(?$$Y@ZY]:;U VQCS
M*),8'228G1CM"1^W+3L$1'T!S"<X['SUQER-!&L@2/?B ",J)[Q8.3T4B165
M4S^Y2BXEM3@JX0K)9Q3)<Q1*($VV;*6(O5<^^%2#FL/A0N'CNT=NW:M$PT@J
MO+:NP+=E0PXOV^+_F43;"[KPH\UT^4D4:0L+7P IKKSX-HP+5/EX/+;;3Z$2
M9"  R5134M3HV$  0O146A?X,4HH)X<:O&7*R*<=(P+N,)Y6-4M<%M*41 \E
MT@=LL3J0/H^<H0,K?<F-I 7(I/9RB5"1I-A2/>2B@G7%DTL3V@H8%"$MT:0)
M)^S$ :?LAF4Y(Y9U%68D55J^N,2W@:"!2$"8+_P7GW!>(N$&^TRXK:/Z&N^V
MSP=;TP^4G4J?6,6M5IP2'[=@)/4B1#5N_ SV(*+D QG(:$[%V":U% 0<0QSX
M$_X^&IKK95Q^_9HN:!*;"<AG7?'H>=KXS@#7U8R$0DT8@(-X(B9$;AJ"CBWA
M&8* G"#%O3+M)S#-VR^F=:8\B%W\)QB*X1"-AYP"0'9# [$H#K?(9\GEYI["
M$0L3D8MLTKD,=!P];<$V&9<O1@MJRX;?;NC9(&OX7*P0B2=@3XV$OW+C_\\-
M?[^XT4Y@MPY?VO]*^P7W9"-'GI%[J)33GA<; FFN;MH@-=0VPGWZ,0>R+-Y8
MMIW+#I^8,@3;D!561J>&>^! QA:N5+PP["@Q:\SMHLJDA.+H*7R7:9U#TBPX
MAP,?1)!NY*V,+WRWC_X2E-P+CIT^L1.Q,V?LYV:%^QG$SPA=6,9^2D5Y4BW3
M -'B&:7G6K>UL(ZCXXJTL8MJS]V R#"4423$'R3:@48]2<]]"?N<D$,P#WG-
M4M[$?^K[LG@AOL02YKO8$"O/[0H>[7P/XC63O;@-C$: 3@+>D& %[4_1SI<G
M!3"<5FJ+C829X ]4>B6=A2N^7$_D?LO)MIJ?Q8RTYT]V"S=D"^YCHA6+9/$D
MB])."E- !30\A:3^LW"%C<.0&_C +2;-TALWY?\2B>0E,F+/=A@:*.&&!H&X
M 'P*ESZ </<;84J%0E( 2375P510%:3X*/VITZ091X230,\%GL[&.LDQ_!'1
M0(R=U(C'FR!;<J=ESO?IR!&*9KCOC%UC(>$ :ZF4"ZQ:KE:^ZX3/%A8\/N"S
M_3F>)RB2G!';#:U>HHQD_3L2\Q-5[TQ,"JGL[. @X-X#HY-G;@/]X+QD2VNG
ML9[=$&3*4C!7*W_FS?_Y(UDO2]R*LW8O\:3Z??,_OH0UTOSTG#5-W!#[2Z3D
M&0E@*6V=#[<[UM4:2S%D%XM\>9.T??5F+Z^H>WYXFVQZ8\AR,)6*C>6^>#H7
M94K7'83=G&KQ_6_%(J2(P#]CMZ@(:K#K2XQ:FLJ-&KN9N+;KC%UQ-)7%8O9*
MVMW?'I\X7\22CU2BK,279A)?CD^7$2:7.?.9<C63KAS,1#ZDJ;WS'";63P4_
MRI_K96BV_'H)J\@6E'-#B?R0K)5\1:?RG=/<:?[_ 5!+ P04    " "A@6I3
MXV=>%[@$  !2%   &P   &)I=FDM,C R,3 Y,S!?,3!Q97@S,GHQ+FAT;=U8
M;6_B.!#^CL1_F$/:JI5X[[6Z HL4(%PC<<"2M-I^-(D#O@UVUC%MN5]_XX10
MWDI[N[357E4!\<O,,^-G7N+&M?-7KYG--*Y-HX/?H/\:CN7TS&:CE'SC;&DY
MW6@-.G=@.W<]\W/.%US5H%(.%3AL1B/HTP<8B1GA^60@#S:5S,_A1MPZ3/?-
MB)PP7H-R#E4,MR9?*[0.*S%U4/11%4C )O@HV62J4'*K:3Y.V9@I.*\6*XU2
MZZC*&/>HWELN7C">:Y[P<136#RHP)"-!'JYI<$\5<PF*)CPJ'#;&1254ODK^
MCWDK58#N:ILCQ^I:;<.Q!GT8=,&Y-J%];9E=,+^:[1O'NC5Q&%>8HVQF>#.R
M;XR^ \X *G_ 3=$N0KL(MMF.MU?.+\I@V&!T!D/'[,#:\F,?Q:XE*8BK\F5J
MAVV,6D;?M N#KSWS#HRV@S/93+5<KKZ(YY4G]X:G]/<\4LQ?Y)H6!U=P3EW%
M!(<'IJ:@IA2^S(E$XX,%C&@HI,IFA \M)FX9!8N[13C5JTX"[_M<U-MB%A*^
M.)'QTQF@H*Z0,\17^ *^D+'$$/$(#RC2W$-PH:*S,95P7LY#M5RMY(%$X+,
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M9 YMA:&LX[#T-1U%ROH-W?*5G7ZS]S=02P,$%     @ H8%J4_X; B#7 0
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MBZ%.+(8M%@W%8J03BU&+14.QN-")Q46+14.QN-2)Q>71'ZM/<]D@-NHG5>Q
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M*F<&))A13G: 43U_9/C0T]UO#O+O_XTL<I[0O;@X9JXU"5$A34LI@(*G 95
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M9PK[3&&?*>R<R?I,H9SK31,YL4GAG:;9AAU(_+&!USW6\=4[%57OM#LO*"E
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M1==<3DK57.ZU6G-Y9!C^Q@]>+!I<"DK\P %K4O5"2E6P#L %<D5*,<MS:G-
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M ]FA$U<K<QE6BJM4E[:7TGD QJ\XBOX1)U_B&^QE28P#OI8BVBE2R]N-F-'
M;@;-2(1!T,D$H21TABKM?Z9:J%0K5L*<,.F7)%K&N9>RL^2IR#-)Y.PR1P*S
MR9B6$""FB)%)&%()(R[MYH VSQY1#;*HPQ.F@%&+6SZNK03=.K4ME 7$&25
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MDYH8-+<CARAE3<A$UR7-;?C(;_LZ>']TP'A ?_F#G2:H=[D<6 N]6M0&$TS
M4BJHY& ,D0T02N97;+##QSA[Z&(R ^)'+G"NG5BU9&SZ#B&\NM=H"(#I6D2H
MVKP@'$"OZ03JZS><%EMR$J<8+W!P2OX,<-R.(!%*6',)8FB5)V@^=MZX<DR=
M2_F8$ H*J0SMHQ3S8X(/7@KFF->*HN,\3\/;94Y3(,Z2*T^1Q4NG9'_;7F=
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MZC^=D[_(S^5/Y!\4!/GE_P-02P,$%     @ HH%J4\6-BS#6(0  <F(" !4
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M$DHE5L?6RO9!ST#/KB!TK[36-,4^T(>H6UV">1W#EIPCY$]XZ811:H9]7MM
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M-JW2G;*-8U-O2A=4?_$OP"P!S#ZM;M\HDX-A3[AB(QJAVK[]%V2="7A'-+^
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M!X3A3INIUS:T<7\K\]L#PF#'[<C4<QO:N,65^>T!8;#S=F3JO0UMW.7*_/:
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M4$L! A0#%     @ H8%J4_E&,M#T"0  N64  !$              ( !
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M,'HQ-2YH=&U02P$"% ,4    " "A@6I394*,!$A.  "%^P$ '
M    @ $@9 $ 8FEV:2TR,#(Q,#DS,%\Q,'%E>#$P>C$V+FAT;5!+ 0(4 Q0
M   ( *&!:E-*&(ASFU8  &Q  @ <              "  :*R 0!B:79I+3(P
M,C$P.3,P7S$P<65X,3!Z,3<N:'1M4$L! A0#%     @ H8%J4W 6-5AP3@
M8O$! !P              ( !=PD" &)I=FDM,C R,3 Y,S!?,3!Q97@Q,'HQ
M."YH=&U02P$"% ,4    " "A@6I32+DKY951  #/^0$ '
M@ $A6 ( 8FEV:2TR,#(Q,#DS,%\Q,'%E>#$P>C$Y+FAT;5!+ 0(4 Q0    (
M *&!:E.AX&DL%0@  %$O   ;              "  ?"I @!B:79I+3(P,C$P
M.3,P7S$P<65X,S%Z,2YH=&U02P$"% ,4    " "A@6I3=4NSPC8(  #4+P
M&P              @ $^L@( 8FEV:2TR,#(Q,#DS,%\Q,'%E>#,Q>C(N:'1M
M4$L! A0#%     @ H8%J4^-G7A>X!   4A0  !L              ( !K;H"
M &)I=FDM,C R,3 Y,S!?,3!Q97@S,GHQ+FAT;5!+ 0(4 Q0    ( *&!:E/Z
M'>4PTP0  . 3   ;              "  9Z_ @!B:79I+3(P,C$P.3,P7S$P
M<65X,S)Z,BYH=&U02P$"% ,4    " "A@6I3_AL"(-<!   Z$0  &@
M        @ &JQ ( 8FEV:2TR,#(Q,#DS,%\Q,'%E>#-Z-2YH=&U02P$"% ,4
M    " "B@6I3\2$U7T *  #0>0  %0              @ &YQ@( 8FEV:2TR
M,#(Q,#DS,%]C86PN>&UL4$L! A0#%     @ HH%J4WG.%6U $   :!,! !4
M             ( !+-$" &)I=FDM,C R,3 Y,S!?9&5F+GAM;%!+ 0(4 Q0
M   ( **!:E,)Z/S\1C(  $H% P 5              "  9_A @!B:79I+3(P
M,C$P.3,P7VQA8BYX;6Q02P$"% ,4    " "B@6I3Q8V+,-8A  !R8@( %0
M            @ $8% , 8FEV:2TR,#(Q,#DS,%]P<F4N>&UL4$L%!@     1
- !$ M@0  "$V P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
